
<html lang="en"     class="pb-page"  data-request-id="685fa2d0-2578-4dd0-a00b-ce66ea8a6654"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b00680;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2015.58.issue-17;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy" /></meta><meta name="dc.Creator" content="Gianluca  Papeo" /></meta><meta name="dc.Creator" content="Helena  Posteri" /></meta><meta name="dc.Creator" content="Daniela  Borghi" /></meta><meta name="dc.Creator" content="Alina A.  Busel" /></meta><meta name="dc.Creator" content="Francesco  Caprera" /></meta><meta name="dc.Creator" content="Elena  Casale" /></meta><meta name="dc.Creator" content="Marina  Ciomei" /></meta><meta name="dc.Creator" content="Alessandra  Cirla" /></meta><meta name="dc.Creator" content="Emiliana  Corti" /></meta><meta name="dc.Creator" content="Matteo  D’Anello" /></meta><meta name="dc.Creator" content="Marina  Fasolini" /></meta><meta name="dc.Creator" content="Barbara  Forte" /></meta><meta name="dc.Creator" content="Arturo  Galvani" /></meta><meta name="dc.Creator" content="Antonella  Isacchi" /></meta><meta name="dc.Creator" content="Alexander  Khvat" /></meta><meta name="dc.Creator" content="Mikhail Y.  Krasavin" /></meta><meta name="dc.Creator" content="Rosita  Lupi" /></meta><meta name="dc.Creator" content="Paolo  Orsini" /></meta><meta name="dc.Creator" content="Rita  Perego" /></meta><meta name="dc.Creator" content="Enrico  Pesenti" /></meta><meta name="dc.Creator" content="Daniele  Pezzetta" /></meta><meta name="dc.Creator" content="Sonia  Rainoldi" /></meta><meta name="dc.Creator" content="Federico  Riccardi-Sirtori" /></meta><meta name="dc.Creator" content="Alessandra  Scolaro" /></meta><meta name="dc.Creator" content="Francesco  Sola" /></meta><meta name="dc.Creator" content="Fabio  Zuccotto" /></meta><meta name="dc.Creator" content="Eduard R.  Felder" /></meta><meta name="dc.Creator" content="Daniele  Donati" /></meta><meta name="dc.Creator" content="Alessia  Montagnoli" /></meta><meta name="dc.Description" content="The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candid..." /></meta><meta name="Description" content="The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candid..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 26, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00680" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00680" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00680" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00680" /></link>
        
    
    

<title>Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00680" /></meta><meta property="og:title" content="Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0021.jpeg" /></meta><meta property="og:description" content="The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00680"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00680">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00680&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00680&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00680&amp;href=/doi/10.1021/acs.jmedchem.5b00680" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 6875-6898</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01095" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b00684" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gianluca++Papeo">Gianluca Papeo</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helena++Posteri">Helena Posteri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniela++Borghi">Daniela Borghi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alina+A.++Busel">Alina A. Busel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Caprera">Francesco Caprera</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena++Casale">Elena Casale</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Ciomei">Marina Ciomei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessandra++Cirla">Alessandra Cirla</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emiliana++Corti">Emiliana Corti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matteo++D%E2%80%99Anello">Matteo D’Anello</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Fasolini">Marina Fasolini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Forte">Barbara Forte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arturo++Galvani">Arturo Galvani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Antonella++Isacchi">Antonella Isacchi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Khvat">Alexander Khvat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mikhail+Y.++Krasavin">Mikhail Y. Krasavin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rosita++Lupi">Rosita Lupi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paolo++Orsini">Paolo Orsini</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rita++Perego">Rita Perego</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Enrico++Pesenti">Enrico Pesenti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniele++Pezzetta">Daniele Pezzetta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sonia++Rainoldi">Sonia Rainoldi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Federico++Riccardi-Sirtori">Federico Riccardi-Sirtori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessandra++Scolaro">Alessandra Scolaro</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesco++Sola">Francesco Sola</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fabio++Zuccotto">Fabio Zuccotto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eduard+R.++Felder">Eduard R. Felder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniele++Donati">Daniele Donati</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alessia++Montagnoli">Alessia Montagnoli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Oncology, Nerviano Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Chemical Diversity Research Institute, Rabochaya St. 2 Khimki, Moscow Region 114401, Russia</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Accelera Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div><div class="corresp-info"><strong>*</strong>Phone: +39-0331581537. Fax: +39-0331581347. E-mail: <a href="/cdn-cgi/l/email-protection#7c1b151d1210091f1d520c1d0c19133c12190e0a151d1213110f521f1311"><span class="__cf_email__" data-cfemail="2b4c424a45475e484a055b4a5b4e446b454e595d424a4544465805484446">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00680&amp;href=/doi/10.1021%2Facs.jmedchem.5b00680" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 6875–6898</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 29, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 May 2015</li><li><span class="item_label"><b>Published</b> online</span>26 August 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 September 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00680" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00680</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6875%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGianluca%2BPapeo%252C%2BHelena%2BPosteri%252C%2BDaniela%2BBorghi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D17%26contentID%3Dacs.jmedchem.5b00680%26title%3DDiscovery%2Bof%2B2-%255B1-%25284%252C4-Difluorocyclohexyl%2529piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-carboxamide%2B%2528NMS-P118%2529%253A%2BA%2BPotent%252C%2BOrally%2BAvailable%252C%2Band%2BHighly%2BSelective%2BPARP-1%2BInhibitor%2Bfor%2BCancer%2BTherapy%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6898%26publicationDate%3DSeptember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00680"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4136</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">55</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00680" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gianluca&quot;,&quot;last_name&quot;:&quot;Papeo&quot;},{&quot;first_name&quot;:&quot;Helena&quot;,&quot;last_name&quot;:&quot;Posteri&quot;},{&quot;first_name&quot;:&quot;Daniela&quot;,&quot;last_name&quot;:&quot;Borghi&quot;},{&quot;first_name&quot;:&quot;Alina&quot;,&quot;last_name&quot;:&quot;A. Busel&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Caprera&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Casale&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Ciomei&quot;},{&quot;first_name&quot;:&quot;Alessandra&quot;,&quot;last_name&quot;:&quot;Cirla&quot;},{&quot;first_name&quot;:&quot;Emiliana&quot;,&quot;last_name&quot;:&quot;Corti&quot;},{&quot;first_name&quot;:&quot;Matteo&quot;,&quot;last_name&quot;:&quot;D’Anello&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Fasolini&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Forte&quot;},{&quot;first_name&quot;:&quot;Arturo&quot;,&quot;last_name&quot;:&quot;Galvani&quot;},{&quot;first_name&quot;:&quot;Antonella&quot;,&quot;last_name&quot;:&quot;Isacchi&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Khvat&quot;},{&quot;first_name&quot;:&quot;Mikhail&quot;,&quot;last_name&quot;:&quot;Y. Krasavin&quot;},{&quot;first_name&quot;:&quot;Rosita&quot;,&quot;last_name&quot;:&quot;Lupi&quot;},{&quot;first_name&quot;:&quot;Paolo&quot;,&quot;last_name&quot;:&quot;Orsini&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Perego&quot;},{&quot;first_name&quot;:&quot;Enrico&quot;,&quot;last_name&quot;:&quot;Pesenti&quot;},{&quot;first_name&quot;:&quot;Daniele&quot;,&quot;last_name&quot;:&quot;Pezzetta&quot;},{&quot;first_name&quot;:&quot;Sonia&quot;,&quot;last_name&quot;:&quot;Rainoldi&quot;},{&quot;first_name&quot;:&quot;Federico&quot;,&quot;last_name&quot;:&quot;Riccardi-Sirtori&quot;},{&quot;first_name&quot;:&quot;Alessandra&quot;,&quot;last_name&quot;:&quot;Scolaro&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Sola&quot;},{&quot;first_name&quot;:&quot;Fabio&quot;,&quot;last_name&quot;:&quot;Zuccotto&quot;},{&quot;first_name&quot;:&quot;Eduard&quot;,&quot;last_name&quot;:&quot;R. Felder&quot;},{&quot;first_name&quot;:&quot;Daniele&quot;,&quot;last_name&quot;:&quot;Donati&quot;},{&quot;first_name&quot;:&quot;Alessia&quot;,&quot;last_name&quot;:&quot;Montagnoli&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;26&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;6875-6898&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00680&quot;},&quot;abstract&quot;:&quot;The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by w&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00680&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00680" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00680&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00680" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00680&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00680" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00680&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00680&amp;href=/doi/10.1021/acs.jmedchem.5b00680" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00680" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00680" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00680%26sid%3Dliteratum%253Aachs%26pmid%3D26222319%26genre%3Darticle%26aulast%3DPapeo%26date%3D2015%26atitle%3DDiscovery%2Bof%2B2-%255B1-%25284%252C4-Difluorocyclohexyl%2529piperidin-4-yl%255D-6-fluoro-3-oxo-2%252C3-dihydro-1H-isoindole-4-carboxamide%2B%2528NMS-P118%2529%253A%2BA%2BPotent%252C%2BOrally%2BAvailable%252C%2Band%2BHighly%2BSelective%2BPARP-1%2BInhibitor%2Bfor%2BCancer%2BTherapy%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D17%26spage%3D6875%26epage%3D6898%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291411" title="Pharmacokinetics">Pharmacokinetics</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/jmcmar.2015.58.issue-17/20150910/jmcmar.2015.58.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118, <b>20by</b>). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of <b>20by</b> with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 113 kDa nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) is the most abundant and well-characterized member of the diphtheria toxin-like ADP-ribosyltransferase (ARTD) family of enzymes.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> PARP-1 (aka ARTD-1) exerts its multifaceted biological roles<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> through the construction of short-lived negatively charged ADP-ribose homopolymers [poly(ADP-ribose), PAR] either on PARP-1 itself (automodification) or on different acceptor proteins (heteromodification). Transferral of monomer units to the growing poly(ADP-ribose) chain exploits the intermediacy of a reactive oxonium ion species which, in turn, arises from the PARP-1-catalyzed detachment of nicotinamide from nicotinamide adenine dinucleotide (NAD<sup>+</sup>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The well-documented involvement of PARP-1 in the signaling and repair of DNA damage as well as its overactivation in several pathological contexts, triggered a number of aggressive medicinal chemistry programs aimed at the discovery of PARP-1 inhibitors, potentially useful in therapeutic areas as diverse as stroke, cardiac ischemia, diabetes, inflammation, and cancer.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">Presently, the primary focus of these efforts still concerns oncology, as testified by the tremendous amount of preclinical and clinical data produced in the field.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> From a historical perspective, PARP-1 inhibitors entered the arena as promising coadjuvant components of standard chemo- and radiotherapy regimens. Later, the discovery that tumor cell lines bearing deficiencies or mutations in DNA-repair genes (e.g., BRCA1 or BRCA2) do not tolerate PARP-1 inhibition,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> fuelled the application of PARP inhibitors as single-agent therapies in breast and ovarian BRCA-mutated cancer settings. More recently, the discovery of new potential combinative synergisms (e.g., PI3K,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> NAMPT,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and EGFR<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> inhibitors) as well as the broadening of “synthetic lethality” contexts (e.g., PTEN<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and ATM<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> mutations, MSI colorectal cancer phenotypes<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and Ewing’s sarcomas<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a>) in which the inhibition of PARP-1 can be therapeutically valuable has further raised interest in this target. Currently, eight PARP inhibitors are at different stages of clinical investigation, targeting several tumors types either in combination or as single agents.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These clinical candidates, as well as all known preclinical PARP-1 inhibitors, were designed to imitate the nicotinamide portion of NAD<sup>+</sup> with which they compete for the corresponding PARP-1 binding site. Accordingly, PARP-1 inhibitors are systematically endowed with two peculiar nicotinamide-mimic motifs: (1) a rotationally constrained primary amide as, for instance, in clinical candidates such as Veliparib (Abbott, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and Niraparib (Merck/Tesaro, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> or (2) an amide embedded in a ring as in Rucaparib (Pfizer/Clovis, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Olaparib (AstraZeneca, now marketed as Lynparza, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and Talazoparib (BioMarin, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Within the PARP family of enzymes, none of these inhibitors selectively inhibits PARP-1. For instance, all the clinical candidates and the vast majority of reported PARP inhibitors also interact with PARP-2 (84% identity and 90% similarity within the PARP signature motif<a onclick="showRef(event, 'ref2 cit3a'); return false;" href="javascript:void(0);" class="ref ref2 cit3a">(2, 3a)</a>) with similar potencies, as recently independently described by Wahlberg<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and ourselves.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> PARP-2 (aka ARTD-2)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> is a 62 kDa nuclear protein and, like PARP-1, is involved in DNA single-strand break repair. However, its contribution to the total DNA damage induced PARP activity is minimal (5 −10%).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Specifically, PARP-2 has been postulated to participate in later steps of the DNA repair process by recognizing gaps and flaps and by the delayed and persistent accumulation at UV laser-induced damaged sites.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Moreover, PARP-2 depleted cells show increased sensitivity to ionizing radiation, indicating a role in the IR induced DNA damage and suggesting a potential application for PARP-2 inhibitors in combination with irradiation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Aside from PARP-1 and -2 overlapping functions, as clearly demonstrated by the embryonic lethality in double knockout mice, <i>PARP-2</i><sup>–/–</sup> single knockout mice show impaired spermatogenesis, adipogenesis, and thymopoiesis. These <i>PARP-2</i><sup>–/–</sup> mice furthermore suffer from increased neuronal loss after ischemic damage and are more prone to develop pancreatitis following chemical insult.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In addition, loss of PARP-2 has recently been shown to shorten erythrocytes lifespan and to impair differentiation of erythroid progenitors, leading to chronic anemia.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As all these physiological functions of PARP-2 can potentially result in undesirable side effects following its inhibition, we reasoned that a potent and highly selective PARP-1 inhibitor, if equally efficacious in cancer therapy as are dual PARP-1/-2 one, might represent a significant advancement in the field. Crucial data that prompted us to embark upon this strategy were the findings of Bryant<a onclick="showRef(event, 'cit7a'); return false;" href="javascript:void(0);" class="ref cit7a">(7a)</a> and Sharp,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> proving that PARP-1 genetic depletion is sufficient to induce death of BRCA2- and BRCA1-deficient tumor cell lines respectively, together with the feasibility of PARP-1 selective inhibitors (<b>1</b> and <b>2</b> (BYK204165), <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> which were, however, designed for different therapeutic applications and did not progress to clinical testing. </div><div class="NLM_p">Herein we describe the synthesis and SAR investigation of isoindolinone-4-carboxamide derivatives, leading to the discovery of 2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (NMS-P118, <b>20by</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). NMS-P118 is a potent (<i>K</i><sub>D</sub> = 0.009 μM) PARP-1 inhibitor, showing 150-fold selectivity over PARP-2 (<i>K</i><sub>D</sub> = 1.39 μM). NMS-P118 possesses excellent pharmacokinetic profile and nearly complete oral bioavailability both in mice and rats. It proved to be highly efficacious in vivo both as single agent in MDA-MB-436 human breast cancer tumors and in combination with Temozolomide in Capan-1 human pancreatic tumors growing as xenografts in the mouse. The compound is well tolerated at highly efficacious doses and is endowed with an excellent ADME profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of PARP inhibitors clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PARP-1 selective inhibitors (<b>1</b>, <b>2</b>), and NMS-P118 (<b>20by</b>) and isoindolinone-containing compounds (<b>3</b>–<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Two synthetic pathways were exploited to access the planned isoindolinone-4-carboxamide derivatives. The first one capitalizes on an intramolecular Diels–Alder reaction as the key step (<a class="ref internalNav" href="#sch1A" aria-label="Scheme 1A">Scheme 1A</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Thus, furfural was initially subjected to a reductive amination protocol in the presence of suitable amines (<b>6a</b>–<b>u</b>) by preforming the Schiff bases which were then reduced with sodium borohydride. The corresponding properly functionalized furanylmethylamines (<b>7a</b>–<b>u</b>) reacted with maleic anhydride in a two-step fashion by first delivering the transient maleic acid monoamide which then underwent an intramolecular Diels–Alder reaction. As anticipated,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> the process is highly stereoselective, with only the <i>exo</i>-isomer being detected in the reaction mixture. </div><div class="NLM_p">The <i>exo</i>-tricyclic adducts (<b>8a</b>–<b>u</b>) were then dehydrated by exposure to concentrated aqueous hydrochloric acid at reflux, followed by conversion of the resulting carboxylic acids (<b>9a</b>–<b>u</b>) into the desired primary amides using the ammonium salt of hydroxybenzotriazole in the presence of EDCI as the coupling agent (<b>10a</b>–<b>u</b>). Despite the lack of a common intermediate, the synthetic sequence depicted in <a class="ref internalNav" href="#sch1A" aria-label="Scheme 1A">Scheme 1A</a> is nonetheless straightforward because isoindolinones precursors (<b>7a</b>–<b>u</b>)–(<b>9a</b>–<b>u</b>) did not require any purification step. Further manipulation of the eastern portion of the isoindolinone core was achieved (<a class="ref internalNav" href="#sch1A" aria-label="Scheme 1B">Scheme 1B</a>) by elaboration of the piperidin-4-yl- moiety of <b>11</b><a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> after debenzylation of <b>10u</b>. Compound <b>11</b> was then subjected to either acylation with acyl chlorides in pyridine or reductive alkylation in different conditions according to the carbonyl- counterpart, affording compound <b>12a</b>–<b>c</b> or <b>13a–ag</b>, respectively. To further investigate SAR within this chemical class, a second synthetic route to access benzo-substituted isoindolinone-4-carboxamide analogues was pursued (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The key step of this alternative approach is the <i>ortho</i> iodination of properly functionalized 2-methylbenzoic acids (<b>14a</b>–<b>d</b>) through C–H activation, as described by Yu et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Intermediates <b>15a</b>–<b>d</b> were then transformed into the corresponding methyl esters <b>16a</b>–<b>d</b> before being subjected to a radical bromination at the benzylic position. Crude benzyl bromides underwent a one-pot nucleophilic displacement–ring closure sequence<a onclick="showRef(event, 'cit28c ref30 ref32'); return false;" href="javascript:void(0);" class="ref cit28c ref30 ref32">(28c, 30, 32)</a> in the presence of easily accessible<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> amines (<b>17x</b>–<b>y</b>), thus yielding iodo-isoindolinone intermediates <b>18</b>. A Rosenmund–von Braun protocol was subsequently applied to efficiently replace the iodine atom with a cyano group. Finally, the resulting isoindolinone-4-carbonitriles (<b>19</b>) were smoothly converted into the corresponding primary amides through a recently disclosed<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> indium(III) chloride-catalyzed transfer of water from acetaldoxime in refluxing toluene, producing compounds <b>20bx</b> and <b>20</b>(<b>a–d</b>)<b>y</b>.</div><figure id="sch1A" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0011.jpeg" id="GRAPHIC-d2220e812-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A) Isoindolinones Synthesis via Intramolecular Diels–Alder Reaction;<sup>a</sup> (B) Elaboration of the piperidin-4-yl- moiety of intermediate <b>11</b><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=sch1A"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Conditions: (a) RNH<sub>2</sub> (<b>6</b>), dioxane or toluene (Dean–Stark), reflux then NaBH<sub>4</sub>, ethanol, rt; (b) maleic anhydride, THF, rt or toluene, reflux; (c) concentrated aqueous hydrochloric acid, reflux; (d) HOBt·NH<sub>3</sub>, EDCI·HCl, DIEA, DMF, rt.</p><p class="last"><span class="fn-label">Scheme b</span>Conditions: (a) 10% palladium on carbon, acetic acid, 50 psi, rt; (b) RCOCl, pyridine, 60 °C; (c) aldehyde or ketone, CH<sub>3</sub>COONa, NaBCNH<sub>3</sub> or NaB(OAc)<sub>3</sub>H, dichloromethane/methanol, rt.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0012.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzo-substituted Isoindolinone Derivatives <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) iodobenzene diacetate, I<sub>2</sub>, Pd(OAc)<sub>2</sub>, DMF, 100 °C; (b) methyl <i>p</i>-toluenesulfonate, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) <i>N</i>-bromosuccinimide, benzoyl peroxide, methyl pivalate, 85 °C, then <b>17x</b>–<b>y</b>, triethylamine, acetonitrile, 90 °C; (d) CuCN, DMF, 110 °C; (e) acetaldoxime, InCl<sub>3</sub>, toluene, reflux.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">By using our recently reported PARP-1 full length (FL) fluorescence polarization displacement assay,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> a high throughput screening (HTS) campaign was conducted on the NMS proprietary chemical collection. Two isoindolinone-4-carboxamide derivatives (<b>10a</b> and <b>10b</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) emerged from this screening, possessing good biochemical activity on PARP-1 (each showing <i>K</i><sub>D</sub> = 0.09 μM). The isoindolinone core is a known privileged scaffold for PARP inhibition,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> either as a feature embedded within a tetracyclic structure (<b>3</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> or also, after appropriate linkage to adenosine, in NAD<sup>+</sup>-resembling compounds such as EB-47 (<b>4</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Such inhibitors rely on the isoindolinone lactam moiety as a nicotinamide mimic. Subsequently, Abbott disclosed a series of 2-substituted isoindolinone-4-carboxamide derivatives (e.g., <b>5</b>, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> in which the carbonyl oxygen atom of the scaffold freezes the primary amide into its biologically active conformation through an intramolecular hydrogen bond, according to the alternative PARP-1 pharmacophore discussed above. All these compounds proved to be potent dual PARP-1/-2 inhibitors.<a onclick="showRef(event, 'ref21 ref30'); return false;" href="javascript:void(0);" class="ref ref21 ref30">(21, 30)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Isoindolinones Preliminary SAR Investigation</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0014.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0015.gif" alt="" id="GRAPHIC-d2220e957-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><i>K</i><sub>D</sub> and IC<sub>50</sub> values are reported as the mean of 2–3 experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Fluorescence polarization displacement assay sensitivity limit (see ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>).</p></div></div><div></div></div><div class="NLM_p">The two low molecular weight compounds which emerged from our HTS campaign are highly efficient ligands<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> of PARP-1 (<b>10a</b>: MW = 218 Da, binding efficiency index (BEI) = 32.3, ligand efficiency (LE) = 0.6; <b>10b</b>: MW = 248 Da, BEI = 28.4, LE = 0.54). Both compounds exhibited the desired mechanism of action in HeLa cells, i.e., both were able to inhibit PARP-1 dependent PAR synthesis in cells at micromolar concentrations following H<sub>2</sub>O<sub>2</sub>-induced DNA damage (PAR assay, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, a fluorescence polarization displacement assay<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> using PARP-2 showed that both <b>10a</b> and <b>10b</b> also significantly bind this isoform (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Despite the moderate cellular activity and the lack of selectivity, the high intrinsic potency of these two hits deserved further investigation. The X-ray cocrystal structures of <b>10b</b> in complex with both human PARP-1 (hPARP-1, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A) and human PARP-2 (hPARP-2, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B) catalytic domains were solved in order to gain insight into the corresponding binding modes. As anticipated,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> the pseudo seven-membered ring, arising from a γ-turn-like intramolecular hydrogen bond, locked the isoindolinone-4-carboxamide core into the <i>anti</i> conformation. This intramolecular interaction minimizes negative entropic contribution to the binding energy balance and allows <b>10b</b> to establish the usual network of hydrogen bonds within the proteins’ catalytic domains (i.e., with Gly863 and Ser904 in hPARP-1 and with Gly429 and Ser470 in hPARP-2) and π-stacking (with Tyr907 in hPARP-1 and Tyr473 in hPARP-2) of a prototypical nicotinamide-mimic inhibitor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> To corroborate the presence of an intramolecular hydrogen bond not only in the crystal form, but also in solution, <sup>1</sup>H NMR spectra of <b>10b</b> in solvents with different polarity were recorded (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The chemical shift difference (Δδ = 3.08 ppm) between the downfield intramolecularly bonded amide proton and the upfield nonbonded one observed in a polar solvent such as DMSO-<i>d</i><sub>6</sub> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A) is fully consistent with this kind of interaction.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> As expected, this difference was further exacerbated (Δδ = 5.44 ppm) in a nonpolar solvent such as CDCl<sub>3</sub> (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). These data were further consolidated by a quantitative assessment<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> of the intramolecular hydrogen bond strength (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">Supporting Information (SI)</a> for details). A closer inspection of the X-ray cocrystal structures of compound <b>10b</b> revealed that the methoxypropyl- side chain did not actively participate in binding of the inhibitor either to PARP-1 or to PARP-2, thus affording the possible opportunity of increasing PARP-1 potency by tailoring the substituent onto the lactam nitrogen atom. To this purpose, an overlay of cocrystal structures of <b>10b</b> and the selective quinazolinone inhibitor <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UK0">1UK0</a>) within hPARP-1 catalytic domain was analyzed (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). This exercise clearly ruled out the possibility to achieve selectivity against PARP-2 by engaging contacts within the adenine-ribose (AD) binding site,<a onclick="showRef(event, 'cit26a'); return false;" href="javascript:void(0);" class="ref cit26a">(26a)</a> as the substituents departing from <b>10b</b> and <b>1</b> point at different portions of the protein (see gray arrows in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Nevertheless, compounds dramatically different in shape such as BYK204165 (<b>2</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> indicated that selectivity against PARP-2 might be achieved by targeting regions of the PARP-1 catalytic domain other than the AD site. Thus, a systematic exploration of this chemical class was undertaken alongside determination of compound selection criteria, based on biochemical potency (PARP-1 <i>K</i><sub>D</sub> ≤ 0.1 μM<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a>) and selectivity (PARP-2 <i>K</i><sub>D</sub>/PARP-1 <i>K</i><sub>D</sub> ratio of about 100<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a>) thresholds. Inhibitors endowed with these features would then be tested to quantify their ability to suppress H<sub>2</sub>O<sub>2</sub>-induced PAR synthesis in HeLa cells, which is exclusively PARP-1 dependent (PAR assay, see above). Derivatives possessing IC<sub>50</sub> ≤ 0.1 μM in this cellular assay would be considered eligible for preclinical profiling. Good oral bioavailability of the selected compounds was considered mandatory for further development. </div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of <b>10b</b> with hPARP-1 (A) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>) and hPARP-2 (B) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX">4ZZX</a>) catalytic domain at 1.9 and 1.7 Å resolution, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Downfield portion of <sup>1</sup>H NMR spectra of a 3 mM solution of <b>10b</b> in DMSO-<i>d</i><sub>6</sub> (top) and CDCl<sub>3</sub> (bottom) showing the Δδ of the two amide protons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>10b</b> (green carbon atoms PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>) and quinazolinone <b>1</b> (light-blue carbon atoms, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UK0">1UK0</a>) in the hPARP-1 binding site. Gray arrows indicate the direction of substituents departing from the nicotinamide-mimic scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">After having established these cutoff criteria, HTS hits <b>10a</b> and <b>10b</b> were employed as a footprint to design a first array of isoindolinones. This set of compounds was assembled by varying: (a) the length of the aliphatic spacer connecting the nitrogen atom of the bicyclic core to the terminal eastern substituent and (b) the nature of the eastern substituent itself. Results are reported in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Thus, within the alkoxy-substituted series, shortening the spacer proved to be detrimental in terms of biochemical potency, regardless of whether the alkoxy group was linear or whether the oxygen atom was embedded in a cycle (compare <b>10c</b> and (±)-<b>10d</b> with <b>10b</b>). On the contrary, a hydroxyethyl substituent (<b>10e</b>) restored potency but did not possess PARP-1 vs PARP-2 selectivity. The biochemical activity of phenyl-substituted derivatives increased 1 order of magnitude upon going from benzyl (<b>10f</b>) to 2-phenylethyl (<b>10g</b>), with the latter being unacceptably potent also against PARP-2. A further elongation of the spacer (<b>10h</b>) impacted neither potency nor selectivity. By replacing the phenyl ring present in <b>10g</b> with a pyridin-2-yl moiety (<b>10i</b>), an increase in potency, mainly against PARP-2, was observed, with a <i>K</i><sub>D</sub> on both isoforms below the assay sensitivity limit.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> By capitalizing on this result, we then investigated a series of isoindolinones encompassing differently substituted tertiary aliphatic amines located at a variable distance from the scaffold. Both the morpholin-4-yl-ethyl- (<b>10j</b>) and the 1-piperidin-1-yl-ethyl- (<b>10l</b>) derivatives showed a lower potency against PARP-1 than the corresponding higher homologues (<b>10k</b> and <b>10m</b>). Furthermore, compounds <b>10k</b> and <b>10m</b> showed, respectively, 160-fold and >110-fold selectivity toward PARP-1 over PARP-2 and were thus also profiled in the cellular PAR assay. While isoindolinone <b>10k</b> showed no significant inhibition of PAR synthesis in cells, the IC<sub>50</sub> value of <b>10m</b>, although modest, prompted us to further decorate the piperidinyl moiety in an effort to obtain more potent derivatives. The introduction of a 2,6-dimethyl substitution (<i>cis</i>-<b>10n</b>), as well as an additional piperidinyl ring (<b>10o</b>), resulted in a dramatic drop of activity. On the contrary, a lipophilic substituent such as a benzyl group in the 4 position of the piperidinyl ring (<b>10p</b>) restored the biochemical potency on both enzymes. The tetrahydroisoquinolin-2-yl-ethyl derivative (<b>10r</b>) proved to be more potent against PARP-1 and more selective toward PARP-2 then the corresponding isomeric tetrahydroquinolin-2-yl-ethyl substituted isoindolinone (<b>10q</b>). Unfortunately, <b>10r</b> showed negligible activity in the cellular PAR assay. A further investigation was then conducted by moving the linker connecting the isoindolinone core to the piperidinyl ring from the 1 to the 4 position of the latter. The resulting derivatives were garnished with a lipophilic substituent onto the piperidinyl nitrogen atom, affording compounds <b>10s</b> and <b>10t</b>. While derivative <b>10s</b> strongly inhibited PARP-1 but its selectivity toward PARP-2 was below our arbitrary threshold, the corresponding regioisomer <b>10t</b> showed high biochemical potency on the target, excellent selectivity, and cellular activity. </div><div class="NLM_p">Compound <b>10t</b> was then subjected to in vitro ADME profiling and pharmacokinetic analysis in mice (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Disappointingly, despite the excellent solubility and good permeability, <b>10t</b> showed high clearance in vivo (230 mL/min/kg) and negligible (<1%) oral bioavailability, thus preventing any further development. The preliminary SAR information emerged from this first cohort of isoindolinones underlines that a three- to four-carbon unit spacer between the bicyclic core and a basic center generally delivers the most potent and selective PARP-1 inhibitors. This observation prompted us to investigate the modulation of the potency and selectivity by embedding the spacer into a piperidine ring, whose nitrogen was initially decorated with a benzyl group (<b>10u</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). This lipophilic moiety was carefully chosen either because of its impact on the inhibitory activity within the series (see <b>10p</b>, <b>10s</b>, and <b>10t</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) or because it can be easily replaced by standard chemistry (<a class="ref internalNav" href="#sch1A" aria-label="Scheme 1B">Scheme 1B</a>). Compound <b>10u</b> proved to be quite potent against PARP-1 and exceedingly selective. However, its ability in inhibiting the PARylation in cells was trifling (IC<sub>50</sub> = 2 μM). A second array of piperidin-4-yl substituted isoindolinones was then synthesized in order both to implement the biochemical and cellular activity and the pharmacokinetic profile of the inhibitor. Results are reported in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. The mandatory requirement of a basic nitrogen atom within this subseries was corroborated by the modest biochemical potency against PARP-1 of amide derivatives such as <b>12a</b>–<b>c</b>. Linear or branched alkyl substituted piperidine (<b>13a</b>–<b>e</b>) delivered potent unselective compounds with flat SAR, while the presence of an oxygen atom within the aliphatic chain (<b>13f</b>) depressed the ability in inhibiting the target. More SAR information was gathered by playing around the initially selected benzyl substituent (<b>10u</b>). Thus, the introduction of a simple (electron donating) methyl substituent in the <i>ortho</i>, <i>meta</i>, and <i>para</i> position of the phenyl ring, respectively, afforded both biochemically potent and selective compounds (<b>13g</b>–<b>i</b>) whose enzymatic activity (<b>13i</b> = <b>13h</b> > <b>13g</b>) did not stringently mirror the cellular one (<b>13i</b> > <b>13g</b> > <b>13h</b>). Moderately deactivating groups such as bromine (<b>13j</b>–<b>l</b>) again confirmed the positive impact of a para substitution (<b>13l</b>) on both biochemical potency and selectivity, however, with no significant activity in cells. Strong electron withdrawing (<b>13m</b>–<b>o</b>) or donating (<b>13p</b>) groups generally worsened the inhibitor profile by delivering poorly active (<b>13m</b>), poorly selective (<b>13o</b>), or compounds lacking cellular activity (<b>13n</b> and <b>13p</b>). The replacement of the phenyl ring with a pyridine (<b>13q</b>–<b>s</b>) produced potent and selective compounds and, in the case of the pyridin-2-ylmethyl derivative (<b>13s</b>), also with good (despite still suboptimal) cellular activity. Biochemically potent PARP-1 inhibitors also emerged by replacing the phenyl ring with a five-membered heterocycle such as thiophene (<b>13t</b>–<b>u</b>), furan (<b>13v</b>–<b>z</b>), and pyrrole (<b>13aa</b>–<b>ab</b>). However, the pair of compounds (<b>13u</b> and <b>13ab</b>) which proved also to be selective against PARP-2 according to our screening criteria delivered disappointing results in PAR assay. Indole regioisomers (<b>13ac</b>–<b>ad</b>) behaved quite differently. While <b>13ac</b> was not selective enough for further profiling, the potent and selective 5-substituted regioisomer (<b>13ad</b>) displayed an excellent cellular activity. Finally, few isoindolinones decorated with nonaromatic rings directly linked to the piperidine moiety (<b>13ae</b>–<b>ag</b>) were investigated. Despite being both potent and exceedingly selective, the 4,4-difluorocyclohexyl<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> substituted isoindolinone (<b>13af</b>) proved to be four times more active in cellular assay then the corresponding tetrahydro-2<i>H</i>-pyran-4-yl derivative (<b>13ae</b>). On the contrary, 1,3-dioxolane-containing compound <b>13ag</b> showed only modest inhibitory activity against PARP-1. Having identified three compounds (<b>13i</b>, <b>13ad</b>, and <b>13af</b>) possessing the suitable biochemical potency, selectivity, and cellular activity, they were further profiled by analyzing their in vitro ADME and pharmacokinetic properties. Whereas permeability, plasma protein binding, and HLM clearance data were, on average, quite similar between the compounds, isoindolinone <b>13af</b> showed a definitely higher solubility (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The PK profiles in mouse allowed selecting <b>13af</b> as the lead compound of this isoindolinones subset (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). In fact, while <b>13i</b> was demonstrated to possess low oral bioavailability (15%), and <b>13ad</b>, despite being orally available (80%), is rapidly cleared from the body (110 mL/min/kg), <b>13af</b> proved to be suitable for oral administration (80%) with high exposure (21 μM·h) and low clearance (17 mL/min/kg). With the proper arrangement of the right end portion of the inhibitor in hand, a final medicinal chemistry refinement was undertaken in the attempt to further improve <b>13af</b> cellular activity. The potency of <b>13af</b> in PAR assay was indeed suboptimal (IC<sub>50</sub> = 0.15 μM). The planned optimization was focused on the preparation of a handful of compounds bearing small substituents on the phenyl ring of the isoindolinone bicyclic core, as the features of the back wall of PARP-1 hosting the nicotinamide moiety prevents the introduction of large groups.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The biochemical and cellular activities of this set of inhibitors are reported in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro ADME Parameters and PK Data of Compound <b>10t</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">PK parameters</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ADME parameters</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">10 mg/kg<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> IV administration</th><th class="colsep0 rowsep0" align="center">10 mg/kg<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a> Oral administration</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility pH 7 (μM)</td><td class="colsep0 rowsep0" align="left"> >225</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.4</td><td class="colsep0 rowsep0" align="left">0.03 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability PAMPA <i>P</i><sub>app</sub> [10<sup>–6</sup> cm/s] (% in membrane)</td><td class="colsep0 rowsep0" align="left">50.0 (20.8)</td><td class="colsep0 rowsep0" align="left">AUC<sub>∞</sub> (μM·h)</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.2</td><td class="colsep0 rowsep0" align="left">0.02 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> (%)</td><td class="colsep0 rowsep0" align="left">98</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="char" char="±">230.0 ± 27.5</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">intrinsic CL (mL/min/kg) HLM<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.0</td><td class="colsep0 rowsep0" align="left">nm<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i><a class="ref internalNav" href="#t2fn6" aria-label="f">f</a> (%)</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="left"> <1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Harlan Nu/Nu mice; <i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Dosed iv (intravenous administration), in situ prepared <b>10t</b> hydrochloride in 5% dextrose; dosed per os (oral administration), 0.5% methocel.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Human liver microsomes.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">nm: not measurable.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Bioavailability.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Piperidin-4-yl Substituted Isoindolinones SAR Investigation<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0016.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0017.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0018.gif" alt="" id="GRAPHIC-d2220e1750-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0019.gif" alt="" id="GRAPHIC-d2220e1751-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Intermediate <b>11</b> (<a class="ref internalNav" href="#sch1A" aria-label="Scheme 1B">Scheme 1B</a>) was not tested as already reported not to be selective against PARP-2 (see ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a> for details).</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last"><i>K</i><sub>D</sub> and IC<sub>50</sub> values are reported as the mean of 2–3 experiments.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Fluorescence polarization displacement assay sensitivity limit (see ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>).</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro ADME Parameters of Selected Piperidin-4-yl Substituted Isoindolinones</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">solubility pH 7 (μM)</th><th class="colsep0 rowsep0" align="center" char=".">permeability PAMPA <i>P</i><sub>app</sub> [10<sup>–6</sup> cm/s] (% in membrane)</th><th class="colsep0 rowsep0" align="center" char=".">PPB<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg) HLM<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13i</b></td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">50.0 (31.0)</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ad</b></td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="char" char=".">41.8 (36.1)</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="char" char="."> > 225</td><td class="colsep0 rowsep0" align="char" char=".">28.8 (9.6)</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="char" char=".">7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Human liver microsomes.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Data of Selected Piperidin-4-yl Substituted Isoindolinones</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">PK data<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> iv</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">PK data<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> per os</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">dose<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>∞</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center" char="±">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char=".">dose<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±">AUC<sub>∞</sub> (μM·h)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13i</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">8.2 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">57.8 ± 13.0</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.2</td><td class="colsep0 rowsep0" align="center">nm<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13ad</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">110.0 ± 40.8</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">0.7 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">1.0 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">3.7 ± 0.4</td><td class="colsep0 rowsep0" align="center">1.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">26.3 ± 4.0</td><td class="colsep0 rowsep0" align="char" char="±">17.1 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">3.4 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">21.0 ± 3.1</td><td class="colsep0 rowsep0" align="center">2.9 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Harlan Nu/Nu mice; <i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Dosed iv (intravenous administration): 5% Tween 80 in 5% dextrose for <b>13i</b>, PEG 400 in 5% dextrose for <b>13ad</b>, and 10% Tween 80 in 5% dextrose for <b>13af</b>.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Dosed per os (oral administration): 0.5% methocel.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Bioavailability.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last">nm: not measurable.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. SAR Investigation of Phenyl Substituted Isoindolinones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0020.gif" alt="" id="GRAPHIC-d2220e2147-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R1</th><th class="colsep0 rowsep0" align="center" char=".">PARP-1 <i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">PARP-2 <i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">PARP-2 <i>K</i><sub>D</sub>/ PARP-1 <i>K</i><sub>D</sub><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></th><th class="colsep0 rowsep0" align="center" char=".">PAR IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="."> <0.030<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">3.937</td><td class="colsep0 rowsep0" align="char" char="."> >131</td><td class="colsep0 rowsep0" align="char" char=".">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20ay</b></td><td class="colsep0 rowsep0" align="left">5-F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">1.880</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td><td class="colsep0 rowsep0" align="char" char=".">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20by</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="."> <0.030</td><td class="colsep0 rowsep0" align="char" char=".">2.500</td><td class="colsep0 rowsep0" align="char" char="."> >83</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20cy</b></td><td class="colsep0 rowsep0" align="left">7-F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.080</td><td class="colsep0 rowsep0" align="char" char="."> >10</td><td class="colsep0 rowsep0" align="char" char="."> >125</td><td class="colsep0 rowsep0" align="char" char=".">1.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20dy</b></td><td class="colsep0 rowsep0" align="left">6-Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="."> <0.030</td><td class="colsep0 rowsep0" align="char" char="."> >10</td><td class="colsep0 rowsep0" align="char" char="."> >333</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20bx</b></td><td class="colsep0 rowsep0" align="left">6-F</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="char" char="."> <0.030</td><td class="colsep0 rowsep0" align="char" char="."> >10</td><td class="colsep0 rowsep0" align="char" char="."> >333</td><td class="colsep0 rowsep0" align="char" char=".">0.09</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last"><i>K</i><sub>D</sub> and IC<sub>50</sub> values are reported as the mean of 2–3 experiments.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Fluorescence polarization displacement assay sensitivity limit (see ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>).</p></div></div></div><div class="NLM_p">As none of the substituents introduced in the different positions of the aromatic ring are expected to deliver any steric clash within the catalytic site of the protein, SAR rationalization has to be found in the substituents’ aptitude in modulating the stereoelectronic properties of the inhibitors. Thus, the tremendous drop in biochemical activity of <b>20ay</b> against PARP-1 was attributed to the loosening of the intramolecular hydrogen bond between the primary amide and the carbonyl oxygen by the fluorine atom in position 5. This effect can be appreciated by observing the small chemical shift differences between the two amide protons in the <sup>1</sup>H NMR spectra of <b>20ay</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 1</a>),<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37, 38)</a> and is reasonably due to electron pair repulsion leading to conformational destabilization where the fluorine atom and the carbonyl are coplanar. A reduction in the intramolecular hydrogen bond strength, again measured as a decrease in the Δδ chemical shift between the two amide protons, might also account for the lower inhibitory activity displayed by the 7-fluoro isoindolinone <b>20cy</b> compared to <b>13af</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 1</a>). On the other hand, in order to rationalize the high biochemical potency observed for both the 6-fluoro <b>20by</b> and the corresponding 6-chloro derivative <b>20dy</b>, additional interactions within the PARP-1 protein binding site were presumed (and later demonstrated, see below) to counterbalance the substituent’s negative impact on hydrogen bond strength (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 1</a>). Because <b>20by</b> was the most potent compound in PAR assay (IC<sub>50</sub> = 0.04 μM), the replacement of fluorine with chlorine atoms onto the cyclohexyl moiety<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> was then investigated by synthesizing compound <b>20bx</b> (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Isoindolinone <b>20bx</b> proved to be biochemically potent, selective against PARP-2 (as were all tested examples belonging to this subseries), and displayed an excellent activity in cells, thus demonstrating the importance of a properly 4-substituted cyclohexyl moiety to deliver PARP-1 inhibitors effective at a cellular level. To gain a deeper insight into <b>20by</b> selectivity profile, the compound was tested against PARP-3 FL (aka ARTD-3; <i>K</i><sub>D</sub> = 0.69 μM),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> TNKS-1 catalytic domain (aka PARP-5a, ARTD-5; <i>K</i><sub>D</sub> > 10 μM),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and sirtuin 1 (SIRT1; IC<sub>50</sub> > 10 μM). Because clinical PARP inhibitors, such as rucaparib and veliparib, show micromolar inhibitory activity also on some kinases,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> compound <b>20by</b> was also tested on a panel of 56 different kinases to assess its selectivity (IC<sub>50</sub> > 10 μM; see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details). Furthermore, to confirm the fluorescence polarization displacement assay data, <b>20by</b>, along with <b>13af</b> and the (unselective) <b>13c</b>, were also tested against PARP-1 and PARP-2 catalytic domain by surface plasmon resonance (SPR), an independent binding assay.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> For comparative purposes, also the clinical candidates olaparib and veliparib (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) were tested in this assay.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> SPR results are reported in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>. While <b>13c</b>, as expected (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), showed similar potency against both isoforms, isoindolinone <b>13af</b> exhibits a PARP-1 <i>K</i><sub>D</sub> = 0.016 μM and has approximately 75-fold less affinity for PARP-2. Finally, compound <b>20by</b> proved to be a single-digit nanomolar PARP-1 inhibitor (<i>K</i><sub>D</sub> = 0.009 μM), with exquisite selectivity versus PARP-2 (<i>K</i><sub>D</sub> = 1.39 μM). Detailed kinetic parameters (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 2</a>) and kinetic analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Figure 1</a>) of this assay can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">Supporting Information</a>. The approximately 30% decrease in mere efficiency of binding (MW = 395 Da, BEI = 20.4, LE = 0.39), compared to the initial hits’ efficiency (vide supra), underscores the fact that late stage optimization of <b>20by</b> favored modifications contributing to the overall developability and bioactivity not just focusing on molecular binding interactions alone.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <sup>1</sup>H NMR Chemical Shifts Difference between Amide Protons of Selected Isoindolinones<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">Δδ (ppm)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="char" char=".">3.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20ay</b></td><td class="colsep0 rowsep0" align="char" char=".">0.24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20by</b></td><td class="colsep0 rowsep0" align="char" char=".">2.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20cy</b></td><td class="colsep0 rowsep0" align="char" char=".">2.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20dy</b></td><td class="colsep0 rowsep0" align="char" char=".">2.82</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last"><sup>1</sup>H NMR spectra were recorded in DMSO-<i>d</i><sub>6</sub> at 25 °C and 3 mM concentration.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>K</i><sub>D</sub> Values and Dissociation Equilibrium Constants for PARP-1 and PARP-2 Catalytic Domain Determined with Biacore T-100</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">PARP-1 CD<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">PARP-2 CD<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>D</sub> (μM)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (min)<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">olaparib</td><td class="colsep0 rowsep0" align="char" char="±">0.00024 ± 0.00012</td><td class="colsep0 rowsep0" align="char" char="±">51.12 ± 1.10</td><td class="colsep0 rowsep0" align="char" char="±">0.00028 ± 0.00013</td><td class="colsep0 rowsep0" align="char" char="±">17.40 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">veliparib</td><td class="colsep0 rowsep0" align="char" char="±">0.0017 ± 0.0003</td><td class="colsep0 rowsep0" align="char" char="±">1.53 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.0058 ± 0.0004</td><td class="colsep0 rowsep0" align="char" char="±">1.10 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0157 ± 0.0005</td><td class="colsep0 rowsep0" align="char" char="±">1.68 ± 0.028</td><td class="colsep0 rowsep0" align="char" char="±">1.219 ± 0.305</td><td class="colsep0 rowsep0" align="char" char="±">0.07 ± 0.0006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.075 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.06</td><td class="colsep0 rowsep0" align="char" char="±">0.118 ± 0.031</td><td class="colsep0 rowsep0" align="char" char="±">0.2 ± 0.068</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20by</b></td><td class="colsep0 rowsep0" align="char" char="±">0.0086 ± 0.0011</td><td class="colsep0 rowsep0" align="char" char="±">3.27 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">1.389 ± 0.383</td><td class="colsep0 rowsep0" align="char" char="±">0.08 ± 0.0008</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">CD: catalytic domain.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Reported values are the average and standard deviation of three independent experiments.</p></div></div></div><div class="NLM_p">Compound <b>20by</b> was tested along with <b>13af</b> for the ability to inhibit proliferation of MDA-MB-436, a triple negative (HER2/ER/PR – ve) breast cancer cell line carrying BRCA1 gene mutation. The isoindolinone <b>20by</b> resulted as being about 4 times more potent compared to <b>13af</b>, with IC<sub>50</sub> of 0.14 and 0.6 μM, respectively, reflecting the higher target inhibition in PAR assay. Cellular models such as MCF-7 and MIA-PaCa-2 that do not have BRCA mutations or HR defects were resistant to both compounds with IC<sub>50</sub>s > 10 μM (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>). By aiming at rationalizing the high selectivity against PARP-2 showed by <b>20by</b>, its X-ray cocrystal structures within the catalytic domains of hPARP-1 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A) and hPARP-2 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B) were solved. As expected, the contacts established by the isoindolinone-4-carboxamide core of <b>20by</b> mirrored those of <b>10b</b> (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A,B). Additionally, the fluorine atom at position 6 fills a small cavity present in the binding sites of both proteins (defined by Phe897, Ala898, Lys903, and Glu988 residues in PARP-1 and by Phe463, Ala464, Lys469, and Glu558 residues in PARP-2) and interacts with the backbone carbonyl of Phe897 in PARP-1 and Phe463 in PARP-2. The (4,4-difluorocyclohexyl)piperidinyl- moiety points toward the donor loop and the α-helical bundle domain, thus allowing the 4,4-difluorocyclohexyl ring to fill an induced pocket, to trigger the rearrangement of α-helix 5 and to establish favorable hydrophobic interactions with a tyrosine residue of the donor loop (Tyr889 in PARP-1 and Tyr455 in PARP-2). The slightly dissimilar orientation of α-helix 5 in the two proteins, together with the presence of different residues (Gln759 and Val762 in PARP-1 and Ile328 and Ser331 in PARP-2), may account for the selectivity observed, as the induced pocket is larger in PARP-1 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A) than in PARP-2 (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>B). As a result, the 4,4-difluorocyclohexyl substituent is better accommodated in PARP-1. The observation that α helix 5 is intrinsically closer to the active site in PARP-2 than in PARP-1<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> further supports the hypothesis that the aforementioned rearrangement is energetically less favorable in PARP-2. To better characterize <b>20by</b>, experiments of cross species metabolic stability in liver hepatocytes (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 3</a>), cytochrome P450 inhibition (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 4</a>), and in vitro myelotoxicity across species (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">SI Table 5</a>), the latter in comparison with olaparib (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), were performed. Compound <b>20by</b> proved to be metabolically stable, it modestly inhibited two cytochrome P450 family members (CYP-2B6 IC<sub>50</sub>, 8.15 μM; CYP-2D6 IC<sub>50</sub>, 9.51 μM) out of eight isoforms tested. Its ability in hampering the proliferation of bone marrow cells was from 5 to >60 times lower than olaparib according to the species.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structures of <b>20by</b> with hPARP-1 (A) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>) and hPARP-2 (B) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>) catalytic domain at 2.7 and 2.2 Å resolution, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Antiproliferative Activity on Tumor Cell Lines<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd no.</th><th class="colsep0 rowsep0" align="center" char=".">MDA-MB-436 (BRCA1 deficient)</th><th class="colsep0 rowsep0" align="center" char=".">MCF-7</th><th class="colsep0 rowsep0" align="center" char=".">MIA-PaCa-2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20by</b></td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char="."> >10</td><td class="colsep0 rowsep0" align="char" char="."> >10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13af</b></td><td class="colsep0 rowsep0" align="char" char=".">0.60</td><td class="colsep0 rowsep0" align="char" char="."> >10</td><td class="colsep0 rowsep0" align="char" char="."> >10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Cells were exposed to different doses of the indicated compounds for 10–14 days, after which colonies were counted and IC<sub>50</sub> values were calculated.</p></div></div></div><div class="NLM_p">Overall, compound <b>20by</b> appeared the most promising and was further progressed by evaluating its ADME and pharmacokinetic parameters in mouse, which proved to be excellent (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>). The compound showed high solubility and permeability, low in vitro and in vivo clearance, and complete oral bioavailability. The pharmacokinetic profile of <b>20by</b> in rat dosed iv at 10 mg/kg and orally at 10 and 100 mg/kg (<a class="ref internalNav" href="#tbl10" aria-label="Table 10">Table 10</a>), mirrored that observed in the mouse, with oral bioavailability >65%, and linearity of exposure with dose.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. In Vitro ADME Parameters and PK Data of Compound <b>20by</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">PK parameters</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">mouse<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">rat<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ADME parameters</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">iv<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a> 10 mg/kg</th><th class="colsep0 rowsep0" align="center" char="±">oral<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a> 10 mg/kg</th><th class="colsep0 rowsep0" align="center" char="±">iv<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a> 10 mg/kg</th><th class="colsep0 rowsep0" align="center">oral<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a> 10 mg/kg</th><th class="colsep0 rowsep0" align="center">oral<a class="ref internalNav" href="#t10fn4" aria-label="d">d</a> 100 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility pH 7 (μM)</td><td class="colsep0 rowsep0" align="left">194</td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (μM)</td><td class="colsep0 rowsep0" align="center">5.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 0.7</td><td class="colsep0 rowsep0" align="center">2.8 ± 0.3</td><td class="colsep0 rowsep0" align="center">17.7 ± 1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">permeability PAMPA <i>P</i><sub>app</sub>  [10<sup>–6</sup>cm/s] (% in membrane)</td><td class="colsep0 rowsep0" align="left">29.1 (10.0)</td><td class="colsep0 rowsep0" align="left">AUC∞ (μM·h)</td><td class="colsep0 rowsep0" align="center">20.7 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">19.7 ± 5.2</td><td class="colsep0 rowsep0" align="char" char="±">40.0 ± 8.0</td><td class="colsep0 rowsep0" align="center">34 ± 2.9</td><td class="colsep0 rowsep0" align="center">251.0 ± 30.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB<a class="ref internalNav" href="#t10fn5" aria-label="e">e</a> (%)</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="center">19.3 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">10.8 ± 2.4</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg) HLM<a class="ref internalNav" href="#t10fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="center">3.9 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.6</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg) rat hepatocytes</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">3.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 1.2</td><td class="colsep0 rowsep0" align="center">3.9 ± 0.1</td><td class="colsep0 rowsep0" align="center">nm<a class="ref internalNav" href="#t10fn7" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i><a class="ref internalNav" href="#t10fn8" aria-label="h">h</a> (%)</td><td class="colsep0 rowsep0" align="center">95</td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">87</td><td class="colsep0 rowsep0" align="center">65</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup>a</sup><p class="last">Harlan Nu/Nu mice; <i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t10fn2"><sup>b</sup><p class="last">Sprague–Dawley rat; <i>n</i> = 3 animals per study.</p></div><div class="footnote" id="t10fn3"><sup>c</sup><p class="last">Dosed iv (intravenous administration), 10% Tween 80 in 5% dextrose; dosed per os (oral administration), 0.5% methocel.</p></div><div class="footnote" id="t10fn4"><sup>d</sup><p class="last">Dosed iv (intravenous administration), 20% DMSO + 40% PEG 400 in 5% dextrose; dosed per os (oral administration), 0.5% methocel.</p></div><div class="footnote" id="t10fn5"><sup>e</sup><p class="last">Plasma protein binding.</p></div><div class="footnote" id="t10fn6"><sup>f</sup><p class="last">Human liver microsomes.</p></div><div class="footnote" id="t10fn7"><sup>g</sup><p class="last">nm: not measurable.</p></div><div class="footnote" id="t10fn8"><sup>h</sup><p class="last">Bioavailability.</p></div></div></div><div class="NLM_p">To assess the in vivo antitumor activity of compound <b>20by</b> when used as single agent, we treated nude mice bearing established subcutaneous MDA-MB-436 tumor xenografts (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Oral administration of compound <b>20by</b> for 28 days (once a day dose of 150 mg/kg) as a methocel suspension significantly inhibited tumor growth, inducing complete response (tumor impalpable) in all treated mice with no signs of toxicity or body weight loss. Six out of seven mice were still tumor free one month after the end of treatment.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antitumor efficacy of <b>20by</b> in BRCA mutated breast cancer model in mice. Mice carrying subcutaneous MDA-MB-436 human breast carcinoma were treated with either vehicle or <b>20by</b> orally administered. Mice were treated once a day for 28 days starting from day 20. Data are represented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We also examined the effect of combining <b>20by</b> with Temozolomide in vivo. Tumor growth of subcutaneously implanted Capan-1 pancreatic xenografts was significantly inhibited when animals were treated by oral administration of 100 mg/kg <b>20by</b> in combination with 50 mg/kg of Temozolomide. Even in the absence of significant antitumor activity for the two compounds given as single agent, <b>20by</b> strongly potentiated Temozolomide, resulting in complete tumor regressions in 3 out of 6 animals (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). Only a slight increase in body weight loss was observed compared to the group treated with Temozolomide alone.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor efficacy of <b>20by</b> in combination with Temozolomide. <b>20by</b> was administered to male athymic nu/nu mice carrying subcutaneously Capan-1 pancreatic cancer, orally once daily for 12 days at the dose of 100 mg/kg, starting on day 9. Temozolomide (TMZ) was administered at a dosage of 50 mg/kg for 5 days starting from day 11. Data are represented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To assess the in vivo pharmacodynamics of <b>20by</b>, Capan-1 xenograft-bearing mice received a single oral administration of 100 mg/kg of compound. Tumors were harvested at 1, 2, 6, and 24 h after treatment, and intratumor PAR levels were determined by ELISA. <b>20by</b> treatment dramatically decreased intratumoral PAR levels at 1, 2, and 6 h after administration, confirming its expected mechanism of action also in vivo. Partial recovery of PAR levels was observed at 24 h (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>).</div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo inhibition of PAR activity. Mice were treated with a single oral dose of <b>20by</b> (100 mg/kg), and intratumoral levels of PAR were assessed by ELISA at 1, 2, 6, and 24 h after dosing. Each bar represents an individual tumor from an individual animal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12050" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12050" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">PARP inhibitors currently undergoing clinical trials in oncology are unselective PARP-1/-2 inhibitors. Poly(ADP-ribose) polymerase-2 (PARP-2), the closest isoform of PARP-1, has a number of reported physiological functions other than its subsidiary role in DNA repair. These considerations inspired our efforts toward developing selective PARP-1 inhibitors as potentially better tolerated drugs, especially in view of potential drug/drug combination settings. An HTS campaign on our proprietary collection was performed, followed by an intensive medicinal chemistry exploration around the resulting moderately potent, but unselective isoindolinone-4-carboxamide hits <b>10a</b> and <b>10b</b>. Investigation of the substituent on the nitrogen atom of the bicylic core allowed the discovery of the selective <b>13af</b>, whose cellular activity and pharmacokinetic properties were, however, still suboptimal. To further gain insight into the SAR of isoindolinone-4-carboxamides, a completely different synthetic route was then implemented to access derivatives modified on the aromatic ring of the bicyclic scaffold. These efforts successfully culminated in the discovery of <b>20by</b> (NMS-P118), a potent and exceedingly selective PARP-1 inhibitor, whose unprecedented selectivity might reside in its distinct binding poses within the catalytic domains of PARP-1 and PARP-2. NMS-P118 shows excellent ADME and pharmacokinetic profiles, high oral availability in the mouse and rat, and high efficacy both as a single agent and in combination with Temozolomide in BRCA1-mutated MDA-MB-436 and BRCA2 deficient Capan-1 human tumor xenograft models, respectively. NMS-P118 was found to be less myelotoxic in vitro than olaparib (now marketed as Lynparza), a dual PARP-1/-2 inhibitor. NMS-P118 is, to our knowledge, the first PARP-1 selective inhibitor with demonstrated anticancer activity as single agent, as well as in combination, and thus we provide compelling proof-of-concept that the sole pharmacological inhibition of PARP-1 vs PARP-2 is sufficient for achieving high antitumor efficacy in BRCA deficient tumor settings.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18">1 Chemistry</h3><div class="NLM_p">All solvents and reagents, unless otherwise stated, were high grade, commercially available, and were used without further purification. All experiments dealing with moisture-sensitive compounds were conducted under dry nitrogen or argon. Organic solutions were evaporated using a Heidolph WB 2001 rotary evaporator at 15–20 mmHg. Thin-layer chromatography was performed on Merck silica gel 60 F<sub>254</sub> precoated plates. Flash chromatography was performed on silica gel (Merck grade 9395, 60A). All tested compounds, reported in the present paper, possess a purity of at least 95% as determined by an HPLC-UV/MS method. HPLC analyses were performed on Waters XTerra RP18 (4.6 mm × 50 mm, 3.5 μm) column using a Waters 2790 HPLC system equipped with a 996 Waters PDA detector and Micromass ZQ single quadrupole mass spectrometer, equipped with an electrospray (ESI) ion source. Mobile phase A was ammonium acetate 5 mM buffer (pH 5.5 with AcOH–acetonitrile 95:5), and mobile phase B was water–acetonitrile (5:95); gradient from 10 to 90% B in 8 min, hold 90% B 2 min; UV detection at 220 and 254 nm; flow rate 1 mL/min; injection volume 10 μL. Full scan mass spectra were recorded in the mass range of 100–800 amu. Capillary voltage was 2.5 kV; source temperature was 120 °C; cone was 10 V. Masses are given as <i>m</i>/<i>z</i> ratio. When necessary, compounds were purified by preparative HPLC on a Waters Symmetry C18 (19 mm × 50 mm, 5 μm) column or on a Waters XTerra RP 18 (30 mm × 150 mm, 5 μm) column using a Waters preparative HPLC 600 equipped with a 996 Waters PDA detector and a Micromass ZMD single quadrupole mass spectrometer, electrospray ionization (positive ion mode). Mobile phase A was water–0.01% TFA, and mobile phase B was acetonitrile; gradient from 10 to 90% B in 8 min, hold 90% B 2 min; flow rate 20 mL/min. Alternatively, mobile phase A was water–0.1% NH<sub>4</sub>OH, and mobile phase B was acetonitrile; gradient from 10 to 100% B in 8 min, hold 100% B 2 min; flow rate 20 mL/min. <sup>1</sup>H NMR spectra were recorded at 28 °C on a Varian INOVA 400 spectrometer operating at 400.5 MHz for <sup>1</sup>H and equipped with 5 mm <sup>1</sup>H{<sup>15</sup>N, <sup>31</sup>P} <i>z</i> axis PFG indirect detection probe, at 25 °C on a Varian INOVA 500 spectrometer operating at 499.75 MHz for <sup>1</sup>H and equipped with 5 mm <sup>1</sup>H{<sup>13</sup>C, <sup>15</sup>N} <i>z</i> axis PFG indirect detection probe and on a Varian Mercury 300 spectrometer operating at 300.5 MHz for <sup>1</sup>H and equipped with 5 mm PFG autoswitchable <sup>1</sup>H, <sup>19</sup>F, <sup>13</sup>C, <sup>31</sup>P probe. Spectra were recorded in DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub>. Chemical shifts were referenced with respect to the residual solvent signal (DMSO-<i>d</i><sub>6</sub>, 2.50 ppm; CDCl<sub>3</sub>, 7.27 ppm). Data are reported as follows: chemical shift (δ), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, bs = broad signal, td = triplet of doublets, dd = doublet of doublets, ddd = doublet of doublets of doublets, m = multiplet), coupling constants (Hz), and number of protons. As formerly reported,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> ESI(+) high-resolution mass spectra (HRMS) were obtained on a Q-Tof Ultima (Waters, Manchester, UK) mass spectrometer directly connected with an Agilent 1100 micro-HPLC system (Palo Alto, US).</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1-Benzyl-<i>N</i>-(furan-2-ylmethyl)piperidin-4-amine (<b>7u</b>)</h4><div class="NLM_p last">An equimolar solution of furan-2-carbaldehyde (4.8 g, 50 mmol) and 1-benzylpiperidin-4-amine <b>6u</b> (9.5 g, 50 mmol) in dioxane (30 mL) was heated to reflux for 8 h by employing a Dean–Stark apparatus. The reaction mixture was concentrated under vacuum and rinsed with ethanol (1000 mL). Sodium borohydride (2.08 g, 55 mmol) was added, and the mixture was left overnight at room temperature. Then it was diluted with water and extracted with diethyl ether. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the title compound, employed in the following steps without any further purification.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 2-(1-Benzylpiperidin-4-yl)-1-oxo-1,2,3,6,7,7a-hexahydro-3a,6-epoxyisoindole-7-carboxylic Acid (<b>8u</b>)</h4><div class="NLM_p last">To a solution of <b>7u</b> (13.3 g, 50 mmol) in tetrahydrofuran (140 mL), maleic anhydride (4.9 g, 50 mmol) was added. The reaction mixture was refluxed for 6 h and stirred overnight at room temperature. The precipitate solid obtained was filtered, washed with diethyl ether, and dried to give the desired compound as a white solid. ESI(+) MS: <i>m</i>/<i>z</i> 369 (MH<sup>+</sup>).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 2-(1-Benzylpiperidin-4-yl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxylic Acid (<b>9u</b>)</h4><div class="NLM_p last">Compound <b>8u</b> (18.4 g, 50 mmol) was dissolved in 37% hydrochloric acid (150 mL), and the solution was refluxed for 3 h. The solvent was removed under reduced pressure to afford the resulting crude as hydrochloride salt. HRMS (ESI+): calcd for C<sub>21</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 351.1703; found 351.1706.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-(1-Benzylpiperidin-4-yl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10u</b>)</h4><div class="NLM_p last">To a solution of <b>9u</b> (19.3 g, 50 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (300 mL) hydroxybenzotriazole ammonium salt (15.2 g, 100 mmol), 1-ethyl-3-(3′-dimethylamino)carbodiimide hydrochloric acid salt (19.2 g, 100 mmol) and triethylamine (17 mL, 200 mmol) were added. The reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate. The solution was washed with 15% ammonium hydroxide, and the organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude was purified by flash chromatography (dichloromethane/methanol 97:3) to afford the title compound (3.5 g, 20% over four steps) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.71 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 7.66 (bs, 1H), 7.36–7.30 (m, 4H), 7.30–7.20 (m, 1H), 4.56 (s, 2H), 4.11–4.00 (m, 1H), 3.51 (s, 2H), 2.96–2.88 (m, 2H), 2.15–2.03 (m, 2H), 1.90–1.70 (m, 4H). HRMS (ESI+): calcd for C<sub>21</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 350.1863; found 350.1874</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Compounds <b>10a</b>–<b>10t</b></h4><div class="NLM_p">By employment of the above-described procedure and using the suitably substituted amine <b>6a</b>–<b>t</b>, compounds <b>10a</b>–<b>t</b> were obtained.</div><div id="sec5_1_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 3-Oxo-2-propyl-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (bs, 1H), 8.20 (d, <i>J</i> = 7.6 Hz, 1H), 7.76 (d, <i>J</i> = 7.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.3 Hz, 1H), 7.66 (bs, 1H), 4.57 (s, 2H), 3.56–3.51 (m, 2H), 1.71–1.61 (m, 2H), 0.89 (t, <i>J</i> = 7.3 Hz, 3H). HRMS (ESI+): calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 219.1128; found 219.1122.</div></div><div id="sec5_1_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 2-(3-Methoxypropyl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (bs, 1H), 8.21 (d, <i>J</i> = 7.7 Hz, 1H), 7.77 (d, <i>J</i> = 7.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.7, 7.3 Hz, 1H), 7.67 (bs, 1H), 4.58 (s, 2H), 3.66–3.60 (m, 2H), 3.40–3.36 (m, 2H), 3.24 (s, 3H), 1.92–1.84 (m, 2H). HRMS (ESI+): calcd for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 249.1234; found 249.1232.</div></div><div id="sec5_1_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 2-(2-Methoxyethyl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.67 (bs, 1H), 4.61 (s, 2H), 3.75 (t, <i>J</i> = 5.3 Hz, 2H), 3.60 (t, <i>J</i> = 5.3 Hz, 2H), 3.28 (s, 3H). HRMS (ESI+): calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 235.1077; found 235.1083.</div></div><div id="sec5_1_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 3-Oxo-2-(tetrahydrofuran-2-ylmethyl)-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (±-<b>10d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.66 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.67 (bs, 1H), 4.71–4.58 (m, 2H), 4.14–4.07 (m, 1H), 3.84–3.76 (m, 1H), 3.73–3.55 (m, 3H), 1.93–2.02 (m, 1H), 1.88–1.77 (m, 2H), 1.63–1.53 (m, 1H). HRMS (ESI+): calcd for C<sub>14</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 261.1234; found 261.1242.</div></div><div id="sec5_1_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 2-(2-Hydroxyethyl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.77 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.2 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.87 (t, <i>J</i> = 5.2 Hz, 1H), 4.63 (s, 2H), 3.70–3.60 (m, 4H). HRMS (ESI+): calcd for C<sub>11</sub>H<sub>13</sub>N<sub>2</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 221.0921; found 221.0919.</div></div><div id="sec5_1_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 2-Benzyl-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.59 (bs, 1H), 8.22–8.17 (m, 1H), 7.75–7.69 (m, 3H), 7.40–7.28 (m, 5H), 4.79 (s, 2H), 4.47 (s, 2H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 267.1128; found 267.1120.</div></div><div id="sec5_1_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 3-Oxo-2-(2-phenylethyl)-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (bs, 1H), 8.19 (dd, <i>J</i> = 7.3. 1.6 Hz, 1H), 7.74 (dd, <i>J</i> = 7.6, 1.6 Hz, 1H), 7.70 (dd, <i>J</i> = 7.6, 7.3 Hz, 1H), 7.66 (bs, 1H), 7.32–7.25 (m, 4H), 7.23–7.18 (m, 1H), 4.49 (s, 2H), 3.85–3.80 (m, 2H), 3.00–2.94 (m, 2H). HRMS (ESI+): calcd for C<sub>17</sub>H<sub>17</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 281.1285; found 281.1295.</div></div><div id="sec5_1_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 3-Oxo-2-(3-phenylpropyl)-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10h</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4. 1.5 Hz, 1H), 7.78–7.75 (m, 1H), 7.75–7.70 (m, 1H), 7.67 (bs, 1H), 7.31–7.24 (m, 4H), 7.20–7.15 (m, 1H), 4.59 (s, 2H), 3.64–3.59 (m, 2H), 2.67–2.60 (m, 2H), 2.01–1.92 (m, 2H). HRMS (ESI+): calcd for C<sub>18</sub>H<sub>19</sub>N<sub>2</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 295.1441; found 295.1433.</div></div><div id="sec5_1_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-Oxo-2-[2-(pyridin-2-yl)ethyl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10i</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.66 (bs, 1H), 8.48 (ddd, <i>J</i> = 4.9, 1.8, 1.0 Hz, 1H), 8.19 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.75 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.73–7.68 (m, 2H), 7.65 (bs, 1H), 7.32 (td, <i>J</i> = 7.8, 1.0 Hz, 1H), 7.23 (ddd, <i>J</i> = 7.5, 4.9, 1.0 Hz, 1H), 4.52 (s, 2H), 3.98–3.93 (m, 2H), 3.15–3.10 (m, 2H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>16</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 282.1237; found 282.1243.</div></div><div id="sec5_1_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 2-[2-(Morpholin-4-yl)ethyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10j</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.78 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.66 (bs, 1H), 4.64 (s, 2H), 3.71 (t, <i>J</i> = 6.2 Hz, 2H), 3.57–3.52 (m, 4H), 2.59 (t, <i>J</i> = 6.2 Hz, 2H), 2.46–2.41 (m, 4H). HRMS (ESI+): calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 290.1499; found 290.1507.</div></div><div id="sec5_1_5_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 2-[3-(Morpholin-4-yl)propyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10k</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.76 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.71 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.65 (bs, 1H), 4.58 (s, 2H), 3.61 (t, <i>J</i> = 7.1 Hz, 2H), 3.53–3.47 (m, 4H), 2.37–2.29 (m, 6H), 1.85–1.76 (m, 2H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 304.1656; found 304.1664.</div></div><div id="sec5_1_5_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 3-Oxo-2-[2-(piperidin-1-yl)ethyl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10l</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (bs, 1H), 8.20 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.78 (dd, <i>J</i> = 7.4. 1.2 Hz, 1H), 7.72 (dd, <i>J</i> = 7.7, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.63 (s, 2H), 3.68 (t, <i>J</i> = 6.3 Hz, 2H), 2.54 (t, <i>J</i> = 6.3 Hz, 2H), 2.43–2.36 (m, 4H), 1.50–1.42 (m, 4H), 1.41–1.32 (m, 2H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 288.1707; found 288.1712.</div></div><div id="sec5_1_5_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 3-Oxo-2-[3-(piperidin-1-yl)propyl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide Hydrochloride (<b>10m</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (bs, 1H), 8.93 (bs, 1H), 8.21 (dd, <i>J</i> = 7.6, 1.1 Hz, 1H), 7.80 (dd, <i>J</i> = 7.4, 1.1 Hz, 1H), 7.74 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.71 (bs, 1H), 4.59 (s, 2H), 3.66 (t, <i>J</i> = 6.6 Hz, 2H), 3.50–3.40 (m, 2H), 3.13–3.03 (m, 2H), 2.92–2.78 (m, 2H), 2.09–1.98 (m, 2H), 1.85–1.75 (m, 2H), 1.73–1.52 (m, 3H), 1.43–1.28 (m, 1H). HRMS (ESI+): calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 302.1863; found 302.1865.</div></div><div id="sec5_1_5_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> <i>cis</i>-2-[3-(2,6-Dimethylpiperidin-1-yl)propyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<i>cis</i>-<b>10n</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (bs, 1H), 8.72 (bs, 1H), 8.21 (dd, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.80 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.74 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.70 (bs, 1H), 4.63 (s, 2H), 3.72–3.64 (m, 2H), 3.35–3.20 (m partially overlapped by water signal, 4 H), 2.06–1.93 (m, 2H), 1.89–1.80 (m, 2H), 1.54–1.43 (m, 4H), 1.25 (d, <i>J</i> = 6.3 Hz, 6H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 330.2176; found 330.2176.</div></div><div id="sec5_1_5_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 2-[3-(1,4′-Bipiperidin-1′-yl)propyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide Dihydrochloride (<b>10o</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (bs, 1H), 9.38 (bs, 2H), 8.21 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.80 (d, <i>J</i> = 7.5, 1H), 7.75 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.72 (bs, 1H), 4.59 (s, 2H), 3.70–2.82 (m, 13H), 2.30–1.30 (m, 12H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>33</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 385.2598; found 385.2611.</div></div><div id="sec5_1_5_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 2-[3-(4-Benzylpiperidin-1-yl)propyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10p</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.78 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.65 (bs, 1H), 7.28–7.23 (m, 2H), 7.19–7.13 (m, 1H), 7.12–7.09 (m, 2H), 4.56 (s, 2H), 3.62–3.56 (m, 2H), 2.87–2.74 (m, 2H), 2.41 (d, <i>J</i> = 6.8 Hz, 2H), 2.33–2.22 (m, 2H), 1.82–1.70 (m, 4H), 1.52–1.37 (m, 3H), 1.11–0.99 (m, 2H). HRMS (ESI+): calcd for C<sub>24</sub>H<sub>30</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 392.2333; found 392.2346.</div></div><div id="sec5_1_5_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 2-[2-(3,4-Dihydroquinolin-1(2<i>H</i>)-yl)ethyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10q</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (bs, 1H), 8.20 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.77 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.69 (bs, 1H), 6.97–6.92 (m, 1H), 6.88–6.85 (m, 1H), 6.75–6.70 (m, 1H), 6.49–6.44 (m, 1H), 4.65 (s, 2H), 3.78–3.73 (m, 2H), 3.58–3.53 (m, 2H), 3.34–3.28 (m overlapped by water signal, 2H), 2.69–2.65 (m, 2H), 1.88–1.80 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 336.1707; found 336.1692.</div></div><div id="sec5_1_5_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 2-[2-(3,4-Dihydroisoquinolin-2(1<i>H</i>)-yl)ethyl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10r</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (bs, 1H), 8.19 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.76 (dd, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.69 (dd, <i>J</i> = 7.7, 7.6 Hz, 1H), 7.66 (bs, 1H), 7.11–7.00 (m, 4H), 4.65 (s, 2H), 3.81 (t, <i>J</i> = 6.2 Hz, 2H), 3.65 (s, 2H), 2.82–2.73 (bs, 6H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 336.1707; found 336.1722.</div></div><div id="sec5_1_5_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 2-{[1-(4-Methylbenzyl)piperidin-4-yl]methyl}-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10s</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.6 Hz, 1H), 7.77–7.74 (m, 1H), 7.74–7.69 (m, 1H), 7.66 (bs, 1H), 7.20–7.07 (m, 4H), 4.57 (s, 2H), 3.46 (d, <i>J</i> = 7.2 Hz, 2H), 3.39 (s, 2H), 2.82–2.72 (m, 2H), 2.27 (s, 3H), 1.95–1.82 (m, 2H), 1.82–1.68 (m, 1H), 1.65–1.53 (m, 2H), 1.30–1.16 (m, 2H). HRMS (ESI+): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 378.2176; found 378.2183.</div></div><div id="sec5_1_5_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 2-{[1-(3-Methylbenzyl)piperidin-4-yl]methyl}-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>10t</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.20 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.77–7.73 (m, 1H), 7.73–7.69 (m, 1H), 7.66 (bs, 1H), 7.20–7.15 (m, 1H), 7.11–7.00 (m, 3H), 4.57 (s, 2H), 3.46 (d, <i>J</i> = 7.3 Hz, 2H), 3.39 (s, 2H), 2.80–2.74 (m, 2H), 2.28 (s, 3H), 1.94–1.85 (m, 2H), 1.83–1.70 (m, 1H), 1.62–1.54 (m, 2H), 1.29–1.18 (m, 2H). HRMS (ESI+): calcd for C<sub>23</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 378.2176; found 378.2188.</div></div></div><div id="sec5_1_5_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-Oxo-2-(piperidin-4-yl)-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide Hydrochloride (<b>11</b>)</h4><div class="NLM_p last">A solution of <b>10u</b> (1.3 g, 3.72 mmol) in acetic acid (100 mL) in the presence of Pd/C 10% (260 mg) was hydrogenated at 50 psi for 8 h. The mixture was filtered over a pad of Celite, and the solution was concentrated to afford the title compound (900 mg, 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (bs, 1H), 8.82 (bs, 1H), 8.59 (bs, 1H), 8.21 (dd, <i>J</i> = 7.5, 1.1 Hz, 1H), 7.82 (dd, <i>J</i> = 7.6, 1.1 Hz 1H), 7.75 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.71 (bs, 1H), 4.56 (s, 2H), 4.32–4.45 (m, 1H), 3.46–3.36 (m overlapped by water signal, 2H), 3.17–3.04 (m, 2H), 2.09–1.92 (m, 4H). HRMS (ESI+): calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 260.1394; found 260.1398.</div></div><div id="sec5_1_5_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-[1-(Cyclopropylcarbonyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>12b</b>)</h4><div class="NLM_p last">To a solution of <b>11</b> (60 mg, 0.23 mmol) in pyridine (2 mL) cyclopropanecarbonyl chloride (26.4 mg, 0.25 mmol) was added. After stirring at 60 °C for 8 h, the solvent was removed under reduced pressure and the crude was purified by flash chromatography (dichloromethane/methanol 95:5) to give the desired compound (32 mg, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (bs, 1H), 8.21 (dd, <i>J</i> = 7.2, 1.6 Hz, 1H), 7.78–7.75 (m, 1H), 7.75–7.71 (m, 1H), 7.69 (bs, 1H), 4.57 (s, 2H), 4.60–4.38 (m, 2H), 4.40–4.30 (m, 1H), 3.40–3.19 (m partially overlapped by water signal, 1H), 2.76–2.65 (m, 1H), 2.07–2.00 (m, 1H), 1.97–1.54 (m, 4H), 0.83–0.67 (m, 4H). HRMS (ESI+): calcd for C<sub>18</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 328.1656; found 328.1669.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Compounds <b>12a</b>–<b>12c</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 2-(1-Acetylpiperidin-4-yl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>12a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (bs, 1H), 8.21 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.78–7.75 (m, 1H), 7.75–7.70 (m, 1H), 7.69 (bs, 1H), 4.55 (s, 2H), 4.58–4.49 (m, 1H), 4.36–4.26 (m, 1H), 3.99–3.91 (m, 1H), 3.15–3.25 (m, 1H), 2.70–2.60 (m, 1H), 2.04 (s, 3H), 1.90–1.70 (m, 3H), 1.68–1.55 (m, 1H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 302.1499; found 302.1506.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 2-[1-(Cyclohexylcarbonyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>12c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (bs, 1H), 8.21 (dd, <i>J</i> = 7.2, 1.7 Hz, 1H), 7.77–7.70 (m, 2H), 7.69 (bs, 1H), 4.62–4.50 (m, 1H), 4.56 (s, 2H), 4.37–4.27 (m, 1H), 4.13–4.02 (m, 1H), 3.24–3.10 (m, 1H), 2.71–2.57 (m, 2H), 1.93–1.50 (m, 8H), 1.47–1.09 (m, 6H). HRMS (ESI+): calcd for C<sub>21</sub>H<sub>28</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 370.2125; found 370.2117.</div></div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13af</b>)</h4><div class="NLM_p last">To a suspension of <b>11</b> (56 mg, 0.19 mmol) in dichloromethane (2 mL), 4,4-difluorocyclohexanone (37.5 mg, 0.28 mmol), sodium acetate (32 mg, 0.38 mmol), and methanol (0.3 mL) were added. The resulting solution was stirred at room temperature for 5 h. Then sodium cyanoborohydride was added and the mixture was stirred overnight. Solvents were removed under reduce pressure, and the residue was dissolved in dichloromethane and washed twice with water. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo, and the residue was purified by flash chromatography (dichloromethane/methanol 95:5) to give the title compound (33 mg, 45%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1 H), 8.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.77–7.74 (m, 1H), 7.74–7.69 (m, 1H), 7.66 (bs, 1H), 4.55 (s, 2H), 4.09–3.95 (m., 1H), 3.00–2.90 (m, 2H), 2.66–2.44 (m overlapped by DMSO signal, 1H), 2.35–2.23 (m, 2H), 2.10–1.96 (m, 2H), 1.94–1.70 (m, 8H), 1.61–1.47 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>26</sub>F<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 378.1988; found 378.1982.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Compounds <b>13a</b>–<b>13ag</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 2-(1-Methylpiperidin-4-yl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.73 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.67 (bs, 1H), 4.56 (s, 2H), 4.06–3.98 (m, 1H), 2.91–2.85 (m, 2H), 2.21 (s, 3H), 2.06–1.97 (m, 2H), 1.88–1.78 (m, 2H), 1.78–1.70 (m, 2H). HRMS (ESI+): calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 274.1550; found 274.1557.</div></div><div id="sec5_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2-(1-Ethylpiperidin-4-yl)-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13b</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.66 (bs, 1H), 4.55 (s, 2H), 4.09–3.98 (m, 1H), 3.01–2.95 (m, 2H), 2.36 (q, <i>J</i> = 7.1 Hz, 2H), 2.02–1.95 (m, 2H), 1.85–1.72 (m, 4H), 1.01 (t, <i>J</i> = 7.1 Hz, 3H). HRMS (ESI+): calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 288.1707; found 288.1707.</div></div><div id="sec5_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 3-Oxo-2-[1-(propan-2-yl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (bs, 1H), 8.21 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.67 (bs, 1H), 4.56 (s, 2H), 4.10–3.96 (m, 1H), 2.96–2.84 (m, 2H), 2.80–2.68 (m, 1H), 2.30–2.18 (m, 2H), 1.83–1.69 (m, 4H), 0.99 (d, <i>J</i> = 6.1 Hz, 6H). HRMS (ESI+): calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 302.1863; found 302.1862.</div></div><div id="sec5_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 2-[1-(2-Methylpropyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.76 (d, <i>J</i> = 7.5 Hz, 1H), 7.72 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.56 (s, 2H), 4.08–3.98 (m, 1H), 2.96–2.89 (m, 2H), 2.06 (d, <i>J</i> = 6.2 Hz, 2H), 2.04–1.95 (m, 2H), 1.87–1.70 (m, 5H), 0.87 (d, <i>J</i> = 6.6 Hz, 6H). HRMS (ESI+): calcd for C<sub>18</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 316.2020; found 316.2020.</div></div><div id="sec5_1_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 2-[1-(Cyclopropylmethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13e</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.66 (bs, 1H), 4.56 (s, 2H), 4.10–3.97 (m, 1H), 3.13–3.04 (m, 2H), 2.21 (d, <i>J</i> = 6.3 Hz, 2 H), 2.10–2.00 (m, 2H), 1.90–1.71 (m, 4H), 0.90–0.80 (m, 1H), 0.50–0.44 (m, 2H), 0.12–0.06 (m, 2H). HRMS (ESI+): calcd for C<sub>18</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 314.1863; found 314.1860.</div></div><div id="sec5_1_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 2-[1-(2-Methoxyethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13f</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.71 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.55 (s, 2H), 4.08–3.97 (m, 1H), 3.44 (t, <i>J</i> = 5.8 Hz, 2H), 3.24 (s, 3H), 3.02–2.95 (m, 2H), 2.53–2.47 (m overlapped by DMSO signal, 2H), 2.14–2.06 (m, 2), 1.86–1.69 (m, 4H). HRMS (ESI+): calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 318.1812; found 318.1811.</div></div><div id="sec5_1_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 2-[1-(2-Methylbenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13g</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.3, 1.6 Hz, 1H), 7.78–7.75 (m, 1H), 7.75–7.70 (m, 1H), 7.67 (bs, 1 H), 7.28–7.23 (m, 1H), 7.19–7.12 (m, 3H), 4.57 (s, 2 H), 4.14–4.02 (m, 1H), 3.47 (s, 2H), 2.96–2.88 (m, 2H), 2.35 (s, 3 H), 2.19–2.10 (m, 2 H), 1.88–1.73 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 364.2020; found 364.2034.</div></div><div id="sec5_1_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 2-[1-(3-Methylbenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13h</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.3, 1.4 Hz, 1H), 7.77 (dd, <i>J</i> = 7.4, 1.4 Hz, 1H), 7.72 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.67 (bs, 1H), 7.25–7.19 (m, 1H), 7.16–7.05 (m, 3H), 4.58 (s, 2H), 4.13–4.00 (m, 1H), 3.47 (s, 2H), 2.98–2.87 (m, 2H), 2.32 (s, 3H), 2.13–2.04 (m, 2H), 1.90–1.72 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 364.2020; found 364.2031.</div></div><div id="sec5_1_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 2-[1-(4-Methylbenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13i</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.72 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.67 (bs, 1 H), 7.23–7.18 (m, 2H), 7.16–7.12 (m, 2H), 4.57 (s, 2H), 4.11–4.00 (m, 1H), 3.46 (s, 2H), 2.96–2.88 (m, 2H), 2.30 (s, 3H), 2.12–2.03 (m, 2H), 1.88–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>26</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 364.2020; found 364.2033.</div></div><div id="sec5_1_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 2-[1-(2-Bromobenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13j</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.73 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.68 (bs, 1H), 7.62 (dd, <i>J</i> = 7.9, 1.0 Hz, 1H), 7.52 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.40 (td, <i>J</i> = 7.5, 1.0 Hz, 1H), 7.23 (td, <i>J</i> = 7.5, 1.3 Hz, 1H), 4.58 (s, 2H), 4.15–4.05 (m, 1H), 3.60 (s, 2H), 3.00–2.92 (m, 2H), 2.29–2.19 (m, 2H), 1.91–1.75 (m, 4H). HRMS (ESI+): calcd for C<sub>21</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 428.0968; found 428.0974.</div></div><div id="sec5_1_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 2-[1-(3-Bromobenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13k</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.21 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.73 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.67 (bs, 1H), 7.54 (s, 1H), 7.49–7.45 (m, 1H), 7.37–7.30 (m, 2H), 4.58 (s, 2H), 4.12–4.00 (m, 1H), 3.53 (s, 2H), 2.95–2.88 (m, 2H), 2.17–2.08 (m, 2H), 1.91–1.74 (m, 4H). HRMS (ESI+): calcd for C<sub>21</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 428.0968; found 428.0975.</div></div><div id="sec5_1_7_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 2-[1-(4-Bromobenzyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13l</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 7.67 (bs, 1H), 7.53 (d, <i>J</i> = 8.3 Hz, 2H), 7.30 (d, <i>J</i> = 8.3 Hz, 2H), 4.57 (s, 2H), 4.12–4.01 (m, 1H), 3.49 (s, 2H), 2.94–2.87 (m, 2H), 2.16–2.06 (m, 2H), 1.90–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>21</sub>H<sub>23</sub>BrN<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 428.0968; found 428.0983.</div></div><div id="sec5_1_7_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 3-Oxo-2-{1-[2-(trifluoromethyl)benzyl]piperidin-4-yl}-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13m</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.85–7.81 (m, 1H), 7.79–7.66 (m, 5H), 7.51–7.46 (m, 1H) 4.59 (s, 2H), 4.15–4.05 (m, 1H), 3.68 (s, 2H), 2.95–2.89 (m, 2H), 2.24–2.16 (m, 2H), 1.92–1.75 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 418.1737; found 418.1745.</div></div><div id="sec5_1_7_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 3-Oxo-2-{1-[3-(trifluoromethyl)benzyl]piperidin-4-yl}-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13n</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 7.73 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.70–7.56 (m, 5H), 4.59 (s, 2H), 4.13–4.03 (m, 1H), 3.63 (s, 2H), 2.96–2.89 (m, 2H), 2.20–2.10 (m, 2H), 1.91–1.74 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 418.1737; found 418.1749.</div></div><div id="sec5_1_7_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 3-Oxo-2-{1-[4-(trifluoromethyl)benzyl]piperidin-4-yl}-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13o</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.6, 1.2 Hz, 1H), 7.74–7.68 (m, 3H), 7.67 (bs, 1H), 7.57 (d, <i>J</i> = 7.9 Hz, 2H), 4.57 (s, 2H), 4.12–4.02 (m, 1H), 3.61 (s, 2H), 2.96–2.88 (m, 2H), 2.19–2.10 (m, 2H), 1.91–1.72 (m, 4H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 418.1737; found 418.1740.</div></div><div id="sec5_1_7_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 2-{1-[4-(Dimethylamino)benzyl]piperidin-4-yl}-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13p</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.19 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.5, 1.3 Hz, 1H), 7.71 (t, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.66 (bs, 1H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 6.69 (d, <i>J</i> = 8.4 Hz, 2H), 4.55 (s, 2H), 4.09–3.98 (m, 1H), 3.36 (s, 2H), 2.96–2.86 (m, 2H), 2.87(s, 6H), 2.06–1.97 (m, 2H), 1.86–1.70 (m, 4H). HRMS (ESI+): calcd for C<sub>23</sub>H<sub>29</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 393.2285; found 393.2293.</div></div><div id="sec5_1_7_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 3-Oxo-2-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13q</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.54–8.51 (m, 2H), 8.21 (dd, <i>J</i> = 7.5, 1.4 Hz, 1H), 7.78 (dd, <i>J</i> = 7.6, 1.4 Hz, 1H), 7.73 (t, <i>J</i> = 7.6, 7.5 Hz, 1H), 7.68 (bs, 1H), 7.37–7.34 (m, 2H), 4.58 (s, 2H), 4.13–4.03 (m, 1H), 3.56 (s, 2H), 2.95–2.88 (m, 2H), 2.20–2.11 (m, 2H), 1.93–1.74 (m, 4H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 351.1816; found 351.1817.</div></div><div id="sec5_1_7_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 3-Oxo-2-[1-(pyridin-3-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13r</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (bs, 1H), 8.52 (s, 1H), 8.48 (d, <i>J</i> = 4.8 Hz, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.77–7.71 (m, 3H), 7.66 (bs, 1H), 7.37 (dd, <i>J</i> = 7.7, 4.8 Hz, 1H), 4.56 (s, 2H), 4.11–4.01 (m, 1H), 3.55 (s, 2H), 2.96–2.87 (m, 2H), 2.19–2.07 (m, 2H), 1.89–1.70 (m, 4H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 351.1816; found 351.1822.</div></div><div id="sec5_1_7_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-Oxo-2-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13s</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.51 (d, <i>J</i> = 4.8 Hz, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.83–7.75 (m, 2H), 7.73 (dd, <i>J</i> = 7.4, 7.4 Hz, 1H), 7.67 (bs, 1H), 7.47 (d, <i>J</i> = 7.8 Hz, 1H), 7.28 (dd, <i>J</i> = 6.8, 4.8 Hz, 1H), 4.58 (s, 2H), 4.14–4.03 (m, 1H), 3.65 (s, 2H), 3.00–2.02 (m, 2H), 2.26–2.14 (m, 2H), 1.93–1.73 (m, 4H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 351.1816; found 351.1815.</div></div><div id="sec5_1_7_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 3-Oxo-2-[1-(thiophen-2-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13t</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1H), 8.21 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.77 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 7.72 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.67 (bs, 1H), 7.46–7.42 (m, 1H), 7.00–6.97 (m, 2H), 4.58 (s, 2H), 4.11–4.01 (m, 1H), 3.73 (s, 2H), 3.03–2.96 (m, 2H), 2.16–2.08 (m, 2H), 1.88–1.74 (m, 4H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 356.1427; found 356.1430.</div></div><div id="sec5_1_7_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-Oxo-2-[1-(thiophen-3-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13u</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.3, 1.3 Hz, 1H), 7.75 (dd, <i>J</i> = 7.4, 1.3, 1H), 7.72 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.67 (bs, 1H), 7.49 (m, 1H), 7.33 (s, 1H), 7.08 (d, <i>J</i> = 4.6 Hz, 1H), 4.57 (s, 2H), 4.10–3.99 (m, 1H), 3.53 (s, 2H), 2.98–2.90 (m, 2H), 2.12–2.02 (m, 2H), 1.90–1.72 (m, 4H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 356.1427; found 356.1432.</div></div><div id="sec5_1_7_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 2-[1-(Furan-2-ylmethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13v</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (bs, 1H), 8.19 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.76 (dd, <i>J</i> = 7.5, 1.3 Hz, 1 H), 7.71 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.66 (bs, 1H), 7.59 (s, 1H), 6.41 (dd, <i>J</i> = 2.4, 1.8 Hz, 1H), 6.30 (d, <i>J</i> = 2.4 Hz, 1H), 4.55 (s, 2H), 4.06–3.97 (m, 1H), 3.53 (s, 2H), 2.97–2.89 (m, 2H), 2.15–2.07 (m, 2H), 1.87–1.70 (m, 4H), HRMS (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 340.1656; found 340.1651.</div></div><div id="sec5_1_7_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 2-[1-(Furan-3-ylmethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13z</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1H), 8.21 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.67 (bs, 1H), 7.62 (s, 1H), 7.58 (s, 1H), 6.45 (s, 1H), 4.56 (s, 2H), 4.11–3.98 (m, 1H), 3.37 (s, 2H), 3.02–2.91 (m, 2H), 2.09–1.99 (m, 2H), 1.88–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 340.1656; found 340.1649.</div></div><div id="sec5_1_7_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 3-Oxo-2-[1-(1<i>H</i>-pyrrol-2-ylmethyl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13aa</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.73 (bs, 1 H), 10.65 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.3 Hz, 1H), 7.77 (dd, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.72 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.67 (bs, 1H), 6.65 (s, 1H), 5.96–5.92 (m, 1H), 5.89 (s, 1H), 4.55 (s, 2H), 4.11–3.97 (m, 1H), 3.44 (s, 2H), 2.99–2.88 (m, 2H), 2.08–1.97 (m, 2H), 1.86–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 339.1816; found 339.1812.</div></div><div id="sec5_1_7_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 2-{1-[(1-Methyl-1<i>H</i>-pyrrol-2-yl)methyl]piperidin-4-yl}-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13ab</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (bs, 1 H), 8.19 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.75 (dd, <i>J</i> = 7.4, 1.2 Hz, 1H), 7.71 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H), 7.66 (bs, 1H), 6.67–6.65 (m, 1H) 5.89–5.85 (m, 2H), 4.55 (s, 2H), 4.10–4.00 (m, 1H), 3.61 (s, 3H), 3.41 (s, 2H), 2.98–2.89 (m, 2H), 2.07–1.97 (m, 2H), 1.80–1.70 (m, 4H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 353.1972; found 353.1984.</div></div><div id="sec5_1_7_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 2-[1-(1<i>H</i>-Indol-4-ylmethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13ac</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.06 (bs, 1H), 10.74 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.75 (dd, <i>J</i> = 7.5, 1.2 Hz, 1H), 7.72 (dd, <i>J</i> = 7.5, 7.4 Hz, 1H), 7.67 (bs, 1H), 7.35–7.28 (m, 2H), 7.08–7.02 (m, 1H), 6.99–6.94 (m, 1H), 6.61 (s, 1H), 4.57 (s, 2H), 4.13–4.02 (m, 1H), 3.75 (s, 2H), 3.04–2.96 (m, 2H), 2.19–2.09 (m, 2H), 1.89–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 389.1972; found 389.1983.</div></div><div id="sec5_1_7_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 2-[1-(1<i>H</i>-Indol-5-ylmethyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13ad</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.01 (bs, 1H), 10.73 (bs, 1H), 8.20 (dd, <i>J</i> = 7.3, 1.5 Hz, 1H), 7.75 (dd, <i>J</i> = 7.4, 1.5 Hz 1H), 7.71 (dd, <i>J</i> = 7.4, 7.3 Hz, 1H). 7.66 (bs, 1H), 7.46 (s, 1H), 7.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.33–7.28 (m, 1H), 7.07 (dd, <i>J</i> = 8.2, 1.3 Hz, 1H), 6.40–6.37 (m, 1H), 4.56 (s, 2H), 4.10–4.00 (m, 1H), 3.56 (s, 2H), 3.00–2.92 (m, 2H), 2.13–2.02 (m, 2H), 1.87–1.71 (m, 4H). HRMS (ESI+): calcd for C<sub>23</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 389.1972; found 389.1970.</div></div><div id="sec5_1_7_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 3-Oxo-2-[1-(tetrahydro-2<i>H</i>-pyran-4-yl)piperidin-4-yl]-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13ae</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (bs, 1H), 8.20 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.71 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.55 (s, 2H), 4.07–3.98 (m, 1H), 3.92–3.85 (m, 2H), 3.35–3.24 (m partially overlapped by water signal, 2H), 3.04–2.96 (m, 2H), 2.47–2.42 (m partially overlapped by DMSO signal, 1H), 2.29–2.19 (m, 2H), 1.81–1.65 (m, 6H), 1.50–1.38 (m, 2H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 344.1969; found 344.1962.</div></div><div id="sec5_1_7_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 2-[1-(1,4-Dioxaspiro[4.5]dec-8-yl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>13ag</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (bs, 1H), 8.20 (dd, <i>J</i> = 7.4, 1.5 Hz, 1H), 7.76 (dd, <i>J</i> = 7.6, 1.5 Hz, 1H), 7.71 (dd, <i>J</i> = 7.6, 7.4 Hz, 1H), 7.66 (bs, 1H), 4.55 (s, 2H), 4.05–3.95 (m, 1H), 3.86–3.80 (m, 4H), 2.97–2.89 (m, 2H), 2.44–2.34 (m, 1H), 2.33–2.23 (m, 2H), 1.80–1.37 (m, 12H). HRMS (ESI+): calcd for C<sub>22</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 400.2231; found 400.2229.</div></div></div><div id="sec5_1_7_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 4-Fluoro-2-iodo-6-methyl-benzoic Acid (<b>15b</b>)</h4><div class="NLM_p last">A mixture of 4-fluoro-2-methyl-benzoic acid <b>14b</b> (20.00 g, 0.130 mol), iodobenzene diacetate (50.15 g, 0.156 mol), iodine (39.52 g, 0.156 mol), and palladium(II) acetate (1.46 g, 0.006 mol) in <i>N</i>,<i>N</i>-dimethylformamide (360 mL) was degassed by cycling vacuum and nitrogen three times and was then heated for 18 h at 100 °C internal temperature, under argon. The resulting dark mixture was cooled to room temperature, diluted with methyl-<i>tert</i>-butylether (200 mL), and treated with a solution of sodium metabisulfite (250 g) in water (500 mL) under efficient stirring. Then, this yellow colored mixture was acidified by slowly adding conc hydrochloric acid (130 mL). The aqueous layer was separated and extracted twice with methyl-<i>tert</i>-butylether (100 mL × 2). The combined organic extracts were treated with a solution of sodium hydroxide pellets (80 g) in water (300 mL) under stirring. The organic layer containing only iodobenzene was discarded, while the aqueous layer was added with sodium chloride, cooled to ice temperature, and brought to pH = 1 with conc hydrochloric acid (130 mL). From this aqueous medium, the product was extracted with methyl-<i>tert</i>-butylether (100 mL × 3) and the combined extracts were dried over Na<sub>2</sub>SO<sub>4</sub> and finally concentrated under reduced pressure, affording the title compound (30.5 g, 84%) as brown solid. This raw material was used in the next step without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.45 (dd, <i>J</i><sub>HH</sub> = 2.4 Hz, <i>J</i><sub>HF</sub> = 7.9, 1H), 6.96 (dd, <i>J</i><sub>HH</sub> = 2.4 Hz, <i>J</i><sub>HF</sub> = 9.1, 1H), 2.46 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 281 (MH<sup>+</sup>).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Compounds <b>15a</b>, <b>15c</b>, <b>15d</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 3-Fluoro-2-iodo-6-methylbenzoic Acid (<b>15a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.69 (bs, 1H), 7.30 (dd, <i>J</i><sub>HH</sub> = 8.9 Hz, <i>J</i><sub>HF</sub> = 5.6 Hz, 1H), 7.19 (dd, <i>J</i><sub>HH</sub> = 8.9 Hz, <i>J</i><sub>HF</sub> = 8.2 Hz, 1H), 2.27 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 281 (MH<sup>+</sup>).</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 3-Fluoro-6-iodo-2-methylbenzoic Acid (<b>15c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.71 (dd, <i>J</i><sub>HH</sub> = 9.0 Hz, <i>J</i><sub>HF</sub> = 5.0 Hz, 1H), 7.04 (dd, <i>J</i><sub>HH</sub> = 9.0 Hz, <i>J</i><sub>HF</sub> = 9.3 Hz, 1H), 2.20 (d, <i>J</i><sub>HF</sub> = 2.2 Hz, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 281 (MH<sup>+</sup>).</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 4-Chloro-2-iodo-6-methylbenzoic Acid (<b>15d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.83–7.81 (m, 1H), 7.47–7.45 (m, 1H), 2.25 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 297 (MH<sup>+</sup>).</div></div></div><div id="sec5_1_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-Fluoro-2-iodo-6-methyl-benzoic Acid Methyl Ester (<b>16b</b>)</h4><div class="NLM_p last">To a solution of <b>15b</b> (30.05 g, 0.109 mol) in <i>N</i>,<i>N</i>-dimethylformamide (300 mL) was added anhydrous potassium carbonate (22.0 g, 0.16 mol) under efficient magnetic stirring. After 15 min, methyl <i>p</i>-toluensulfonate (30.7 g, 0.16 mol) was added. The brown suspension was stirred at room temperature for 2 h. Potassium acetate (12.4 g, 0.13 mol) was then added to destroy the unreacted methyl <i>p</i>-toluensulfonate, and the mixture was stirred overnight. The thick reaction mixture was diluted with methyl-<i>tert</i>-butylether (100 mL) and washed with water (600 mL); the aqueous layer was separated and extracted twice with methyl-<i>tert</i>-butylether (70 mL × 2). The combined organic extracts were washed with brine (50 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure to a solid residue. This material was purified by flash chromatography (<i>n</i>-hexane/ethyl acetate 9:1), affording the desired compound (26.2 g, 81%) as colorless oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.63 (dd, <i>J</i><sub>HH</sub> = 2.4 Hz, <i>J</i><sub>HF</sub> = 8.3 Hz, 1H), 7.25 (dd, <i>J</i><sub>HH</sub> = 2.4 Hz, <i>J</i><sub>HF</sub> = 9.6 Hz, 1H), 3.86 (s, 3H), 2.27 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 295 (MH<sup>+</sup>).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Compounds <b>16a</b>, <b>16c</b>, <b>16d</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> Methyl 3-Fluoro-2-iodo-6-methylbenzoate (<b>16a</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.29 (dd, <i>J</i><sub>HH</sub> = 8.4 Hz, <i>J</i><sub>HF</sub> = 5.2 Hz, 1H), 7.25 (dd, <i>J</i><sub>HH</sub> = 8.4 Hz, <i>J</i><sub>HF</sub> = 8.0 Hz, 1H), 3.89 (s, 3H), 2.24 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 295 (MH<sup>+</sup>).</div></div><div id="sec5_1_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> Methyl 3-Fluoro-6-iodo-2-methylbenzoate (<b>16c</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.75 (dd, <i>J</i><sub>HH</sub> = 8.7 Hz, <i>J</i><sub>HF</sub> = 5.0 Hz, 1H), 7.11 (dd, <i>J</i><sub>HH</sub> = 8.7 Hz, <i>J</i><sub>HF</sub> = 9.5 Hz 1H), 3.89 (s, 3H), 2.16 (d, <i>J</i><sub>HF</sub> = 2.3 Hz, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 295 (MH<sup>+</sup>).</div></div><div id="sec5_1_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> Methyl 4-Chloro-2-iodo-6-methylbenzoate (<b>16d</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.82 (m, 1H), 7.46 (m, 1H), 3.87 (s, 3H), 2.25 (s, 3H). ESI(+) MS: <i>m</i>/<i>z</i> 311 (MH<sup>+</sup>).</div></div></div><div id="sec5_1_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-5-fluoro-7-iodo-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18by</b>)</h4><div class="NLM_p last">To a solution of <b>16b</b> (2.2 g, 7.5 mmol) in methyl pivalate (13 mL), <i>N</i>-bromosuccinimide (2.2 g, 12.3 mmol) and benzoylperoxide (146 mg, 0.78 mmol) were added. The reaction mixture was stirred at 85 °C under nitrogen atmosphere for 3 h. Crude was filtered on Gooch and washed with toluene. Volatiles were evaporated, and the residue was dissolved in acetonitrile (21 mL). Triethylamine (2.8 mL, 20.4 mmol) and <b>17y</b> (1.5 g, 6.8 mmol) were added, and the reaction mixture was stirred at 90 °C for 4 h. Crude was diluted with dichloromethane and washed with 15% ammonium hydroxide. The organic phase was dried over sodium sulfate, filtered, and evaporated. Column chromatography (dichloromethane/ethanol: 95/5) afforded title compound (1.9 g, 58%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.80 (dd, <i>J</i><sub>HH</sub> = 2.2 Hz, <i>J</i><sub>HF</sub> = 8.9 Hz, 1H), 7.51 (dd, <i>J</i><sub>HH</sub> = 2.2 Hz, <i>J</i><sub>HF</sub> = 8.3 Hz, 1H), 4.37 (s, 2H), 4.02–3.89 (m, 1H), 2.99–2.88 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.33–2.21 (m, 2H), 2.10–1.97 (m, 2H), 1.90–1.67 (m, 8H), 1.61–1.47 (m, 2H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>23</sub>F<sub>3</sub>IN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup> 479.0802; found 479.0803.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Compounds <b>18ay</b>, <b>18cy</b>, and <b>18dy</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material. the following compounds were obtained:</div><div id="sec5_1_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-7-iodo-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18ay</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.57 (dd, <i>J</i><sub>HH</sub> = 8.2 Hz, <i>J</i><sub>HF</sub> = 4.6 Hz, 1H), 7.45 (dd, <i>J</i><sub>HH</sub> = 8.2 Hz, <i>J</i><sub>HF</sub> = 8.4 Hz, 1H), 4.36 (s, 2H), 4.02–3.92 (m, 1H), 2.98–2.90 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.32–2.22 (m, 2H), 2.10–1.96 (m, 2H), 1.91–1.69 (m, 8H), 1.60–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>22</sub>F<sub>3</sub>IN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup> 479.0802; found 479.0790.</div></div><div id="sec5_1_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-4-fluoro-7-iodo-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18cy</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 4.5 Hz, 1H), 7.24 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 8.7 Hz, 1H), 4.47 (s, 2H), 4.01–3.90 (m, 1H), 2.97–2.90 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.31–2.22 (m, 2H), 2.11–1.93 (m, 2H), 1.92–1.67 (m, 8H), 1.61–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>19</sub>H<sub>23</sub>F<sub>3</sub>IN<sub>2</sub>O<sup>+</sup> [M + H]<sup>+</sup> 479.0802; found 479.0804.</div></div><div id="sec5_1_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-5-chloro-7-iodo-2,3-dihydro-1<i>H</i>-isoindol-1-one (<b>18dy</b>)</h5><div class="NLM_p last">ESI(+) MS: <i>m</i>/<i>z</i> 495 (MH+). After HPLC-MS analysis, compound <b>18dy</b> was submitted to the next step without further purification and <sup>1</sup>H NMR characterization.</div></div></div><div id="sec5_1_10_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carbonitrile (<b>19by</b>)</h4><div class="NLM_p last"><b>18by</b> (1.9 g, 3.97 mmol) and copper(I) cyanide (534 mg, 5.96 mmol) were dissolved in <i>N</i>,<i>N</i>-dimethylformamide (16 mL), and the resulted solution was refluxed under nitrogen atmosphere for 3 h. The solvent was removed under reduced pressure, and the residue was diluted with dichloromethane and washed with 15% ammonium hydroxide. Organic phase was dried over sodium sulfate, filtered, and evaporated. Column chromatography (dichloromethane/ethanol: 95/5) afforded title compound (1.28 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.95 (dd, <i>J</i><sub>HH</sub> = 2.2 Hz, <i>J</i><sub>HF</sub> = 9.2 Hz, 1H), 7.83 (dd, <i>J</i><sub>HH</sub> = 2.2 Hz, <i>J</i><sub>HF</sub> = 8.3 Hz, 1H), 4.49 (m, 2H), 3.98–3.89 (m, 1H), 2.98–2.86 (m, 2H), 2.51–2.41 (m overlapped by DMSO signal, 1H), 2.33–2.19 (m, 2H), 2.07–1.92 (m, 2H), 1.90–1.64 (m, 8H), 1.58–1.43 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup> 378.1788; found 378.1782.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Compounds <b>19ay</b>, <b>19cy</b>, and <b>19dy</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-5-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carbonitrile (<b>19ay</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.98 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 4.6 Hz, 1H), 7.74 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 9.8 Hz, 1H), 4.51 (s, 2H), 4.02–3.92 (m, 1H), 2.97–2.90 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.34–2.23 (m, 2H), 2.11–1.96 (m, 2H), 1.93–1.67 (m, 8H), 1.61–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>F<sub>3</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup> 378.1788; found 378.1779.</div></div><div id="sec5_1_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 7-Fluoro-2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carbonitrile (<b>19cy</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.05 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 4.3 Hz, 1H), 7.65 (dd, <i>J</i><sub>HH</sub> = 8.5 Hz, <i>J</i><sub>HF</sub> = 8.7 Hz, 1H), 4.62 (s, 2H), 4.02–3.92 (m, 1H), 2.97–2.90 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.34–2.24 (m, 2H), 2.11–1.96 (m, 2H), 1.93–1.67 (m, 8H), 1.61–1.48 (m, 2H). ESI(+) MS: <i>m</i>/<i>z</i> 378 (MH<sup>+</sup>).</div></div><div id="sec5_1_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 6-Chloro-2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carbonitrile (<b>19dy</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.15 (d, <i>J</i> = 1.8 Hz, 1H), 8.06 (d, <i>J</i> = 1.8 Hz, 1H), 4.52 (s, 2H), 4.01–3.91 (m, 1H), 2.97–2.90 (m, 2H), 2.55–2.44 (m overlapped by DMSO signal, 1H), 2.33–2.22 (m, 2H), 2.10–1.96 (m, 2H), 1.92–1.69 (m, 8H), 1.63–1.46 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>23</sub>ClF<sub>2</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup> 394.1492; found 394.1502.</div></div></div><div id="sec5_1_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 2-[1-(4,4-Difluorocyclohexyl)-piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>20by</b>)</h4><div class="NLM_p last">To a solution of <b>19by</b> (2.81 g; 7.44 mmol) in toluene (28 mL), acetaldoxime (4.4 g; 74.4 mmol) and indium(III) chloride (82 mg; 0.37 mmol) were added at room temperature. The resulting solution was heated at reflux for 1 h then concentrated under reduced pressure. The residue was taken up with water, 2-propanol, and dichloromethane. The organic layer was separated and finally concentrated under reduced pressure. The resulting crude was crystallized from ethanol, delivering, after drying, the desired compound (1.82 g, 62%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.77 (bs, 1H), 7.89 (dd, <i>J</i><sub>HH</sub> = 2.6 Hz, <i>J</i><sub>HF</sub> = 10.9 Hz, 1H), 7.85 (bs, 1H), 7.66 (dd, <i>J</i><sub>HH</sub> = 2.6 Hz, <i>J</i><sub>HF</sub> = 7.7 Hz, 1H), 4.56 (s, 2H), 4.04–3.94 (m, 1H), 2.98–2.91 (m, 2H), 2.53–2.45 (m, overlapped by DMSO signal, 1H), 2.32–2.22 (m, 2H), 2.10–1.96 (m, 2H), 1.92–1.67 (m, 8H), 1.60–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 396.1894; found 396.1890.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Compounds <b>20ay</b>, <b>20cy</b>, and <b>20dy</b></h4><div class="NLM_p">Operating in an analogous way but employing suitably substituted starting material, the following compounds were obtained:</div><div id="sec5_1_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-5-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>20ay</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.86 (bs, 1H), 7.62 (bs, 1H), 7.59 (dd, <i>J</i><sub>HH</sub> = 8.4 Hz, <i>J</i><sub>HF</sub> = 4.5 Hz, 1H), 7.44 (dd, <i>J</i><sub>HH</sub> = 8.4 Hz, <i>J</i><sub>HF</sub> = 9.6 Hz, 1H), 4.42 (s, 2H), 3.99–3.89 (m, 1H), 2.97–2.90 (m, 2H), 2.53–2.45 (m overlapped by DMSO signal, 1H), 2.32–2.23 (m, 2H), 2.10–1.96 (m, 2H), 1.91–1.66 (m, 8H), 1.61–1.46 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 396.1894; found 396.1884.</div></div><div id="sec5_1_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-7-fluoro-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>20cy</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (bs, 1H), 8.26 (dd, <i>J</i><sub>HH</sub> = 8.8 Hz, <i>J</i><sub>HF</sub> = 5.2 Hz, 1H), 7.71 (bs, 1H), 7.57 (dd, <i>J</i><sub>HH</sub> = 8.8 Hz, <i>J</i><sub>HF</sub> = 8.4 Hz, 1H), 4.63 (s, 2H), 4.06–3.95 (m, 1H), 2.99–2.91 (m, 2H), 2.56–2.44 (m overlapped by DMSO signal, 1H), 2.34–2.22 (m, 2H), 2.09–1.97 (m, 2H), 1.93–1.71 (m, 8H), 1.61–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>25</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 396.1894; found 396.1900.</div></div><div id="sec5_1_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 6-Chloro-2-[1-(4,4-difluorocyclohexyl)piperidin-4-yl]-3-oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamide (<b>20dy</b>)</h5><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (bs, 1H), 8.12 (d, <i>J</i> = 2.1 Hz, 1H), 7.89 (d, <i>J</i> = 2.1 Hz, 1H), 7.86 (bs, 1H), 4.56 (s, 2H), 4.05–3.95 (m, 1H), 2.98–2.91 (m, 2H), 2.54–2.45 (m overlapped by DMSO signal, 1H), 2.32–2.23 (m, 2H), 2.10–1.97 (m, 2H), 1.91–1.68 (m, 8H), 1.61–1.48 (m, 2H). HRMS (ESI+): calcd for C<sub>20</sub>H<sub>25</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 412.1598; found 412.159</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105">2 Biochemistry</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106">2.1 Protein Production</h4><div class="NLM_p last">PARP-1 full length (FL) and catalytic domain (CD), PARP-2 FL and CD, PARP-3 FL, and TNKS-1 CD were prepared as previously described.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107">2.2 Fluorescence Polarization Displacement Assay</h4><div class="NLM_p last">Fluorescence polarization displacement assay on PARP-1 FL, PARP-2 FL, PARP-3 FL, and TNKS-1 CD was performed as reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108">2.3 Surface Plasmon Resonance Binding Assay</h4><div class="NLM_p last">Surface plasmon resonance binding assay on PARP-1 CD and on PARP-2 CD was conducted as previously reported.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109">2.4 Kinase Assay</h4><div class="NLM_p last">Compound <b>20by</b> was profiled as previously described<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> on 56 different kinases (ABL, ACK1, AKT1, ALK, AUR1, AUR2, BRK, BUB1, CDC7/DBF4, CDK2/CYCA, CHK1, CK2, EEF2K, EGFR1, ERK2, EphA2, FAK, FGFR1, FLT3, GSK3beta, Haspin, IGFR1, IKK2, IR, JAK1, JAK2, JAK3, KIT, LCK, LYN, MAPKAPK2, MELK, MET, MNK2, MPS1, MST4, NEK6, NIM1, P38alpha, PAK4, PDGFRb, PDK1, PERK, PIM1, PIM2, PKAalpha, PKCbeta, PLK1, RET, SULU1, Syk, TLK2, TRKA, TYK2, VEGFR2, ZAP70). The IC<sub>50</sub> values were found to be >10 μM for all enzymes tested.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110">2.5 HTS Campaign</h4><div class="NLM_p last">See ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a> for HTS experimental details.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111">3 Cell Biology</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112">3.1 PAR Assay</h4><div class="NLM_p">Cellular activity of PARP-1 inhibitors was assessed by measuring the inhibition of the hydrogen peroxide induced PAR formation in HeLa cells (ECACC). Cellular PAR levels were measured by immunocytochemistry and quantified using an ArrayScan vTi instrument (Cellomics Thermo Scientific).</div><div class="NLM_p last">Studies were performed as follows: 6000 cells/well were seeded in 96-well plates (PerkinElmer) in MEM/10% FCS and incubated for 24 h at 37 °C, 5% carbon dioxide. Test compounds were then added at the required concentration for 30 min. DNA damage was then induced by adding hydrogen peroxide at the concentration of 0.1 mM for 15 min. Concentration curves were prepared in MEM/10% FCS from compound stocks in DMSO, and final DMSO concentration was 0.002% (v/v). Duplicate wells for each concentration point were prepared with a typical highest compound concentration of 20 μM and serial dilution 1:3. Plates were dried and fixed by adding cold methanol–acetone (70:30) solution for 15 min at room temperature, fixing solution was aspired, and wells were air-dried for 5 min and then dehydrated in PBS. Nonspecific binding sites were blocked by incubating wells for 30 min in PBS containing 5% (w/v) FBS 0.05% Tween 20. Wells were then incubated for 1 h at room temperature in PBS containing anti-PAR mouse monoclonal antibody (Anti-PAR, mouse mAb 10H, Tulip Catalogue no. 1020) diluted 1:200 in blocking solution. After three washes in PBS, wells incubated in PBS (w/v) 5% FBS 0.05% Tween 20 containing 2 μg/mL Cy2-conjugated Goat anti-mouse secondary antibody (Amersham Pharmacia Biotech catalogue no. PA 42002) (absorption maximum 489 nm fluorescence maximum 506 nm) and 1 μg/mL DAPI (4′,6-diamidino-2-phenylindole dilactate, absorption maximum 359 nm fluorescence maximum 461 nm, Sigma catalogue no. D9564). After washing further three times in PBS, cellular PAR immunoreactivity was assessed using the ArrayScan vTi instrument, with a Zeiss 10× 0.5 NA objective and applying the CytoNucTrans V3 algorithm (Cellomics/Thermo Fisher) with a XF100 filter. At least 10 fields, corresponding to at least 900 cells, were read for each well. Compound IC<sub>50</sub>s were derived from sigmoidal interpolation functions of experimental data using GraphPad Prism software.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113">3.2 Colony Forming Assay</h4><div class="NLM_p last">Inhibition of cell proliferation was evaluated as follows: cells were seeded at a density of 600 cells/cm<sup>2</sup> in RPMI medium, supplemented with 10% FBS. After 24 h, medium was replaced with the same containing increasing serial dilutions of inhibitor starting from a highest concentration of 10 μM. After 10 days, cells were fixed and stained with crystal violet. Colonies were counted using Infrared Scanner (Odyssey Li-Cor). All the experiments were performed in duplicate. IC<sub>50</sub> was calculated using the GraphPad Prism software.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114">4 X-ray Crystallographic Data</h3><div class="NLM_p last">Crystals of the catalytic domain of hPARP-1 in complex with compound <b>10b</b> and <b>20by</b> were grown at 4 °C using the vapor diffusion method from a solution of 2 M ammonium sulfate, 2% Peg 400, and 0.1 M Tris, pH 8. Before crystallization, the protein was concentrated at 10 mg/mL in a buffer containing 50 mM TrisHCl, pH 8.0, 150 mM sodium chloride, 10% glycerol, 14 mM β-mercaptoethanol, and 0.1% β-octylglucoside. Compounds <b>10b</b> and <b>20by</b> were added to the protein solution at a final concentration of 0.5 mM. Small cocrystals of <b>10b</b> grew in a few days and were optimized using streak seeding. On the contrary, the catalytic domain of hPARP-1 in complex with <b>20by</b> crystallized only after several months, giving a different crystal form (space group of hPARP-1–<b>20by</b> crystal is <i>I</i>222, while for hPARP-1–<b>10b</b> crystal is <i>C</i>2). For data collection, crystals were cryoprotected in a mother liquor solution containing 30% glycerol and frozen in liquid nitrogen. Crystals of the catalytic domain of hPARP-2 in complex with compounds <b>10b</b> and <b>20by</b> were obtained at 4 °C by the vapor diffusion method (hanging drops), mixing equal volumes of a protein solution (10 mg/mL of protein in 50 mM TrisHCl, pH 8.5, 150 mM sodium chloride, and 0.5 mM dithiothreitol (DTT) containing either <b>10b</b> or <b>20by</b> at a final concentration of 0.5 mM) and the reservoir solution consisting of 25% PEG 4000, 0.2 M magnesium chloride, and 0.1 M TrisHCl, pH 8.5. Addition of 0.1% β-octylglucoside and streak seeding improved the quality and reproducibility of the crystals. Crystals were further transferred to a cryoprotectant solution (reservoir solution supplemented with 30% glycerol) and frozen in liquid nitrogen. Diffraction data for the different complexes were collected at ESRF (Grenoble, France). Data were indexed and integrated using Mosflm and Scala,<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> structures were refined with Refmac,<a onclick="showRef(event, 'ref48 ref49'); return false;" href="javascript:void(0);" class="ref ref48 ref49">(48, 49)</a> and model building was performed with Coot.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> All structures have been deposited to the Protein Data Bank (PDB) with accession codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX">4ZZX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115">5 ADME Data</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116">5.1 Solubility</h4><div class="NLM_p last">Solubility at pH = 7 was measured as previously reported.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117">5.2 Cell Permeability</h4><div class="NLM_p last">PAMPA permeability assay was performed as described.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118">5.3 Plasma Protein Binding</h4><div class="NLM_p last">Plasma protein binding was evaluated according to the methodology already described.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119">5.4 Intrinsic Clearance in Human Liver Microsomes (HLM)</h4><div class="NLM_p last">Metabolic stability in the presence of human liver microsomes was assessed as reported.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120">5.5 Intrinsic Clearance in Rat Hepatocytes</h4><div class="NLM_p last">Clearance determination in rat hepatocytes was performed as previously described.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></div></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121">6 In Vivo Pharmacokinetic Studies</h3><div class="NLM_p">All procedures adopted for housing and handling of animals were in strict compliance with Italian and European guidelines for Laboratory Animal Welfare and the protocols were approved by IRB.</div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122">6.1 Pharmacokinetics in Mouse</h4><div class="NLM_p last">The pharmacokinetic profile and the oral bioavailability of the compounds have been investigated in mouse (Balb, Nu/Nu, Harlan, Italy) in ad hoc pharmacokinetic studies. The compounds were formulated for intravenous bolus administration as follows: 5% Tween 80 in 5% dextrose for <b>13i</b>; PEG 400 in 5% dextrose for <b>13ad</b>; 10% Tween 80 in 5% dextrose for <b>13af</b> and <b>20by</b>. Oral administration was performed by using the compounds formulated in 0.5% methylcellulose. A single administration at the dose of 10 mg/kg was given, and three male animals for each route were used. All blood samples were taken from retro-orbital vein at 5 min, 30 min, 1 h, 3 h, 6 h, and 24 h after intravenous administration and 15 min, 30 min, 1 h, 3 h, 6 h, and 24 h after oral administration. Plasma samples were prepared by plasma proteins precipitation by adding 200 μL of acetonitrile to 20 μL of plasma in a 96-well plate. After capping and vortex mixing, the plate was centrifuged for 15 min at 4000 rpm. The supernatant was considered as final extract and injected onto the LC-MS/MS system (UHPLC system, Waters Acquity using BEH HILIC 50 mm × 2.1 mm 1.7 μm analytical column; MS instrument, Waters TQD equipped with electrospray ion source operating in positive ion mode). Lower limit of quantification is 5.0 ng/mL, and upper limit of quantification is 5000 ng/mL. Pharmacokinetic analysis was performed with WinNonlin software (version 5.2.1) using a noncompartmental method (linear trapezoidal rule and linear regression analysis of natural log-transformed plasma concentrations vs time data). Oral bioavailability (<i>F</i>) was calculated from the ratio of average oral to IV (intravenous) dose-normalized plasma AUC values.</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123">6.2 Pharmacokinetics in Rat</h4><div class="NLM_p last">The pharmacokinetic profile and the oral bioavailability of the compounds have been investigated in rat (Sprague–Dawley, Charles River Laboratories, Italy) in ad hoc pharmacokinetic studies. Compound <b>20by</b> was formulated for intravenous bolus administration in 20% DMSO + 40% PEG 400 in 5% dextrose. Oral administration was performed by using a <b>20by</b> suspension in 0.5% methylcellulose. A single administration at the dose of 10 mg/kg for each route, and a single oral administration at the dose of 100 mg/kg were given. Three male animals for each study were used. All blood samples were taken by means of a cannula implanted in the superior vena cava via the jugular vein at 5 min, 30 min, 1 h, 3 h, 6 h,and 24 h after intravenous administration and 15 min, 30 min, 1 h, 3 h, 6 h, and 24 h after oral administration. Plasma samples were prepared by plasma proteins precipitation by adding 200 μL of acetonitrile to 20 μL of plasma in a 96-well plate. After capping and vortex mixing, the plate was centrifuged for 15 min at 3700 rpm at 6 °C. The supernatant was considered as final extract and injected onto the LC-MS/MS system (HPLC system, Hewlett-Packard 1100 series using Zorbax SB CN 75 mm × 4.6 mm 3.5 μm analytical column; MS instrument, MDS/SCIEX 4000QTRAP equipped with TURBO ION SPRAY source operating in positive ion mode). Lower limit of quantification is 4.3 ng/mL, and upper limit of quantification is 1030 ng/mL. Pharmacokinetic analysis was performed with Watson package (version 6.4.0.04) and Excel spreadsheet (Microsoft Inc., Seattle, USA) using a noncompartmental method (linear trapezoidal rule and linear regression analysis of natural log-transformed plasma concentrations vs time data). Absolute bioavailability (<i>F</i>) was calculated from the ratio of average oral to IV (intravenous) dose-normalized plasma AUC (area under curve) values.</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124">7 In Vivo Pharmacology</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125">7.1 <b>20by</b> Antitumor Activity As Single Agent</h4><div class="NLM_p last">The antitumor activity of compound <b>20by</b> was investigated in female athymic nu/nu mice carrying subcutaneously MDA-MB-436 triple negative BRCA1 mutated breast cancer. When tumors reached an average volume of ∼150 mm<sup>3</sup>, mice were randomized into various treatment groups and were treated orally, once a day, for 28 consecutive days, with <b>20by</b> (150 mg/kg) or empty vehicle (1% Tween 80 in methocel). Median tumor volume of seven mice per group was determined by caliper and was plotted over time to monitor tumor growth (first day of treatment is day 21).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126">7.2 <b>20by</b> Antitumor Activity in Combination with Temozolomide (TMZ)</h4><div class="NLM_p last">In a combination study with Temozolomide, <b>20by</b> was administered to male athymic nu/nu mice carrying subcutaneously implanted Capan-1 pancreatic cancer cells, orally once daily for 12 days at the dose of 100 mg/kg, starting on day 9. Temozolomide was administered in glucosate at a dosage of 50 mg/kg for 5 days starting from day 11.</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127">8 In Vivo Pharmacodynamics</h3><div class="NLM_p last">Tumors of animals treated with a single oral administration of <b>20by</b> (100 mg/kg) were harvested at 2, 4, 8, and 24 h, homogenized in PBS, and extracted with lysis buffer. Levels of PAR in the tumor lysates were determined by ELISA. Plates were first coated with anti-PAR monoclonal antibody (Tulip) for 2 h at 37 °C and then washed with PBS 0.1% Tween 20. After blocking, 10 mg of tumor lysates were added to the plate in triplicate and left overnight at 4 °C in PBS 2% BSA and 0.5% SDS. The day after the plates were washed and the polyclonal primary antibody, anti-PAR (Trevigen) was added, diluted 1:2000 in PBS 2% BSA and mouse serum 1:500. Two hours later, the plates were washed with PBS 0.1% Tween 20 and incubated with the secondary antibody anti-HRP (Amersham) diluted 1:1000 in the same buffer as for the primary antibody. The substrate Supersignal ELISA Pico was than added after washes, and the plates were read at 425 nm.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i128"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00680">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00680" class="ext-link">10.1021/acs.jmedchem.5b00680</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Quantitative assessment of the intramolecular hydrogen bond strength of selected isoindolinones; detailed kinetic parameters and kinetic analysis of surface plasmon resonance binding assay; experimental details concerning in vitro evaluation of cross species metabolism, cytochrome P450 inhibition, and mielotoxicity of compound <b>20by</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Isoindolinones preliminary SAR investigation molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_002.xls" class="ext-link">XLS</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf">jm5b00680_si_001.pdf (86.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_002.xls">jm5b00680_si_002.xls (25.0 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">All structures have been deposited to the Protein Data Bank (PDB) with accession codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX">4ZZX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b00680" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57026" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57026" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gianluca Papeo</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f7909e96999b829496d98796879298b7999285819e9699989a84d994989a"><span class="__cf_email__" data-cfemail="1d7a747c7371687e7c336d7c6d78725d73786f6b747c7372706e337e7270">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helena Posteri</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniela Borghi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alina A. Busel</span> - <span class="hlFld-Affiliation affiliation">Chemical Diversity Research Institute, Rabochaya St. 2 Khimki, Moscow Region  114401, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Caprera</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Casale</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Ciomei</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandra Cirla</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emiliana Corti</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matteo D’Anello</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Fasolini</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Forte</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arturo Galvani</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonella Isacchi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Khvat</span> - <span class="hlFld-Affiliation affiliation">Chemical Diversity Research Institute, Rabochaya St. 2 Khimki, Moscow Region  114401, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mikhail Y. Krasavin</span> - <span class="hlFld-Affiliation affiliation">Chemical Diversity Research Institute, Rabochaya St. 2 Khimki, Moscow Region  114401, Russia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rosita Lupi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paolo Orsini</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Perego</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Enrico Pesenti</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniele Pezzetta</span> - <span class="hlFld-Affiliation affiliation">Accelera Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonia Rainoldi</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Federico Riccardi-Sirtori</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessandra Scolaro</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Sola</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fabio Zuccotto</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eduard R. Felder</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniele Donati</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alessia Montagnoli</span> - <span class="hlFld-Affiliation affiliation">Oncology, Nerviano
Medical Sciences Srl, Viale Pasteur 10, 20014 Nerviano, Milan, Italy</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2220e7540-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i132">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the technical skill and support of the Experimental Therapy Team, the Biochemical Screening Group, and Analytical Chemistry Department of NMS.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i133" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i133"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i134" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i134"> Abbreviations Used</h2><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">adenine-ribose</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion</p></td></tr><tr><td class="NLM_term">ARTD</td><td class="NLM_def"><p class="first last">ADP-ribosyltransferase diphtheria toxin-like</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration versus time curve up to the last detectable concentration</p></td></tr><tr><td class="NLM_term">BEI</td><td class="NLM_def"><p class="first last">binding efficiency index</p></td></tr><tr><td class="NLM_term">BRCA</td><td class="NLM_def"><p class="first last">breast cancer susceptibility gene</p></td></tr><tr><td class="NLM_term">BSA</td><td class="NLM_def"><p class="first last">bovine serum albumine</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">catalytic domain</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">DAPI</td><td class="NLM_def"><p class="first last">4′,6-diamidino-2-phenylindole</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">dithiothreitol</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ELISA</td><td class="NLM_def"><p class="first last">enzyme-linked immunosorbent assay</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">FBS</td><td class="NLM_def"><p class="first last">fetal bovine serum</p></td></tr><tr><td class="NLM_term">FCS</td><td class="NLM_def"><p class="first last">fetal calf serum</p></td></tr><tr><td class="NLM_term">FL</td><td class="NLM_def"><p class="first last">full length</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">homologous recombination</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">LE</td><td class="NLM_def"><p class="first last">ligand efficiency</p></td></tr><tr><td class="NLM_term">MEM</td><td class="NLM_def"><p class="first last">minimum essential medium</p></td></tr><tr><td class="NLM_term">MSI</td><td class="NLM_def"><p class="first last">microsatellite instability</p></td></tr><tr><td class="NLM_term">NAD<sup>+</sup></td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide</p></td></tr><tr><td class="NLM_term">NAMPT</td><td class="NLM_def"><p class="first last">nicotinamide phosphoribosyltransferase</p></td></tr><tr><td class="NLM_term">PAR</td><td class="NLM_def"><p class="first last">poly(ADP-ribose)</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate buffered saline</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">RPMI</td><td class="NLM_def"><p class="first last">Roswell Park Memorial Institute (culture medium)</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SDS</td><td class="NLM_def"><p class="first last">sodium dodecyl sulfate</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of measurement</p></td></tr><tr><td class="NLM_term">SIRT1</td><td class="NLM_def"><p class="first last">sirtuin 1</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">terminal half-life</p></td></tr><tr><td class="NLM_term">TNKS-1</td><td class="NLM_def"><p class="first last">tankyrase-1</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i135">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47046" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47046" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hottiger, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lüscher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch-Nolte, F.</span><span> </span><span class="NLM_article-title">Toward a unified nomenclature for mammalian ADP-ribosyltransferases</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.tibs.2009.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tibs.2009.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20106667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVegs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=208-219&author=M.+O.+Hottigerauthor=P.+O.+Hassaauthor=B.+L%C3%BCscherauthor=H.+Sch%C3%BClerauthor=F.+Koch-Nolte&title=Toward+a+unified+nomenclature+for+mammalian+ADP-ribosyltransferases&doi=10.1016%2Fj.tibs.2009.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a unified nomenclature for mammalian ADP-ribosyltransferases</span></div><div class="casAuthors">Hottiger, Michael O.; Hassa, Paul O.; Luescher, Bernhard; Schueler, Herwig; Koch-Nolte, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  ADP-ribosylation is a post-translational modification of proteins catalyzed by ADP-ribosyltransferases.  It comprises the transfer of the ADP-ribose moiety from NAD+ to specific amino acid residues on substrate proteins or to ADP-ribose itself.  Currently, 22 human genes encoding proteins that possess an ADP-ribosyltransferase catalytic domain are known.  Recent structural and enzymol. evidence of poly(ADP-ribose)polymerase (PARP) family members demonstrate that earlier proposed names and classifications of these proteins are no longer accurate.  Here we summarize these new findings and propose a new consensus nomenclature for all ADP-ribosyltransferases (ARTs) based on the catalyzed reaction and on structural features.  A unified nomenclature would facilitate communication between researchers both inside and outside the ADP-ribosylation field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg6kR-35XzU7Vg90H21EOLACvtfcHk0ljr5fWkqP5rUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVegs70%253D&md5=0e63a298da9140bea11180b58bec7357</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2009.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2009.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DKoch-Nolte%26aufirst%3DF.%26atitle%3DToward%2520a%2520unified%2520nomenclature%2520for%2520mammalian%2520ADP-ribosyltransferases%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26spage%3D208%26epage%3D219%26doi%3D10.1016%2Fj.tibs.2009.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Krishnakumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.molcel.2010.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20603072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8-24&author=R.+Krishnakumarauthor=W.+L.+Kraus&title=The+PARP+side+of+the+nucleus%3A+molecular+actions%2C+physiological+outcomes%2C+and+clinical+targets&doi=10.1016%2Fj.molcel.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span></div><div class="casAuthors">Krishnakumar, Raga; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-24</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus.  Recent studies have begun to connect the mol. functions of PARP-1 to specific physiol. and pathol. outcomes, many of which can be altered by an expanding array of chem. inhibitors of PARP enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy5Mj-wajemLVg90H21EOLACvtfcHk0lj6CnuSDaOtbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D&md5=afb9423e09ed68d2bfa589ed0d7b9f13</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DThe%2520PARP%2520side%2520of%2520the%2520nucleus%253A%2520molecular%2520actions%252C%2520physiological%2520outcomes%252C%2520and%2520clinical%2520targets%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D39%26spage%3D8%26epage%3D24%26doi%3D10.1016%2Fj.molcel.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yelamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacuna, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampurdanes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Caballero, J.</span><span> </span><span class="NLM_article-title">PARP-1 and PARP-2: new players in tumour development</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=21968702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Kntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=328-346&author=J.+Yelamosauthor=J.+Farresauthor=L.+Lacunaauthor=C.+Ampurdanesauthor=J.+Martin-Caballero&title=PARP-1+and+PARP-2%3A+new+players+in+tumour+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 and PARP-2: new players in tumour development</span></div><div class="casAuthors">Yelamos, Jose; Farres, Jordi; Llacuna, Laura; Ampurdanes, Coral; Martin-Caballero, Juan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-346</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 belong to a family of enzymes that, using NAD+ as a substrate, catalyze poly(ADP-ribosyl)ation of proteins.  PARP-1 and PARP-2 catalytic activity is stimulated by DNAstrand breaks targeting mainly proteins involved in chromatin structure and DNA metab., providing strong support for a dual role of both PARP-1 and PARP-2 in the DNA damage response as DNA damage sensors and signal transducers to downstream effectors.  The DNA damage response has important consequences for genomic stability and tumor development.  In order to manipulate DNA damage responses to selectively induce tumor cell death, a considerable effort is centered on defining the mol. mechanisms that allow cells to detect, respond to, and repair DNA damage.  PARP inhibitors that compete with NAD+ at the highly conserved enzyme active site are arisen as new potential therapeutic strategies as chemo- and radio-potentiation and for the treatment of cancers with specific DNA repair defects as single-agent therapies.  In the present review, we highlight emerging information about the redundant and specific functions of PARP-1 and PARP-2 in genome surveillance and DNA repair pathways.  Understanding these roles might provide invaluable clues to design new cancer therapeutic approaches.  In addn., we provide an overview of ongoing clin. trials with PARP inhibitors and the value of PARP-1 and PARP-2 expression as prognostic biomarkers in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCyD_d1BJyCLVg90H21EOLACvtfcHk0lj6CnuSDaOtbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Kntr8%253D&md5=b2a7b4eede3a41a9279031a2032b8ed8</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYelamos%26aufirst%3DJ.%26aulast%3DFarres%26aufirst%3DJ.%26aulast%3DLacuna%26aufirst%3DL.%26aulast%3DAmpurdanes%26aufirst%3DC.%26aulast%3DMartin-Caballero%26aufirst%3DJ.%26atitle%3DPARP-1%2520and%2520PARP-2%253A%2520new%2520players%2520in%2520tumour%2520development%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2011%26volume%3D1%26spage%3D328%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryu, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2453</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span><span class="refDoi"> DOI: 10.1021/cr5004248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5004248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2453-2481&author=K.+W.+Ryuauthor=D.-S.+Kimauthor=W.+L.+Kraus&title=New+Facets+in+the+Regulation+of+Gene+Expression+by+ADP-Ribosylation+and+Poly%28ADP-ribose%29+Polymerases&doi=10.1021%2Fcr5004248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span></div><div class="casAuthors">Ryu, Keun Woo; Kim, Dae-Seok; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2453-2481</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the role of poly(ADP-ribose) polymerases (PARPs) and ADP-ribosylation in gene regulation, with a particular emphasis on the role of PARPs in RNA biol.  Topics include: the PARP family; NAD+ metab. and PARP-1; PARP-1 in gene regulation including chromatin modulation, transcription regulation, and non-coding RNA regulation; and PARP-1 in ribosome biogenesis, stress response, circadian rhythm, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF0xfFz6hkG7Vg90H21EOLACvtfcHk0liqSYPy5eThSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D&md5=496f79e7a373d08dd7c116fe9d74eb1a</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1021%2Fcr5004248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5004248%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DD.-S.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DNew%2520Facets%2520in%2520the%2520Regulation%2520of%2520Gene%2520Expression%2520by%2520ADP-Ribosylation%2520and%2520Poly%2528ADP-ribose%2529%2520Polymerases%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2453%26epage%3D2481%26doi%3D10.1021%2Fcr5004248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+Poly%28ADP-ribose%29+Polymerase-1+%28PARP-1%29+Inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0liqSYPy5eThSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase-1%2520%2528PARP-1%2529%2520Inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+Curtinauthor=C.+Szabo&title=Therapeutic+applications+of+PARP+inhibitors%3A+anticancer+therapy+and+beyond&doi=10.1016%2Fj.mam.2013.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0li7EANeK8cnpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256%26doi%3D10.1016%2Fj.mam.2013.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Small-molecule PARP modulators – Current status and future therapeutic potential</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=577-586&author=T.+D.+Penning&title=Small-molecule+PARP+modulators+%E2%80%93+Current+status+and+future+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSmall-molecule%2520PARP%2520modulators%2520%25E2%2580%2593%2520Current%2520status%2520and%2520future%2520therapeutic%2520potential%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D577%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Development of poly (ADP-Ribose)polymerase (PARP) inhibitors in oncology</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/S0065-7743(10)45014-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2FS0065-7743%2810%2945014-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=229-243&author=P.+Jones&title=Development+of+poly+%28ADP-Ribose%29polymerase+%28PARP%29+inhibitors+in+oncology&doi=10.1016%2FS0065-7743%2810%2945014-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945014-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945014-9%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520poly%2520%2528ADP-Ribose%2529polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520oncology%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D229%26epage%3D243%26doi%3D10.1016%2FS0065-7743%2810%2945014-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Advances in using PARP inhibitors to treat cancer</span> <span class="citation_source-journal">BMC Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="refDoi"> DOI: 10.1186/1741-7015-10-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1186%2F1741-7015-10-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22401667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslansLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=25&author=S.+Kummarauthor=A.+Chenauthor=R.+E.+Parchmentauthor=R.+J.+Kindersauthor=J.+Jiauthor=J.+E.+Tomaszewskiauthor=J.+H.+Doroshow&title=Advances+in+using+PARP+inhibitors+to+treat+cancer&doi=10.1186%2F1741-7015-10-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in using PARP inhibitors to treat cancer</span></div><div class="casAuthors">Kummar, Shivaani; Chen, Alice; Parchment, Ralph E.; Kinders, Robert J.; Ji, Jay; Tomaszewski, Joseph E.; Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a crit. role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair.  PARP1 is overexpressed in a variety of cancers, and its expression has been assocd. with overall prognosis in cancer, esp. breast cancer.  A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clin. activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes.  Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ_-91orX7mbVg90H21EOLACvtfcHk0li7EANeK8cnpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslansLY%253D&md5=b60f719dfdd95e4c9ac876882a1ad056</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-10-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-10-25%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DAdvances%2520in%2520using%2520PARP%2520inhibitors%2520to%2520treat%2520cancer%26jtitle%3DBMC%2520Med.%26date%3D2012%26volume%3D10%26spage%3D25%26doi%3D10.1186%2F1741-7015-10-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors</span> <span class="citation_source-journal">Drug Discovery Today: Dis. Models</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e51</span><span class="NLM_x">–</span> <span class="NLM_lpage">e58</span><span class="refDoi"> DOI: 10.1016/j.ddmod.2012.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.ddmod.2012.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xktleitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=e51-e58&author=N.+J.+Curtin&title=Poly%28ADP-ribose%29+polymerase+%28PARP%29+and+PARP+inhibitors&doi=10.1016%2Fj.ddmod.2012.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors</span></div><div class="casAuthors">Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Disease Models</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e51-e58</span>CODEN:
                <span class="NLM_cas:coden">DDTDBP</span>;
        ISSN:<span class="NLM_cas:issn">1740-6757</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage.  PARP inhibitors have been under development since 1980 and first entered clin. trial in 2003.  They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in other DNA repair pathways.  There are now nine PARP inhibitors undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr86pCJ2PNT_bVg90H21EOLACvtfcHk0li6lThlWJykdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xktleitb0%253D&md5=0c837fbfeab0f4156c8d16b1c0b5cd31</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.ddmod.2012.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddmod.2012.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520and%2520PARP%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Dis.%2520Models%26date%3D2012%26volume%3D9%26spage%3De51%26epage%3De58%26doi%3D10.1016%2Fj.ddmod.2012.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Maxwell, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span> </span><span class="NLM_article-title">Cancer treatment according to <i>BRCA1</i> and <i>BRCA2</i> mutations</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2012.123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnrclinonc.2012.123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22825375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=520-528&author=K.+N.+Maxwellauthor=S.+M.+Domchek&title=Cancer+treatment+according+to+BRCA1+and+BRCA2+mutations&doi=10.1038%2Fnrclinonc.2012.123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment according to BRCA1 and BRCA2 mutations</span></div><div class="casAuthors">Maxwell, Kara N.; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">520-528</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Identification of germline mutations assocd. with significant cancer susceptibility has the potential to change all aspects of an individual's care, from screening to cancer treatment.  For example, women with germline mutations in BRCA1 and BRCA2 have markedly elevated risks of breast and ovarian cancer and the identification of these germline mutations has led to specific screening and prevention strategies.  More recently, advances in the understanding of the biol. function of BRCA1 and BRCA2 have led to clin. trials testing targeted therapies in this population, particularly poly(ADP-ribose) polymerase (PARP) inhibitors.  Unfortunately, the development of PARP inhibitors has not been as rapid as anticipated and has been more challenging than expected.  Somatic mutations identified in many cancer types have allowed the development of therapeutics that target these mutated genes, and many of these agents obtained rapid regulatory approval and are currently in widespread clin. practice.  Diagnostic testing has a central role in targeted cancer therapeutics for both somatic and germline mutations.  Although the era of mol. medicine and targeted therapies has led to significant changes in the practice of oncol., new challenges continue to arise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZAs-JKyS0bVg90H21EOLACvtfcHk0li6lThlWJykdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7zM&md5=c6da652ff478b6175e184f98cc7c13c2</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.123%26sid%3Dliteratum%253Aachs%26aulast%3DMaxwell%26aufirst%3DK.%2BN.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DCancer%2520treatment%2520according%2520to%2520BRCA1%2520and%2520BRCA2%2520mutations%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D520%26epage%3D528%26doi%3D10.1038%2Fnrclinonc.2012.123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ström, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Strategies for the use of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy</span> <span class="citation_source-journal">Biomolecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.3390/biom2040635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.3390%2Fbiom2040635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=635-649&author=C.+E.+Str%C3%B6mauthor=T.+Helleday&title=Strategies+for+the+use+of+poly%28adenosine+diphosphate+ribose%29+polymerase+%28PARP%29+inhibitors+in+cancer+therapy&doi=10.3390%2Fbiom2040635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.3390%2Fbiom2040635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom2040635%26sid%3Dliteratum%253Aachs%26aulast%3DStr%25C3%25B6m%26aufirst%3DC.%2BE.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520the%2520use%2520of%2520poly%2528adenosine%2520diphosphate%2520ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DBiomolecules%26date%3D2012%26volume%3D2%26spage%3D635%26epage%3D649%26doi%3D10.3390%2Fbiom2040635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Davar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumer, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamieh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawbi, H.</span><span> </span><span class="NLM_article-title">Role of PARP inhibitors in cancer biology and therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3907</span><span class="NLM_x">–</span> <span class="NLM_lpage">3921</span><span class="refDoi"> DOI: 10.2174/092986712802002464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.2174%2F092986712802002464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22788767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12nu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3907-3921&author=D.+Davarauthor=J.+H.+Beumerauthor=L.+Hamiehauthor=H.+Tawbi&title=Role+of+PARP+inhibitors+in+cancer+biology+and+therapy&doi=10.2174%2F092986712802002464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Role of PARP inhibitors in cancer biology and therapy</span></div><div class="casAuthors">Davar, D.; Beumer, J. H.; Hamieh, L.; Tawbi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3907-3921</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncol. heralded the clin. development of poly(ADP-ribose) polymerase (PARP) inhibitors.  Although initially developed to exploit synthetic lethality in models of cancer assocd. with defective DNA repair, our burgeoning knowledge of PARP biol. has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases.  In this review article, we briefly review the mechanisms of DNA repair and pre-clin. development of PARP inhibitors before discussing the clin. development of the various PARP inhibitors in depth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRQaaaS9jHi7Vg90H21EOLACvtfcHk0ljHiz1DInj8dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12nu73I&md5=70350a0d3159a740ca4ae3dfe6b5db25</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.2174%2F092986712802002464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712802002464%26sid%3Dliteratum%253Aachs%26aulast%3DDavar%26aufirst%3DD.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DHamieh%26aufirst%3DL.%26aulast%3DTawbi%26aufirst%3DH.%26atitle%3DRole%2520of%2520PARP%2520inhibitors%2520in%2520cancer%2520biology%2520and%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3907%26epage%3D3921%26doi%3D10.2174%2F092986712802002464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: an update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span><span class="refDoi"> DOI: 10.1517/13543776.2013.768615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1517%2F13543776.2013.768615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23379721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=503-514&author=G.+Papeoauthor=E.+Casaleauthor=A.+Montagnoliauthor=A.+Cirla&title=PARP+inhibitors+in+cancer+therapy%3A+an+update&doi=10.1517%2F13543776.2013.768615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in cancer therapy: an update</span></div><div class="casAuthors">Papeo, Gianluca; Casale, Elena; Montagnoli, Alessia; Cirla, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">503-514</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Inhibitors of the poly(ADP-ribose) polymerases (PARPs) family of proteins are currently being evaluated as potential anticancer medicines at both preclin. and clin. levels.  They have the peculiarity to increase the efficacy of DNA-damaging agents and to selectively target tumor cells with specific DNA repair defects.  This later development of these drugs should make it possible, in principle, to selectively target neoplastic vs healthy cells, thus realizing the Ehrlich's magic bullet concept of a personalized and tailored cure of diseases.  Areas covered: This review is designed to provide the readers with a brief summary and an update on PARP inhibitors in the oncol. field, by covering the recent patent literature (2010 - 2012: and Questel Intellectual Property Portal [QPat] database search).  Expert opinion: Presently, along with a no. of preclin. candidates, there are eight PARP inhibitors in the clinic as either single agents or in combination with various chemotherapy and radiotherapy regimens.  The tremendous efforts underneath those results testify the high interest on the target.  The investigation and understanding of the cross-reactivity among members of the PARPs family as well as a deeper knowledge of their biol. functions may lead to a more profound characterization of the PARP inhibitor's profile.  This, in turn, will cast addnl. light on this exciting approach in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Nta0RH4Y1bVg90H21EOLACvtfcHk0ljHiz1DInj8dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmt7Y%253D&md5=2562742e9548db15aca2e42476e45683</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.768615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.768615%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D503%26epage%3D514%26doi%3D10.1517%2F13543776.2013.768615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors: polypharmacology vs selective inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span><span class="refDoi"> DOI: 10.1111/febs.12298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1111%2Ffebs.12298" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+inhibitors%3A+polypharmacology+vs+selective+inhibition&doi=10.1111%2Ffebs.12298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6i&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12298%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520polypharmacology%2520vs%2520selective%2520inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575%26doi%3D10.1111%2Ffebs.12298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0liJXlHproCN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0liJXlHproCN2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-García, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Lockhart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grueso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodón, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellisen, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F2159-8290.CD-11-0348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1036-1047&author=Y.+H.+Ibrahimauthor=C.+Garc%C3%ADa-Garc%C3%ADaauthor=V.+Serraauthor=L.+Heauthor=K.+Torres-Lockhartauthor=A.+Pratauthor=P.+Antonauthor=P.+Cozarauthor=M.+Guzm%C3%A1nauthor=J.+Gruesoauthor=O.+Rodr%C3%ADguezauthor=M.+T.+Calvoauthor=C.+Auraauthor=O.+D%C3%ADezauthor=I.+T.+Rubioauthor=J.+P%C3%A9rezauthor=J.+Rod%C3%B3nauthor=J.+Cort%C3%A9sauthor=L.+W.+Ellisenauthor=M.+Scaltritiauthor=J.+Baselga&title=PI3K+Inhibition+impairs+BRCA1%2F2+expression+and+sensitizes+BRCA-proficient+triple-negative+breast+cancer+to+PARP+inhibition&doi=10.1158%2F2159-8290.CD-11-0348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0348%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DC.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTorres-Lockhart%26aufirst%3DK.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DAnton%26aufirst%3DP.%26aulast%3DCozar%26aufirst%3DP.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DO.%26aulast%3DCalvo%26aufirst%3DM.%2BT.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DD%25C3%25ADez%26aufirst%3DO.%26aulast%3DRubio%26aufirst%3DI.%2BT.%26aulast%3DP%25C3%25A9rez%26aufirst%3DJ.%26aulast%3DRod%25C3%25B3n%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPI3K%2520Inhibition%2520impairs%2520BRCA1%252F2%2520expression%2520and%2520sensitizes%2520BRCA-proficient%2520triple-negative%2520breast%2520cancer%2520to%2520PARP%2520inhibition%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1036%26epage%3D1047%26doi%3D10.1158%2F2159-8290.CD-11-0348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Juvekar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burga, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunsford, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmañà, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssiotis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scully, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asara, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, G. M.</span><span> </span><span class="NLM_article-title">Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of <i>BRCA1</i>-related breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F2159-8290.CD-11-0336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1048-1063&author=A.+Juvekarauthor=L.+N.+Burgaauthor=H.+Huauthor=E.+P.+Lunsfordauthor=Y.+H.+Ibrahimauthor=J.+Balma%C3%B1%C3%A0author=A.+Rajendranauthor=A.+Papaauthor=K.+Spencerauthor=C.+A.+Lyssiotisauthor=C.+Nardellaauthor=P.+P.+Pandolfiauthor=J.+Baselgaauthor=R.+Scullyauthor=J.+M.+Asaraauthor=L.+C.+Cantleyauthor=G.+M.+Wulf&title=Combining+a+PI3K+inhibitor+with+a+PARP+inhibitor+provides+an+effective+therapy+for+a+mouse+model+of+BRCA1-related+breast+cancer&doi=10.1158%2F2159-8290.CD-11-0336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0336%26sid%3Dliteratum%253Aachs%26aulast%3DJuvekar%26aufirst%3DA.%26aulast%3DBurga%26aufirst%3DL.%2BN.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DLunsford%26aufirst%3DE.%2BP.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DBalma%25C3%25B1%25C3%25A0%26aufirst%3DJ.%26aulast%3DRajendran%26aufirst%3DA.%26aulast%3DPapa%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DNardella%26aufirst%3DC.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DScully%26aufirst%3DR.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26atitle%3DCombining%2520a%2520PI3K%2520inhibitor%2520with%2520a%2520PARP%2520inhibitor%2520provides%2520an%2520effective%2520therapy%2520for%2520a%2520mouse%2520model%2520of%2520BRCA1-related%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1048%26epage%3D1063%26doi%3D10.1158%2F2159-8290.CD-11-0336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kigozi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Weverwijk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span><span class="refDoi"> DOI: 10.1002/emmm.201201250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Femmm.201201250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22933245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVeiur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1087-1096&author=I.+Bajramiauthor=A.+Kigoziauthor=A.+Van+Weverwijkauthor=R.+Broughauthor=J.+Frankumauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethality+of+PARP+and+NAMPT+inhibition+in+triple-negative+breast+cancer+cells&doi=10.1002%2Femmm.201201250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells</span></div><div class="casAuthors">Bajrami, Ilirjana; Kigozi, Asha; Van Weverwijk, Antoinette; Brough, Rachel; Frankum, Jessica; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1087-1096</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-neg. (ER-, PR-, HER2-neg.) breast cancers.  However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial.  To better understand the mechanisms that det. the response to PARP inhibitors, we investigated whether enzymes involved in metab. of the PARP substrate, β-NAD+, might alter the response to a clin. PARP inhibitor.  Using an olaparib sensitization screen in a triple-neg. (TN) breast cancer model, we identified nicotinamide phosphoribosyltransferase (NAMPT) as a non-redundant modifier of olaparib response.  NAMPT is a rate-limiting enzyme involved in the generation of the PARP substrate β-NAD+ and the suppression of β-NAD+ levels by NAMPT inhibition most likely explains these observations.  Importantly, the combination of a NAMPT small mol. inhibitor, FK866, with olaparib inhibited TN breast tumor growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMPT/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDlMhMk2Q7WbVg90H21EOLACvtfcHk0li2Cy61QQ9wPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVeiur7M&md5=c97061b1a3505cce8230352f5bb9f07e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201250%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DKigozi%26aufirst%3DA.%26aulast%3DVan%2BWeverwijk%26aufirst%3DA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DFrankum%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520of%2520PARP%2520and%2520NAMPT%2520inhibition%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D1087%26epage%3D1096%26doi%3D10.1002%2Femmm.201201250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Nowsheen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. S.</span><span> </span><span class="NLM_article-title">Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46614</span><span class="refDoi"> DOI: 10.1371/journal.pone.0046614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1371%2Fjournal.pone.0046614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46614&author=S.+Nowsheenauthor=T.+Cooperauthor=J.+A.+Stanleyauthor=E.+S.+Yang&title=Synthetic+lethal+interactions+between+EGFR+and+PARP+inhibition+in+human+triple+negative+breast+cancer+cells&doi=10.1371%2Fjournal.pone.0046614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046614%26sid%3Dliteratum%253Aachs%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DT.%26aulast%3DStanley%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DSynthetic%2520lethal%2520interactions%2520between%2520EGFR%2520and%2520PARP%2520inhibition%2520in%2520human%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46614%26doi%3D10.1371%2Fjournal.pone.0046614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mendes-Pereira, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of <i>PTEN</i> mutant cells with PARP inhibitors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1002/emmm.200900041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Femmm.200900041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20049735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=315-322&author=A.+M.+Mendes-Pereiraauthor=S.+A.+Martinauthor=R.+Broughauthor=A.+McCarthyauthor=J.+R.+Taylorauthor=J.-S.+Kimauthor=T.+Waldmanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethal+targeting+of+PTEN+mutant+cells+with+PARP+inhibitors&doi=10.1002%2Femmm.200900041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span></div><div class="casAuthors">Mendes-Pereira, Ana M.; Martin, Sarah A.; Brough, Rachel; McCarthy, Afshan; Taylor, Jessica R.; Kim, Jung-Sik; Waldman, Todd; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers.  Recent evidence suggests that PTEN is important for the maintenance of genome stability.  Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumor cells.  The HR deficiency caused by PTEN deficiency, sensitizes tumor cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo.  PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2.  The data we present here now suggests that the clin. assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqq6kbXT_l7Vg90H21EOLACvtfcHk0lg0xpD1gkaffA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK&md5=c14c7e0d1ae6a753deabbfb125dcc5a2</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2Femmm.200900041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.200900041%26sid%3Dliteratum%253Aachs%26aulast%3DMendes-Pereira%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DS.%2BA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.-S.%26aulast%3DWaldman%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520PTEN%2520mutant%2520cells%2520with%2520PARP%2520inhibitors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D315%26epage%3D322%26doi%3D10.1002%2Femmm.200900041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Garcia-Cao, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasiou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rameh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carracedo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Heiden, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haigis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Systemic elevation of PTEN induces a tumor-suppressive metabolic state</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.cell.2012.02.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=49-62&author=I.+Garcia-Caoauthor=M.+S.+Songauthor=R.+M.+Hobbsauthor=G.+Laurentauthor=C.+Giorgiauthor=V.+C.+de+Boerauthor=D.+Anastasiouauthor=K.+Itoauthor=A.+T.+Sasakiauthor=L.+Ramehauthor=A.+Carracedoauthor=M.+G.+Vander+Heidenauthor=L.+C.+Cantleyauthor=P.+Pintonauthor=M.+C.+Haigisauthor=P.+P.+Pandolfi&title=Systemic+elevation+of+PTEN+induces+a+tumor-suppressive+metabolic+state&doi=10.1016%2Fj.cell.2012.02.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Cao%26aufirst%3DI.%26aulast%3DSong%26aufirst%3DM.%2BS.%26aulast%3DHobbs%26aufirst%3DR.%2BM.%26aulast%3DLaurent%26aufirst%3DG.%26aulast%3DGiorgi%26aufirst%3DC.%26aulast%3Dde%2BBoer%26aufirst%3DV.%2BC.%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DA.%2BT.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DCarracedo%26aufirst%3DA.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPinton%26aufirst%3DP.%26aulast%3DHaigis%26aufirst%3DM.%2BC.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DSystemic%2520elevation%2520of%2520PTEN%2520induces%2520a%2520tumor-suppressive%2520metabolic%2520state%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D49%26epage%3D62%26doi%3D10.1016%2Fj.cell.2012.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turhan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamò, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span> </span><span class="NLM_article-title">ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1535-7163.MCT-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20124459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=347-357&author=C.+T.+Williamsonauthor=H.+Muzikauthor=A.+G.+Turhanauthor=A.+Zam%C3%B2author=M.+J.+O%27Connorauthor=D.+G.+Bebbauthor=S.+P.+Lees-Miller&title=ATM+deficiency+sensitizes+mantle+cell+lymphoma+cells+to+poly%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1158%2F1535-7163.MCT-09-0872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors</span></div><div class="casAuthors">Williamson, Chris T.; Muzik, Huong; Turhan, Ali G.; Zamo, Alberto; O'Connor, Mark J.; Bebb, D. Gwyn; Lees-Miller, Susan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality.  However, whether this approach is applicable to other human cancers with defects in other DNA repair genes has yet to be detd.  The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL).  Here, the authors characterize a panel of MCL cell lines for ATM status and function and investigate the potential for synthetic lethality in MCL in the presence of small-mol. inhibitors of PARP-1.  The authors show that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function.  Significantly, Granta-519 and UPN2 cells were more sensitive to PARP-1 inhibition than were the ATM-proficient MCL cell lines examd.  Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. xenografts of ATM-deficient Granta-519 cells while producing only a modest effect on overall survival of mice bearing xenografts of the ATM-proficient cell line, Z138.  Thus, PARP inhibitors have therapeutic potential in the treatment of MCL, and the concept of synthetic lethality extends to human cancers with ATM alterations.  Mol Cancer Ther; 9(2); 347-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQmQjsqIbdVrVg90H21EOLACvtfcHk0lg0xpD1gkaffA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D&md5=6243397aa39febdd9bd613b413a1f9ad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMuzik%26aufirst%3DH.%26aulast%3DTurhan%26aufirst%3DA.%2BG.%26aulast%3DZam%25C3%25B2%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%2BJ.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26atitle%3DATM%2520deficiency%2520sensitizes%2520mantle%2520cell%2520lymphoma%2520cells%2520to%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D347%26epage%3D357%26doi%3D10.1158%2F1535-7163.MCT-09-0872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Vilar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, S. B.</span><span> </span><span class="NLM_article-title">Microsatellite instability in colorectal cancer-the stable evidence</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2009.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnrclinonc.2009.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20142816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=153-162&author=E.+Vilarauthor=S.+B.+Gruber&title=Microsatellite+instability+in+colorectal+cancer-the+stable+evidence&doi=10.1038%2Fnrclinonc.2009.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microsatellite instability in colorectal cancer-the stable evidence</span></div><div class="casAuthors">Vilar, Eduardo; Gruber, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-162</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review that presents an overview of microsatellite instability (MSI), including its clin. features and applications.  MSI is a frequent mol. phenomenon of colorectal cancer and is assocd. with deficient DNA mismatch repair.  The authors discuss the prognostic and predictive value of MSI and how it can be used to improve our knowledge of other cancer subtypes.  Microsatellite instability (MSI) is the mol. fingerprint of a deficient mismatch repair system.  Approx. 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2.  Methods to detect MSI are well established and routinely incorporated into clin. practice.  A clin. and mol. profile of MSI tumors has been described, leading to the concept of an MSI phenotype in CRC.  Studies have confirmed that MSI tumors have a better prognosis than microsatellite stable CRC, but MSI cancers do not necessarily have the same response to the chemotherapeutic strategies used to treat microsatellite stable tumors.  Specifically, stage II MSI tumors might not benefit from 5-fluorouracil-based adjuvant chemotherapy regimens.  New data suggest possible advantages of irinotecan-based regimens, but these findings require further clarification.  Characterization of the mol. basis of MSI in CRC is underway and initial results show that mutations in genes encoding kinases and candidate genes with microsatellite tracts are over-represented in MSI tumors.  Transcriptome expression profiles of MSI tumors and systems biol. approaches are providing the opportunity to develop targeted therapeutics for MSI CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptR5PjUGt7rLVg90H21EOLACvtfcHk0lhpMY_SL5m0HA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFemsbs%253D&md5=760bd08201b6e6a8dd4b25b64fb60625</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.237%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DS.%2BB.%26atitle%3DMicrosatellite%2520instability%2520in%2520colorectal%2520cancer-the%2520stable%2520evidence%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26spage%3D153%26epage%3D162%26doi%3D10.1038%2Fnrclinonc.2009.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Maroun, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1613</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F0008-5472.CAN-11-3648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1608-1613&author=J.+C.+Brennerauthor=F.+Y.+Fengauthor=S.+Hanauthor=S.+Patelauthor=S.+V.+Goyalauthor=L.+M.+Bou-Marounauthor=M.+Liuauthor=R.+Lonigroauthor=J.+R.+Prensnerauthor=S.+A.+Tomlinsauthor=A.+M.+Chinnaiyan&title=PARP-1+inhibition+as+a+targeted+strategy+to+treat+Ewing%E2%80%99s+sarcoma&doi=10.1158%2F0008-5472.CAN-11-3648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3648%26sid%3Dliteratum%253Aachs%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGoyal%26aufirst%3DS.%2BV.%26aulast%3DBou-Maroun%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLonigro%26aufirst%3DR.%26aulast%3DPrensner%26aufirst%3DJ.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DPARP-1%2520inhibition%2520as%2520a%2520targeted%2520strategy%2520to%2520treat%2520Ewing%25E2%2580%2599s%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1608%26epage%3D1613%26doi%3D10.1158%2F0008-5472.CAN-11-3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly-(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly-%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly-%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and −2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+%E2%88%922+mutant+tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors</span></div><div class="casAuthors">Jones, Philip; Altamura, Sergio; Boueres, Julia; Ferrigno, Federica; Fonsi, Massimiliano; Giomini, Claudia; Lamartina, Stefania; Monteagudo, Edith; Ontoria, Jesus M.; Orsale, Maria Vittoria; Palumbi, Maria Cecilia; Pesci, Silvia; Roscilli, Giuseppe; Scarpelli, Rita; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Rowley, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7170-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors.  This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells.  Extrahepatic oxidn. by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported.  These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clin. trials.  This compd. displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, resp., and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range.  MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFTodq58wELVg90H21EOLACvtfcHk0lgrAfhJqYdxTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM&md5=ff6662626b95805aeece659fec25133c</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520%25E2%2588%25922%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+a+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination</span></div><div class="casAuthors">Jones, Philip; Wilcoxen, Keith; Rowley, Michael; Toniatti, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3302-3314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes.  It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells.  We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability.  Niraparib was characterized in a no. of preclin. models before moving to phase I clin. trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients.  It is currently being tested in phase 3 clin. trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaJDnhFDPhbVg90H21EOLACvtfcHk0lgrAfhJqYdxTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D&md5=ffb7cb2503acde0a1e3452448d98693f</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0lgrAfhJqYdxTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0ljZdySvTMUA7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5015</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=L.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency&doi=10.1158%2F1078-0432.CCR-13-1391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0ljZdySvTMUA7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015%26doi%3D10.1158%2F1078-0432.CCR-13-1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping Poly(ADP-Ribose) Polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+Poly%28ADP-Ribose%29+Polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0lgbBCwp-tM_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520Poly%2528ADP-Ribose%2529%2520Polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öncü, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1038/nbt.2121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.-G.+Thorsellauthor=E.+Polauthor=A.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors&doi=10.1038%2Fnbt.2121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0lgbBCwp-tM_3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3DA.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288%26doi%3D10.1038%2Fnbt.2121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieffine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span> </span><span class="NLM_article-title">Insights into PARP inhibitors selectivity using fluorescence polarization and surface plasmon resonance binding assays</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1177/1087057114538319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1177%2F1087057114538319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=24916412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2lsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1212-1219&author=G.+Papeoauthor=N.+Avanziauthor=S.+Bettoniauthor=A.+Leoneauthor=M.+Paolucciauthor=R.+Peregoauthor=F.+Quartieriauthor=F.+Riccardi-Sirtoriauthor=S.+Thieffineauthor=A.+Montagnoliauthor=R.+Lupi&title=Insights+into+PARP+inhibitors+selectivity+using+fluorescence+polarization+and+surface+plasmon+resonance+binding+assays&doi=10.1177%2F1087057114538319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into PARP inhibitors' selectivity using fluorescence polarization and surface plasmon resonance binding assays</span></div><div class="casAuthors">Papeo, Gianluca; Avanzi, Nilla; Bettoni, Serena; Leone, Antonella; Paolucci, Mauro; Perego, Rita; Quartieri, Francesca; Riccardi-Sirtori, Federico; Thieffine, Sandrine; Montagnoli, Alessia; Lupi, Rosita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1212-1219, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">PARP inhibitors are an exciting new class of antineoplastic drugs that have been proven to be efficacious as single agents in cancer settings with inherent DNA repair defects, as well as in combination with DNA-damaging chemotherapeutics.  Currently, they are designed to target the catalytic domain of PARP-1, the most studied member of the family, with a key role in the DNA-damage repair process.  Because PARP inhibitors are substrate (NAD+) competitors, there is a need for a deeper understanding of their cross-reactivity.  This is particularly relevant for PARP-2, the PARP-1 closest homolog, for which an embryonic lethal phenotype has been obsd. in double knockout mice.  In this study, we describe the development and validation of binding assays based on fluorescence polarization (FP) and surface plasmon resonance (SPR) techniques.  PARP-1, PARP-2, PARP-3, and TNKS-1 FP displacement assays are set up by employing ad hoc synthesized probes.  These assays are suitable for high-throughput screening (HTS) and selectivity profiling, thus allowing the identification of NAD+ binding site selective inhibitors.  The PARP-1 and PARP-2 complementary SPR binding assays confirm displacement data and the in-depth inhibitor characterization.  Moreover, these formats have the potential to be broadly applicable to other members of the PARP family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnA9zw-zWzt7Vg90H21EOLACvtfcHk0liNebVXy47crQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2lsLvM&md5=79a05a435023d7011290bc33396cd1f6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1177%2F1087057114538319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057114538319%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBettoni%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DPaolucci%26aufirst%3DM.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DLupi%26aufirst%3DR.%26atitle%3DInsights%2520into%2520PARP%2520inhibitors%2520selectivity%2520using%2520fluorescence%2520polarization%2520and%2520surface%2520plasmon%2520resonance%2520binding%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2014%26volume%3D19%26spage%3D1212%26epage%3D1219%26doi%3D10.1177%2F1087057114538319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Yélamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span> </span><span class="NLM_article-title">Toward specific functions of poly(ADP-ribose) polymerase-2</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/j.molmed.2008.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.molmed.2008.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=169-178&author=J.+Y%C3%A9lamosauthor=V.+Schreiberauthor=F.+Dantzer&title=Toward+specific+functions+of+poly%28ADP-ribose%29+polymerase-2&doi=10.1016%2Fj.molmed.2008.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2008.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2008.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DY%25C3%25A9lamos%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26atitle%3DToward%2520specific%2520functions%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-2%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D169%26epage%3D178%26doi%3D10.1016%2Fj.molmed.2008.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Antolin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3023</span><span class="NLM_x">–</span> <span class="NLM_lpage">3028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3023-3028&author=A.+A.+Antolinauthor=J.+Mestres&title=Linking+off-target+kinase+pharmacology+to+the+differential+cellular+effects+observed+among+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DLinking%2520off-target%2520kinase%2520pharmacology%2520to%2520the%2520differential%2520cellular%2520effects%2520observed%2520among%2520PARP%2520inhibitors%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3023%26epage%3D3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Farrés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llacuna, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Caballero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampurdanés, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Contreras, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florensa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villunger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandéz-Capetillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yélamos, J.</span><span> </span><span class="NLM_article-title">PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span><span class="refDoi"> DOI: 10.1038/cdd.2014.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fcdd.2014.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25501596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1144-1157&author=J.+Farr%C3%A9sauthor=L.+Llacunaauthor=J.+Martin-Caballeroauthor=C.+Mart%C3%ADnezauthor=J.+J.+Lozanoauthor=C.+Ampurdan%C3%A9sauthor=A.+J.+L%C3%B3pez-Contrerasauthor=L.+Florensaauthor=J.+Navarroauthor=E.+Ottinaauthor=F.+Dantzerauthor=V.+Schreiberauthor=A.+Villungerauthor=O.+Fernand%C3%A9z-Capetilloauthor=J.+Y%C3%A9lamos&title=PARP-2+sustains+erythropoiesis+in+mice+by+limiting+replicative+stress+in+erythroid+progenitors&doi=10.1038%2Fcdd.2014.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors</span></div><div class="casAuthors">Farres, J.; Llacuna, L.; Martin-Caballero, J.; Martinez, C.; Lozano, J. J.; Ampurdanes, C.; Lopez-Contreras, A. J.; Florensa, L.; Navarro, J.; Ottina, E.; Dantzer, F.; Schreiber, V.; Villunger, A.; Fernandez-Capetillo, O.; Yelamos, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1144-1157</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erythropoiesis is a tightly regulated process in which multipotential hematopoietic stem cells produce mature red blood cells.  Here we show that deletion of poly(ADP-ribose) polymerase-2 (PARP-2) in mice leads to chronic anemia at steady state, despite increased erythropoietin plasma levels, a phenomenon not obsd. in mice lacking PARP-1.  Loss of PARP-2 causes shortened lifespan of erythrocytes and impaired differentiation of erythroid progenitors.  In erythroblasts, PARP-2 deficiency triggers replicative stress, as indicated by the presence of micronuclei, the accumulation of γ-H2AX (phospho-histone H2AX) in S-phase cells and constitutive CHK1 and replication protein A phosphorylation.  Transcriptome analyses revealed the activation of the p53-dependent DNA-damage response pathways in PARP-2-deficient cells, culminating in the upregulation of cell-cycle and cell death regulators, concomitant with G2/M arrest and apoptosis.  Strikingly, while loss of the proapoptotic p53 target gene Puma restored hematocrit levels in the PARP-2-deficient mice, loss of the cell-cycle regulator and CDK inhibitor p21 leads to perinatal death by exacerbating impaired fetal liver erythropoiesis in PARP-2-deficient embryos.  Although the anemia displayed by PARP-2-deficient mice is compatible with life, mice die rapidly when exposed to stress-induced enhanced hemolysis.  Our results pinpoint an essential role for PARP-2 in erythropoiesis by limiting replicative stress that becomes essential in the absence of p21 and in the context of enhanced hemolysis, highlighting the potential effect that might arise from the design and use of PARP inhibitors that specifically inactivate PARP proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5EaGt9u1xrVg90H21EOLACvtfcHk0liNebVXy47crQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKnur%252FJ&md5=07d6e706bbb8efd8c3aa0d31d13d1f99</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2014.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2014.202%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLlacuna%26aufirst%3DL.%26aulast%3DMartin-Caballero%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DLozano%26aufirst%3DJ.%2BJ.%26aulast%3DAmpurdan%25C3%25A9s%26aufirst%3DC.%26aulast%3DL%25C3%25B3pez-Contreras%26aufirst%3DA.%2BJ.%26aulast%3DFlorensa%26aufirst%3DL.%26aulast%3DNavarro%26aufirst%3DJ.%26aulast%3DOttina%26aufirst%3DE.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DVillunger%26aufirst%3DA.%26aulast%3DFernand%25C3%25A9z-Capetillo%26aufirst%3DO.%26aulast%3DY%25C3%25A9lamos%26aufirst%3DJ.%26atitle%3DPARP-2%2520sustains%2520erythropoiesis%2520in%2520mice%2520by%2520limiting%2520replicative%2520stress%2520in%2520erythroid%2520progenitors%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2015%26volume%3D22%26spage%3D1144%26epage%3D1157%26doi%3D10.1038%2Fcdd.2014.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Goldberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsulic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, P. A.</span><span> </span><span class="NLM_article-title">Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1073/pnas.1016538108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1073%2Fpnas.1016538108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=745-750&author=M.+S.+Goldbergauthor=D.+Xingauthor=Y.+Renauthor=S.+Orsulicauthor=S.+N.+Bhatiaauthor=P.+A.+Sharp&title=Nanoparticle-mediated+delivery+of+siRNA+targeting+Parp1+extends+survival+of+mice+bearing+tumors+derived+from+Brca1-deficient+ovarian+cancer+cells&doi=10.1073%2Fpnas.1016538108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1016538108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1016538108%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DM.%2BS.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DOrsulic%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DSharp%26aufirst%3DP.%2BA.%26atitle%3DNanoparticle-mediated%2520delivery%2520of%2520siRNA%2520targeting%2520Parp1%2520extends%2520survival%2520of%2520mice%2520bearing%2520tumors%2520derived%2520from%2520Brca1-deficient%2520ovarian%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D745%26epage%3D750%26doi%3D10.1073%2Fpnas.1016538108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">–</span> <span class="NLM_lpage">1390</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.09.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling&doi=10.1016%2Fj.bmc.2005.09.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0liWsZwvKYSWxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2Fj.bmc.2005.09.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span> </span><span class="NLM_article-title">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">–</span> <span class="NLM_lpage">5581</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2007.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=17804225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5577-5581&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=A.+Iwashitaauthor=K.+Mihara&title=Rational+design+of+conformationally+restricted+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase&doi=10.1016%2Fj.bmcl.2007.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Iwashita, Akinori; Mihara, Kayoko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5577-5581</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A successful design of conformationally restricted novel quinazolinone derivs. linked via a cyclopentene moiety as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been developed.  One selected member of the new series, 8-chloro-2-[(3S)-3-(4-phenylpiperidin-1-yl)cyclopent-1-en-1-yl]quinazolin-4(3H)-one (S-16d, I), was found to be highly potent with IC50 = 8.7 nM and good brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvYPS7NANArVg90H21EOLACvtfcHk0liWsZwvKYSWxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK&md5=3ff78c0d7dbce0960a07274207348330</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520conformationally%2520restricted%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5577%26epage%3D5581%26doi%3D10.1016%2Fj.bmcl.2007.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Eltze, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbrenner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürkle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span> </span><span class="NLM_article-title">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1587</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1124/mol.108.048751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1124%2Fmol.108.048751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1587-1598&author=T.+Eltzeauthor=R.+Boerauthor=T.+Wagnerauthor=S.+Weinbrennerauthor=M.+C.+McDonaldauthor=C.+Thiemermannauthor=A.+B%C3%BCrkleauthor=T.+Klein&title=Imidazoquinolinone%2C+imidazopyridine%2C+and+isoquinolindione+derivatives+as+novel+and+potent+inhibitors+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29%3A+a+comparison+with+standard+PARP+inhibitors&doi=10.1124%2Fmol.108.048751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.048751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.048751%26sid%3Dliteratum%253Aachs%26aulast%3DEltze%26aufirst%3DT.%26aulast%3DBoer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeinbrenner%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DM.%2BC.%26aulast%3DThiemermann%26aufirst%3DC.%26aulast%3DB%25C3%25BCrkle%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26atitle%3DImidazoquinolinone%252C%2520imidazopyridine%252C%2520and%2520isoquinolindione%2520derivatives%2520as%2520novel%2520and%2520potent%2520inhibitors%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%253A%2520a%2520comparison%2520with%2520standard%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1587%26epage%3D1598%26doi%3D10.1124%2Fmol.108.048751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidorenko, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chernyshev, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grudinin, D. G.</span><span> </span><span class="NLM_article-title">Preparative synthesis of 7-carboxy-2-R-isoindol-1-ones</span> <span class="citation_source-journal">Chem. Heterocycl. Compd.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1023/B:COHC.0000023763.75894.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1023%2FB%3ACOHC.0000023763.75894.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=22-28&author=A.+V.+Varlamovauthor=E.+V.+Boltukhinaauthor=F.+I.+Zubkovauthor=N.+V.+Sidorenkoauthor=A.+I.+Chernyshevauthor=D.+G.+Grudinin&title=Preparative+synthesis+of+7-carboxy-2-R-isoindol-1-ones&doi=10.1023%2FB%3ACOHC.0000023763.75894.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparative synthesis of 7-carboxy-2-R-isoindol-1-ones</span></div><div class="casAuthors">Varlamov, A. V.; Boltukhina, E. V.; Zubkov, F. I.; Sidorenko, N. V.; Chernyshev, A. I.; Grudinin, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-28</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Stereoselective [4 + 2]-cycloaddn. of secondary furfurylamines to maleic anhydride gave epoxyisoindolones [I; R = benzyl, tetrahydrofurfuryl, cycloalkyl, (un)substituted Ph, etc.], which were heated with H3PO4 to give carboxyisoindolones (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHV8Tz9z5TgrVg90H21EOLACvtfcHk0li_H3fO7z4GpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFSrsrw%253D&md5=f59c9c7eafea99d462f001ec831947f3</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1023%2FB%3ACOHC.0000023763.75894.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ACOHC.0000023763.75894.63%26sid%3Dliteratum%253Aachs%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DSidorenko%26aufirst%3DN.%2BV.%26aulast%3DChernyshev%26aufirst%3DA.%2BI.%26aulast%3DGrudinin%26aufirst%3DD.%2BG.%26atitle%3DPreparative%2520synthesis%2520of%25207-carboxy-2-R-isoindol-1-ones%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2004%26volume%3D40%26spage%3D22%26epage%3D28%26doi%3D10.1023%2FB%3ACOHC.0000023763.75894.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Medimagh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatti, S.</span><span> </span><span class="NLM_article-title">5-Amino-2-furylmethylamines – appealing precursors of amino-isoindolinones?</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1055/s-0029-1218614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1055%2Fs-0029-1218614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=770-774&author=R.+Medimaghauthor=S.+Marqueauthor=D.+Primauthor=S.+Chatti&title=5-Amino-2-furylmethylamines+%E2%80%93+appealing+precursors+of+amino-isoindolinones%3F&doi=10.1055%2Fs-0029-1218614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218614%26sid%3Dliteratum%253Aachs%26aulast%3DMedimagh%26aufirst%3DR.%26aulast%3DMarque%26aufirst%3DS.%26aulast%3DPrim%26aufirst%3DD.%26aulast%3DChatti%26aufirst%3DS.%26atitle%3D5-Amino-2-furylmethylamines%2520%25E2%2580%2593%2520appealing%2520precursors%2520of%2520amino-isoindolinones%253F%26jtitle%3DSynthesis%26date%3D2010%26volume%3D2010%26spage%3D770%26epage%3D774%26doi%3D10.1055%2Fs-0029-1218614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ball, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuthbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodsham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever-Abbas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottschling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchozak, B.</span><span> </span><span class="NLM_article-title">Isoindolone formation via intramolecular Diels-Alder reaction</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1021/op300002f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300002f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=741-747&author=M.+Ballauthor=A.+Boydauthor=G.+Churchillauthor=M.+Cuthbertauthor=M.+Drewauthor=M.+Fieldingauthor=G.+Fordauthor=L.+Frodshamauthor=M.+Goldenauthor=K.+Leslieauthor=S.+Lyonsauthor=B.+McKeever-Abbasauthor=A.+Starkauthor=P.+Tomlinauthor=S.+Gottschlingauthor=A.+Hajarauthor=J.-l.+Jiangauthor=J.+Loauthor=B.+Suchozak&title=Isoindolone+formation+via+intramolecular+Diels-Alder+reaction&doi=10.1021%2Fop300002f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28cR"><div class="casContent"><span class="casTitleNuber">28c</span><div class="casTitle"><span class="NLM_cas:atitle">Isoindolone formation via intramolecular Diels-Alder reaction</span></div><div class="casAuthors">Ball, Matthew; Boyd, Alistair; Churchill, Gwydion; Cuthbert, Murray; Drew, Mark; Fielding, Mark; Ford, Gair; Frodsham, Lianne; Golden, Michael; Leslie, Kevin; Lyons, Sarah; McKeever-Abbas, Ben; Stark, Andrew; Tomlin, Paula; Gottschling, Stephen; Hajar, Abraham; Jiang, Ji-long; Lo, Josephine; Suchozak, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intramol. Diels-Alder reaction provides a useful synthetic methodol. to build biol. active and synthetically useful isoindolone ring systems.  An application of this methodol., providing an efficient manufg. route to an mGluR2 pos. allosteric modulator via a 1,5,7-substituted isoindolone, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn-kJxO1Cip7Vg90H21EOLACvtfcHk0li_H3fO7z4GpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFartLw%253D&md5=4c6dc750782e83440200699e464fdc1b</span></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1021%2Fop300002f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300002f%26sid%3Dliteratum%253Aachs%26aulast%3DBall%26aufirst%3DM.%26aulast%3DBoyd%26aufirst%3DA.%26aulast%3DChurchill%26aufirst%3DG.%26aulast%3DCuthbert%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DM.%26aulast%3DFielding%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DG.%26aulast%3DFrodsham%26aufirst%3DL.%26aulast%3DGolden%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DLyons%26aufirst%3DS.%26aulast%3DMcKeever-Abbas%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DTomlin%26aufirst%3DP.%26aulast%3DGottschling%26aufirst%3DS.%26aulast%3DHajar%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DJ.-l.%26aulast%3DLo%26aufirst%3DJ.%26aulast%3DSuchozak%26aufirst%3DB.%26atitle%3DIsoindolone%2520formation%2520via%2520intramolecular%2520Diels-Alder%2520reaction%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D741%26epage%3D747%26doi%3D10.1021%2Fop300002f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zaytsev, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailova, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Airiyan, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galkina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golubev, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">Cycloaddition of furfurylamines to maleic anhydride and its substituted derivatives</span> <span class="citation_source-journal">Chem. Heterocycl. Compd.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1007/s10593-012-1023-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs10593-012-1023-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFKnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=505-513&author=V.+P.+Zaytsevauthor=N.+M.+Mikhailovaauthor=I.+K.+Airiyanauthor=E.+V.+Galkinaauthor=V.+D.+Golubevauthor=E.+V.+Nikitinaauthor=F.+I.+Zubkovauthor=A.+V.+Varlamov&title=Cycloaddition+of+furfurylamines+to+maleic+anhydride+and+its+substituted+derivatives&doi=10.1007%2Fs10593-012-1023-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28dR"><div class="casContent"><span class="casTitleNuber">28d</span><div class="casTitle"><span class="NLM_cas:atitle">Cycloaddition of furfurylamines to maleic anhydride and its substituted derivatives</span></div><div class="casAuthors">Zaytsev, V. P.; Mikhailova, N. M.; Airiyan, I. K.; Galkina, E. V.; Golubev, V. D.; Nikitina, E. V.; Zubkov, F. I.; Varlamov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">505-513</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The regio- and stereoselectivity of the [4 + 2] cycloaddn. of maleic, citraconic, dichloromaleic, and dibromomaleic anhydrides to difurfuryl amines and secondary furfurylamines were studied.  N-Furfuryl-, N-phenyl-, and N-benzylhexahydrooxoepoxyisoindole-7-carboxylic acids were synthesized.  An approach was developed for obtaining hexahydroepoxyoxoisoindole-7-carboxylic acid unsubstituted at the nitrogen atom.  Aromatization of the oxabicycloheptene fragment of the dihaloepoxyisoindolonecarboxylic acids gave a series of 7-carboxy-2-R-isoindol-1-ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OzSoQnPcRrVg90H21EOLACvtfcHk0ljmNrnUPYJ_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFKnsL0%253D&md5=c46aa05f050544b27d6a620c0615b4ad</span></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1007%2Fs10593-012-1023-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-012-1023-1%26sid%3Dliteratum%253Aachs%26aulast%3DZaytsev%26aufirst%3DV.%2BP.%26aulast%3DMikhailova%26aufirst%3DN.%2BM.%26aulast%3DAiriyan%26aufirst%3DI.%2BK.%26aulast%3DGalkina%26aufirst%3DE.%2BV.%26aulast%3DGolubev%26aufirst%3DV.%2BD.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DCycloaddition%2520of%2520furfurylamines%2520to%2520maleic%2520anhydride%2520and%2520its%2520substituted%2520derivatives%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2012%26volume%3D48%26spage%3D505%26epage%3D513%26doi%3D10.1007%2Fs10593-012-1023-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">De Cesco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deslandes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantin, L.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittermaier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moitessier, N.</span><span> </span><span class="NLM_article-title">Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6306</span><span class="NLM_x">–</span> <span class="NLM_lpage">6315</span><span class="refDoi"> DOI: 10.1021/jm3002839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6306-6315&author=S.+De+Cescoauthor=S.+Deslandesauthor=E.+Therrienauthor=D.+Levanauthor=M.+Cuetoauthor=R.+Schmidtauthor=L.-D.+Cantinauthor=A.+Mittermaierauthor=L.+Juillerat-Jeanneretauthor=N.+Moitessier&title=Virtual+screening+and+computational+optimization+for+the+discovery+of+covalent+prolyl+oligopeptidase+inhibitors+with+activity+in+human+cells&doi=10.1021%2Fjm3002839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28eR"><div class="casContent"><span class="casTitleNuber">28e</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening and Computational Optimization for the Discovery of Covalent Prolyl Oligopeptidase Inhibitors with Activity in Human Cells</span></div><div class="casAuthors">De Cesco, Stephane; Deslandes, Sebastien; Therrien, Eric; Levan, David; Cueto, Mickael; Schmidt, Ralf; Cantin, Louis-David; Mittermaier, Anthony; Juillerat-Jeanneret, Lucienne; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6306-6315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our docking program, Fitted, implemented in our computational platform, Forecaster, has been modified to carry out automated virtual screening of covalent inhibitors.  With this modified version of the program, virtual screening and further docking-based optimization of a selected hit led to the identification of potential covalent reversible inhibitors of prolyl oligopeptidase activity.  After visual inspection, a virtual hit mol. together with four analogs were selected for synthesis and made in one-five chem. steps.  Biol. evaluations on recombinant POP and FAPα enzymes, cell exts., and living cells demonstrated high potency and selectivity for POP over FAPα and DPPIV.  Three compds. even exhibited high nanomolar inhibitory activities in intact living human cells and acceptable metabolic stability.  This small set of mols. also demonstrated that covalent binding and/or geometrical constraints to the ligand/protein complex may lead to an increase in bioactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaE7_T4KEl5rVg90H21EOLACvtfcHk0ljmNrnUPYJ_Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Onu7Y%253D&md5=4c6cd8245e91cad790e4bab9254dcb3f</span></div><a href="/servlet/linkout?suffix=cit28e&amp;dbid=16384&amp;doi=10.1021%2Fjm3002839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002839%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DDeslandes%26aufirst%3DS.%26aulast%3DTherrien%26aufirst%3DE.%26aulast%3DLevan%26aufirst%3DD.%26aulast%3DCueto%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCantin%26aufirst%3DL.-D.%26aulast%3DMittermaier%26aufirst%3DA.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DVirtual%2520screening%2520and%2520computational%2520optimization%2520for%2520the%2520discovery%2520of%2520covalent%2520prolyl%2520oligopeptidase%2520inhibitors%2520with%2520activity%2520in%2520human%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6306%26epage%3D6315%26doi%3D10.1021%2Fjm3002839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turchin, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisov, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">New synthetic approach to substituted isoindolo[2,1-<i>a</i>]quinoline carboxylic acids via intramolecular Diels-Alder reaction of 4-(<i>N</i>-furyl-2)-4-arylaminobutenes-1 with maleic anhydride</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4099</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1016/j.tet.2005.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tet.2005.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=4099-4113&author=F.+I.+Zubkovauthor=E.+V.+Boltukhinaauthor=K.+F.+Turchinauthor=R.+S.+Borisovauthor=A.+V.+Varlamov&title=New+synthetic+approach+to+substituted+isoindolo%5B2%2C1-a%5Dquinoline+carboxylic+acids+via+intramolecular+Diels-Alder+reaction+of+4-%28N-furyl-2%29-4-arylaminobutenes-1+with+maleic+anhydride&doi=10.1016%2Fj.tet.2005.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">New synthetic approach to substituted isoindolo[2,1-a]quinoline carboxylic acids via intramolecular Diels-Alder reaction of 4-(N-furyl-2)-4-arylaminobutenes-1 with maleic anhydride</span></div><div class="casAuthors">Zubkov, Fedor I.; Boltukhina, Ekaterina V.; Turchin, Konstantin F.; Borisov, Roman S.; Varlamov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4099-4113</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acylation of substituted 4-(2-furyl)-4-arylaminobut-1-enes I (R1 = H, Me; R2 = H, 2-Me, 4-MeO, etc.) with maleic anhydride provided 2-allyl-6-carboxy-4-oxo-3-aza-10-oxatricyclo[5.2.1.01.5]dec-8-enes II in high yields under mild reaction conditions.  The Diels-Alder adducts II are formed via an initial amide formation followed by a stereoselective intramol. [4 + 2] exo-cycloaddn. reaction.  Treatment of the tricyclic compds. II with phosphoric acid at high temps. (70-120 °C) promoted cyclic ether opening, intramol. cyclization and aromatization to give the corresponding tetracyclic compds., 5,6,6a,11-tetrahydro-10-carboxyisoindolo[2,1-a]quinolines III, in moderate yields.  The influence of the acid and the reaction temp. on the cyclization reactions are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2D8UY4749vrVg90H21EOLACvtfcHk0lhew6kB9MW1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyisrs%253D&md5=30ea646d218c5d98cf50dd24fa53e511</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DTurchin%26aufirst%3DK.%2BF.%26aulast%3DBorisov%26aufirst%3DR.%2BS.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DNew%2520synthetic%2520approach%2520to%2520substituted%2520isoindolo%255B2%252C1-a%255Dquinoline%2520carboxylic%2520acids%2520via%2520intramolecular%2520Diels-Alder%2520reaction%2520of%25204-%2528N-furyl-2%2529-4-arylaminobutenes-1%2520with%2520maleic%2520anhydride%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D4099%26epage%3D4113%26doi%3D10.1016%2Fj.tet.2005.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">Novel approach to isoindolo[2,1-<i>a</i>]quinolines: synthesis of 1- and 3-halo-substituted 11-oxo-5,6,6a,11-tetrahydroisoindolo[2,1-<i>a</i>]quinoline-10-carboxylic acids</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">1859</span><span class="NLM_x">–</span> <span class="NLM_lpage">1875</span><span class="refDoi"> DOI: 10.1055/s-2005-869948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1055%2Fs-2005-869948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=1859-1875&author=E.+V.+Boltukhinaauthor=F.+I.+Zubkovauthor=E.+V.+Nikitinaauthor=A.+V.+Varlamov&title=Novel+approach+to+isoindolo%5B2%2C1-a%5Dquinolines%3A+synthesis+of+1-+and+3-halo-substituted+11-oxo-5%2C6%2C6a%2C11-tetrahydroisoindolo%5B2%2C1-a%5Dquinoline-10-carboxylic+acids&doi=10.1055%2Fs-2005-869948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869948%26sid%3Dliteratum%253Aachs%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DNovel%2520approach%2520to%2520isoindolo%255B2%252C1-a%255Dquinolines%253A%2520synthesis%2520of%25201-%2520and%25203-halo-substituted%252011-oxo-5%252C6%252C6a%252C11-tetrahydroisoindolo%255B2%252C1-a%255Dquinoline-10-carboxylic%2520acids%26jtitle%3DSynthesis%26date%3D2005%26volume%3D2005%26spage%3D1859%26epage%3D1875%26doi%3D10.1055%2Fs-2005-869948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G.-D.</span><span> </span><span class="NLM_article-title">Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2009.12.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1023-1026&author=V.+B.+Gandhiauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+Parkauthor=V.+L.+Girandaauthor=T.+D.+Penningauthor=G.-D.+Zhu&title=Discovery+and+SAR+of+substituted+3-oxoisoindoline-4-carboxamides+as+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmcl.2009.12.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.-D.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520substituted%25203-oxoisoindoline-4-carboxamides%2520as%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1023%26epage%3D1026%26doi%3D10.1016%2Fj.bmcl.2009.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Mei, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maugel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.-Q.</span><span> </span><span class="NLM_article-title">Pd<sup>II</sup>-Catalyzed monoselective <i>ortho</i> halogenation of C-H bonds assisted by counter cations: a complementary method to directed <i>ortho</i> lithiation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5215</span><span class="NLM_x">–</span> <span class="NLM_lpage">5219</span><span class="refDoi"> DOI: 10.1002/anie.200705613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fanie.200705613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1antL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5215-5219&author=T.-S.+Meiauthor=R.+Giriauthor=N.+Maugelauthor=J.-Q.+Yu&title=PdII-Catalyzed+monoselective+ortho+halogenation+of+C-H+bonds+assisted+by+counter+cations%3A+a+complementary+method+to+directed+ortho+lithiation&doi=10.1002%2Fanie.200705613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PdII-catalyzed monoselective ortho halogenation of C-H bonds assisted by counter cations: a complementary method to directed ortho lithiation</span></div><div class="casAuthors">Mei, Tian-Sheng; Giri, Ramesh; Maugel, Nathan; Yu, Jin-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">5215-5219</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The yield and selectivity of monoselective ortho halogenation of benzoic acid derivs. were improved greatly by using tetraalkyl ammonium salts as additives.  These effects are attributed to the influence of counter cations.  The halogenated products are versatile intermediates for the construction of substituted arom. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhdHMzxnlpsbVg90H21EOLACvtfcHk0lhew6kB9MW1cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1antL8%253D&md5=2766ba56d107e3d2b57fc8a712fa1f60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.200705613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200705613%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DT.-S.%26aulast%3DGiri%26aufirst%3DR.%26aulast%3DMaugel%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DJ.-Q.%26atitle%3DPdII-Catalyzed%2520monoselective%2520ortho%2520halogenation%2520of%2520C-H%2520bonds%2520assisted%2520by%2520counter%2520cations%253A%2520a%2520complementary%2520method%2520to%2520directed%2520ortho%2520lithiation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D5215%26epage%3D5219%26doi%3D10.1002%2Fanie.200705613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2003.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=81-85&author=P.+G.+Jagtapauthor=G.+J.+Southanauthor=E.+Balogluauthor=S.+Ramauthor=J.+G.+Mableyauthor=A.+Martonauthor=A.+Salzmanauthor=C.+Szabo&title=The+discovery+and+synthesis+of+novel+adenosine+substituted+2%2C3-dihydro-1H-isoindol-1-ones%3A+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2003.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DRam%26aufirst%3DS.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSalzman%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520substituted%25202%252C3-dihydro-1H-isoindol-1-ones%253A%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D81%26epage%3D85%26doi%3D10.1016%2Fj.bmcl.2003.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Papeo, G. M. E.; Anatolievna Busel, A.; Khvat, A.; Krasavin, M. Y.; Forte, B.; Zuccotto, F.</span><span> </span><span class="NLM_article-title">3-Oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamides as PARP inhibitors</span>. Patent WO2011/006794,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+M.+E.+Papeo&author=A.+Anatolievna+Busel&author=A.+Khvat&author=M.+Y.+Krasavin&author=B.+Forte&author=F.+Zuccotto&title=3-Oxo-2%2C3-dihydro-1H-isoindole-4-carboxamides+as+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%2BM.%2BE.%26atitle%3D3-Oxo-2%252C3-dihydro-1H-isoindole-4-carboxamides%2520as%2520PARP%2520inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. N.</span><span> </span><span class="NLM_article-title">An efficient InCl<sub>3</sub>-catalyzed hydration of nitriles to amides: acetaldoxime as an effective water surrogate</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1589</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2010.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tetlet.2010.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvF2qt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=1589-1591&author=E.+S.+Kimauthor=H.+S.+Leeauthor=S.+H.+Kimauthor=J.+N.+Kim&title=An+efficient+InCl3-catalyzed+hydration+of+nitriles+to+amides%3A+acetaldoxime+as+an+effective+water+surrogate&doi=10.1016%2Fj.tetlet.2010.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient InCl3-catalyzed hydration of nitriles to amides: acetaldoxime as an effective water surrogate</span></div><div class="casAuthors">Kim, Eun Sun; Lee, Hyun Seung; Kim, Sung Hwan; Kim, Jae Nyoung</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1589-1591</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient InCl3-catalyzed hydration protocol of nitriles to amides was developed.  The reaction was carried out in toluene at refluxing temp. with the aid of acetaldoxime as an effective water surrogate to produce amides in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlkQc6OhyvbVg90H21EOLACvtfcHk0lhqL4GhcEsXXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvF2qt7Y%253D&md5=5df76d0d04e146ab1223a803285255f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BN.%26atitle%3DAn%2520efficient%2520InCl3-catalyzed%2520hydration%2520of%2520nitriles%2520to%2520amides%253A%2520acetaldoxime%2520as%2520an%2520effective%2520water%2520surrogate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D1589%26epage%3D1591%26doi%3D10.1016%2Fj.tetlet.2010.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Li, J.-H.; Zhang, J.; Jackson, P. F.; Maclin, K. M.</span><span> </span><span class="NLM_article-title">Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage</span>. U.S. Patent 6306889,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.-H.+Li&author=J.+Zhang&author=P.+F.+Jackson&author=K.+M.+Maclin&title=Compounds%2C+methods+and+pharmaceutical+compositions+for+treating+neural+or+cardiovascular+tissue+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-H.%26atitle%3DCompounds%252C%2520methods%2520and%2520pharmaceutical%2520compositions%2520for%2520treating%2520neural%2520or%2520cardiovascular%2520tissue%2520damage%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0liDpZ12TBhpeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perišić, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. E.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.drudis.2010.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20727982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=804-811&author=C.+Abad-Zapateroauthor=O.+Peri%C5%A1i%C4%87author=J.+Wassauthor=A.+P.+Bentoauthor=J.+Overingtonauthor=B.+Al-Lazikaniauthor=M.+E.+Johnson&title=Ligand+efficiency+indices+for+an+effective+mapping+of+chemico-biological+space%3A+the+concept+of+an+atlas-like+representation&doi=10.1016%2Fj.drudis.2010.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation</span></div><div class="casAuthors">Abad-Zapatero, Cele; Perisic, Ognjen; Wass, John; Bento, A. Patricia; Overington, John; Al-Lazikani, Bissan; Johnson, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">804-811</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  We propose a numerical framework that permits an effective atlas-like representation of chemico-biol. space based on a series of Cartesian planes mapping the ligands with the corresponding targets connected by an affinity parameter (K i or related).  The numerical framework is derived from the concept of ligand efficiency indexes, which provide a natural coordinate system combining the potency toward the target (biol. space) with the physicochem. properties of the ligand (chem. space).  This framework facilitates navigation in the multidimensional drug discovery space using map-like representations based on pairs of combined variables related to the efficiency of the ligands per Dalton (mol. wt. or no. of non-hydrogen atoms) and per unit of polar surface area (or no. of polar atoms).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4D5FkxdfoLVg90H21EOLACvtfcHk0liDpZ12TBhpeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqurrJ&md5=8ccee251c53513905dbd13c93a4ec1ed</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DPeri%25C5%25A1i%25C4%2587%26aufirst%3DO.%26aulast%3DWass%26aufirst%3DJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DOverington%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520an%2520effective%2520mapping%2520of%2520chemico-biological%2520space%253A%2520the%2520concept%2520of%2520an%2520atlas-like%2520representation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D804%26epage%3D811%26doi%3D10.1016%2Fj.drudis.2010.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lord, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Design, synthesis and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span><span class="refDoi"> DOI: 10.1021/jm8013629</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=868-877&author=A.-M.+Lordauthor=M.+F.+Mahonauthor=M.+D.+Lloydauthor=M.+D.+Threadgill&title=Design%2C+synthesis+and+evaluation+in+vitro+of+quinoline-8-carboxamides%2C+a+new+class+of+poly%28adenosine-diphosphate-ribose%29polymerase-1+%28PARP-1%29+inhibitor&doi=10.1021%2Fjm8013629"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fjm8013629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013629%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DA.-M.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DLloyd%26aufirst%3DM.%2BD.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520in%2520vitro%2520of%2520quinoline-8-carboxamides%252C%2520a%2520new%2520class%2520of%2520poly%2528adenosine-diphosphate-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D868%26epage%3D877%26doi%3D10.1021%2Fjm8013629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gorobets, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yermolayev, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurinov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolstoy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenderovich, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadbeater, N. E.</span><span> </span><span class="NLM_article-title">Difference between <sup>1</sup>H NMR signals of primary amide protons as a simple spectral index of the amide intramolecular hydrogen bond strength</span> <span class="citation_source-journal">J. Phys. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1002/poc.1910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fpoc.1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVams78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=287-295&author=N.+Y.+Gorobetsauthor=S.+A.+Yermolayevauthor=T.+Gurleyauthor=A.+A.+Gurinovauthor=P.+M.+Tolstoyauthor=I.+G.+Shenderovichauthor=N.+E.+Leadbeater&title=Difference+between+1H+NMR+signals+of+primary+amide+protons+as+a+simple+spectral+index+of+the+amide+intramolecular+hydrogen+bond+strength&doi=10.1002%2Fpoc.1910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Difference between 1H NMR signals of primary amide protons as a simple spectral index of the amide intramolecular hydrogen bond strength</span></div><div class="casAuthors">Gorobets, Nikolay Yu.; Yermolayev, Sergey A.; Gurley, Thomas; Gurinov, Andrey A.; Tolstoy, Peter M.; Shenderovich, Ilya G.; Leadbeater, Nicholas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-295</span>CODEN:
                <span class="NLM_cas:coden">JPOCEE</span>;
        ISSN:<span class="NLM_cas:issn">0894-3230</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The effect of the intramol. H-bonding of the primary amide group on the spectral properties and reactivity of this group towards electrophiles has been studied in systematic rows of 1,2,5,6,7,8-hexahydro-7,7-dimethyl-2,5-dioxo-1-R-quinoline-3-carboxamides and 2-aryliminocoumarin-3-carboxamides using 1H and 15N NMR spectroscopy and the kinetics of model reactions.  The upfield signal of the amide proton that is not intramolecularly H-bonded (Ha) depends on external factors such as solvent nature and concn.  At the same time, the downfield chem. shift of the Hb proton (bonded by the intramol. hydrogen bond) depends mostly on the strength of the intramol. H-bond, which is affected by such internal factor as electron nature of substituent R.  The substituent's influence on the Hb proton's chem. shift is more effective in deuterochloroform medium than in DMSO-d6 where the intramol. hydrogen bond is less stable.  The value Δδ(H) = δ(Hb) - δ(Ha) is suggested as a simple comparative spectral index of the intramol. hydrogen bond strength in these and similar compds.  By contrast, the effect of R on the 15N NMR chem. shift of the amide nitrogen has turned out to be too small to est. changes of the electron d. at the nitrogen.  The effect of the intramol. H-bond on the reactivity of the amide group is twofold.  When the cleavage of the H-bond occurs on the rate limiting step it dramatically reduces the reaction rate.  In the other case, the strengthening of the H-bond favors the reaction rate because of the increase of the electron d. at the amide nitrogen.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxnyXz8SSrrVg90H21EOLACvtfcHk0lgowBQjn6e1Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVams78%253D&md5=87e009b30f3aec3f5a0ff3901b230e4d</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1002%2Fpoc.1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpoc.1910%26sid%3Dliteratum%253Aachs%26aulast%3DGorobets%26aufirst%3DN.%2BY.%26aulast%3DYermolayev%26aufirst%3DS.%2BA.%26aulast%3DGurley%26aufirst%3DT.%26aulast%3DGurinov%26aufirst%3DA.%2BA.%26aulast%3DTolstoy%26aufirst%3DP.%2BM.%26aulast%3DShenderovich%26aufirst%3DI.%2BG.%26aulast%3DLeadbeater%26aufirst%3DN.%2BE.%26atitle%3DDifference%2520between%25201H%2520NMR%2520signals%2520of%2520primary%2520amide%2520protons%2520as%2520a%2520simple%2520spectral%2520index%2520of%2520the%2520amide%2520intramolecular%2520hydrogen%2520bond%2520strength%26jtitle%3DJ.%2520Phys.%2520Org.%2520Chem.%26date%3D2012%26volume%3D25%26spage%3D287%26epage%3D295%26doi%3D10.1002%2Fpoc.1910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Abraham, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acree, W. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliev, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, W. L.</span><span> </span><span class="NLM_article-title">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">11075</span><span class="NLM_x">–</span> <span class="NLM_lpage">11083</span><span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+Method+for+the+Quantitative+Assessment+of+Intramolecular+Hydrogen+Bonding%3B+Application+to+Physicochemical%2C+Environmental%2C+and+Biochemical+Properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0lgowBQjn6e1Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520Method%2520for%2520the%2520Quantitative%2520Assessment%2520of%2520Intramolecular%2520Hydrogen%2520Bonding%253B%2520Application%2520to%2520Physicochemical%252C%2520Environmental%252C%2520and%2520Biochemical%2520Properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">As the <i>K</i><sub>D</sub> sensitivity limit of the fluorescence polarization assay used to evaluate the biochemical potency of the inhibitors is 0.030 μM, a <i>K</i><sub>D</sub> ≥ 2 μM threshold against PARP-2 was introduced to evaluate the selectivity of the compounds that reach the aforementioned assay limit against PARP-1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">The 4,4-difluorocyclohexyl moiety was chosen in light of its purported superior metabolic stability compared to the corresponding unsubstituted cyclohexyl derivative. See, for example:</p></div><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dorr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macartney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Burchnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span> </span><span class="NLM_article-title">Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4721</span><span class="NLM_x">–</span> <span class="NLM_lpage">4732</span><span class="refDoi"> DOI: 10.1128/AAC.49.11.4721-4732.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1128%2FAAC.49.11.4721-4732.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=16251317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Siu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4721-4732&author=P.+Dorrauthor=M.+Westbyauthor=S.+Dobbsauthor=P.+Griffinauthor=B.+Irvineauthor=M.+Macartneyauthor=J.+Moriauthor=G.+Rickettauthor=C.+Smith-Burchnellauthor=C.+Napierauthor=R.+Websterauthor=D.+Armourauthor=D.+Priceauthor=B.+Stammenauthor=A.+Woodauthor=M.+Perros&title=Maraviroc+%28UK-427%2C857%29%2C+a+Potent%2C+Orally+Bioavailable%2C+and+Selective+Small-Molecule+Inhibitor+of+Chemokine+Receptor+CCR5+with+Broad-Spectrum+Anti-Human+Immunodeficiency+Virus+Type+1+Activity&doi=10.1128%2FAAC.49.11.4721-4732.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity</span></div><div class="casAuthors">Dorr, Patrick; Westby, Mike; Dobbs, Susan; Griffin, Paul; Irvine, Becky; Macartney, Malcolm; Mori, Julie; Rickett, Graham; Smith-Burchnell, Caroline; Napier, Carolyn; Webster, Rob; Armour, Duncan; Price, David; Stammen, Blanda; Wood, Anthony; Perros, Manos</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4721-4732</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent antihuman immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacol. properties.  Maraviroc is the product of a medicinal chem. effort initiated following identification of an imidazopyridine CCR5 ligand from a high-throughput screen of the Pfizer compd. file.  Maraviroc demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested, including 43 primary isolates from various clades and diverse geog. origin (geometric mean 90% inhibitory concn. of 2.0 nM).  Maraviroc was active against 200 clin. derived HIV-1 envelope-recombinant pseudoviruses, 100 of which were derived from viruses resistant to existing drug classes.  There was little difference in the sensitivity of the 200 viruses to maraviroc, as illustrated by the biol. cutoff in this assay (= geometric mean plus two std. deviations [SD] of 1.7-fold).  The mechanism of action of maraviroc was established using cell-based assays, where it blocked binding of viral envelope, gp120, to CCR5 to prevent the membrane fusion events necessary for viral entry.  Maraviroc did not affect CCR5 cell surface levels or assocd. intracellular signaling, confirming it as a functional antagonist of CCR5.  Maraviroc has no detectable in vitro cytotoxicity and is highly selective for CCR5, as confirmed against a wide range of receptors and enzymes, including the hERG ion channel (50% inhibitory concn., > 10 μM), indicating potential for an excellent clin. safety profile.  Studies in preclin. in vitro and in vivo models predicted maraviroc to have human pharmacokinetics consistent with once- or twice-daily dosing following oral administration.  Clin. trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0Z8KdsHODrVg90H21EOLACvtfcHk0lgowBQjn6e1Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Siu7rM&md5=561aea68490f7c6d3ec0f65676450155</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.11.4721-4732.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.11.4721-4732.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DP.%26aulast%3DWestby%26aufirst%3DM.%26aulast%3DDobbs%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DIrvine%26aufirst%3DB.%26aulast%3DMacartney%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DRickett%26aufirst%3DG.%26aulast%3DSmith-Burchnell%26aufirst%3DC.%26aulast%3DNapier%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DArmour%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DPerros%26aufirst%3DM.%26atitle%3DMaraviroc%2520%2528UK-427%252C857%2529%252C%2520a%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520and%2520Selective%2520Small-Molecule%2520Inhibitor%2520of%2520Chemokine%2520Receptor%2520CCR5%2520with%2520Broad-Spectrum%2520Anti-Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4721%26epage%3D4732%26doi%3D10.1128%2FAAC.49.11.4721-4732.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Bradykinin B<sub>1</sub> receptor antagonists: An α-hydroxy amide with an improved metabolism profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5107</span><span class="NLM_x">–</span> <span class="NLM_lpage">5110</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2008.07.126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5107-5110&author=S.+D.+Kudukauthor=R.+K.+Changauthor=R.+M.+DiPardoauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Bradykinin+B1+receptor+antagonists%3A+An+%CE%B1-hydroxy+amide+with+an+improved+metabolism+profile&doi=10.1016%2Fj.bmcl.2008.07.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.126%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBradykinin%2520B1%2520receptor%2520antagonists%253A%2520An%2520%25CE%25B1-hydroxy%2520amide%2520with%2520an%2520improved%2520metabolism%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5107%26epage%3D5110%26doi%3D10.1016%2Fj.bmcl.2008.07.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Robichaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thérien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isabel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, S. N.</span><span> </span><span class="NLM_article-title">Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6410</span><span class="NLM_x">–</span> <span class="NLM_lpage">6420</span><span class="refDoi"> DOI: 10.1021/jm800610j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800610j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6410-6420&author=J.+Robichaudauthor=W.+C.+Blackauthor=M.+Th%C3%A9rienauthor=J.+Paquetauthor=R.+M.+Oballaauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=Q.+Wangauthor=E.+Isabelauthor=S.+L%C3%A9gerauthor=C.+Mellonauthor=D.+B.+Kimmelauthor=G.+Wesolowskiauthor=M.+D.+Percivalauthor=F.+Mass%C3%A9author=S.+Desmaraisauthor=J.-P.+Falgueyretauthor=S.+N.+Crane&title=Identification+of+a+nonbasic%2C+nitrile-containing+cathepsin+K+inhibitor+%28MK-1256%29+that+is+efficacious+in+a+monkey+model+of+osteoporosis&doi=10.1021%2Fjm800610j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800610j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800610j%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26aulast%3DTh%25C3%25A9rien%26aufirst%3DM.%26aulast%3DPaquet%26aufirst%3DJ.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DIsabel%26aufirst%3DE.%26aulast%3DL%25C3%25A9ger%26aufirst%3DS.%26aulast%3DMellon%26aufirst%3DC.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DMass%25C3%25A9%26aufirst%3DF.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DFalgueyret%26aufirst%3DJ.-P.%26aulast%3DCrane%26aufirst%3DS.%2BN.%26atitle%3DIdentification%2520of%2520a%2520nonbasic%252C%2520nitrile-containing%2520cathepsin%2520K%2520inhibitor%2520%2528MK-1256%2529%2520that%2520is%2520efficacious%2520in%2520a%2520monkey%2520model%2520of%2520osteoporosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6410%26epage%3D6420%26doi%3D10.1021%2Fjm800610j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Boudra, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouquin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaslin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordeliéres, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mégnin-Chanet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaudon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">PARP-2 depletion results in lower radiation cell survival but cell line specific differences in poly(ADP-ribose) levels</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1007/s00018-014-1765-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs00018-014-1765-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25336152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=1585-1597&author=M.+T.+Boudraauthor=C.+Bolinauthor=S.+Chikerauthor=A.+Fouquinauthor=T.+Zarembaauthor=L.+Vaslinauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A9resauthor=F.+M%C3%A9gnin-Chanetauthor=V.+Favaudonauthor=M.+Fernetauthor=V.+Pennaneachauthor=J.+Hall&title=PARP-2+depletion+results+in+lower+radiation+cell+survival+but+cell+line+specific+differences+in+poly%28ADP-ribose%29+levels&doi=10.1007%2Fs00018-014-1765-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels</span></div><div class="casAuthors">Boudra, Mohammed-Tayyib; Bolin, Celeste; Chiker, Sara; Fouquin, Alexis; Zaremba, Tomasz; Vaslin, Laurence; Biard, Denis; Cordelieres, Fabrice P.; Megnin-Chanet, Frederique; Favaudon, Vincent; Fernet, Marie; Pennaneach, Vincent; Hall, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1585-1597</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-2 (PARP-2) activity contributes to a cells' poly(ADP-ribosyl)ating potential and like PARP-1, has been implicated in several DNA repair pathways including base excision repair and DNA single strand break repair.  Here the consequences of its stable depletion in HeLa, U20S, and AS3WT2 cells were examd.  All three PARP-2 depleted models showed increased sensitivity to the cell killing effects on ionizing radiation as reported in PARP-2 depleted mouse embryonic fibroblasts providing further evidence for a role in DNA strand break repair.  The PARP-2 depleted HeLa cells also showed both higher constitutive and DNA damage-induced levels of polymers of ADP-ribose (PAR) assocd. with unchanged PARP-1 protein levels, but higher PARP activity and a concomitant lower PARG protein levels and activity.  These changes were accompanied by a reduced maximal recruitment of PARP-1, XRCC1, PCNA, and PARG to DNA damage sites.  This PAR-assocd. phenotype could be reversed in HeLa cells on re-expression of PARP-2 and was not seen in U20S and AS3WT2 cells.  These results highlight the complexity of the relationship between different members of the PARP family on PAR metab. and suggest that cell model dependent phenotypes assocd. with the absence of PARP-2 exist within a common background of radiation sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSltAiaCa2JbVg90H21EOLACvtfcHk0lhQa-8fbFLkYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gt73F&md5=8c7788a7d7b2e3765044e1d4bfad55e4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1765-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1765-2%26sid%3Dliteratum%253Aachs%26aulast%3DBoudra%26aufirst%3DM.%2BT.%26aulast%3DBolin%26aufirst%3DC.%26aulast%3DChiker%26aufirst%3DS.%26aulast%3DFouquin%26aufirst%3DA.%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DVaslin%26aufirst%3DL.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A9res%26aufirst%3DF.%2BP.%26aulast%3DM%25C3%25A9gnin-Chanet%26aufirst%3DF.%26aulast%3DFavaudon%26aufirst%3DV.%26aulast%3DFernet%26aufirst%3DM.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DPARP-2%2520depletion%2520results%2520in%2520lower%2520radiation%2520cell%2520survival%2520but%2520cell%2520line%2520specific%2520differences%2520in%2520poly%2528ADP-ribose%2529%2520levels%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D1585%26epage%3D1597%26doi%3D10.1007%2Fs00018-014-1765-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1056</span><span class="NLM_x">–</span> <span class="NLM_lpage">1058</span><span class="refDoi"> DOI: 10.1021/bi902079y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi902079y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1056-1058&author=T.+Karlbergauthor=M.+Hammarstr%C3%B6mauthor=P.+Sch%C3%BCtzauthor=L.+Svenssonauthor=H.+Sch%C3%BCler&title=Crystal+Structure+of+the+Catalytic+Domain+of+Human+PARP2+in+Complex+with+PARP+Inhibitor+ABT-888&doi=10.1021%2Fbi902079y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fbi902079y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi902079y%26sid%3Dliteratum%253Aachs%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DP.%26aulast%3DSvensson%26aufirst%3DL.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520PARP2%2520in%2520Complex%2520with%2520PARP%2520Inhibitor%2520ABT-888%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D1056%26epage%3D1058%26doi%3D10.1021%2Fbi902079y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirtori, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1002/rcm.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+R.+Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer&doi=10.1002%2Frcm.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0ljWSKsEGNfjVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DSirtori%26aufirst%3DF.%2BR.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517%26doi%3D10.1002%2Frcm.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disingrini, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantegani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salom, B.</span><span> </span><span class="NLM_article-title">The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s11030-012-9361-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs11030-012-9361-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=27-51&author=E.+R.+Felderauthor=A.+Badariauthor=T.+Disingriniauthor=S.+Manteganiauthor=C.+Orreniusauthor=N.+Avanziauthor=A.+Isacchiauthor=B.+Salom&title=The+generation+of+purinome-targeted+libraries+as+a+means+to+diversify+ATP-mimetic+chemical+classes+for+lead+finding&doi=10.1007%2Fs11030-012-9361-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs11030-012-9361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-012-9361-6%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DBadari%26aufirst%3DA.%26aulast%3DDisingrini%26aufirst%3DT.%26aulast%3DMantegani%26aufirst%3DS.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSalom%26aufirst%3DB.%26atitle%3DThe%2520generation%2520of%2520purinome-targeted%2520libraries%2520as%2520a%2520means%2520to%2520diversify%2520ATP-mimetic%2520chemical%2520classes%2520for%2520lead%2520finding%26jtitle%3DMol.%2520Diversity%26date%3D2012%26volume%3D16%26spage%3D27%26epage%3D51%26doi%3D10.1007%2Fs11030-012-9361-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span>GraphPad Prism; <span class="NLM_publisher-name">GraphPad Software, Inc.</span>: <span class="NLM_publisher-loc">7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA.</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GraphPad+Prism%3B+GraphPad+Software%2C+Inc.%3A+7825+Fay+Avenue%2C+Suite+230+La+Jolla%2C+CA+92037+USA.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGraphPad%2520Prism%26pub%3DGraphPad%2520Software%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span> </span><span class="NLM_article-title">Integration of macromolecular diffraction data</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1696</span><span class="NLM_x">–</span> <span class="NLM_lpage">1702</span><span class="refDoi"> DOI: 10.1107/S090744499900846X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS090744499900846X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=1696-1702&author=A.+G.+W.+Leslie&title=Integration+of+macromolecular+diffraction+data&doi=10.1107%2FS090744499900846X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS090744499900846X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS090744499900846X%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DIntegration%2520of%2520macromolecular%2520diffraction%2520data%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1999%26volume%3D55%26spage%3D1696%26epage%3D1702%26doi%3D10.1107%2FS090744499900846X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Collaborative Computational Project, Number 4</span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative+Computational+Project%2C+Number+4&title=The+CCP4+suite%3A+programs+for+protein+crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lj5sbZ66yBA5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lj4_tzLITJ1HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Beria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarelli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span> </span><span class="NLM_article-title">Identification of 4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline derivatives as a new class of orally and selective polo-like kinase 1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3551</span><span class="refDoi"> DOI: 10.1021/jm901713n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901713n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3532-3551&author=I.+Beriaauthor=D.+Ballinariauthor=J.+A.+Bertrandauthor=D.+Borghiauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=P.+Cappellaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=A.+Ciavolellaauthor=C.+Cristianiauthor=V.+Crociauthor=A.+De+Pontiauthor=G.+Fachinauthor=R.+D.+Fergusonauthor=J.+Lansenauthor=J.+K.+Mollauthor=E.+Pesentiauthor=H.+Posteriauthor=R.+Peregoauthor=M.+Rocchettiauthor=P.+Storiciauthor=D.+Volpiauthor=B.+Valsasina&title=Identification+of+4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline+derivatives+as+a+new+class+of+orally+and+selective+polo-like+kinase+1+inhibitors&doi=10.1021%2Fjm901713n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm901713n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901713n%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDe%2BPonti%26aufirst%3DA.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFerguson%26aufirst%3DR.%2BD.%26aulast%3DLansen%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%2BK.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DIdentification%2520of%25204%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520orally%2520and%2520selective%2520polo-like%2520kinase%25201%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3532%26epage%3D3551%26doi%3D10.1021%2Fjm901713n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jupp, P.</span><span> </span><span class="NLM_article-title">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1002/jps.20075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fjps.20075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15124203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1440-1453&author=E.+H.+Kernsauthor=L.+Diauthor=S.+Petuskyauthor=M.+Farrisauthor=R.+Leyauthor=P.+Jupp&title=Combined+application+of+parallel+artificial+membrane+permeability+assay+and+Caco-2+permeability+assays+in+drug+discovery&doi=10.1002%2Fjps.20075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Petusky, Susan; Farris, Michele; Ley, Rob; Jupp, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1440-1453</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Data from permeability profiling using the parallel artificial membrane permeability assay (PAMPA) and cell monolayer (Caco-2 and MDR1-MDCKII) methods were compared for two published compd. sets and one inhouse set.  A majority of compds. in each set correlated (R2 = 0.76-0.92), indicating the predominance of passive diffusion in the permeation of these compds.  Compds. that did not correlate grouped into two subsets.  One subset had higher PAMPA permeability than cell monolayer permeability and consisted of compds. that are subject to secretory mechanisms: efflux or reduced passive diffusion of bases under Caco-2 when run under a pH gradient.  The other subset had higher cell monolayer permeability than PAMPA permeability and consisted of compds. that are subject to absorptive mechanisms: paracellular, active transport, or increased passive diffusion of acids under Caco-2 when run under a pH gradient.  Given the characteristics of the two methods, these studies suggest how PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of permeation mechanisms in drug discovery.  During early discovery, all compds. can be rapidly screened using PAMPA at low pH and neutral pH to assess passive diffusion permeability to indicate potential for gastrointestinal and cell assay permeation.  During intermediate discovery, selected compds. can be addnl. assayed by apical-to-basolateral Caco-2, which, in combination with PAMPA data, indicates susceptibility to addnl. permeation mechanisms (secretory and absorptive).  During mid-to-late discovery, selected candidates can be examd. in detail via multiple directional Caco-2 expts. and with transporter inhibitors for complete characterization of permeation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG1M-v5UG2RLVg90H21EOLACvtfcHk0lj4_tzLITJ1HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D&md5=428596e93f30763e94ced9341d23a02e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjps.20075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20075%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DFarris%26aufirst%3DM.%26aulast%3DLey%26aufirst%3DR.%26aulast%3DJupp%26aufirst%3DP.%26atitle%3DCombined%2520application%2520of%2520parallel%2520artificial%2520membrane%2520permeability%2520assay%2520and%2520Caco-2%2520permeability%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1440%26epage%3D1453%26doi%3D10.1002%2Fjps.20075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g','cit6h','cit6i'],'ref7':['cit7a','cit7b'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28a','cit28b','cit28c','cit28d','cit28e'],'ref29':['cit29a','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37a','cit37b'],'ref38':['cit38'],'ref39':[],'ref40':['cit40a','cit40b'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 55 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Justina Šileikytė, Sunil Sundalam, Larry L. David, <span class="NLM_string-name hlFld-ContribAuthor">Michael S. Cohen</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical Proteomics Approach for Profiling the NAD Interactome. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (18)
                                     , 6787-6791. <a href="https://doi.org/10.1021/jacs.1c01302" title="DOI URL">https://doi.org/10.1021/jacs.1c01302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c01302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c01302%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DChemical%252BProteomics%252BApproach%252Bfor%252BProfiling%252Bthe%252BNAD%252BInteractome%26aulast%3D%25C5%25A0ileikyt%25C4%2597%26aufirst%3DJustina%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D02022021%26date%3D29042021%26volume%3D143%26issue%3D18%26spage%3D6787%26epage%3D6791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hexiang Wang, Bo Ren, Ye Liu, Beibei Jiang, Yin Guo, Min Wei, Lusong Luo, Xianzhao Kuang, Ming Qiu, Lei Lv, Hong Xu, Ruipeng Qi, Huibin Yan, Dexu Xu, Zhiwei Wang, Chang-Xin Huo, Yutong Zhu, Yuan Zhao, Yiyuan Wu, Zhen Qin, Dan Su, Tristin Tang, Fan Wang, Xuebing Sun, Yingcai Feng, Hao Peng, Xing Wang, Yajuan Gao, Yong Liu, Wenfeng Gong, Fenglong Yu, Xuesong Liu, Lai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Changyou Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15541-15563. <a href="https://doi.org/10.1021/acs.jmedchem.0c01346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPamiparib%252B%252528BGB-290%252529%25252C%252Ba%252BPotent%252Band%252BSelective%252BPoly%252B%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252BInhibitor%252Bin%252BClinical%252BDevelopment%26aulast%3DWang%26aufirst%3DHexiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01082020%26date%3D02122020%26volume%3D63%26issue%3D24%26spage%3D15541%26epage%3D15563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chaoguo Cao, Jie Yang, Yong Chen, Peiting Zhou, Yingwei Wang, Wu Du, Lifeng Zhao, <span class="NLM_string-name hlFld-ContribAuthor">Yuanwei Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11012-11033. <a href="https://doi.org/10.1021/acs.jmedchem.0c00821" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00821</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00821&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00821%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BSK-575%252Bas%252Ba%252BHighly%252BPotent%252Band%252BEfficacious%252BProteolysis-Targeting%252BChimera%252BDegrader%252Bof%252BPARP1%252Bfor%252BTreating%252BCancers%26aulast%3DCao%26aufirst%3DChaoguo%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D01062020%26date%3D24092020%26date%3D14092020%26volume%3D63%26issue%3D19%26spage%3D11012%26epage%3D11033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Gianluca Papeo, Paolo Orsini, Nilla R. Avanzi, Daniela Borghi, Elena Casale, Marina Ciomei, Alessandra Cirla, Viviana Desperati, Daniele Donati, Eduard R. Felder, Arturo Galvani, Marco Guanci, Antonella Isacchi, Helena Posteri, Sonia Rainoldi, Federico Riccardi-Sirtori, Alessandra Scolaro, <span class="NLM_string-name hlFld-ContribAuthor">Alessia Montagnoli</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 534-538. <a href="https://doi.org/10.1021/acsmedchemlett.8b00569" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00569%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BStereospecific%252BPARP-1%252BInhibitor%252BIsoindolinone%252BNMS-P515%26aulast%3DPapeo%26aufirst%3DGianluca%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D22112018%26date%3D13032019%26date%3D15032019%26date%3D13032019%26volume%3D10%26issue%3D4%26spage%3D534%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chuanlong Guo, Lijun Wang, Xiuxue Li, Shuaiyu Wang, Xuemin Yu, Kuo Xu, Yue Zhao, Jiao Luo, Xiangqian Li, Bo Jiang, <span class="NLM_string-name hlFld-ContribAuthor">Dayong Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bromophenol–Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (6)
                                     , 3051-3067. <a href="https://doi.org/10.1021/acs.jmedchem.8b01946" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01946</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01946%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BBromophenol%2525E2%252580%252593Thiosemicarbazone%252BHybrids%252Bas%252BPotent%252BSelective%252BInhibitors%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252B%252528PARP-1%252529%252Bfor%252BUse%252Bin%252BCancer%26aulast%3DGuo%26aufirst%3DChuanlong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D19032019%26date%3D07032019%26volume%3D62%26issue%3D6%26spage%3D3051%26epage%3D3067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann-Gerd  Thorsell</span>, <span class="hlFld-ContribAuthor ">Torun  Ekblad</span>, <span class="hlFld-ContribAuthor ">Tobias  Karlberg</span>, <span class="hlFld-ContribAuthor ">Mirjam  Löw</span>, <span class="hlFld-ContribAuthor ">Ana Filipa  Pinto</span>, <span class="hlFld-ContribAuthor ">Lionel  Trésaugues</span>, <span class="hlFld-ContribAuthor ">Martin  Moche</span>, <span class="hlFld-ContribAuthor ">Michael S.  Cohen</span>, and <span class="hlFld-ContribAuthor ">Herwig  Schüler</span>  . </span><span class="cited-content_cbyCitation_article-title">Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (4)
                                     , 1262-1271. <a href="https://doi.org/10.1021/acs.jmedchem.6b00990" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00990</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00990%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BBasis%252Bfor%252BPotency%252Band%252BPromiscuity%252Bin%252BPoly%252528ADP-ribose%252529%252BPolymerase%252B%252528PARP%252529%252Band%252BTankyrase%252BInhibitors%26aulast%3DThorsell%26aufirst%3DAnn-Gerd%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D13072016%26date%3D21122016%26date%3D23022017%26date%3D02122016%26volume%3D60%26issue%3D4%26spage%3D1262%26epage%3D1271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying-Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Ping-Yuan  Wang</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Guang-Fu  Yang</span>, <span class="hlFld-ContribAuthor ">Ao  Zhang</span>, and <span class="hlFld-ContribAuthor ">Ze-Hong  Miao</span>  . </span><span class="cited-content_cbyCitation_article-title">An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (21)
                                     , 9575-9598. <a href="https://doi.org/10.1021/acs.jmedchem.6b00055" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00055%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252BUpdate%252Bon%252BPoly%252528ADP-ribose%252529polymerase-1%252B%252528PARP-1%252529%252BInhibitors%25253A%252BOpportunities%252Band%252BChallenges%252Bin%252BCancer%252BTherapy%26aulast%3DWang%26aufirst%3DYing-Qing%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D13012016%26date%3D27072016%26date%3D10112016%26date%3D14072016%26volume%3D59%26issue%3D21%26spage%3D9575%26epage%3D9598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bing  Wang</span>, <span class="hlFld-ContribAuthor ">Daniel  Chu</span>, <span class="hlFld-ContribAuthor ">Ying  Feng</span>, <span class="hlFld-ContribAuthor ">Yuqiao  Shen</span>, <span class="hlFld-ContribAuthor ">Mika  Aoyagi-Scharber</span>, and <span class="hlFld-ContribAuthor ">Leonard E.  Post</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (1)
                                     , 335-357. <a href="https://doi.org/10.1021/acs.jmedchem.5b01498" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01498</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01498%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252B%2525288S%25252C9R%252529-5-Fluoro-8-%2525284-fluorophenyl%252529-9-%2525281-methyl-1H-1%25252C2%25252C4-triazol-5-yl%252529-2%25252C7%25252C8%25252C9-tetrahydro-3H-pyrido%25255B4%25252C3%25252C2-de%25255Dphthalazin-3-one%252B%252528BMN%252B673%25252C%252BTalazoparib%252529%25252C%252Ba%252BNovel%25252C%252BHighly%252BPotent%25252C%252Band%252BOrally%252BEfficacious%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%25252F2%252BInhibitor%25252C%252Bas%252Ban%252BAnticancer%252BAgent%26aulast%3DWang%26aufirst%3DBing%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D27092015%26date%3D23122015%26date%3D14012016%26date%3D10122015%26volume%3D59%26issue%3D1%26spage%3D335%26epage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Uday Kiran  Velagapudi</span>, <span class="hlFld-ContribAuthor ">Bhargav A.  Patel</span>, <span class="hlFld-ContribAuthor ">Xuwei  Shao</span>, <span class="hlFld-ContribAuthor ">Sanjai Kumar  Pathak</span>, <span class="hlFld-ContribAuthor ">Dana V.  Ferraris</span>, <span class="hlFld-ContribAuthor ">Tanaji T.  Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (7)
                                     , 609-623. <a href="https://doi.org/10.1080/13543776.2021.1886275" title="DOI URL">https://doi.org/10.1080/13543776.2021.1886275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1886275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1886275%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DRecent%252Bdevelopment%252Bin%252Bthe%252Bdiscovery%252Bof%252BPARP%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282016-2020%252529%26aulast%3DVelagapudi%26aufirst%3DUday%2BKiran%26date%3D2021%26date%3D2021%26volume%3D31%26issue%3D7%26spage%3D609%26epage%3D623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueqian  Zuo</span>, <span class="hlFld-ContribAuthor ">Haibo  Zhao</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Recognition</span><span> <strong>2021,</strong> <em>34 </em>
                                    (7)
                                     <a href="https://doi.org/10.1002/jmr.2891" title="DOI URL">https://doi.org/10.1002/jmr.2891</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jmr.2891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjmr.2891%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Recognition%26atitle%3DSystematic%252Binhibitor%252Bselectivity%252Bbetween%252BPARP1%252Band%252BPARP2%252Benzymes%25253A%252BMolecular%252Bimplications%252Bfor%252Bovarian%252Bcancer%252Bpersonalized%252Btherapy%26aulast%3DZuo%26aufirst%3DXueqian%26date%3D2021%26date%3D2021%26volume%3D34%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob O.  Spiegel</span>, <span class="hlFld-ContribAuthor ">Bennett  Van Houten</span>, <span class="hlFld-ContribAuthor ">Jacob D.  Durrant</span>. </span><span class="cited-content_cbyCitation_article-title">PARP1: Structural insights and pharmacological targets for inhibition. </span><span class="cited-content_cbyCitation_journal-name">DNA Repair</span><span> <strong>2021,</strong> <em>103 </em>, 103125. <a href="https://doi.org/10.1016/j.dnarep.2021.103125" title="DOI URL">https://doi.org/10.1016/j.dnarep.2021.103125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.dnarep.2021.103125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.dnarep.2021.103125%26sid%3Dliteratum%253Aachs%26jtitle%3DDNA%2520Repair%26atitle%3DPARP1%25253A%252BStructural%252Binsights%252Band%252Bpharmacological%252Btargets%252Bfor%252Binhibition%26aulast%3DSpiegel%26aufirst%3DJacob%2BO.%26date%3D2021%26volume%3D103%26spage%3D103125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Liliana  Raimundo</span>, <span class="hlFld-ContribAuthor ">Juliana  Calheiros</span>, <span class="hlFld-ContribAuthor ">Lucília  Saraiva</span>. </span><span class="cited-content_cbyCitation_article-title">Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 3438. <a href="https://doi.org/10.3390/cancers13143438" title="DOI URL">https://doi.org/10.3390/cancers13143438</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13143438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13143438%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DExploiting%252BDNA%252BDamage%252BRepair%252Bin%252BPrecision%252BCancer%252BTherapy%25253A%252BBRCA1%252Bas%252Ba%252BPrime%252BTherapeutic%252BTarget%26aulast%3DRaimundo%26aufirst%3DLiliana%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D3438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed T.A.  Boraei</span>, <span class="hlFld-ContribAuthor ">Elsayed H.  Eltamany</span>, <span class="hlFld-ContribAuthor ">Ibrahim A.I.  Ali</span>, <span class="hlFld-ContribAuthor ">Sara M.  Gebriel</span>, <span class="hlFld-ContribAuthor ">Mohamed S.  Nafie</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>111 </em>, 104877. <a href="https://doi.org/10.1016/j.bioorg.2021.104877" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104877%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bnew%252Bsubstituted%252Bpyridine%252Bderivatives%252Bas%252Bpotent%252Banti-liver%252Bcancer%252Bagents%252Bthrough%252Bapoptosis%252Binduction%25253A%252BIn%252Bvitro%25252C%252Bin%252Bvivo%25252C%252Band%252Bin%252Bsilico%252Bintegrated%252Bapproaches%26aulast%3DBoraei%26aufirst%3DAhmed%2BT.A.%26date%3D2021%26volume%3D111%26spage%3D104877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maninder  Singh</span>, <span class="hlFld-ContribAuthor ">Jyotika  Rajawat</span>, <span class="hlFld-ContribAuthor ">Jitendra  Kuldeep</span>, <span class="hlFld-ContribAuthor ">Nidhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Durga Prasad  Mishra</span>, <span class="hlFld-ContribAuthor ">Mohammad Imran  Siddiqi</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>45 </em>, 1-14. <a href="https://doi.org/10.1080/07391102.2021.1913229" title="DOI URL">https://doi.org/10.1080/07391102.2021.1913229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1913229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1913229%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIntegrated%252Bsupport%252Bvector%252Bmachine%252Band%252Bpharmacophore%252Bbased%252Bvirtual%252Bscreening%252Bdriven%252Bidentification%252Bof%252Bthiophene%252Bcarboxamide%252Bscaffold%252Bcontaining%252Bcompound%252Bas%252Bpotential%252BPARP1%252Binhibitor%26aulast%3DSingh%26aufirst%3DManinder%26date%3D2021%26date%3D2021%26volume%3D45%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lotte  van Beek</span>, <span class="hlFld-ContribAuthor ">Éilís  McClay</span>, <span class="hlFld-ContribAuthor ">Saleha  Patel</span>, <span class="hlFld-ContribAuthor ">Marianne  Schimpl</span>, <span class="hlFld-ContribAuthor ">Laura  Spagnolo</span>, <span class="hlFld-ContribAuthor ">Taiana  Maia de Oliveira</span>. </span><span class="cited-content_cbyCitation_article-title">PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (10)
                                     , 5112. <a href="https://doi.org/10.3390/ijms22105112" title="DOI URL">https://doi.org/10.3390/ijms22105112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22105112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22105112%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPARP%252BPower%25253A%252BA%252BStructural%252BPerspective%252Bon%252BPARP1%25252C%252BPARP2%25252C%252Band%252BPARP3%252Bin%252BDNA%252BDamage%252BRepair%252Band%252BNucleosome%252BRemodelling%26aulast%3Dvan%2BBeek%26aufirst%3DLotte%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D10%26spage%3D5112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garri  Manasaryan</span>, <span class="hlFld-ContribAuthor ">Dmitry  Suplatov</span>, <span class="hlFld-ContribAuthor ">Sergey  Pushkarev</span>, <span class="hlFld-ContribAuthor ">Viktor  Drobot</span>, <span class="hlFld-ContribAuthor ">Alexander  Kuimov</span>, <span class="hlFld-ContribAuthor ">Vytas  Švedas</span>, <span class="hlFld-ContribAuthor ">Dmitry  Nilov</span>. </span><span class="cited-content_cbyCitation_article-title">Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (6)
                                     , 1201. <a href="https://doi.org/10.3390/cancers13061201" title="DOI URL">https://doi.org/10.3390/cancers13061201</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13061201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13061201%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBioinformatic%252BAnalysis%252Bof%252Bthe%252BNicotinamide%252BBinding%252BSite%252Bin%252BPoly%252528ADP-Ribose%252529%252BPolymerase%252BFamily%252BProteins%26aulast%3DManasaryan%26aufirst%3DGarri%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D6%26spage%3D1201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anissa Nofita  Sari</span>, <span class="hlFld-ContribAuthor ">Ahmed  Elwakeel</span>, <span class="hlFld-ContribAuthor ">Jaspreet Kaur  Dhanjal</span>, <span class="hlFld-ContribAuthor ">Vipul  Kumar</span>, <span class="hlFld-ContribAuthor ">Durai  Sundar</span>, <span class="hlFld-ContribAuthor ">Sunil C.  Kaul</span>, <span class="hlFld-ContribAuthor ">Renu  Wadhwa</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Characterization of MortaparibPlus—A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 835. <a href="https://doi.org/10.3390/cancers13040835" title="DOI URL">https://doi.org/10.3390/cancers13040835</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040835%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DIdentification%252Band%252BCharacterization%252Bof%252BMortaparibPlus%2525E2%252580%252594A%252BNovel%252BTriazole%252BDerivative%252BThat%252BTargets%252BMortalin-p53%252BInteraction%252Band%252BInhibits%252BCancer-Cell%252BProliferation%252Bby%252BWild-Type%252Bp53-Dependent%252Band%252B-Independent%252BMechanisms%26aulast%3DSari%26aufirst%3DAnissa%2BNofita%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaosa  Chang</span>, <span class="hlFld-ContribAuthor ">Dejuan  Sun</span>, <span class="hlFld-ContribAuthor ">Danfeng  Shi</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Yanmei  Chen</span>, <span class="hlFld-ContribAuthor ">Kai  Zhang</span>, <span class="hlFld-ContribAuthor ">Huidan  Tan</span>, <span class="hlFld-ContribAuthor ">Jie  Liu</span>, <span class="hlFld-ContribAuthor ">Bo  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 156-180. <a href="https://doi.org/10.1016/j.apsb.2020.06.003" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.06.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.06.003%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bquinazolin-4%2525283H%252529-one%252Bderivatives%252Bco-targeting%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Band%252Bbromodomain%252Bcontaining%252Bprotein%252B4%252Bfor%252Bbreast%252Bcancer%252Btherapy%26aulast%3DChang%26aufirst%3DXiaosa%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D156%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Woosung  Jeon</span>, <span class="hlFld-ContribAuthor ">Dongsup  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-78537-2" title="DOI URL">https://doi.org/10.1038/s41598-020-78537-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-78537-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-78537-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DAutonomous%252Bmolecule%252Bgeneration%252Busing%252Breinforcement%252Blearning%252Band%252Bdocking%252Bto%252Bdevelop%252Bpotential%252Bnovel%252Binhibitors%26aulast%3DJeon%26aufirst%3DWoosung%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caleb M  Kam</span>, <span class="hlFld-ContribAuthor ">Amanda L  Tauber</span>, <span class="hlFld-ContribAuthor ">Dean L  Oosthuizen</span>, <span class="hlFld-ContribAuthor ">Stephan M  Levonis</span>, <span class="hlFld-ContribAuthor ">Stephanie S  Schweiker</span>. </span><span class="cited-content_cbyCitation_article-title">In silico
              family-wide profiling and 3D modelling of the poly(ADP-ribose) polymerase superfamily. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (23)
                                     , 2105-2122. <a href="https://doi.org/10.4155/fmc-2020-0274" title="DOI URL">https://doi.org/10.4155/fmc-2020-0274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0274%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DIn%252Bsilico%252Bfamily-wide%252Bprofiling%252Band%252B3D%252Bmodelling%252Bof%252Bthe%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252Bsuperfamily%26aulast%3DKam%26aufirst%3DCaleb%2BM%26date%3D2020%26volume%3D12%26issue%3D23%26spage%3D2105%26epage%3D2122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jacob O.  Spiegel</span>, <span class="hlFld-ContribAuthor ">Jacob D.  Durrant</span>. </span><span class="cited-content_cbyCitation_article-title">AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cheminformatics</span><span> <strong>2020,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13321-020-00429-4" title="DOI URL">https://doi.org/10.1186/s13321-020-00429-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13321-020-00429-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13321-020-00429-4%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cheminformatics%26atitle%3DAutoGrow4%25253A%252Ban%252Bopen-source%252Bgenetic%252Balgorithm%252Bfor%252Bde%252Bnovo%252Bdrug%252Bdesign%252Band%252Blead%252Boptimization%26aulast%3DSpiegel%26aufirst%3DJacob%2BO.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillaume  Gaullier</span>, <span class="hlFld-ContribAuthor ">Genevieve  Roberts</span>, <span class="hlFld-ContribAuthor ">Uma M.  Muthurajan</span>, <span class="hlFld-ContribAuthor ">Samuel  Bowerman</span>, <span class="hlFld-ContribAuthor ">Johannes  Rudolph</span>, <span class="hlFld-ContribAuthor ">Jyothi  Mahadevan</span>, <span class="hlFld-ContribAuthor ">Asmita  Jha</span>, <span class="hlFld-ContribAuthor ">Purushka S.  Rae</span>, <span class="hlFld-ContribAuthor ">Karolin  Luger</span>, . </span><span class="cited-content_cbyCitation_article-title">Bridging of nucleosome-proximal DNA double-strand breaks by PARP2 enhances its interaction with HPF1. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2020,</strong> <em>15 </em>
                                    (11)
                                     , e0240932. <a href="https://doi.org/10.1371/journal.pone.0240932" title="DOI URL">https://doi.org/10.1371/journal.pone.0240932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0240932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0240932%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DBridging%252Bof%252Bnucleosome-proximal%252BDNA%252Bdouble-strand%252Bbreaks%252Bby%252BPARP2%252Benhances%252Bits%252Binteraction%252Bwith%252BHPF1%26aulast%3DGaullier%26aufirst%3DGuillaume%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D11%26spage%3De0240932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Jian-Quan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiang-Shan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Copper(I)-catalyzed synthesis of isoindolo[1,2-b]quinazoline derivatives via an α-arylation under Pd and ligand free conditions. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (46)
                                     , 152508. <a href="https://doi.org/10.1016/j.tetlet.2020.152508" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152508%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DCopper%252528I%252529-catalyzed%252Bsynthesis%252Bof%252Bisoindolo%25255B1%25252C2-b%25255Dquinazoline%252Bderivatives%252Bvia%252Ban%252B%2525CE%2525B1-arylation%252Bunder%252BPd%252Band%252Bligand%252Bfree%252Bconditions%26aulast%3DZhang%26aufirst%3DYan%26date%3D2020%26volume%3D61%26issue%3D46%26spage%3D152508" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yann  Corre</span>, <span class="hlFld-ContribAuthor ">Vincent  Rysak</span>, <span class="hlFld-ContribAuthor ">Márton  Nagyházi</span>, <span class="hlFld-ContribAuthor ">Dorottya  Kalocsai</span>, <span class="hlFld-ContribAuthor ">Xavier  Trivelli</span>, <span class="hlFld-ContribAuthor ">Jean‐Pierre  Djukic</span>, <span class="hlFld-ContribAuthor ">Francine  Agbossou‐Niedercorn</span>, <span class="hlFld-ContribAuthor ">Christophe  Michon</span>. </span><span class="cited-content_cbyCitation_article-title">One‐Pot Controlled Reduction of Conjugated Amides by Sequential Double Hydrosilylation Catalyzed by an Iridium(III) Metallacycle. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (39)
                                     , 6212-6220. <a href="https://doi.org/10.1002/ejoc.202001061" title="DOI URL">https://doi.org/10.1002/ejoc.202001061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne%2525E2%252580%252590Pot%252BControlled%252BReduction%252Bof%252BConjugated%252BAmides%252Bby%252BSequential%252BDouble%252BHydrosilylation%252BCatalyzed%252Bby%252Ban%252BIridium%252528III%252529%252BMetallacycle%26aulast%3DCorre%26aufirst%3DYann%26date%3D2020%26date%3D2020%26volume%3D2020%26issue%3D39%26spage%3D6212%26epage%3D6220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Zhao</span>, <span class="hlFld-ContribAuthor ">Liu-Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Ting  Jiang</span>, <span class="hlFld-ContribAuthor ">Jing  Long</span>, <span class="hlFld-ContribAuthor ">Zhong-Ye  Ma</span>, <span class="hlFld-ContribAuthor ">Ai-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Yan  Cheng</span>, <span class="hlFld-ContribAuthor ">Dong-Sheng  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112570. <a href="https://doi.org/10.1016/j.ejmech.2020.112570" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112570</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112570%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bups%252Band%252Bdowns%252Bof%252BPoly%252528ADP-ribose%252529%252BPolymerase-1%252Binhibitors%252Bin%252Bcancer%252Btherapy%2525E2%252580%252593Current%252Bprogress%252Band%252Bfuture%252Bdirection%26aulast%3DZhao%26aufirst%3DYue%26date%3D2020%26volume%3D203%26spage%3D112570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Wang</span>, <span class="hlFld-ContribAuthor ">Yalong  Cong</span>, <span class="hlFld-ContribAuthor ">Mengxin  Li</span>, <span class="hlFld-ContribAuthor ">Jinxiao  Bao</span>, <span class="hlFld-ContribAuthor ">Yifei  Qi</span>, <span class="hlFld-ContribAuthor ">John Z. H.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Mechanism of Selective Binding of NMS-P118 to PARP-1 and PARP-2: A Computational Perspective. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00050" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00050%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DMolecular%252BMechanism%252Bof%252BSelective%252BBinding%252Bof%252BNMS-P118%252Bto%252BPARP-1%252Band%252BPARP-2%25253A%252BA%252BComputational%252BPerspective%26aulast%3DWang%26aufirst%3DRan%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bakhyt T  Matkarimov</span>, <span class="hlFld-ContribAuthor ">Dmitry O  Zharkov</span>, <span class="hlFld-ContribAuthor ">Murat K  Saparbaev</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage. </span><span class="cited-content_cbyCitation_journal-name">Mutagenesis</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 107-118. <a href="https://doi.org/10.1093/mutage/gez045" title="DOI URL">https://doi.org/10.1093/mutage/gez045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/mutage/gez045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fmutage%2Fgez045%26sid%3Dliteratum%253Aachs%26jtitle%3DMutagenesis%26atitle%3DMechanistic%252Binsight%252Binto%252Bthe%252Brole%252Bof%252BPoly%252528ADP-ribosyl%252529ation%252Bin%252BDNA%252Btopology%252Bmodulation%252Band%252Bresponse%252Bto%252BDNA%252Bdamage%26aulast%3DMatkarimov%26aufirst%3DBakhyt%2BT%26date%3D2020%26date%3D2019%26volume%3D35%26issue%3D1%26spage%3D107%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frederick A.  Luzzio</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and reactivity of fluorinated heterocycles. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-84. <a href="https://doi.org/10.1016/bs.aihch.2020.02.001" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.02.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.02.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.02.001%26sid%3Dliteratum%253Aachs%26atitle%3DSynthesis%252Band%252Breactivity%252Bof%252Bfluorinated%252Bheterocycles%26aulast%3DLuzzio%26aufirst%3DFrederick%2BA.%26date%3D2020%26spage%3D1%26epage%3D84%26pub%3DElsevier%26date%3D2020%26volume%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuliya V.  Sherstyuk</span>, <span class="hlFld-ContribAuthor ">Nikita V.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">Maria V.  Sukhanova</span>, <span class="hlFld-ContribAuthor ">Roman Y.  Peshkov</span>, <span class="hlFld-ContribAuthor ">Ilia V.  Eltsov</span>, <span class="hlFld-ContribAuthor ">Mikhail M.  Kutuzov</span>, <span class="hlFld-ContribAuthor ">Tatiana A.  Kurgina</span>, <span class="hlFld-ContribAuthor ">Ekaterina A.  Belousova</span>, <span class="hlFld-ContribAuthor ">Vladimir A.  Ivanisenko</span>, <span class="hlFld-ContribAuthor ">Olga I.  Lavrik</span>, <span class="hlFld-ContribAuthor ">Vladimir N.  Silnikov</span>, <span class="hlFld-ContribAuthor ">Tatyana V.  Abramova</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     , 214. <a href="https://doi.org/10.3390/ijms21010214" title="DOI URL">https://doi.org/10.3390/ijms21010214</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21010214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21010214%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BMolecular%252BModeling%252BStudy%252Bof%252BConjugates%252Bof%252BADP%252Band%252BMorpholino%252BNucleosides%252Bas%252BA%252BNovel%252BClass%252Bof%252BInhibitors%252Bof%252BPARP-1%25252C%252BPARP-2%252Band%252BPARP-3%26aulast%3DSherstyuk%26aufirst%3DYuliya%2BV.%26date%3D2020%26date%3D2019%26volume%3D21%26issue%3D1%26spage%3D214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongye  Hu</span>, <span class="hlFld-ContribAuthor ">Buran  Chen</span>, <span class="hlFld-ContribAuthor ">Danni  Zheng</span>, <span class="hlFld-ContribAuthor ">Guanli  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods. </span><span class="cited-content_cbyCitation_journal-name">PeerJ</span><span> <strong>2020,</strong> <em>8 </em>, e9241. <a href="https://doi.org/10.7717/peerj.9241" title="DOI URL">https://doi.org/10.7717/peerj.9241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7717/peerj.9241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7717%2Fpeerj.9241%26sid%3Dliteratum%253Aachs%26jtitle%3DPeerJ%26atitle%3DRevealing%252Bthe%252Bselective%252Bmechanisms%252Bof%252Binhibitors%252Bto%252BPARP-1%252Band%252BPARP-2%252Bvia%252Bmultiple%252Bcomputational%252Bmethods%26aulast%3DHu%26aufirst%3DHongye%26date%3D2020%26date%3D2020%26volume%3D8%26spage%3De9241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Nan  Zhang</span>, <span class="hlFld-ContribAuthor ">Qinqin  Cheng</span>, <span class="hlFld-ContribAuthor ">Jingwen  Chen</span>, <span class="hlFld-ContribAuthor ">Albert T.  Lam</span>, <span class="hlFld-ContribAuthor ">Yanran  Lu</span>, <span class="hlFld-ContribAuthor ">Zhefu  Dai</span>, <span class="hlFld-ContribAuthor ">Hua  Pei</span>, <span class="hlFld-ContribAuthor ">Nikolai M.  Evdokimov</span>, <span class="hlFld-ContribAuthor ">Stan G.  Louie</span>, <span class="hlFld-ContribAuthor ">Yong  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A ribose-functionalized NAD+ with unexpected high activity and selectivity for protein poly-ADP-ribosylation. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-12215-4" title="DOI URL">https://doi.org/10.1038/s41467-019-12215-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-12215-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-12215-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DA%252Bribose-functionalized%252BNAD%25252B%252Bwith%252Bunexpected%252Bhigh%252Bactivity%252Band%252Bselectivity%252Bfor%252Bprotein%252Bpoly-ADP-ribosylation%26aulast%3DZhang%26aufirst%3DXiao-Nan%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed T.A.  Boraei</span>, <span class="hlFld-ContribAuthor ">Pankaj K.  Singh</span>, <span class="hlFld-ContribAuthor ">Mario  Sechi</span>, <span class="hlFld-ContribAuthor ">Sandro  Satta</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111621. <a href="https://doi.org/10.1016/j.ejmech.2019.111621" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111621</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111621&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111621%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bfunctionalized%252B1%25252C2%25252C4-triazoles%252Bas%252BPARP-1%252Binhibitors%252Bin%252Bbreast%252Bcancer%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bevaluation%26aulast%3DBoraei%26aufirst%3DAhmed%2BT.A.%26date%3D2019%26volume%3D182%26spage%3D111621" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonathan E.  Wilson</span>, <span class="hlFld-ContribAuthor ">Joshua  Garvey</span>, <span class="hlFld-ContribAuthor ">Kennedy M.  Taveras</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of isoindolinones: Intramolecular [4+2] cycloaddition/retro [4+2] of pyridone propiolamides. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (41)
                                     , 151105. <a href="https://doi.org/10.1016/j.tetlet.2019.151105" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.151105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.151105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.151105%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Bisoindolinones%25253A%252BIntramolecular%252B%25255B4%25252B2%25255D%252Bcycloaddition%25252Fretro%252B%25255B4%25252B2%25255D%252Bof%252Bpyridone%252Bpropiolamides%26aulast%3DWilson%26aufirst%3DJonathan%2BE.%26date%3D2019%26volume%3D60%26issue%3D41%26spage%3D151105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alvin Z.  Lu</span>, <span class="hlFld-ContribAuthor ">Ryan  Abo</span>, <span class="hlFld-ContribAuthor ">Yue  Ren</span>, <span class="hlFld-ContribAuthor ">Bin  Gui</span>, <span class="hlFld-ContribAuthor ">Jan-Rung  Mo</span>, <span class="hlFld-ContribAuthor ">Danielle  Blackwell</span>, <span class="hlFld-ContribAuthor ">Tim  Wigle</span>, <span class="hlFld-ContribAuthor ">Heike  Keilhack</span>, <span class="hlFld-ContribAuthor ">Mario  Niepel</span>. </span><span class="cited-content_cbyCitation_article-title">Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>167 </em>, 97-106. <a href="https://doi.org/10.1016/j.bcp.2019.05.007" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.05.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.05.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DEnabling%252Bdrug%252Bdiscovery%252Bfor%252Bthe%252BPARP%252Bprotein%252Bfamily%252Bthrough%252Bthe%252Bdetection%252Bof%252Bmono-ADP-ribosylation%26aulast%3DLu%26aufirst%3DAlvin%2BZ.%26date%3D2019%26volume%3D167%26spage%3D97%26epage%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Blanpain</span>, <span class="hlFld-ContribAuthor ">James H.  Clark</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Farmer</span>, <span class="hlFld-ContribAuthor ">Yuanlong  Guo</span>, <span class="hlFld-ContribAuthor ">Ian D. V.  Ingram</span>, <span class="hlFld-ContribAuthor ">John E.  Kendrick</span>, <span class="hlFld-ContribAuthor ">Stefan B.  Lawrenson</span>, <span class="hlFld-ContribAuthor ">Michael  North</span>, <span class="hlFld-ContribAuthor ">George  Rodgers</span>, <span class="hlFld-ContribAuthor ">Adrian C.  Whitwood</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid Ring‐Opening Metathesis Polymerization of Monomers Obtained from Biomass‐Derived Furfuryl Amines and Maleic Anhydride. </span><span class="cited-content_cbyCitation_journal-name">ChemSusChem</span><span> <strong>2019,</strong> <em>5 </em><a href="https://doi.org/10.1002/cssc.201900748" title="DOI URL">https://doi.org/10.1002/cssc.201900748</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cssc.201900748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcssc.201900748%26sid%3Dliteratum%253Aachs%26jtitle%3DChemSusChem%26atitle%3DRapid%252BRing%2525E2%252580%252590Opening%252BMetathesis%252BPolymerization%252Bof%252BMonomers%252BObtained%252Bfrom%252BBiomass%2525E2%252580%252590Derived%252BFurfuryl%252BAmines%252Band%252BMaleic%252BAnhydride%26aulast%3DBlanpain%26aufirst%3DAnna%26date%3D2019%26date%3D2019%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junko  Murai</span>, <span class="hlFld-ContribAuthor ">Yves  Pommier</span>. </span><span class="cited-content_cbyCitation_article-title">PARP Trapping Beyond Homologous Recombination and Platinum Sensitivity in Cancers. </span><span class="cited-content_cbyCitation_journal-name">Annual Review of Cancer Biology</span><span> <strong>2019,</strong> <em>3 </em>
                                    (1)
                                     , 131-150. <a href="https://doi.org/10.1146/annurev-cancerbio-030518-055914" title="DOI URL">https://doi.org/10.1146/annurev-cancerbio-030518-055914</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1146/annurev-cancerbio-030518-055914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1146%2Fannurev-cancerbio-030518-055914%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnual%2520Review%2520of%2520Cancer%2520Biology%26atitle%3DPARP%252BTrapping%252BBeyond%252BHomologous%252BRecombination%252Band%252BPlatinum%252BSensitivity%252Bin%252BCancers%26aulast%3DMurai%26aufirst%3DJunko%26date%3D2019%26volume%3D3%26issue%3D1%26spage%3D131%26epage%3D150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Priyancy G.  Jain</span>, <span class="hlFld-ContribAuthor ">Bhumika D.  Patel</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>165 </em>, 198-215. <a href="https://doi.org/10.1016/j.ejmech.2019.01.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252Bchemistry%252Bapproaches%252Bof%252Bpoly%252BADP-Ribose%252Bpolymerase%252B1%252B%252528PARP1%252529%252Binhibitors%252Bas%252Banticancer%252Bagents%252B-%252BA%252Brecent%252Bupdate%26aulast%3DJain%26aufirst%3DPriyancy%2BG.%26date%3D2019%26volume%3D165%26spage%3D198%26epage%3D215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Albert A.  Antolin</span>, <span class="hlFld-ContribAuthor ">Joseph E.  Tym</span>, <span class="hlFld-ContribAuthor ">Angeliki  Komianou</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Bissan  Al-Lazikani</span>. </span><span class="cited-content_cbyCitation_article-title">Objective, Quantitative, Data-Driven Assessment of Chemical Probes. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2018,</strong> <em>25 </em>
                                    (2)
                                     , 194-205.e5. <a href="https://doi.org/10.1016/j.chembiol.2017.11.004" title="DOI URL">https://doi.org/10.1016/j.chembiol.2017.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2017.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2017.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DObjective%25252C%252BQuantitative%25252C%252BData-Driven%252BAssessment%252Bof%252BChemical%252BProbes%26aulast%3DAntolin%26aufirst%3DAlbert%2BA.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D194%26epage%3D205.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Haiping  Yao</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Hailong  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of quinazoline-2,4(1
              H
              ,3
              H
              )-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (17)
                                     , 3189-3202. <a href="https://doi.org/10.1039/C8OB00286J" title="DOI URL">https://doi.org/10.1039/C8OB00286J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB00286J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB00286J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bquinazoline-2%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529-dione%252Bderivatives%252Bas%252Bnovel%252BPARP-1%25252F2%252Binhibitors%25253A%252Bdesign%25252C%252Bsynthesis%252Band%252Btheir%252Bantitumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D17%26spage%3D3189%26epage%3D3202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. L.  Zakharenko</span>, <span class="hlFld-ContribAuthor ">N. A.  Lebedeva</span>, <span class="hlFld-ContribAuthor ">O. I.  Lavrik</span>. </span><span class="cited-content_cbyCitation_article-title">DNA Repair Enzymes as Promising Targets in Oncotherapy. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>44 </em>
                                    (1)
                                     , 1-18. <a href="https://doi.org/10.1134/S1068162017060140" title="DOI URL">https://doi.org/10.1134/S1068162017060140</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162017060140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162017060140%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3DDNA%252BRepair%252BEnzymes%252Bas%252BPromising%252BTargets%252Bin%252BOncotherapy%26aulast%3DZakharenko%26aufirst%3DA.%2BL.%26date%3D2018%26date%3D2018%26volume%3D44%26issue%3D1%26spage%3D1%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dimitrios T.  Trafalis</span>, <span class="hlFld-ContribAuthor ">Aikaterini  Polonifi</span>, <span class="hlFld-ContribAuthor ">Panayiotis  Dalezis</span>, <span class="hlFld-ContribAuthor ">Nikolaos  Nikoleousakos</span>, <span class="hlFld-ContribAuthor ">Sotirios  Katsamakas</span>, <span class="hlFld-ContribAuthor ">Vasiliki  Sarli</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2017,</strong> <em>90 </em>
                                    (5)
                                     , 854-866. <a href="https://doi.org/10.1111/cbdd.13006" title="DOI URL">https://doi.org/10.1111/cbdd.13006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13006%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DTargeting%252Bon%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252Bactivity%252Bwith%252BDNA-damaging%252Bhybrid%252Blactam-steroid%252Balkylators%252Bin%252Bwild-type%252Band%252BBRCA1-mutated%252Bovarian%252Bcancer%252Bcells%26aulast%3DTrafalis%26aufirst%3DDimitrios%2BT.%26date%3D2017%26date%3D2017%26volume%3D90%26issue%3D5%26spage%3D854%26epage%3D866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Navriti  Chadha</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore based design of some multi-targeted compounds targeted against pathways of diabetic complications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2017,</strong> <em>76 </em>, 412-418. <a href="https://doi.org/10.1016/j.jmgm.2017.07.020" title="DOI URL">https://doi.org/10.1016/j.jmgm.2017.07.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2017.07.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2017.07.020%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DPharmacophore%252Bbased%252Bdesign%252Bof%252Bsome%252Bmulti-targeted%252Bcompounds%252Btargeted%252Bagainst%252Bpathways%252Bof%252Bdiabetic%252Bcomplications%26aulast%3DChadha%26aufirst%3DNavriti%26date%3D2017%26volume%3D76%26spage%3D412%26epage%3D418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hailong  Zhao</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Guonan  Cui</span>, <span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Fangfang  Lai</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel quinazoline-2,4(1 H ,3 H )-dione derivatives as potent PARP-2 selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (15)
                                     , 4045-4054. <a href="https://doi.org/10.1016/j.bmc.2017.05.052" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.05.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.05.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.05.052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bquinazoline-2%25252C4%2525281%252BH%252B%25252C3%252BH%252B%252529-dione%252Bderivatives%252Bas%252Bpotent%252BPARP-2%252Bselective%252Binhibitors%26aulast%3DZhao%26aufirst%3DHailong%26date%3D2017%26volume%3D25%26issue%3D15%26spage%3D4045%26epage%3D4054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Shaopeng  Chen</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Ning  Wang</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Shuangshuang  Miao</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuzong  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (15)
                                     , 4100-4109. <a href="https://doi.org/10.1016/j.bmc.2017.05.058" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.05.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.05.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.05.058%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOlaparib%252Bhydroxamic%252Bacid%252Bderivatives%252Bas%252Bdual%252BPARP%252Band%252BHDAC%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DYuan%26aufirst%3DZigao%26date%3D2017%26volume%3D25%26issue%3D15%26spage%3D4100%26epage%3D4109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  Zhou</span>, <span class="hlFld-ContribAuthor ">Ming  Ji</span>, <span class="hlFld-ContribAuthor ">Zhixiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Ran  Cao</span>, <span class="hlFld-ContribAuthor ">Xiaoguang  Chen</span>, <span class="hlFld-ContribAuthor ">Bailing  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>132 </em>, 26-41. <a href="https://doi.org/10.1016/j.ejmech.2017.03.013" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.013%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-substituted%252B1%252BH%252B-benzo%25255B%252Bd%252B%25255Dimmidazole-4-carboxamide%252Bderivatives%252Bas%252Bnovel%252Bpoly%252528ADP-ribose%252529polymerase-1%252Binhibitors%252Bwith%252Bin%2525C2%2525A0vivo%252Banti-tumor%252Bactivity%26aulast%3DZhou%26aufirst%3DJie%26date%3D2017%26volume%3D132%26spage%3D26%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Jiwei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenlu  Li</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Changjun  Chen</span>, <span class="hlFld-ContribAuthor ">Chunmei  Gao</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">PARP inhibitors as antitumor agents: a patent update (2013-2015). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2017,</strong> <em>27 </em>
                                    (3)
                                     , 363-382. <a href="https://doi.org/10.1080/13543776.2017.1259413" title="DOI URL">https://doi.org/10.1080/13543776.2017.1259413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2017.1259413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2017.1259413%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DPARP%252Binhibitors%252Bas%252Bantitumor%252Bagents%25253A%252Ba%252Bpatent%252Bupdate%252B%2525282013-2015%252529%26aulast%3DYuan%26aufirst%3DZigao%26date%3D2017%26date%3D2016%26volume%3D27%26issue%3D3%26spage%3D363%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">F. A.  Kucherov</span>, <span class="hlFld-ContribAuthor ">K. I.  Galkin</span>, <span class="hlFld-ContribAuthor ">E. G.  Gordeev</span>, <span class="hlFld-ContribAuthor ">V. P.  Ananikov</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient route for the construction of polycyclic systems from bioderived HMF. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2017,</strong> <em>19 </em>
                                    (20)
                                     , 4858-4864. <a href="https://doi.org/10.1039/C7GC02211E" title="DOI URL">https://doi.org/10.1039/C7GC02211E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7GC02211E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7GC02211E%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DEfficient%252Broute%252Bfor%252Bthe%252Bconstruction%252Bof%252Bpolycyclic%252Bsystems%252Bfrom%252Bbioderived%252BHMF%26aulast%3DKucherov%26aufirst%3DF.%2BA.%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D20%26spage%3D4858%26epage%3D4864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chandan  Kumar</span>, <span class="hlFld-ContribAuthor ">Nidhi  Rani</span>, <span class="hlFld-ContribAuthor ">Palanisamy Thanga  Velan Lakshmi</span>, <span class="hlFld-ContribAuthor ">Annamalai  Arunachalam</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (1)
                                     , 37-60. <a href="https://doi.org/10.4155/fmc-2016-0113" title="DOI URL">https://doi.org/10.4155/fmc-2016-0113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0113%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Blook%252Bof%252Bpoly%252528ADP-ribose%252529%252Bpolymerase%252Binhibition%252Bstrategies%252Band%252Bfuture%252Bdirections%252Bfor%252Bcancer%252Btherapy%26aulast%3DKumar%26aufirst%3DChandan%26date%3D2017%26volume%3D9%26issue%3D1%26spage%3D37%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lenka  Oplustil O'Connor</span>, <span class="hlFld-ContribAuthor ">Stuart L.  Rulten</span>, <span class="hlFld-ContribAuthor ">Aaron N.  Cranston</span>, <span class="hlFld-ContribAuthor ">Rajesh  Odedra</span>, <span class="hlFld-ContribAuthor ">Henry  Brown</span>, <span class="hlFld-ContribAuthor ">Janneke E.  Jaspers</span>, <span class="hlFld-ContribAuthor ">Louise  Jones</span>, <span class="hlFld-ContribAuthor ">Charlotte  Knights</span>, <span class="hlFld-ContribAuthor ">Bastiaan  Evers</span>, <span class="hlFld-ContribAuthor ">Attilla  Ting</span>, <span class="hlFld-ContribAuthor ">Robert H.  Bradbury</span>, <span class="hlFld-ContribAuthor ">Marina  Pajic</span>, <span class="hlFld-ContribAuthor ">Sven  Rottenberg</span>, <span class="hlFld-ContribAuthor ">Jos  Jonkers</span>, <span class="hlFld-ContribAuthor ">David  Rudge</span>, <span class="hlFld-ContribAuthor ">Niall M.B.  Martin</span>, <span class="hlFld-ContribAuthor ">Keith W.  Caldecott</span>, <span class="hlFld-ContribAuthor ">Alan  Lau</span>, <span class="hlFld-ContribAuthor ">Mark J.  O'Connor</span>. </span><span class="cited-content_cbyCitation_article-title">The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2016,</strong> <em>76 </em>
                                    (20)
                                     , 6084-6094. <a href="https://doi.org/10.1158/0008-5472.CAN-15-3240" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-15-3240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-15-3240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-15-3240%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DThe%252BPARP%252BInhibitor%252BAZD2461%252BProvides%252BInsights%252Binto%252Bthe%252BRole%252Bof%252BPARP3%252BInhibition%252Bfor%252BBoth%252BSynthetic%252BLethality%252Band%252BTolerability%252Bwith%252BChemotherapy%252Bin%252BPreclinical%252BModels%26aulast%3DOplustil%2BO%2527Connor%26aufirst%3DLenka%26date%3D2016%26date%3D2016%26volume%3D76%26issue%3D20%26spage%3D6084%26epage%3D6094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam C.  ElNaggar</span>, <span class="hlFld-ContribAuthor ">Uksha  Saini</span>, <span class="hlFld-ContribAuthor ">Shan  Naidu</span>, <span class="hlFld-ContribAuthor ">Ross  Wanner</span>, <span class="hlFld-ContribAuthor ">Millie  Sudhakar</span>, <span class="hlFld-ContribAuthor ">John  Fowler</span>, <span class="hlFld-ContribAuthor ">Masaki  Nagane</span>, <span class="hlFld-ContribAuthor ">Periannan  Kuppusamy</span>, <span class="hlFld-ContribAuthor ">David E.  Cohn</span>, <span class="hlFld-ContribAuthor ">Karuppaiyah  Selvendiran</span>. </span><span class="cited-content_cbyCitation_article-title">Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Biology & Therapy</span><span> <strong>2016,</strong> <em>17 </em>
                                    (10)
                                     , 1107-1115. <a href="https://doi.org/10.1080/15384047.2016.1210733" title="DOI URL">https://doi.org/10.1080/15384047.2016.1210733</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384047.2016.1210733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384047.2016.1210733%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Biology%2520%2526%2520Therapy%26atitle%3DAnticancer%252Bpotential%252Bof%252Bdiarylidenyl%252Bpiperidone%252Bderivatives%25252C%252BHO-4200%252Band%252BH-4318%25252C%252Bin%252Bcisplatin%252Bresistant%252Bprimary%252Bovarian%252Bcancer%26aulast%3DElNaggar%26aufirst%3DAdam%2BC.%26date%3D2016%26date%3D2016%26volume%3D17%26issue%3D10%26spage%3D1107%26epage%3D1115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hsien-Feng  Liao</span>, <span class="hlFld-ContribAuthor ">Chien-Chin  Lee</span>, <span class="hlFld-ContribAuthor ">Pei-Chi  Hsiao</span>, <span class="hlFld-ContribAuthor ">Yi-Fong  Chen</span>, <span class="hlFld-ContribAuthor ">Chih-Hua  Tseng</span>, <span class="hlFld-ContribAuthor ">Cherng-Chyi  Tzeng</span>, <span class="hlFld-ContribAuthor ">Yeh-Long  Chen</span>, <span class="hlFld-ContribAuthor ">Jui-Chang  Chen</span>, <span class="hlFld-ContribAuthor ">Ya-Sian  Chang</span>, <span class="hlFld-ContribAuthor ">Jan-Gowth  Chang</span>. </span><span class="cited-content_cbyCitation_article-title">TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2016,</strong> <em>82 </em>, 649-659. <a href="https://doi.org/10.1016/j.biopha.2016.06.002" title="DOI URL">https://doi.org/10.1016/j.biopha.2016.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2016.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2016.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DTCH1036%25252C%252Ba%252Bindeno%25255B1%25252C2-c%25255Dquinoline%252Bderivative%25252C%252Bpotentially%252Binhibited%252Bthe%252Bgrowth%252Bof%252Bhuman%252Bbrain%252Bmalignant%252Bglioma%252B%252528GBM%252529%252B8401%252Bcells%252Bvia%252Bsuppression%252Bof%252Bthe%252Bexpression%252Bof%252BSuv39h1%252Band%252BPARP%26aulast%3DLiao%26aufirst%3DHsien-Feng%26date%3D2016%26volume%3D82%26spage%3D649%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Passeri</span>, <span class="hlFld-ContribAuthor ">Emidio  Camaioni</span>, <span class="hlFld-ContribAuthor ">Paride  Liscio</span>, <span class="hlFld-ContribAuthor ">Paola  Sabbatini</span>, <span class="hlFld-ContribAuthor ">Martina  Ferri</span>, <span class="hlFld-ContribAuthor ">Andrea  Carotti</span>, <span class="hlFld-ContribAuthor ">Nicola  Giacchè</span>, <span class="hlFld-ContribAuthor ">Roberto  Pellicciari</span>, <span class="hlFld-ContribAuthor ">Antimo  Gioiello</span>, <span class="hlFld-ContribAuthor ">Antonio  Macchiarulo</span>. </span><span class="cited-content_cbyCitation_article-title">Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2016,</strong> <em>11 </em>
                                    (12)
                                     , 1219-1226. <a href="https://doi.org/10.1002/cmdc.201500391" title="DOI URL">https://doi.org/10.1002/cmdc.201500391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201500391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201500391%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DConcepts%252Band%252BMolecular%252BAspects%252Bin%252Bthe%252BPolypharmacology%252Bof%252BPARP-1%252BInhibitors%26aulast%3DPasseri%26aufirst%3DDaniela%26date%3D2016%26date%3D2015%26volume%3D11%26issue%3D12%26spage%3D1219%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ran  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2016,</strong> <em>22 </em>
                                    (4)
                                     <a href="https://doi.org/10.1007/s00894-016-2952-x" title="DOI URL">https://doi.org/10.1007/s00894-016-2952-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-016-2952-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-016-2952-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DFree%252Benergy%252Bcalculation%252Bprovides%252Binsight%252Binto%252Bthe%252Baction%252Bmechanism%252Bof%252Bselective%252BPARP-1%252Binhibitor%26aulast%3DCao%26aufirst%3DRan%26date%3D2016%26date%3D2016%26volume%3D22%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Navnath S.  Gavande</span>, <span class="hlFld-ContribAuthor ">Pamela S.  VanderVere-Carozza</span>, <span class="hlFld-ContribAuthor ">Hilary D.  Hinshaw</span>, <span class="hlFld-ContribAuthor ">Shadia I.  Jalal</span>, <span class="hlFld-ContribAuthor ">Catherine R.  Sears</span>, <span class="hlFld-ContribAuthor ">Katherine S.  Pawelczak</span>, <span class="hlFld-ContribAuthor ">John J.  Turchi</span>. </span><span class="cited-content_cbyCitation_article-title">DNA repair targeted therapy: The past or future of cancer treatment?. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2016,</strong> <em>160 </em>, 65-83. <a href="https://doi.org/10.1016/j.pharmthera.2016.02.003" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2016.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2016.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2016.02.003%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DDNA%252Brepair%252Btargeted%252Btherapy%25253A%252BThe%252Bpast%252Bor%252Bfuture%252Bof%252Bcancer%252Btreatment%25253F%26aulast%3DGavande%26aufirst%3DNavnath%2BS.%26date%3D2016%26volume%3D160%26spage%3D65%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhouling  Xie</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Youli  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Zhao</span>, <span class="hlFld-ContribAuthor ">He  Jiao</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and bioevaluation of 1H-indole-4-carboxamide derivatives as potent poly(ADP-ribose) polymerase-1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (84)
                                     , 80784-80796. <a href="https://doi.org/10.1039/C6RA12591C" title="DOI URL">https://doi.org/10.1039/C6RA12591C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA12591C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA12591C%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbioevaluation%252Bof%252B1H-indole-4-carboxamide%252Bderivatives%252Bas%252Bpotent%252Bpoly%252528ADP-ribose%252529%252Bpolymerase-1%252Binhibitors%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D84%26spage%3D80784%26epage%3D80796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of PARP inhibitors clinical candidates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PARP-1 selective inhibitors (<b>1</b>, <b>2</b>), and NMS-P118 (<b>20by</b>) and isoindolinone-containing compounds (<b>3</b>–<b>5</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1A" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0011.jpeg" id="rightTab-GRAPHIC-d2220e812-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A) Isoindolinones Synthesis via Intramolecular Diels–Alder Reaction;<sup>a</sup> (B) Elaboration of the piperidin-4-yl- moiety of intermediate <b>11</b><sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=sch1A"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Conditions: (a) RNH<sub>2</sub> (<b>6</b>), dioxane or toluene (Dean–Stark), reflux then NaBH<sub>4</sub>, ethanol, rt; (b) maleic anhydride, THF, rt or toluene, reflux; (c) concentrated aqueous hydrochloric acid, reflux; (d) HOBt·NH<sub>3</sub>, EDCI·HCl, DIEA, DMF, rt.</p><p class="last"><span class="fn-label">Scheme b</span>Conditions: (a) 10% palladium on carbon, acetic acid, 50 psi, rt; (b) RCOCl, pyridine, 60 °C; (c) aldehyde or ketone, CH<sub>3</sub>COONa, NaBCNH<sub>3</sub> or NaB(OAc)<sub>3</sub>H, dichloromethane/methanol, rt.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0012.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Benzo-substituted Isoindolinone Derivatives <b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) iodobenzene diacetate, I<sub>2</sub>, Pd(OAc)<sub>2</sub>, DMF, 100 °C; (b) methyl <i>p</i>-toluenesulfonate, K<sub>2</sub>CO<sub>3</sub>, DMF, rt; (c) <i>N</i>-bromosuccinimide, benzoyl peroxide, methyl pivalate, 85 °C, then <b>17x</b>–<b>y</b>, triethylamine, acetonitrile, 90 °C; (d) CuCN, DMF, 110 °C; (e) acetaldoxime, InCl<sub>3</sub>, toluene, reflux.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structures of <b>10b</b> with hPARP-1 (A) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>) and hPARP-2 (B) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX">4ZZX</a>) catalytic domain at 1.9 and 1.7 Å resolution, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Downfield portion of <sup>1</sup>H NMR spectra of a 3 mM solution of <b>10b</b> in DMSO-<i>d</i><sub>6</sub> (top) and CDCl<sub>3</sub> (bottom) showing the Δδ of the two amide protons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Overlay of cocrystal structures of <b>10b</b> (green carbon atoms PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>) and quinazolinone <b>1</b> (light-blue carbon atoms, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UK0">1UK0</a>) in the hPARP-1 binding site. Gray arrows indicate the direction of substituents departing from the nicotinamide-mimic scaffolds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Cocrystal structures of <b>20by</b> with hPARP-1 (A) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>) and hPARP-2 (B) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>) catalytic domain at 2.7 and 2.2 Å resolution, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Antitumor efficacy of <b>20by</b> in BRCA mutated breast cancer model in mice. Mice carrying subcutaneous MDA-MB-436 human breast carcinoma were treated with either vehicle or <b>20by</b> orally administered. Mice were treated once a day for 28 days starting from day 20. Data are represented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Antitumor efficacy of <b>20by</b> in combination with Temozolomide. <b>20by</b> was administered to male athymic nu/nu mice carrying subcutaneously Capan-1 pancreatic cancer, orally once daily for 12 days at the dose of 100 mg/kg, starting on day 9. Temozolomide (TMZ) was administered at a dosage of 50 mg/kg for 5 days starting from day 11. Data are represented as mean ± SEM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/medium/jm-2015-006805_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo inhibition of PAR activity. Mice were treated with a single oral dose of <b>20by</b> (100 mg/kg), and intratumoral levels of PAR were assessed by ELISA at 1, 2, 6, and 24 h after dosing. Each bar represents an individual tumor from an individual animal.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-17/acs.jmedchem.5b00680/20150904/images/large/jm-2015-006805_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00680&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i135">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50208" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50208" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hottiger, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassa, P. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lüscher, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koch-Nolte, F.</span><span> </span><span class="NLM_article-title">Toward a unified nomenclature for mammalian ADP-ribosyltransferases</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">208</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.tibs.2009.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tibs.2009.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20106667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVegs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=208-219&author=M.+O.+Hottigerauthor=P.+O.+Hassaauthor=B.+L%C3%BCscherauthor=H.+Sch%C3%BClerauthor=F.+Koch-Nolte&title=Toward+a+unified+nomenclature+for+mammalian+ADP-ribosyltransferases&doi=10.1016%2Fj.tibs.2009.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a unified nomenclature for mammalian ADP-ribosyltransferases</span></div><div class="casAuthors">Hottiger, Michael O.; Hassa, Paul O.; Luescher, Bernhard; Schueler, Herwig; Koch-Nolte, Friedrich</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Biochemical Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">TBSCDB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0004</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  ADP-ribosylation is a post-translational modification of proteins catalyzed by ADP-ribosyltransferases.  It comprises the transfer of the ADP-ribose moiety from NAD+ to specific amino acid residues on substrate proteins or to ADP-ribose itself.  Currently, 22 human genes encoding proteins that possess an ADP-ribosyltransferase catalytic domain are known.  Recent structural and enzymol. evidence of poly(ADP-ribose)polymerase (PARP) family members demonstrate that earlier proposed names and classifications of these proteins are no longer accurate.  Here we summarize these new findings and propose a new consensus nomenclature for all ADP-ribosyltransferases (ARTs) based on the catalyzed reaction and on structural features.  A unified nomenclature would facilitate communication between researchers both inside and outside the ADP-ribosylation field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg6kR-35XzU7Vg90H21EOLACvtfcHk0ljuhlghE6ss_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVegs70%253D&md5=0e63a298da9140bea11180b58bec7357</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.tibs.2009.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tibs.2009.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DHottiger%26aufirst%3DM.%2BO.%26aulast%3DHassa%26aufirst%3DP.%2BO.%26aulast%3DL%25C3%25BCscher%26aufirst%3DB.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DKoch-Nolte%26aufirst%3DF.%26atitle%3DToward%2520a%2520unified%2520nomenclature%2520for%2520mammalian%2520ADP-ribosyltransferases%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D2010%26volume%3D35%26spage%3D208%26epage%3D219%26doi%3D10.1016%2Fj.tibs.2009.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Krishnakumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span><span class="refDoi"> DOI: 10.1016/j.molcel.2010.06.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.molcel.2010.06.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20603072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2010&pages=8-24&author=R.+Krishnakumarauthor=W.+L.+Kraus&title=The+PARP+side+of+the+nucleus%3A+molecular+actions%2C+physiological+outcomes%2C+and+clinical+targets&doi=10.1016%2Fj.molcel.2010.06.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets</span></div><div class="casAuthors">Krishnakumar, Raga; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-24</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The abundant nuclear enzyme PARP-1, a multifunctional regulator of chromatin structure, transcription, and genomic integrity, plays key roles in a wide variety of processes in the nucleus.  Recent studies have begun to connect the mol. functions of PARP-1 to specific physiol. and pathol. outcomes, many of which can be altered by an expanding array of chem. inhibitors of PARP enzymic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy5Mj-wajemLVg90H21EOLACvtfcHk0lidQNfMNrQKww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFejsr4%253D&md5=afb9423e09ed68d2bfa589ed0d7b9f13</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2010.06.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2010.06.017%26sid%3Dliteratum%253Aachs%26aulast%3DKrishnakumar%26aufirst%3DR.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DThe%2520PARP%2520side%2520of%2520the%2520nucleus%253A%2520molecular%2520actions%252C%2520physiological%2520outcomes%252C%2520and%2520clinical%2520targets%26jtitle%3DMol.%2520Cell%26date%3D2010%26volume%3D39%26spage%3D8%26epage%3D24%26doi%3D10.1016%2Fj.molcel.2010.06.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yelamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacuna, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampurdanes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Caballero, J.</span><span> </span><span class="NLM_article-title">PARP-1 and PARP-2: new players in tumour development</span> <span class="citation_source-journal">Am. J. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">328</span><span class="NLM_x">–</span> <span class="NLM_lpage">346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=21968702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Kntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=328-346&author=J.+Yelamosauthor=J.+Farresauthor=L.+Lacunaauthor=C.+Ampurdanesauthor=J.+Martin-Caballero&title=PARP-1+and+PARP-2%3A+new+players+in+tumour+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3aR"><div class="casContent"><span class="casTitleNuber">3a</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-1 and PARP-2: new players in tumour development</span></div><div class="casAuthors">Yelamos, Jose; Farres, Jordi; Llacuna, Laura; Ampurdanes, Coral; Martin-Caballero, Juan</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">328-346</span>CODEN:
                <span class="NLM_cas:coden">AJCRFT</span>;
        ISSN:<span class="NLM_cas:issn">2156-6976</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 belong to a family of enzymes that, using NAD+ as a substrate, catalyze poly(ADP-ribosyl)ation of proteins.  PARP-1 and PARP-2 catalytic activity is stimulated by DNAstrand breaks targeting mainly proteins involved in chromatin structure and DNA metab., providing strong support for a dual role of both PARP-1 and PARP-2 in the DNA damage response as DNA damage sensors and signal transducers to downstream effectors.  The DNA damage response has important consequences for genomic stability and tumor development.  In order to manipulate DNA damage responses to selectively induce tumor cell death, a considerable effort is centered on defining the mol. mechanisms that allow cells to detect, respond to, and repair DNA damage.  PARP inhibitors that compete with NAD+ at the highly conserved enzyme active site are arisen as new potential therapeutic strategies as chemo- and radio-potentiation and for the treatment of cancers with specific DNA repair defects as single-agent therapies.  In the present review, we highlight emerging information about the redundant and specific functions of PARP-1 and PARP-2 in genome surveillance and DNA repair pathways.  Understanding these roles might provide invaluable clues to design new cancer therapeutic approaches.  In addn., we provide an overview of ongoing clin. trials with PARP inhibitors and the value of PARP-1 and PARP-2 expression as prognostic biomarkers in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCyD_d1BJyCLVg90H21EOLACvtfcHk0lidQNfMNrQKww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Kntr8%253D&md5=b2a7b4eede3a41a9279031a2032b8ed8</span></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYelamos%26aufirst%3DJ.%26aulast%3DFarres%26aufirst%3DJ.%26aulast%3DLacuna%26aufirst%3DL.%26aulast%3DAmpurdanes%26aufirst%3DC.%26aulast%3DMartin-Caballero%26aufirst%3DJ.%26atitle%3DPARP-1%2520and%2520PARP-2%253A%2520new%2520players%2520in%2520tumour%2520development%26jtitle%3DAm.%2520J.%2520Cancer%2520Res.%26date%3D2011%26volume%3D1%26spage%3D328%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ryu, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraus, W. L.</span><span> </span><span class="NLM_article-title">New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases</span> <span class="citation_source-journal">Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2453</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span><span class="refDoi"> DOI: 10.1021/cr5004248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr5004248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=2453-2481&author=K.+W.+Ryuauthor=D.-S.+Kimauthor=W.+L.+Kraus&title=New+Facets+in+the+Regulation+of+Gene+Expression+by+ADP-Ribosylation+and+Poly%28ADP-ribose%29+Polymerases&doi=10.1021%2Fcr5004248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases</span></div><div class="casAuthors">Ryu, Keun Woo; Kim, Dae-Seok; Kraus, W. Lee</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2453-2481</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the role of poly(ADP-ribose) polymerases (PARPs) and ADP-ribosylation in gene regulation, with a particular emphasis on the role of PARPs in RNA biol.  Topics include: the PARP family; NAD+ metab. and PARP-1; PARP-1 in gene regulation including chromatin modulation, transcription regulation, and non-coding RNA regulation; and PARP-1 in ribosome biogenesis, stress response, circadian rhythm, and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF0xfFz6hkG7Vg90H21EOLACvtfcHk0lidQNfMNrQKww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1yrsg%253D%253D&md5=496f79e7a373d08dd7c116fe9d74eb1a</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1021%2Fcr5004248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr5004248%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DK.%2BW.%26aulast%3DKim%26aufirst%3DD.-S.%26aulast%3DKraus%26aufirst%3DW.%2BL.%26atitle%3DNew%2520Facets%2520in%2520the%2520Regulation%2520of%2520Gene%2520Expression%2520by%2520ADP-Ribosylation%2520and%2520Poly%2528ADP-ribose%2529%2520Polymerases%26jtitle%3DChem.%2520Rev.%26date%3D2015%26volume%3D115%26spage%3D2453%26epage%3D2481%26doi%3D10.1021%2Fcr5004248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Ferraris, D. V.</span><span> </span><span class="NLM_article-title">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From concept to clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4561</span><span class="NLM_x">–</span> <span class="NLM_lpage">4584</span><span class="refDoi"> DOI: 10.1021/jm100012m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100012m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4561-4584&author=D.+V.+Ferraris&title=Evolution+of+Poly%28ADP-ribose%29+Polymerase-1+%28PARP-1%29+Inhibitors.+From+concept+to+clinic&doi=10.1021%2Fjm100012m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic</span></div><div class="casAuthors">Ferraris, Dana V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4561-4584</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerase-1 (PARP-1) has been an actively pursued drug discovery target for almost 3 decades.  Often referred to as the "guardian angel of DNA", this abundant nuclear enzyme has been the focus of over 20 medicinal chem. programs in a wide range of therapeutic areas encompassing stroke, cardiac ischemia, cancer, inflammation, and diabetes.  Despite the great therapeutic potential for this target and the tremendous academic and industrial efforts dedicated to it, only recently have PARP-1 inhibitors made headway in clin. trials.  Recent results from several PARP-1 inhibitors in phase II clin. trials for cancer therapy have attracted the attention of national media.  Of the several potential therapeutic indications for PARP-1 inhibitors, the two major areas that hold the most promise are ischemia and cancer.  This review is structured to provide the readers with a brief summary of the rationale for PARP-1 as a therapeutic target, to explain the PARP-1 inhibitor pharmacophore, and to provide an update on the progress of the PARP-1 drug discovery programs.  This Perspective will offer a historical account of the crit. PARP-1 publications that instilled the interest of the biopharmaceutical industry in the late 1980s and early 1990s.  Furthermore, I will discuss why PARP- 1 received so much attention in the late 1990s and early 2000s followed by the slight decline in the medicinal chem. efforts today.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPhFTTs4raarVg90H21EOLACvtfcHk0liBa-MGIy_YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1WksLs%253D&md5=6c093238562c908d45dfcd2f3055457d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Fjm100012m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100012m%26sid%3Dliteratum%253Aachs%26aulast%3DFerraris%26aufirst%3DD.%2BV.%26atitle%3DEvolution%2520of%2520Poly%2528ADP-ribose%2529%2520Polymerase-1%2520%2528PARP-1%2529%2520Inhibitors.%2520From%2520concept%2520to%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4561%26epage%3D4584%26doi%3D10.1021%2Fjm100012m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Curtin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">Therapeutic applications of PARP inhibitors: anticancer therapy and beyond</span> <span class="citation_source-journal">Mol. Aspects Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1217</span><span class="NLM_x">–</span> <span class="NLM_lpage">1256</span><span class="refDoi"> DOI: 10.1016/j.mam.2013.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.mam.2013.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23370117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1217-1256&author=N.+Curtinauthor=C.+Szabo&title=Therapeutic+applications+of+PARP+inhibitors%3A+anticancer+therapy+and+beyond&doi=10.1016%2Fj.mam.2013.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond</span></div><div class="casAuthors">Curtin, Nicola J.; Szabo, Csaba</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Aspects of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1217-1256</span>CODEN:
                <span class="NLM_cas:coden">MAMED5</span>;
        ISSN:<span class="NLM_cas:issn">0098-2997</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The aim of this article is to describe the current and potential clin. translation of pharmacol. inhibitors of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases.  The first section of the present review summarizes the available preclin. and clin. data with PARP inhibitors in various forms of cancer.  In this context, the role of PARP in single-strand DNA break repair is relevant, leading to replication-assocd. lesions that cannot be repaired if homologous recombination repair (HRR) is defective, and the synthetic lethality of PARP inhibitors in HRR-defective cancer.  HRR defects are classically assocd. with BRCA1 and 2 mutations assocd. with familial breast and ovarian cancer, but there may be many other causes of HRR defects.  Thus, PARP inhibitors may be the drugs of choice for BRCA mutant breast and ovarian cancers, and extend beyond these tumors if appropriate biomarkers can be developed to identify HRR defects.  Multiple lines of preclin. data demonstrate that PARP inhibition increases cytotoxicity and tumor growth delay in combination with temozolomide, topoisomerase inhibitors and ionizing radiation.  Both single agent and combination clin. trials are underway.  The final part of the first section of the present review summarizes the current status of the various PARP inhibitors that are in various stages of clin. development.  The second section of the present review summarizes the role of PARP in selected non-oncol. indications.  In a no. of severe, acute diseases (such as stroke, neurotrauma, circulatory shock and acute myocardial infarction) the clin. translatability of PARP inhibition is supported by multiple lines of preclin. data, as well as observational data demonstrating PARP activation in human tissue samples.  In these disease indications, PARP overactivation due to oxidative and nitrative stress drives cell necrosis and pro-inflammatory gene expression, which contributes to disease pathol.  Accordingly, multiple lines of preclin. data indicate the efficacy of PARP inhibitors to preserve viable tissue and to down-regulate inflammatory responses.  As the clin. trials with PARP inhibitors in various forms of cancer progress, it is hoped that a second line of clin. investigations, aimed at testing of PARP inhibitors for various non-oncol. indications, will be initiated, as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP4INVXcZ0zbVg90H21EOLACvtfcHk0liBa-MGIy_YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislyqtrc%253D&md5=6a514e160666b5dde38e1365211cd41e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.mam.2013.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mam.2013.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DTherapeutic%2520applications%2520of%2520PARP%2520inhibitors%253A%2520anticancer%2520therapy%2520and%2520beyond%26jtitle%3DMol.%2520Aspects%2520Med.%26date%3D2013%26volume%3D34%26spage%3D1217%26epage%3D1256%26doi%3D10.1016%2Fj.mam.2013.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Penning, T. D.</span><span> </span><span class="NLM_article-title">Small-molecule PARP modulators – Current status and future therapeutic potential</span> <span class="citation_source-journal">Curr. Opin. Drug Discovery Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">577</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=577-586&author=T.+D.+Penning&title=Small-molecule+PARP+modulators+%E2%80%93+Current+status+and+future+therapeutic+potential"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26atitle%3DSmall-molecule%2520PARP%2520modulators%2520%25E2%2580%2593%2520Current%2520status%2520and%2520future%2520therapeutic%2520potential%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2010%26volume%3D13%26spage%3D577%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jones, P.</span><span> </span><span class="NLM_article-title">Development of poly (ADP-Ribose)polymerase (PARP) inhibitors in oncology</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">229</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/S0065-7743(10)45014-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2FS0065-7743%2810%2945014-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=229-243&author=P.+Jones&title=Development+of+poly+%28ADP-Ribose%29polymerase+%28PARP%29+inhibitors+in+oncology&doi=10.1016%2FS0065-7743%2810%2945014-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945014-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945014-9%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520poly%2520%2528ADP-Ribose%2529polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520oncology%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D229%26epage%3D243%26doi%3D10.1016%2FS0065-7743%2810%2945014-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kummar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parchment, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinders, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomaszewski, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doroshow, J. H.</span><span> </span><span class="NLM_article-title">Advances in using PARP inhibitors to treat cancer</span> <span class="citation_source-journal">BMC Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="refDoi"> DOI: 10.1186/1741-7015-10-25</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1186%2F1741-7015-10-25" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22401667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslansLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=25&author=S.+Kummarauthor=A.+Chenauthor=R.+E.+Parchmentauthor=R.+J.+Kindersauthor=J.+Jiauthor=J.+E.+Tomaszewskiauthor=J.+H.+Doroshow&title=Advances+in+using+PARP+inhibitors+to+treat+cancer&doi=10.1186%2F1741-7015-10-25"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in using PARP inhibitors to treat cancer</span></div><div class="casAuthors">Kummar, Shivaani; Chen, Alice; Parchment, Ralph E.; Kinders, Robert J.; Ji, Jay; Tomaszewski, Joseph E.; Doroshow, James H.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">BMMECZ</span>;
        ISSN:<span class="NLM_cas:issn">1741-7015</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  The poly (ADP-ribose) polymerase (PARP) family of enzymes plays a crit. role in the maintenance of DNA integrity as part of the base excision pathway of DNA repair.  PARP1 is overexpressed in a variety of cancers, and its expression has been assocd. with overall prognosis in cancer, esp. breast cancer.  A series of new therapeutic agents that are potent inhibitors of the PARP1 and PARP2 isoforms have demonstrated important clin. activity in patients with breast or ovarian cancers that are caused by mutations in either the BRCA1 or 2 genes.  Results from such studies may define a new therapeutic paradigm, wherein simultaneous loss of the capacity to repair DNA damage may have antitumor activity in itself, as well as enhance the antineoplastic potential of cytotoxic chemotherapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ_-91orX7mbVg90H21EOLACvtfcHk0liBa-MGIy_YeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslansLY%253D&md5=b60f719dfdd95e4c9ac876882a1ad056</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1186%2F1741-7015-10-25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1741-7015-10-25%26sid%3Dliteratum%253Aachs%26aulast%3DKummar%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DA.%26aulast%3DParchment%26aufirst%3DR.%2BE.%26aulast%3DKinders%26aufirst%3DR.%2BJ.%26aulast%3DJi%26aufirst%3DJ.%26aulast%3DTomaszewski%26aufirst%3DJ.%2BE.%26aulast%3DDoroshow%26aufirst%3DJ.%2BH.%26atitle%3DAdvances%2520in%2520using%2520PARP%2520inhibitors%2520to%2520treat%2520cancer%26jtitle%3DBMC%2520Med.%26date%3D2012%26volume%3D10%26spage%3D25%26doi%3D10.1186%2F1741-7015-10-25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors</span> <span class="citation_source-journal">Drug Discovery Today: Dis. Models</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">e51</span><span class="NLM_x">–</span> <span class="NLM_lpage">e58</span><span class="refDoi"> DOI: 10.1016/j.ddmod.2012.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.ddmod.2012.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xktleitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=e51-e58&author=N.+J.+Curtin&title=Poly%28ADP-ribose%29+polymerase+%28PARP%29+and+PARP+inhibitors&doi=10.1016%2Fj.ddmod.2012.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors</span></div><div class="casAuthors">Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today: Disease Models</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e51-e58</span>CODEN:
                <span class="NLM_cas:coden">DDTDBP</span>;
        ISSN:<span class="NLM_cas:issn">1740-6757</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage.  PARP inhibitors have been under development since 1980 and first entered clin. trial in 2003.  They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in other DNA repair pathways.  There are now nine PARP inhibitors undergoing clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr86pCJ2PNT_bVg90H21EOLACvtfcHk0lhiiL6ZFEmr8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xktleitb0%253D&md5=0c837fbfeab0f4156c8d16b1c0b5cd31</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.ddmod.2012.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ddmod.2012.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPoly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520and%2520PARP%2520inhibitors%26jtitle%3DDrug%2520Discovery%2520Today%253A%2520Dis.%2520Models%26date%3D2012%26volume%3D9%26spage%3De51%26epage%3De58%26doi%3D10.1016%2Fj.ddmod.2012.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Maxwell, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domchek, S. M.</span><span> </span><span class="NLM_article-title">Cancer treatment according to <i>BRCA1</i> and <i>BRCA2</i> mutations</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">520</span><span class="NLM_x">–</span> <span class="NLM_lpage">528</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2012.123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnrclinonc.2012.123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22825375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7zM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=520-528&author=K.+N.+Maxwellauthor=S.+M.+Domchek&title=Cancer+treatment+according+to+BRCA1+and+BRCA2+mutations&doi=10.1038%2Fnrclinonc.2012.123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment according to BRCA1 and BRCA2 mutations</span></div><div class="casAuthors">Maxwell, Kara N.; Domchek, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">520-528</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Identification of germline mutations assocd. with significant cancer susceptibility has the potential to change all aspects of an individual's care, from screening to cancer treatment.  For example, women with germline mutations in BRCA1 and BRCA2 have markedly elevated risks of breast and ovarian cancer and the identification of these germline mutations has led to specific screening and prevention strategies.  More recently, advances in the understanding of the biol. function of BRCA1 and BRCA2 have led to clin. trials testing targeted therapies in this population, particularly poly(ADP-ribose) polymerase (PARP) inhibitors.  Unfortunately, the development of PARP inhibitors has not been as rapid as anticipated and has been more challenging than expected.  Somatic mutations identified in many cancer types have allowed the development of therapeutics that target these mutated genes, and many of these agents obtained rapid regulatory approval and are currently in widespread clin. practice.  Diagnostic testing has a central role in targeted cancer therapeutics for both somatic and germline mutations.  Although the era of mol. medicine and targeted therapies has led to significant changes in the practice of oncol., new challenges continue to arise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZAs-JKyS0bVg90H21EOLACvtfcHk0lhiiL6ZFEmr8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kjs7zM&md5=c6da652ff478b6175e184f98cc7c13c2</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2012.123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2012.123%26sid%3Dliteratum%253Aachs%26aulast%3DMaxwell%26aufirst%3DK.%2BN.%26aulast%3DDomchek%26aufirst%3DS.%2BM.%26atitle%3DCancer%2520treatment%2520according%2520to%2520BRCA1%2520and%2520BRCA2%2520mutations%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D9%26spage%3D520%26epage%3D528%26doi%3D10.1038%2Fnrclinonc.2012.123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Ström, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Strategies for the use of poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors in cancer therapy</span> <span class="citation_source-journal">Biomolecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">649</span><span class="refDoi"> DOI: 10.3390/biom2040635</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6f&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.3390%2Fbiom2040635" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=635-649&author=C.+E.+Str%C3%B6mauthor=T.+Helleday&title=Strategies+for+the+use+of+poly%28adenosine+diphosphate+ribose%29+polymerase+%28PARP%29+inhibitors+in+cancer+therapy&doi=10.3390%2Fbiom2040635"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.3390%2Fbiom2040635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom2040635%26sid%3Dliteratum%253Aachs%26aulast%3DStr%25C3%25B6m%26aufirst%3DC.%2BE.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DStrategies%2520for%2520the%2520use%2520of%2520poly%2528adenosine%2520diphosphate%2520ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DBiomolecules%26date%3D2012%26volume%3D2%26spage%3D635%26epage%3D649%26doi%3D10.3390%2Fbiom2040635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Davar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beumer, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamieh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tawbi, H.</span><span> </span><span class="NLM_article-title">Role of PARP inhibitors in cancer biology and therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3907</span><span class="NLM_x">–</span> <span class="NLM_lpage">3921</span><span class="refDoi"> DOI: 10.2174/092986712802002464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.2174%2F092986712802002464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22788767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht12nu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3907-3921&author=D.+Davarauthor=J.+H.+Beumerauthor=L.+Hamiehauthor=H.+Tawbi&title=Role+of+PARP+inhibitors+in+cancer+biology+and+therapy&doi=10.2174%2F092986712802002464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Role of PARP inhibitors in cancer biology and therapy</span></div><div class="casAuthors">Davar, D.; Beumer, J. H.; Hamieh, L.; Tawbi, H.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3907-3921</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Deeper understanding of DNA repair mechanisms and their potential value as therapeutic targets in oncol. heralded the clin. development of poly(ADP-ribose) polymerase (PARP) inhibitors.  Although initially developed to exploit synthetic lethality in models of cancer assocd. with defective DNA repair, our burgeoning knowledge of PARP biol. has resulted in these agents being exploited both in cancer with select chemotherapeutic agents and in non-malignant diseases.  In this review article, we briefly review the mechanisms of DNA repair and pre-clin. development of PARP inhibitors before discussing the clin. development of the various PARP inhibitors in depth.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRQaaaS9jHi7Vg90H21EOLACvtfcHk0lhiiL6ZFEmr8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht12nu73I&md5=70350a0d3159a740ca4ae3dfe6b5db25</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.2174%2F092986712802002464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712802002464%26sid%3Dliteratum%253Aachs%26aulast%3DDavar%26aufirst%3DD.%26aulast%3DBeumer%26aufirst%3DJ.%2BH.%26aulast%3DHamieh%26aufirst%3DL.%26aulast%3DTawbi%26aufirst%3DH.%26atitle%3DRole%2520of%2520PARP%2520inhibitors%2520in%2520cancer%2520biology%2520and%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3907%26epage%3D3921%26doi%3D10.2174%2F092986712802002464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirla, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors in cancer therapy: an update</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">503</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span><span class="refDoi"> DOI: 10.1517/13543776.2013.768615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1517%2F13543776.2013.768615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23379721" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvFWmt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=503-514&author=G.+Papeoauthor=E.+Casaleauthor=A.+Montagnoliauthor=A.+Cirla&title=PARP+inhibitors+in+cancer+therapy%3A+an+update&doi=10.1517%2F13543776.2013.768615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">PARP inhibitors in cancer therapy: an update</span></div><div class="casAuthors">Papeo, Gianluca; Casale, Elena; Montagnoli, Alessia; Cirla, Alessandra</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">503-514</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Inhibitors of the poly(ADP-ribose) polymerases (PARPs) family of proteins are currently being evaluated as potential anticancer medicines at both preclin. and clin. levels.  They have the peculiarity to increase the efficacy of DNA-damaging agents and to selectively target tumor cells with specific DNA repair defects.  This later development of these drugs should make it possible, in principle, to selectively target neoplastic vs healthy cells, thus realizing the Ehrlich's magic bullet concept of a personalized and tailored cure of diseases.  Areas covered: This review is designed to provide the readers with a brief summary and an update on PARP inhibitors in the oncol. field, by covering the recent patent literature (2010 - 2012: and Questel Intellectual Property Portal [QPat] database search).  Expert opinion: Presently, along with a no. of preclin. candidates, there are eight PARP inhibitors in the clinic as either single agents or in combination with various chemotherapy and radiotherapy regimens.  The tremendous efforts underneath those results testify the high interest on the target.  The investigation and understanding of the cross-reactivity among members of the PARPs family as well as a deeper knowledge of their biol. functions may lead to a more profound characterization of the PARP inhibitor's profile.  This, in turn, will cast addnl. light on this exciting approach in treating cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Nta0RH4Y1bVg90H21EOLACvtfcHk0lhprs7cjQoX0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvFWmt7Y%253D&md5=2562742e9548db15aca2e42476e45683</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.768615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.768615%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DCirla%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D503%26epage%3D514%26doi%3D10.1517%2F13543776.2013.768615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6i"><span><span class="NLM_label">(i) </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camaioni, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span> </span><span class="NLM_article-title">PARP inhibitors: polypharmacology vs selective inhibition</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">3563</span><span class="NLM_x">–</span> <span class="NLM_lpage">3575</span><span class="refDoi"> DOI: 10.1111/febs.12298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6i&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1111%2Ffebs.12298" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2013&pages=3563-3575&author=T.+Ekbladauthor=E.+Camaioniauthor=H.+Sch%C3%BClerauthor=A.+Macchiarulo&title=PARP+inhibitors%3A+polypharmacology+vs+selective+inhibition&doi=10.1111%2Ffebs.12298"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6i&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12298%26sid%3Dliteratum%253Aachs%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3DCamaioni%26aufirst%3DE.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DMacchiarulo%26aufirst%3DA.%26atitle%3DPARP%2520inhibitors%253A%2520polypharmacology%2520vs%2520selective%2520inhibition%26jtitle%3DFEBS%2520J.%26date%3D2013%26volume%3D280%26spage%3D3563%26epage%3D3575%26doi%3D10.1111%2Ffebs.12298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bryant, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">913</span><span class="NLM_x">–</span> <span class="NLM_lpage">917</span><span class="refDoi"> DOI: 10.1038/nature03443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnature03443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15829966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=913-917&author=H.+E.+Bryantauthor=N.+Schultzauthor=H.+D.+Thomasauthor=K.+M.+Parkerauthor=D.+Flowerauthor=E.+Lopezauthor=S.+Kyleauthor=M.+Meuthauthor=N.+J.+Curtinauthor=T.+Helleday&title=Specific+killing+of+BRCA2-deficient+tumours+with+inhibitors+of+poly%28ADP-ribose%29+polymerase&doi=10.1038%2Fnature03443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Bryant, Helen E.; Schultz, Niklas; Thomas, Huw D.; Parker, Kayan M.; Flower, Dan; Lopez, Elena; Kyle, Suzanne; Meuth, Mark; Curtin, Nicola J.; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">913-917</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage.  Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumors.  Here, the authors show that PARP inhibitors trigger γ-H2AX and RAD51 foci formation.  The authors propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair.  Furthermore, the authors show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired.  Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells.  The authors exploit this requirement in order to kill BRCA2-deficient tumors by PARP inhibition alone.  Treatment with PARP inhibitors is likely to be highly tumor specific, because only the tumors (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination.  The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumor, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZJ6B7d7dB77Vg90H21EOLACvtfcHk0lhprs7cjQoX0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrY%253D&md5=44631eba667cf75ef99c31d011d6db44</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature03443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03443%26sid%3Dliteratum%253Aachs%26aulast%3DBryant%26aufirst%3DH.%2BE.%26aulast%3DSchultz%26aufirst%3DN.%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DParker%26aufirst%3DK.%2BM.%26aulast%3DFlower%26aufirst%3DD.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMeuth%26aufirst%3DM.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DSpecific%2520killing%2520of%2520BRCA2-deficient%2520tumours%2520with%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D913%26epage%3D917%26doi%3D10.1038%2Fnature03443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Farmer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCabe, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tutt, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santarosa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">434</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">921</span><span class="refDoi"> DOI: 10.1038/nature03445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnature03445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15829967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=434&publication_year=2005&pages=917-921&author=H.+Farmerauthor=N.+McCabeauthor=C.+J.+Lordauthor=A.+N.+Tuttauthor=D.+A.+Johnsonauthor=T.+B.+Richardsonauthor=M.+Santarosaauthor=K.+J.+Dillonauthor=I.+Hicksonauthor=C.+Knightsauthor=N.+M.+Martinauthor=S.+P.+Jacksonauthor=G.+C.+Smithauthor=A.+Ashworth&title=Targeting+the+DNA+repair+defect+in+BRCA+mutant+cells+as+a+therapeutic+strategy&doi=10.1038%2Fnature03445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</span></div><div class="casAuthors">Farmer, Hannah; McCabe, Nuala; Lord, Christopher J.; Tutt, Andrew N. J.; Johnson, Damian A.; Richardson, Tobias B.; Santarosa, Manuela; Dillon, Krystyna J.; Hickson, Ian; Knights, Charlotte; Martin, Niall M. B.; Jackson, Stephen P.; Smith, Graeme C. M.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">434</span>
        (<span class="NLM_cas:issue">7035</span>),
    <span class="NLM_cas:pages">917-921</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers.  Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks.  The authors show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis.  This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination.  These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVTKE4mFwfrVg90H21EOLACvtfcHk0lhprs7cjQoX0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtFOmsrc%253D&md5=03b5ba0adc21a5627fe17ae535f45078</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnature03445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature03445%26sid%3Dliteratum%253Aachs%26aulast%3DFarmer%26aufirst%3DH.%26aulast%3DMcCabe%26aufirst%3DN.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DTutt%26aufirst%3DA.%2BN.%26aulast%3DJohnson%26aufirst%3DD.%2BA.%26aulast%3DRichardson%26aufirst%3DT.%2BB.%26aulast%3DSantarosa%26aufirst%3DM.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DJackson%26aufirst%3DS.%2BP.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTargeting%2520the%2520DNA%2520repair%2520defect%2520in%2520BRCA%2520mutant%2520cells%2520as%2520a%2520therapeutic%2520strategy%26jtitle%3DNature%26date%3D2005%26volume%3D434%26spage%3D917%26epage%3D921%26doi%3D10.1038%2Fnature03445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-García, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serra, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Lockhart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cozar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzmán, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grueso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodríguez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calvo, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aura, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díez, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubio, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodón, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellisen, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">PI3K Inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1036</span><span class="NLM_x">–</span> <span class="NLM_lpage">1047</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F2159-8290.CD-11-0348" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1036-1047&author=Y.+H.+Ibrahimauthor=C.+Garc%C3%ADa-Garc%C3%ADaauthor=V.+Serraauthor=L.+Heauthor=K.+Torres-Lockhartauthor=A.+Pratauthor=P.+Antonauthor=P.+Cozarauthor=M.+Guzm%C3%A1nauthor=J.+Gruesoauthor=O.+Rodr%C3%ADguezauthor=M.+T.+Calvoauthor=C.+Auraauthor=O.+D%C3%ADezauthor=I.+T.+Rubioauthor=J.+P%C3%A9rezauthor=J.+Rod%C3%B3nauthor=J.+Cort%C3%A9sauthor=L.+W.+Ellisenauthor=M.+Scaltritiauthor=J.+Baselga&title=PI3K+Inhibition+impairs+BRCA1%2F2+expression+and+sensitizes+BRCA-proficient+triple-negative+breast+cancer+to+PARP+inhibition&doi=10.1158%2F2159-8290.CD-11-0348"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0348%26sid%3Dliteratum%253Aachs%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DC.%26aulast%3DSerra%26aufirst%3DV.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DTorres-Lockhart%26aufirst%3DK.%26aulast%3DPrat%26aufirst%3DA.%26aulast%3DAnton%26aufirst%3DP.%26aulast%3DCozar%26aufirst%3DP.%26aulast%3DGuzm%25C3%25A1n%26aufirst%3DM.%26aulast%3DGrueso%26aufirst%3DJ.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DO.%26aulast%3DCalvo%26aufirst%3DM.%2BT.%26aulast%3DAura%26aufirst%3DC.%26aulast%3DD%25C3%25ADez%26aufirst%3DO.%26aulast%3DRubio%26aufirst%3DI.%2BT.%26aulast%3DP%25C3%25A9rez%26aufirst%3DJ.%26aulast%3DRod%25C3%25B3n%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DJ.%26aulast%3DEllisen%26aufirst%3DL.%2BW.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPI3K%2520Inhibition%2520impairs%2520BRCA1%252F2%2520expression%2520and%2520sensitizes%2520BRCA-proficient%2520triple-negative%2520breast%2520cancer%2520to%2520PARP%2520inhibition%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1036%26epage%3D1047%26doi%3D10.1158%2F2159-8290.CD-11-0348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Juvekar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burga, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lunsford, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmañà, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajendran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyssiotis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardella, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scully, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asara, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wulf, G. M.</span><span> </span><span class="NLM_article-title">Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of <i>BRCA1</i>-related breast cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1048</span><span class="NLM_x">–</span> <span class="NLM_lpage">1063</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0336</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F2159-8290.CD-11-0336" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=1048-1063&author=A.+Juvekarauthor=L.+N.+Burgaauthor=H.+Huauthor=E.+P.+Lunsfordauthor=Y.+H.+Ibrahimauthor=J.+Balma%C3%B1%C3%A0author=A.+Rajendranauthor=A.+Papaauthor=K.+Spencerauthor=C.+A.+Lyssiotisauthor=C.+Nardellaauthor=P.+P.+Pandolfiauthor=J.+Baselgaauthor=R.+Scullyauthor=J.+M.+Asaraauthor=L.+C.+Cantleyauthor=G.+M.+Wulf&title=Combining+a+PI3K+inhibitor+with+a+PARP+inhibitor+provides+an+effective+therapy+for+a+mouse+model+of+BRCA1-related+breast+cancer&doi=10.1158%2F2159-8290.CD-11-0336"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0336&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0336%26sid%3Dliteratum%253Aachs%26aulast%3DJuvekar%26aufirst%3DA.%26aulast%3DBurga%26aufirst%3DL.%2BN.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DLunsford%26aufirst%3DE.%2BP.%26aulast%3DIbrahim%26aufirst%3DY.%2BH.%26aulast%3DBalma%25C3%25B1%25C3%25A0%26aufirst%3DJ.%26aulast%3DRajendran%26aufirst%3DA.%26aulast%3DPapa%26aufirst%3DA.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DLyssiotis%26aufirst%3DC.%2BA.%26aulast%3DNardella%26aufirst%3DC.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DScully%26aufirst%3DR.%26aulast%3DAsara%26aufirst%3DJ.%2BM.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DWulf%26aufirst%3DG.%2BM.%26atitle%3DCombining%2520a%2520PI3K%2520inhibitor%2520with%2520a%2520PARP%2520inhibitor%2520provides%2520an%2520effective%2520therapy%2520for%2520a%2520mouse%2520model%2520of%2520BRCA1-related%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2012%26volume%3D2%26spage%3D1048%26epage%3D1063%26doi%3D10.1158%2F2159-8290.CD-11-0336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Bajrami, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kigozi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Weverwijk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frankum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1096</span><span class="refDoi"> DOI: 10.1002/emmm.201201250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Femmm.201201250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22933245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVeiur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1087-1096&author=I.+Bajramiauthor=A.+Kigoziauthor=A.+Van+Weverwijkauthor=R.+Broughauthor=J.+Frankumauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethality+of+PARP+and+NAMPT+inhibition+in+triple-negative+breast+cancer+cells&doi=10.1002%2Femmm.201201250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells</span></div><div class="casAuthors">Bajrami, Ilirjana; Kigozi, Asha; Van Weverwijk, Antoinette; Brough, Rachel; Frankum, Jessica; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1087-1096</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">PARP inhibitors have been proposed as a potential targeted therapy for patients with triple-neg. (ER-, PR-, HER2-neg.) breast cancers.  However, it is as yet unclear as to whether single agent or combination therapy using PARP inhibitors would be most beneficial.  To better understand the mechanisms that det. the response to PARP inhibitors, we investigated whether enzymes involved in metab. of the PARP substrate, β-NAD+, might alter the response to a clin. PARP inhibitor.  Using an olaparib sensitization screen in a triple-neg. (TN) breast cancer model, we identified nicotinamide phosphoribosyltransferase (NAMPT) as a non-redundant modifier of olaparib response.  NAMPT is a rate-limiting enzyme involved in the generation of the PARP substrate β-NAD+ and the suppression of β-NAD+ levels by NAMPT inhibition most likely explains these observations.  Importantly, the combination of a NAMPT small mol. inhibitor, FK866, with olaparib inhibited TN breast tumor growth in vivo to a greater extent than either single agent alone suggesting that assessing NAMPT/PARP inhibitor combinations for the treatment of TN breast cancer may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDlMhMk2Q7WbVg90H21EOLACvtfcHk0lgfpjgaFNKV8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVeiur7M&md5=c97061b1a3505cce8230352f5bb9f07e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1002%2Femmm.201201250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201201250%26sid%3Dliteratum%253Aachs%26aulast%3DBajrami%26aufirst%3DI.%26aulast%3DKigozi%26aufirst%3DA.%26aulast%3DVan%2BWeverwijk%26aufirst%3DA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DFrankum%26aufirst%3DJ.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethality%2520of%2520PARP%2520and%2520NAMPT%2520inhibition%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D1087%26epage%3D1096%26doi%3D10.1002%2Femmm.201201250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Nowsheen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, E. S.</span><span> </span><span class="NLM_article-title">Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46614</span><span class="refDoi"> DOI: 10.1371/journal.pone.0046614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1371%2Fjournal.pone.0046614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46614&author=S.+Nowsheenauthor=T.+Cooperauthor=J.+A.+Stanleyauthor=E.+S.+Yang&title=Synthetic+lethal+interactions+between+EGFR+and+PARP+inhibition+in+human+triple+negative+breast+cancer+cells&doi=10.1371%2Fjournal.pone.0046614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046614%26sid%3Dliteratum%253Aachs%26aulast%3DNowsheen%26aufirst%3DS.%26aulast%3DCooper%26aufirst%3DT.%26aulast%3DStanley%26aufirst%3DJ.%2BA.%26aulast%3DYang%26aufirst%3DE.%2BS.%26atitle%3DSynthetic%2520lethal%2520interactions%2520between%2520EGFR%2520and%2520PARP%2520inhibition%2520in%2520human%2520triple%2520negative%2520breast%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46614%26doi%3D10.1371%2Fjournal.pone.0046614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mendes-Pereira, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarthy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waldman, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Synthetic lethal targeting of <i>PTEN</i> mutant cells with PARP inhibitors</span> <span class="citation_source-journal">EMBO Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">322</span><span class="refDoi"> DOI: 10.1002/emmm.200900041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Femmm.200900041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20049735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2009&pages=315-322&author=A.+M.+Mendes-Pereiraauthor=S.+A.+Martinauthor=R.+Broughauthor=A.+McCarthyauthor=J.+R.+Taylorauthor=J.-S.+Kimauthor=T.+Waldmanauthor=C.+J.+Lordauthor=A.+Ashworth&title=Synthetic+lethal+targeting+of+PTEN+mutant+cells+with+PARP+inhibitors&doi=10.1002%2Femmm.200900041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors</span></div><div class="casAuthors">Mendes-Pereira, Ana M.; Martin, Sarah A.; Brough, Rachel; McCarthy, Afshan; Taylor, Jessica R.; Kim, Jung-Sik; Waldman, Todd; Lord, Christopher J.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6-7</span>),
    <span class="NLM_cas:pages">315-322</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The tumor suppressor gene, phosphatase and tensin homolog (PTEN), is one of the most commonly mutated genes in human cancers.  Recent evidence suggests that PTEN is important for the maintenance of genome stability.  Here, we show that PTEN deficiency causes a homologous recombination (HR) defect in human tumor cells.  The HR deficiency caused by PTEN deficiency, sensitizes tumor cells to potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), both in vitro and in vivo.  PARP inhibitors are now showing considerable promise in the clinic, specifically in patients with mutations in either of the breast cancer susceptibility genes BRCA1 or BRCA2.  The data we present here now suggests that the clin. assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPqq6kbXT_l7Vg90H21EOLACvtfcHk0lhWbJ8p-ZRLbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSltL%252FK&md5=c14c7e0d1ae6a753deabbfb125dcc5a2</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1002%2Femmm.200900041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.200900041%26sid%3Dliteratum%253Aachs%26aulast%3DMendes-Pereira%26aufirst%3DA.%2BM.%26aulast%3DMartin%26aufirst%3DS.%2BA.%26aulast%3DBrough%26aufirst%3DR.%26aulast%3DMcCarthy%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DJ.%2BR.%26aulast%3DKim%26aufirst%3DJ.-S.%26aulast%3DWaldman%26aufirst%3DT.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DSynthetic%2520lethal%2520targeting%2520of%2520PTEN%2520mutant%2520cells%2520with%2520PARP%2520inhibitors%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2009%26volume%3D1%26spage%3D315%26epage%3D322%26doi%3D10.1002%2Femmm.200900041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Garcia-Cao, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hobbs, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurent, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giorgi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Boer, V. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anastasiou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rameh, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carracedo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vander Heiden, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantley, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinton, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haigis, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandolfi, P. P.</span><span> </span><span class="NLM_article-title">Systemic elevation of PTEN induces a tumor-suppressive metabolic state</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">149</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span><span class="refDoi"> DOI: 10.1016/j.cell.2012.02.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.cell.2012.02.030" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=49-62&author=I.+Garcia-Caoauthor=M.+S.+Songauthor=R.+M.+Hobbsauthor=G.+Laurentauthor=C.+Giorgiauthor=V.+C.+de+Boerauthor=D.+Anastasiouauthor=K.+Itoauthor=A.+T.+Sasakiauthor=L.+Ramehauthor=A.+Carracedoauthor=M.+G.+Vander+Heidenauthor=L.+C.+Cantleyauthor=P.+Pintonauthor=M.+C.+Haigisauthor=P.+P.+Pandolfi&title=Systemic+elevation+of+PTEN+induces+a+tumor-suppressive+metabolic+state&doi=10.1016%2Fj.cell.2012.02.030"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.030%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Cao%26aufirst%3DI.%26aulast%3DSong%26aufirst%3DM.%2BS.%26aulast%3DHobbs%26aufirst%3DR.%2BM.%26aulast%3DLaurent%26aufirst%3DG.%26aulast%3DGiorgi%26aufirst%3DC.%26aulast%3Dde%2BBoer%26aufirst%3DV.%2BC.%26aulast%3DAnastasiou%26aufirst%3DD.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DA.%2BT.%26aulast%3DRameh%26aufirst%3DL.%26aulast%3DCarracedo%26aufirst%3DA.%26aulast%3DVander%2BHeiden%26aufirst%3DM.%2BG.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DPinton%26aufirst%3DP.%26aulast%3DHaigis%26aufirst%3DM.%2BC.%26aulast%3DPandolfi%26aufirst%3DP.%2BP.%26atitle%3DSystemic%2520elevation%2520of%2520PTEN%2520induces%2520a%2520tumor-suppressive%2520metabolic%2520state%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D49%26epage%3D62%26doi%3D10.1016%2Fj.cell.2012.02.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Williamson, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muzik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turhan, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zamò, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebb, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lees-Miller, S. P.</span><span> </span><span class="NLM_article-title">ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1535-7163.MCT-09-0872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20124459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=347-357&author=C.+T.+Williamsonauthor=H.+Muzikauthor=A.+G.+Turhanauthor=A.+Zam%C3%B2author=M.+J.+O%27Connorauthor=D.+G.+Bebbauthor=S.+P.+Lees-Miller&title=ATM+deficiency+sensitizes+mantle+cell+lymphoma+cells+to+poly%28ADP-ribose%29+polymerase-1+inhibitors&doi=10.1158%2F1535-7163.MCT-09-0872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors</span></div><div class="casAuthors">Williamson, Chris T.; Muzik, Huong; Turhan, Ali G.; Zamo, Alberto; O'Connor, Mark J.; Bebb, D. Gwyn; Lees-Miller, Susan P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">347-357</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-1 (PARP-1) inhibition is toxic to cells with mutations in the breast and ovarian cancer susceptibility genes BRCA1 or BRCA2, a concept termed synthetic lethality.  However, whether this approach is applicable to other human cancers with defects in other DNA repair genes has yet to be detd.  The ataxia telangiectasia mutated (ATM) gene is altered in several human cancers including mantle cell lymphoma (MCL).  Here, the authors characterize a panel of MCL cell lines for ATM status and function and investigate the potential for synthetic lethality in MCL in the presence of small-mol. inhibitors of PARP-1.  The authors show that Granta-519 and UPN2 cells have low levels of ATM protein, are defective in DNA damage-induced ATM-dependent signaling, are radiation sensitive, and have cell cycle checkpoint defects: all characteristics of defective ATM function.  Significantly, Granta-519 and UPN2 cells were more sensitive to PARP-1 inhibition than were the ATM-proficient MCL cell lines examd.  Furthermore, the PARP-1 inhibitor olaparib (known previously as AZD2281/KU-0059436) significantly decreased tumor growth and increased overall survival in mice bearing s.c. xenografts of ATM-deficient Granta-519 cells while producing only a modest effect on overall survival of mice bearing xenografts of the ATM-proficient cell line, Z138.  Thus, PARP inhibitors have therapeutic potential in the treatment of MCL, and the concept of synthetic lethality extends to human cancers with ATM alterations.  Mol Cancer Ther; 9(2); 347-57.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQmQjsqIbdVrVg90H21EOLACvtfcHk0lhWbJ8p-ZRLbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslektb8%253D&md5=6243397aa39febdd9bd613b413a1f9ad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0872%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DC.%2BT.%26aulast%3DMuzik%26aufirst%3DH.%26aulast%3DTurhan%26aufirst%3DA.%2BG.%26aulast%3DZam%25C3%25B2%26aufirst%3DA.%26aulast%3DO%2527Connor%26aufirst%3DM.%2BJ.%26aulast%3DBebb%26aufirst%3DD.%2BG.%26aulast%3DLees-Miller%26aufirst%3DS.%2BP.%26atitle%3DATM%2520deficiency%2520sensitizes%2520mantle%2520cell%2520lymphoma%2520cells%2520to%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D347%26epage%3D357%26doi%3D10.1158%2F1535-7163.MCT-09-0872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Vilar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, S. B.</span><span> </span><span class="NLM_article-title">Microsatellite instability in colorectal cancer-the stable evidence</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">162</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2009.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnrclinonc.2009.237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20142816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFemsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=153-162&author=E.+Vilarauthor=S.+B.+Gruber&title=Microsatellite+instability+in+colorectal+cancer-the+stable+evidence&doi=10.1038%2Fnrclinonc.2009.237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microsatellite instability in colorectal cancer-the stable evidence</span></div><div class="casAuthors">Vilar, Eduardo; Gruber, Stephen B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-162</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review that presents an overview of microsatellite instability (MSI), including its clin. features and applications.  MSI is a frequent mol. phenomenon of colorectal cancer and is assocd. with deficient DNA mismatch repair.  The authors discuss the prognostic and predictive value of MSI and how it can be used to improve our knowledge of other cancer subtypes.  Microsatellite instability (MSI) is the mol. fingerprint of a deficient mismatch repair system.  Approx. 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2.  Methods to detect MSI are well established and routinely incorporated into clin. practice.  A clin. and mol. profile of MSI tumors has been described, leading to the concept of an MSI phenotype in CRC.  Studies have confirmed that MSI tumors have a better prognosis than microsatellite stable CRC, but MSI cancers do not necessarily have the same response to the chemotherapeutic strategies used to treat microsatellite stable tumors.  Specifically, stage II MSI tumors might not benefit from 5-fluorouracil-based adjuvant chemotherapy regimens.  New data suggest possible advantages of irinotecan-based regimens, but these findings require further clarification.  Characterization of the mol. basis of MSI in CRC is underway and initial results show that mutations in genes encoding kinases and candidate genes with microsatellite tracts are over-represented in MSI tumors.  Transcriptome expression profiles of MSI tumors and systems biol. approaches are providing the opportunity to develop targeted therapeutics for MSI CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptR5PjUGt7rLVg90H21EOLACvtfcHk0lhWbJ8p-ZRLbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFemsbs%253D&md5=760bd08201b6e6a8dd4b25b64fb60625</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2009.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2009.237%26sid%3Dliteratum%253Aachs%26aulast%3DVilar%26aufirst%3DE.%26aulast%3DGruber%26aufirst%3DS.%2BB.%26atitle%3DMicrosatellite%2520instability%2520in%2520colorectal%2520cancer-the%2520stable%2520evidence%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D7%26spage%3D153%26epage%3D162%26doi%3D10.1038%2Fnrclinonc.2009.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Brenner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goyal, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bou-Maroun, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonigro, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prensner, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, A. M.</span><span> </span><span class="NLM_article-title">PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1608</span><span class="NLM_x">–</span> <span class="NLM_lpage">1613</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-3648</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F0008-5472.CAN-11-3648" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1608-1613&author=J.+C.+Brennerauthor=F.+Y.+Fengauthor=S.+Hanauthor=S.+Patelauthor=S.+V.+Goyalauthor=L.+M.+Bou-Marounauthor=M.+Liuauthor=R.+Lonigroauthor=J.+R.+Prensnerauthor=S.+A.+Tomlinsauthor=A.+M.+Chinnaiyan&title=PARP-1+inhibition+as+a+targeted+strategy+to+treat+Ewing%E2%80%99s+sarcoma&doi=10.1158%2F0008-5472.CAN-11-3648"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-3648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-3648%26sid%3Dliteratum%253Aachs%26aulast%3DBrenner%26aufirst%3DJ.%2BC.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DGoyal%26aufirst%3DS.%2BV.%26aulast%3DBou-Maroun%26aufirst%3DL.%2BM.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLonigro%26aufirst%3DR.%26aulast%3DPrensner%26aufirst%3DJ.%2BR.%26aulast%3DTomlins%26aufirst%3DS.%2BA.%26aulast%3DChinnaiyan%26aufirst%3DA.%2BM.%26atitle%3DPARP-1%2520inhibition%2520as%2520a%2520targeted%2520strategy%2520to%2520treat%2520Ewing%25E2%2580%2599s%2520sarcoma%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1608%26epage%3D1613%26doi%3D10.1158%2F0008-5472.CAN-11-3648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donawho, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bontcheva-Diaz, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouska, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osterling, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span> </span><span class="NLM_article-title">Discovery of the poly-(ADP-ribose) polymerase (PARP) inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">514</span><span class="NLM_x">–</span> <span class="NLM_lpage">523</span><span class="refDoi"> DOI: 10.1021/jm801171j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801171j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=514-523&author=T.+D.+Penningauthor=G.+D.+Zhuauthor=V.+B.+Gandhiauthor=J.+Gongauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+K.+Donawhoauthor=D.+J.+Frostauthor=V.+Bontcheva-Diazauthor=J.+J.+Bouskaauthor=D.+J.+Osterlingauthor=A.+M.+Olsonauthor=K.+C.+Marshauthor=Y.+Luoauthor=V.+L.+Giranda&title=Discovery+of+the+poly-%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+2-%5B%28R%29-2-methylpyrrolidin-2-yl%5D-1H-benzimidazole-4-carboxamide+%28ABT-888%29+for+the+treatment+of+cancer&doi=10.1021%2Fjm801171j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm801171j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801171j%26sid%3Dliteratum%253Aachs%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.%2BD.%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DDonawho%26aufirst%3DC.%2BK.%26aulast%3DFrost%26aufirst%3DD.%2BJ.%26aulast%3DBontcheva-Diaz%26aufirst%3DV.%26aulast%3DBouska%26aufirst%3DJ.%2BJ.%26aulast%3DOsterling%26aufirst%3DD.%2BJ.%26aulast%3DOlson%26aufirst%3DA.%2BM.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26atitle%3DDiscovery%2520of%2520the%2520poly-%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%25202-%255B%2528R%2529-2-methylpyrrolidin-2-yl%255D-1H-benzimidazole-4-carboxamide%2520%2528ABT-888%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D514%26epage%3D523%26doi%3D10.1021%2Fjm801171j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boueres, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrigno, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fonsi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giomini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamartina, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monteagudo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ontoria, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsale, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palumbi, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesci, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roscilli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarpelli, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span> </span><span class="NLM_article-title">Discovery of 2-{4-[(3<i>S</i>)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and −2 mutant tumors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7185</span><span class="refDoi"> DOI: 10.1021/jm901188v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901188v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7170-7185&author=P.+Jonesauthor=S.+Altamuraauthor=J.+Boueresauthor=F.+Ferrignoauthor=M.+Fonsiauthor=C.+Giominiauthor=S.+Lamartinaauthor=E.+Monteagudoauthor=J.+M.+Ontoriaauthor=M.+V.+Orsaleauthor=M.+C.+Palumbiauthor=S.+Pesciauthor=G.+Roscilliauthor=R.+Scarpelliauthor=C.+Schultz-Fademrechtauthor=C.+Toniattiauthor=M.+Rowley&title=Discovery+of+2-%7B4-%5B%283S%29-piperidin-3-yl%5Dphenyl%7D-2H-indazole-7-carboxamide+%28MK-4827%29%3A+a+novel+oral+poly%28ADP-ribose%29polymerase+%28PARP%29+inhibitor+efficacious+in+BRCA-1+and+%E2%88%922+mutant+tumors&doi=10.1021%2Fjm901188v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors</span></div><div class="casAuthors">Jones, Philip; Altamura, Sergio; Boueres, Julia; Ferrigno, Federica; Fonsi, Massimiliano; Giomini, Claudia; Lamartina, Stefania; Monteagudo, Edith; Ontoria, Jesus M.; Orsale, Maria Vittoria; Palumbi, Maria Cecilia; Pesci, Silvia; Roscilli, Giuseppe; Scarpelli, Rita; Schultz-Fademrecht, Carsten; Toniatti, Carlo; Rowley, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7170-7185</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We disclose the development of a novel series of 2-phenyl-2H-indazole-7-carboxamides as poly(ADP-ribose)polymerase (PARP) 1 and 2 inhibitors.  This series was optimized to improve enzyme and cellular activity, and the resulting PARP inhibitors display antiproliferation activities against BRCA-1 and BRCA-2 deficient cancer cells, with high selectivity over BRCA proficient cells.  Extrahepatic oxidn. by CYP450 1A1 and 1A2 was identified as a metabolic concern, and strategies to improve pharmacokinetic properties are reported.  These efforts culminated in the identification of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827), which displays good pharmacokinetic properties and is currently in phase I clin. trials.  This compd. displays excellent PARP 1 and 2 inhibition with IC50 = 3.8 and 2.1 nM, resp., and in a whole cell assay, it inhibited PARP activity with EC50 = 4 nM and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2 with CC50 in the 10-100 nM range.  MK-4827 was well tolerated in vivo and demonstrated efficacy as a single agent in a xenograft model of BRCA-1 deficient cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFTodq58wELVg90H21EOLACvtfcHk0ljnNkMkyCXIEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtleisLjM&md5=ff6662626b95805aeece659fec25133c</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm901188v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901188v%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DBoueres%26aufirst%3DJ.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DFonsi%26aufirst%3DM.%26aulast%3DGiomini%26aufirst%3DC.%26aulast%3DLamartina%26aufirst%3DS.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DOntoria%26aufirst%3DJ.%2BM.%26aulast%3DOrsale%26aufirst%3DM.%2BV.%26aulast%3DPalumbi%26aufirst%3DM.%2BC.%26aulast%3DPesci%26aufirst%3DS.%26aulast%3DRoscilli%26aufirst%3DG.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DToniatti%26aufirst%3DC.%26aulast%3DRowley%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%257B4-%255B%25283S%2529-piperidin-3-yl%255Dphenyl%257D-2H-indazole-7-carboxamide%2520%2528MK-4827%2529%253A%2520a%2520novel%2520oral%2520poly%2528ADP-ribose%2529polymerase%2520%2528PARP%2529%2520inhibitor%2520efficacious%2520in%2520BRCA-1%2520and%2520%25E2%2588%25922%2520mutant%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7170%26epage%3D7185%26doi%3D10.1021%2Fjm901188v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jones, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilcoxen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toniatti, C.</span><span> </span><span class="NLM_article-title">Niraparib: a poly(ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">3302</span><span class="NLM_x">–</span> <span class="NLM_lpage">3314</span><span class="refDoi"> DOI: 10.1021/jm5018237</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5018237" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=3302-3314&author=P.+Jonesauthor=K.+Wilcoxenauthor=M.+Rowleyauthor=C.+Toniatti&title=Niraparib%3A+a+poly%28ADP-ribose%29+polymerase+%28PARP%29+inhibitor+for+the+treatment+of+tumors+with+defective+homologous+recombination&doi=10.1021%2Fjm5018237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination</span></div><div class="casAuthors">Jones, Philip; Wilcoxen, Keith; Rowley, Michael; Toniatti, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3302-3314</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repair following damage by endogenous or exogenous processes.  It has become clear over the past decade that inhibition of PARP in the context of defects in other DNA repair mechanisms provide a tumor specific way to kill cancer cells.  We describe the rationale for this approach and the design and discovery of niraparib, a potent PARP-1/2 inhibitor with good cell based activity, selectivity for cancer over normal cells, and oral bioavailability.  Niraparib was characterized in a no. of preclin. models before moving to phase I clin. trials, where it showed excellent human pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PARP inhibition, and had promising activity in cancer patients.  It is currently being tested in phase 3 clin. trials as maintenance therapy in ovarian cancer and as a treatment for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsaJDnhFDPhbVg90H21EOLACvtfcHk0lhhduOBURdvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktFams7s%253D&md5=ffb7cb2503acde0a1e3452448d98693f</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm5018237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5018237%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DP.%26aulast%3DWilcoxen%26aufirst%3DK.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DToniatti%26aufirst%3DC.%26atitle%3DNiraparib%253A%2520a%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520tumors%2520with%2520defective%2520homologous%2520recombination%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D3302%26epage%3D3314%26doi%3D10.1021%2Fjm5018237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Thomas, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabrese, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batey, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hostomsky, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kyle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maegley, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skalitzky, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.-Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">945</span><span class="NLM_x">–</span> <span class="NLM_lpage">956</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0552</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1535-7163.MCT-06-0552" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=17363489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=945-956&author=H.+D.+Thomasauthor=C.+R.+Calabreseauthor=M.+A.+Bateyauthor=S.+Cananauthor=Z.+Hostomskyauthor=S.+Kyleauthor=K.+A.+Maegleyauthor=D.+R.+Newellauthor=D.+Skalitzkyauthor=L.-Z.+Wangauthor=S.+E.+Webberauthor=N.+J.+Curtin&title=Preclinical+selection+of+a+novel+poly%28ADP-ribose%29+polymerase+inhibitor+for+clinical+trial&doi=10.1158%2F1535-7163.MCT-06-0552"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial</span></div><div class="casAuthors">Thomas, Huw D.; Calabrese, Christopher R.; Batey, Michael A.; Canan, Stacie; Hostomsky, Zdenek; Kyle, Suzanne; Maegley, Karen A.; Newell, David R.; Skalitzky, Donald; Wang, Lan-Zhen; Webber, Stephen E.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-956</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase (PARP)-1 (EC 2.4.2.30) is a nuclear enzyme that promotes the base excision repair of DNA breaks.  Inhibition of PARP-1 enhances the efficacy of DNA alkylating agents, topoisomerase I poisons, and ionizing radiation.  Our aim was to identify a PARP inhibitor for clin. trial from a panel of 42 potent PARP inhibitors (Ki, 1.4-15.1 nmol/L) based on the quinazolinone, benzimidazole, tricyclic benzimidazole, tricyclic indole, and tricyclic indole-1-one core structures.  We evaluated chemosensitization of temozolomide and topotecan using LoVo and SW620 human colorectal cells; in vitro radiosensitization was measured using LoVo cells, and the enhancement of antitumor activity of temozolomide was evaluated in mice bearing SW620 xenografts.  Excellent chemopotentiation and radiopotentiation were obsd. in vitro, with 17 of the compds. causing a greater temozolomide and topotecan sensitization than the benchmark inhibitor AG14361 and 10 compds. were more potent radiosensitizers than AG14361.  In tumor-bearing mice, none of the compds. were toxic when given alone, and the antitumor activity of the PARP inhibitor-temozolomide combinations was unrelated to toxicity.  Compds. that were more potent chemosensitizers in vivo than AG14361 were also more potent in vitro, validating in vitro assays as a prescreen.  These studies have identified a compd., AG14447, as a PARP inhibitor with outstanding in vivo chemosensitization potency at tolerable doses, which is at least 10 times more potent than the initial lead, AG14361.  The phosphate salt of AG14447 (AG014699), which has improved aq. soly., has been selected for clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-3D2oL2giLVg90H21EOLACvtfcHk0lhhduOBURdvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nurw%253D&md5=b451bf2c1fc836cc5a800c2799e5d211</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0552&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0552%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DH.%2BD.%26aulast%3DCalabrese%26aufirst%3DC.%2BR.%26aulast%3DBatey%26aufirst%3DM.%2BA.%26aulast%3DCanan%26aufirst%3DS.%26aulast%3DHostomsky%26aufirst%3DZ.%26aulast%3DKyle%26aufirst%3DS.%26aulast%3DMaegley%26aufirst%3DK.%2BA.%26aulast%3DNewell%26aufirst%3DD.%2BR.%26aulast%3DSkalitzky%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.-Z.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DPreclinical%2520selection%2520of%2520a%2520novel%2520poly%2528ADP-ribose%2529%2520polymerase%2520inhibitor%2520for%2520clinical%2520trial%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D945%26epage%3D956%26doi%3D10.1158%2F1535-7163.MCT-06-0552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Menear, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adcock, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockcroft, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copsey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cranston, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drzewiecki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javaid, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerrigan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knights, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lau, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loh, V. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, I. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N. M.</span><span> </span><span class="NLM_article-title">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6581</span><span class="NLM_x">–</span> <span class="NLM_lpage">6591</span><span class="refDoi"> DOI: 10.1021/jm8001263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8001263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6581-6591&author=K.+A.+Menearauthor=C.+Adcockauthor=R.+Boulterauthor=X.+L.+Cockcroftauthor=L.+Copseyauthor=A.+Cranstonauthor=K.+J.+Dillonauthor=J.+Drzewieckiauthor=S.+Garmanauthor=S.+Gomezauthor=H.+Javaidauthor=F.+Kerriganauthor=C.+Knightsauthor=A.+Lauauthor=V.+M.+Lohauthor=I.+T.+Matthewsauthor=S.+Mooreauthor=M.+J.+O%E2%80%99Connorauthor=G.+C.+Smithauthor=N.+M.+Martin&title=4-%5B3-%284-Cyclopropanecarbonylpiperazine-1-carbonyl%29-4-fluorobenzyl%5D-2H-phthalazin-1-one%3A+a+novel+bioavailable+inhibitor+of+poly%28ADP-ribose%29+polymerase-1&doi=10.1021%2Fjm8001263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1</span></div><div class="casAuthors">Menear, Keith A.; Adcock, Claire; Boulter, Robert; Cockcroft, Xiao-ling; Copsey, Louise; Cranston, Aaron; Dillon, Krystyna J.; Drzewiecki, Jan; Garman, Sheila; Gomez, Sylvie; Javaid, Hashim; Kerrigan, Frank; Knights, Charlotte; Lau, Alan; Loh, Vincent M., Jr.; Matthews, Ian T. W.; Moore, Stephen; O'Connor, Mark J.; Smith, Graeme C. M.; Martin, Niall M. B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6581-6591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chem.-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy.  In this article, we disclose a novel series of substituted 4-benzyl-2H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2.  Optimized compds. from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines.  Compd. 47 is currently undergoing clin. development for the treatment of BRCA1- and BRCA2-defective cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IKtdcfeWCbVg90H21EOLACvtfcHk0lhhduOBURdvng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs7vE&md5=45aff9bb506360ec26c1c0039388240e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm8001263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8001263%26sid%3Dliteratum%253Aachs%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DAdcock%26aufirst%3DC.%26aulast%3DBoulter%26aufirst%3DR.%26aulast%3DCockcroft%26aufirst%3DX.%2BL.%26aulast%3DCopsey%26aufirst%3DL.%26aulast%3DCranston%26aufirst%3DA.%26aulast%3DDillon%26aufirst%3DK.%2BJ.%26aulast%3DDrzewiecki%26aufirst%3DJ.%26aulast%3DGarman%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DJavaid%26aufirst%3DH.%26aulast%3DKerrigan%26aufirst%3DF.%26aulast%3DKnights%26aufirst%3DC.%26aulast%3DLau%26aufirst%3DA.%26aulast%3DLoh%26aufirst%3DV.%2BM.%26aulast%3DMatthews%26aufirst%3DI.%2BT.%26aulast%3DMoore%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DM.%2BJ.%26aulast%3DSmith%26aufirst%3DG.%2BC.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26atitle%3D4-%255B3-%25284-Cyclopropanecarbonylpiperazine-1-carbonyl%2529-4-fluorobenzyl%255D-2H-phthalazin-1-one%253A%2520a%2520novel%2520bioavailable%2520inhibitor%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6581%26epage%3D6591%26doi%3D10.1021%2Fjm8001263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rehman, F. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boshuizen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajrami, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">BMN673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5003</span><span class="NLM_x">–</span> <span class="NLM_lpage">5015</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-1391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1158%2F1078-0432.CCR-13-1391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23881923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=5003-5015&author=Y.+Shenauthor=F.+L.+Rehmanauthor=Y.+Fengauthor=J.+Boshuizenauthor=L.+Bajramiauthor=R.+Elliottauthor=B.+Wangauthor=C.+J.+Lordauthor=L.+E.+Postauthor=A.+Ashworth&title=BMN673%2C+a+novel+and+highly+potent+PARP1%2F2+inhibitor+for+the+treatment+of+human+cancers+with+DNA+repair+deficiency&doi=10.1158%2F1078-0432.CCR-13-1391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency</span></div><div class="casAuthors">Shen, Yuqiao; Rehman, Farah L.; Feng, Ying; Boshuizen, Julia; Bajrami, Ilirjana; Elliott, Richard; Wang, Bing; Lord, Christopher J.; Post, Leonard E.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5003-5015</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair.  Here, we describe BMN 673, a novel, highly potent PARP1/2 inhibitor with favorable metabolic stability, oral bioavailability, and pharmacokinetic properties.  Exptl. Design: Potency and selectivity of BMN 673 was detd. by biochem. assays.  Anticancer activity either as a single-agent or in combination with other antitumor agents was evaluated both in vitro and in xenograft cancer models.  Results: BMN 673 is a potent PARP1/2 inhibitor (PARP1 IC50 = 0.57 nmol/L), but it does not inhibit other enzymes that we have tested.  BMN 673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concns. than earlier generation PARP1/2 inhibitors (such as olaparib, rucaparib, and veliparib).  In vitro, BMN 673 selectively targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors.  BMN 673 is readily orally bioavailable, with more than 40% abs. oral bioavailability in rats when dosed in carboxylmethyl cellulose.  Oral administration of BMN 673 elicited remarkable antitumor activity in vivo; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses in mice.  Synergistic or additive antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs.  Conclusion: BMN 673 is currently in early-phase clin. development and represents a promising PARP1/2 inhibitor with potentially advantageous features in its drug class.  Clin Cancer Res; 19(18); 5003-15. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWdmHIVEuoz7Vg90H21EOLACvtfcHk0lhjcy5R2YHXWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyns77J&md5=f58b67f14784c0a0fa1197caffd8d96d</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-1391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-1391%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DRehman%26aufirst%3DF.%2BL.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DBoshuizen%26aufirst%3DJ.%26aulast%3DBajrami%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLord%26aufirst%3DC.%2BJ.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DBMN673%252C%2520a%2520novel%2520and%2520highly%2520potent%2520PARP1%252F2%2520inhibitor%2520for%2520the%2520treatment%2520of%2520human%2520cancers%2520with%2520DNA%2520repair%2520deficiency%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D5003%26epage%3D5015%26doi%3D10.1158%2F1078-0432.CCR-13-1391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoyagi-Scharber, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B.</span><span> </span><span class="NLM_article-title">Trapping Poly(ADP-Ribose) Polymerase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">446</span><span class="NLM_x">–</span> <span class="NLM_lpage">457</span><span class="refDoi"> DOI: 10.1124/jpet.114.222448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1124%2Fjpet.114.222448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25758918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=446-457&author=Y.+Shenauthor=M.+Aoyagi-Scharberauthor=B.+Wang&title=Trapping+Poly%28ADP-Ribose%29+Polymerase&doi=10.1124%2Fjpet.114.222448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Trapping poly(ADP-ribose) polymerase</span></div><div class="casAuthors">Shen, Yuqiao; Aoyagi-Scharber, Mika; Wang, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">446-457</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Recent findings indicate that a major mechanism by which poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage.  The PARP enzyme-inhibitor complex "locks" onto damaged DNA and prevents DNA repair, replication, and transcription, leading to cell death.  Several clin.-stage PARP inhibitors, including veliparib, rucaparib, olaparib, niraparib, and talazoparib, have been evaluated for their PARP-trapping activity.  Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP closely correlating with each drug's ability to kill cancer cells.  In this article, we review the available data on mol. interactions between these clin.-stage PARP inhibitors and PARP proteins, and discuss how their biol. differences might be explained by the trapping mechanism.  We also discuss how to use the PARP-trapping mechanism to guide the development of PARP inhibitors as a new class of cancer therapy, both for single-agent and combination treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf7H8kc8UmXLVg90H21EOLACvtfcHk0lhjcy5R2YHXWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1WgsLc%253D&md5=36ceb95db0a63ab9ce002906df555482</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.222448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.222448%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAoyagi-Scharber%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DB.%26atitle%3DTrapping%2520Poly%2528ADP-Ribose%2529%2520Polymerase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D446%26epage%3D457%26doi%3D10.1124%2Fjpet.114.222448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wahlberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouznetsova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macchiarulo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsell, A.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pol, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frostell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekblad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Öncü, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kull, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicciari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weigelt, J.</span><span> </span><span class="NLM_article-title">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">283</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span><span class="refDoi"> DOI: 10.1038/nbt.2121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fnbt.2121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=22343925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=283-288&author=E.+Wahlbergauthor=T.+Karlbergauthor=E.+Kouznetsovaauthor=N.+Markovaauthor=A.+Macchiaruloauthor=A.-G.+Thorsellauthor=E.+Polauthor=A.+Frostellauthor=T.+Ekbladauthor=D.+%C3%96nc%C3%BCauthor=B.+Kullauthor=G.+M.+Robertsonauthor=R.+Pellicciariauthor=H.+Sch%C3%BClerauthor=J.+Weigelt&title=Family-wide+chemical+profiling+and+structural+analysis+of+PARP+and+tankyrase+inhibitors&doi=10.1038%2Fnbt.2121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors</span></div><div class="casAuthors">Wahlberg, Elisabet; Karlberg, Tobias; Kouznetsova, Ekaterina; Markova, Natalia; Macchiarulo, Antonio; Thorsell, Ann-Gerd; Pol, Ewa; Frostell, Aasa; Ekblad, Torun; Oencue, Delal; Kull, Bjoern; Robertson, Graeme Michael; Pellicciari, Roberto; Schueler, Herwig; Weigelt, Johan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-288</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clin. trials as cancer therapeutics, yet the specificity of many of these compds. is unknown.  Here we evaluated a series of 185 small-mol. inhibitors, including research reagents and compds. being tested clin., for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2.  Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these mols. lack specificity and have promiscuous inhibitory activity.  We also detd. X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes.  In addn. to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYSebsCVufibVg90H21EOLACvtfcHk0lhjcy5R2YHXWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVKrsb4%253D&md5=71f17fd5b6bb602dd70c8fcc17df95f9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2121%26sid%3Dliteratum%253Aachs%26aulast%3DWahlberg%26aufirst%3DE.%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DKouznetsova%26aufirst%3DE.%26aulast%3DMarkova%26aufirst%3DN.%26aulast%3DMacchiarulo%26aufirst%3DA.%26aulast%3DThorsell%26aufirst%3DA.-G.%26aulast%3DPol%26aufirst%3DE.%26aulast%3DFrostell%26aufirst%3DA.%26aulast%3DEkblad%26aufirst%3DT.%26aulast%3D%25C3%2596nc%25C3%25BC%26aufirst%3DD.%26aulast%3DKull%26aufirst%3DB.%26aulast%3DRobertson%26aufirst%3DG.%2BM.%26aulast%3DPellicciari%26aufirst%3DR.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26aulast%3DWeigelt%26aufirst%3DJ.%26atitle%3DFamily-wide%2520chemical%2520profiling%2520and%2520structural%2520analysis%2520of%2520PARP%2520and%2520tankyrase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2012%26volume%3D30%26spage%3D283%26epage%3D288%26doi%3D10.1038%2Fnbt.2121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Papeo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bettoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leone, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paolucci, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quartieri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riccardi-Sirtori, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieffine, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span> </span><span class="NLM_article-title">Insights into PARP inhibitors selectivity using fluorescence polarization and surface plasmon resonance binding assays</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1212</span><span class="NLM_x">–</span> <span class="NLM_lpage">1219</span><span class="refDoi"> DOI: 10.1177/1087057114538319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1177%2F1087057114538319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=24916412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2lsLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=1212-1219&author=G.+Papeoauthor=N.+Avanziauthor=S.+Bettoniauthor=A.+Leoneauthor=M.+Paolucciauthor=R.+Peregoauthor=F.+Quartieriauthor=F.+Riccardi-Sirtoriauthor=S.+Thieffineauthor=A.+Montagnoliauthor=R.+Lupi&title=Insights+into+PARP+inhibitors+selectivity+using+fluorescence+polarization+and+surface+plasmon+resonance+binding+assays&doi=10.1177%2F1087057114538319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into PARP inhibitors' selectivity using fluorescence polarization and surface plasmon resonance binding assays</span></div><div class="casAuthors">Papeo, Gianluca; Avanzi, Nilla; Bettoni, Serena; Leone, Antonella; Paolucci, Mauro; Perego, Rita; Quartieri, Francesca; Riccardi-Sirtori, Federico; Thieffine, Sandrine; Montagnoli, Alessia; Lupi, Rosita</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1212-1219, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">PARP inhibitors are an exciting new class of antineoplastic drugs that have been proven to be efficacious as single agents in cancer settings with inherent DNA repair defects, as well as in combination with DNA-damaging chemotherapeutics.  Currently, they are designed to target the catalytic domain of PARP-1, the most studied member of the family, with a key role in the DNA-damage repair process.  Because PARP inhibitors are substrate (NAD+) competitors, there is a need for a deeper understanding of their cross-reactivity.  This is particularly relevant for PARP-2, the PARP-1 closest homolog, for which an embryonic lethal phenotype has been obsd. in double knockout mice.  In this study, we describe the development and validation of binding assays based on fluorescence polarization (FP) and surface plasmon resonance (SPR) techniques.  PARP-1, PARP-2, PARP-3, and TNKS-1 FP displacement assays are set up by employing ad hoc synthesized probes.  These assays are suitable for high-throughput screening (HTS) and selectivity profiling, thus allowing the identification of NAD+ binding site selective inhibitors.  The PARP-1 and PARP-2 complementary SPR binding assays confirm displacement data and the in-depth inhibitor characterization.  Moreover, these formats have the potential to be broadly applicable to other members of the PARP family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnA9zw-zWzt7Vg90H21EOLACvtfcHk0liIQy-RQPoBXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2lsLvM&md5=79a05a435023d7011290bc33396cd1f6</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1177%2F1087057114538319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057114538319%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DBettoni%26aufirst%3DS.%26aulast%3DLeone%26aufirst%3DA.%26aulast%3DPaolucci%26aufirst%3DM.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DQuartieri%26aufirst%3DF.%26aulast%3DRiccardi-Sirtori%26aufirst%3DF.%26aulast%3DThieffine%26aufirst%3DS.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DLupi%26aufirst%3DR.%26atitle%3DInsights%2520into%2520PARP%2520inhibitors%2520selectivity%2520using%2520fluorescence%2520polarization%2520and%2520surface%2520plasmon%2520resonance%2520binding%2520assays%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2014%26volume%3D19%26spage%3D1212%26epage%3D1219%26doi%3D10.1177%2F1087057114538319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Yélamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span> </span><span class="NLM_article-title">Toward specific functions of poly(ADP-ribose) polymerase-2</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/j.molmed.2008.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.molmed.2008.02.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=169-178&author=J.+Y%C3%A9lamosauthor=V.+Schreiberauthor=F.+Dantzer&title=Toward+specific+functions+of+poly%28ADP-ribose%29+polymerase-2&doi=10.1016%2Fj.molmed.2008.02.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2008.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2008.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DY%25C3%25A9lamos%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DDantzer%26aufirst%3DF.%26atitle%3DToward%2520specific%2520functions%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-2%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2008%26volume%3D14%26spage%3D169%26epage%3D178%26doi%3D10.1016%2Fj.molmed.2008.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Antolin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestres, J.</span><span> </span><span class="NLM_article-title">Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3023</span><span class="NLM_x">–</span> <span class="NLM_lpage">3028</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3023-3028&author=A.+A.+Antolinauthor=J.+Mestres&title=Linking+off-target+kinase+pharmacology+to+the+differential+cellular+effects+observed+among+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAntolin%26aufirst%3DA.%2BA.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DLinking%2520off-target%2520kinase%2520pharmacology%2520to%2520the%2520differential%2520cellular%2520effects%2520observed%2520among%2520PARP%2520inhibitors%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D3023%26epage%3D3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Farrés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llacuna, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Caballero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martínez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozano, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ampurdanés, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Contreras, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Florensa, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dantzer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villunger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandéz-Capetillo, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yélamos, J.</span><span> </span><span class="NLM_article-title">PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1144</span><span class="NLM_x">–</span> <span class="NLM_lpage">1157</span><span class="refDoi"> DOI: 10.1038/cdd.2014.202</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1038%2Fcdd.2014.202" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25501596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFKnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=1144-1157&author=J.+Farr%C3%A9sauthor=L.+Llacunaauthor=J.+Martin-Caballeroauthor=C.+Mart%C3%ADnezauthor=J.+J.+Lozanoauthor=C.+Ampurdan%C3%A9sauthor=A.+J.+L%C3%B3pez-Contrerasauthor=L.+Florensaauthor=J.+Navarroauthor=E.+Ottinaauthor=F.+Dantzerauthor=V.+Schreiberauthor=A.+Villungerauthor=O.+Fernand%C3%A9z-Capetilloauthor=J.+Y%C3%A9lamos&title=PARP-2+sustains+erythropoiesis+in+mice+by+limiting+replicative+stress+in+erythroid+progenitors&doi=10.1038%2Fcdd.2014.202"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors</span></div><div class="casAuthors">Farres, J.; Llacuna, L.; Martin-Caballero, J.; Martinez, C.; Lozano, J. J.; Ampurdanes, C.; Lopez-Contreras, A. J.; Florensa, L.; Navarro, J.; Ottina, E.; Dantzer, F.; Schreiber, V.; Villunger, A.; Fernandez-Capetillo, O.; Yelamos, J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1144-1157</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Erythropoiesis is a tightly regulated process in which multipotential hematopoietic stem cells produce mature red blood cells.  Here we show that deletion of poly(ADP-ribose) polymerase-2 (PARP-2) in mice leads to chronic anemia at steady state, despite increased erythropoietin plasma levels, a phenomenon not obsd. in mice lacking PARP-1.  Loss of PARP-2 causes shortened lifespan of erythrocytes and impaired differentiation of erythroid progenitors.  In erythroblasts, PARP-2 deficiency triggers replicative stress, as indicated by the presence of micronuclei, the accumulation of γ-H2AX (phospho-histone H2AX) in S-phase cells and constitutive CHK1 and replication protein A phosphorylation.  Transcriptome analyses revealed the activation of the p53-dependent DNA-damage response pathways in PARP-2-deficient cells, culminating in the upregulation of cell-cycle and cell death regulators, concomitant with G2/M arrest and apoptosis.  Strikingly, while loss of the proapoptotic p53 target gene Puma restored hematocrit levels in the PARP-2-deficient mice, loss of the cell-cycle regulator and CDK inhibitor p21 leads to perinatal death by exacerbating impaired fetal liver erythropoiesis in PARP-2-deficient embryos.  Although the anemia displayed by PARP-2-deficient mice is compatible with life, mice die rapidly when exposed to stress-induced enhanced hemolysis.  Our results pinpoint an essential role for PARP-2 in erythropoiesis by limiting replicative stress that becomes essential in the absence of p21 and in the context of enhanced hemolysis, highlighting the potential effect that might arise from the design and use of PARP inhibitors that specifically inactivate PARP proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5EaGt9u1xrVg90H21EOLACvtfcHk0liIQy-RQPoBXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFKnur%252FJ&md5=07d6e706bbb8efd8c3aa0d31d13d1f99</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2014.202&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2014.202%26sid%3Dliteratum%253Aachs%26aulast%3DFarr%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLlacuna%26aufirst%3DL.%26aulast%3DMartin-Caballero%26aufirst%3DJ.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DLozano%26aufirst%3DJ.%2BJ.%26aulast%3DAmpurdan%25C3%25A9s%26aufirst%3DC.%26aulast%3DL%25C3%25B3pez-Contreras%26aufirst%3DA.%2BJ.%26aulast%3DFlorensa%26aufirst%3DL.%26aulast%3DNavarro%26aufirst%3DJ.%26aulast%3DOttina%26aufirst%3DE.%26aulast%3DDantzer%26aufirst%3DF.%26aulast%3DSchreiber%26aufirst%3DV.%26aulast%3DVillunger%26aufirst%3DA.%26aulast%3DFernand%25C3%25A9z-Capetillo%26aufirst%3DO.%26aulast%3DY%25C3%25A9lamos%26aufirst%3DJ.%26atitle%3DPARP-2%2520sustains%2520erythropoiesis%2520in%2520mice%2520by%2520limiting%2520replicative%2520stress%2520in%2520erythroid%2520progenitors%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2015%26volume%3D22%26spage%3D1144%26epage%3D1157%26doi%3D10.1038%2Fcdd.2014.202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Goldberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsulic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhatia, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharp, P. A.</span><span> </span><span class="NLM_article-title">Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">745</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span><span class="refDoi"> DOI: 10.1073/pnas.1016538108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1073%2Fpnas.1016538108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=745-750&author=M.+S.+Goldbergauthor=D.+Xingauthor=Y.+Renauthor=S.+Orsulicauthor=S.+N.+Bhatiaauthor=P.+A.+Sharp&title=Nanoparticle-mediated+delivery+of+siRNA+targeting+Parp1+extends+survival+of+mice+bearing+tumors+derived+from+Brca1-deficient+ovarian+cancer+cells&doi=10.1073%2Fpnas.1016538108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1016538108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1016538108%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DM.%2BS.%26aulast%3DXing%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DOrsulic%26aufirst%3DS.%26aulast%3DBhatia%26aufirst%3DS.%2BN.%26aulast%3DSharp%26aufirst%3DP.%2BA.%26atitle%3DNanoparticle-mediated%2520delivery%2520of%2520siRNA%2520targeting%2520Parp1%2520extends%2520survival%2520of%2520mice%2520bearing%2520tumors%2520derived%2520from%2520Brca1-deficient%2520ovarian%2520cancer%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D745%26epage%3D750%26doi%3D10.1073%2Fpnas.1016538108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamijo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohkubo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warizaya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hattori, K.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1378</span><span class="NLM_x">–</span> <span class="NLM_lpage">1390</span><span class="refDoi"> DOI: 10.1016/j.bmc.2005.09.061</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmc.2005.09.061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=16288880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=1378-1390&author=J.+Ishidaauthor=H.+Yamamotoauthor=Y.+Kidoauthor=K.+Kamijoauthor=K.+Muranoauthor=H.+Miyakeauthor=M.+Ohkuboauthor=T.+Kinoshitaauthor=M.+Warizayaauthor=A.+Iwashitaauthor=K.+Miharaauthor=N.+Matsuokaauthor=K.+Hattori&title=Discovery+of+potent+and+selective+PARP-1+and+PARP-2+inhibitors%3A+SBDD+analysis+via+a+combination+of+X-ray+structural+study+and+homology+modeling&doi=10.1016%2Fj.bmc.2005.09.061"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling</span></div><div class="casAuthors">Ishida, Junya; Yamamoto, Hirofumi; Kido, Yoshiyuki; Kamijo, Kazunori; Murano, Kenji; Miyake, Hiroshi; Ohkubo, Mitsuru; Kinoshita, Takayoshi; Warizaya, Masaichi; Iwashita, Akinori; Mihara, Kayoko; Matsuoka, Nobuya; Hattori, Kouji</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1378-1390</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We disclose herein our efforts aimed at discovery of selective PARP-1 and PARP-2 inhibitors.  We have recently discovered several novel classes of quinazolinones, quinazolidinones, and quinoxalines as potent PARP-1 inhibitors, which may represent attractive therapeutic candidates.  In PARP enzyme assays using recombinant PARP-1 and PARP-2, the quinazolinone derivs. displayed relatively high selectivity for PARP-1 and quinoxaline derivs. showed superior selectivity for PARP-2, and the quinazolidinone derivs. did not have selectivity for PARP-1/2.  Structure-based drug design anal. via a combination of X-ray structural study utilizing the complexes of inhibitors and human PARP-1 catalytic domain, and homol. modeling using murine PARP-2 suggested distinct interactions of inhibitors with PARP-1 and PARP-2.  These findings provide a new structural framework for the design of selective inhibitors for PARP-1 and PARP-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrukfYFsnRIEbVg90H21EOLACvtfcHk0ljjfsxtX8RKEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVGjtw%253D%253D&md5=9f72cd79428d0c006e2995c19a345c0f</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2005.09.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2005.09.061%26sid%3Dliteratum%253Aachs%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DKamijo%26aufirst%3DK.%26aulast%3DMurano%26aufirst%3DK.%26aulast%3DMiyake%26aufirst%3DH.%26aulast%3DOhkubo%26aufirst%3DM.%26aulast%3DKinoshita%26aufirst%3DT.%26aulast%3DWarizaya%26aufirst%3DM.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DN.%26aulast%3DHattori%26aufirst%3DK.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520PARP-1%2520and%2520PARP-2%2520inhibitors%253A%2520SBDD%2520analysis%2520via%2520a%2520combination%2520of%2520X-ray%2520structural%2520study%2520and%2520homology%2520modeling%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D1378%26epage%3D1390%26doi%3D10.1016%2Fj.bmc.2005.09.061" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hattori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kido, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishida, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwashita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mihara, K.</span><span> </span><span class="NLM_article-title">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">5577</span><span class="NLM_x">–</span> <span class="NLM_lpage">5581</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2007.07.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2007.07.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=17804225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=5577-5581&author=K.+Hattoriauthor=Y.+Kidoauthor=H.+Yamamotoauthor=J.+Ishidaauthor=A.+Iwashitaauthor=K.+Mihara&title=Rational+design+of+conformationally+restricted+quinazolinone+inhibitors+of+poly%28ADP-ribose%29polymerase&doi=10.1016%2Fj.bmcl.2007.07.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase</span></div><div class="casAuthors">Hattori, Kouji; Kido, Yoshiyuki; Yamamoto, Hirofumi; Ishida, Junya; Iwashita, Akinori; Mihara, Kayoko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5577-5581</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A successful design of conformationally restricted novel quinazolinone derivs. linked via a cyclopentene moiety as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors has been developed.  One selected member of the new series, 8-chloro-2-[(3S)-3-(4-phenylpiperidin-1-yl)cyclopent-1-en-1-yl]quinazolin-4(3H)-one (S-16d, I), was found to be highly potent with IC50 = 8.7 nM and good brain penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosvYPS7NANArVg90H21EOLACvtfcHk0ljjfsxtX8RKEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVGisLfK&md5=3ff78c0d7dbce0960a07274207348330</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.07.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.07.091%26sid%3Dliteratum%253Aachs%26aulast%3DHattori%26aufirst%3DK.%26aulast%3DKido%26aufirst%3DY.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DIshida%26aufirst%3DJ.%26aulast%3DIwashita%26aufirst%3DA.%26aulast%3DMihara%26aufirst%3DK.%26atitle%3DRational%2520design%2520of%2520conformationally%2520restricted%2520quinazolinone%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529polymerase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D5577%26epage%3D5581%26doi%3D10.1016%2Fj.bmcl.2007.07.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Eltze, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinbrenner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thiemermann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürkle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, T.</span><span> </span><span class="NLM_article-title">Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1587</span><span class="NLM_x">–</span> <span class="NLM_lpage">1598</span><span class="refDoi"> DOI: 10.1124/mol.108.048751</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1124%2Fmol.108.048751" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2008&pages=1587-1598&author=T.+Eltzeauthor=R.+Boerauthor=T.+Wagnerauthor=S.+Weinbrennerauthor=M.+C.+McDonaldauthor=C.+Thiemermannauthor=A.+B%C3%BCrkleauthor=T.+Klein&title=Imidazoquinolinone%2C+imidazopyridine%2C+and+isoquinolindione+derivatives+as+novel+and+potent+inhibitors+of+the+poly%28ADP-ribose%29+polymerase+%28PARP%29%3A+a+comparison+with+standard+PARP+inhibitors&doi=10.1124%2Fmol.108.048751"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.108.048751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.108.048751%26sid%3Dliteratum%253Aachs%26aulast%3DEltze%26aufirst%3DT.%26aulast%3DBoer%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWeinbrenner%26aufirst%3DS.%26aulast%3DMcDonald%26aufirst%3DM.%2BC.%26aulast%3DThiemermann%26aufirst%3DC.%26aulast%3DB%25C3%25BCrkle%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26atitle%3DImidazoquinolinone%252C%2520imidazopyridine%252C%2520and%2520isoquinolindione%2520derivatives%2520as%2520novel%2520and%2520potent%2520inhibitors%2520of%2520the%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%253A%2520a%2520comparison%2520with%2520standard%2520PARP%2520inhibitors%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D74%26spage%3D1587%26epage%3D1598%26doi%3D10.1124%2Fmol.108.048751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidorenko, N. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chernyshev, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grudinin, D. G.</span><span> </span><span class="NLM_article-title">Preparative synthesis of 7-carboxy-2-R-isoindol-1-ones</span> <span class="citation_source-journal">Chem. Heterocycl. Compd.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">28</span><span class="refDoi"> DOI: 10.1023/B:COHC.0000023763.75894.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1023%2FB%3ACOHC.0000023763.75894.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtFSrsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2004&pages=22-28&author=A.+V.+Varlamovauthor=E.+V.+Boltukhinaauthor=F.+I.+Zubkovauthor=N.+V.+Sidorenkoauthor=A.+I.+Chernyshevauthor=D.+G.+Grudinin&title=Preparative+synthesis+of+7-carboxy-2-R-isoindol-1-ones&doi=10.1023%2FB%3ACOHC.0000023763.75894.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Preparative synthesis of 7-carboxy-2-R-isoindol-1-ones</span></div><div class="casAuthors">Varlamov, A. V.; Boltukhina, E. V.; Zubkov, F. I.; Sidorenko, N. V.; Chernyshev, A. I.; Grudinin, D. G.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-28</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic/Consultants Bureau</span>)
        </div><div class="casAbstract">Stereoselective [4 + 2]-cycloaddn. of secondary furfurylamines to maleic anhydride gave epoxyisoindolones [I; R = benzyl, tetrahydrofurfuryl, cycloalkyl, (un)substituted Ph, etc.], which were heated with H3PO4 to give carboxyisoindolones (II).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHV8Tz9z5TgrVg90H21EOLACvtfcHk0ljjfsxtX8RKEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtFSrsrw%253D&md5=f59c9c7eafea99d462f001ec831947f3</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1023%2FB%3ACOHC.0000023763.75894.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FB%253ACOHC.0000023763.75894.63%26sid%3Dliteratum%253Aachs%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DSidorenko%26aufirst%3DN.%2BV.%26aulast%3DChernyshev%26aufirst%3DA.%2BI.%26aulast%3DGrudinin%26aufirst%3DD.%2BG.%26atitle%3DPreparative%2520synthesis%2520of%25207-carboxy-2-R-isoindol-1-ones%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2004%26volume%3D40%26spage%3D22%26epage%3D28%26doi%3D10.1023%2FB%3ACOHC.0000023763.75894.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Medimagh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marque, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatti, S.</span><span> </span><span class="NLM_article-title">5-Amino-2-furylmethylamines – appealing precursors of amino-isoindolinones?</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2010</span><span class="NLM_x">, </span> <span class="NLM_fpage">770</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span><span class="refDoi"> DOI: 10.1055/s-0029-1218614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1055%2Fs-0029-1218614" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2010&publication_year=2010&pages=770-774&author=R.+Medimaghauthor=S.+Marqueauthor=D.+Primauthor=S.+Chatti&title=5-Amino-2-furylmethylamines+%E2%80%93+appealing+precursors+of+amino-isoindolinones%3F&doi=10.1055%2Fs-0029-1218614"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218614%26sid%3Dliteratum%253Aachs%26aulast%3DMedimagh%26aufirst%3DR.%26aulast%3DMarque%26aufirst%3DS.%26aulast%3DPrim%26aufirst%3DD.%26aulast%3DChatti%26aufirst%3DS.%26atitle%3D5-Amino-2-furylmethylamines%2520%25E2%2580%2593%2520appealing%2520precursors%2520of%2520amino-isoindolinones%253F%26jtitle%3DSynthesis%26date%3D2010%26volume%3D2010%26spage%3D770%26epage%3D774%26doi%3D10.1055%2Fs-0029-1218614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ball, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyd, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuthbert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drew, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fielding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frodsham, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golden, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyons, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever-Abbas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottschling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hajar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suchozak, B.</span><span> </span><span class="NLM_article-title">Isoindolone formation via intramolecular Diels-Alder reaction</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">747</span><span class="refDoi"> DOI: 10.1021/op300002f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op300002f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFartLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=741-747&author=M.+Ballauthor=A.+Boydauthor=G.+Churchillauthor=M.+Cuthbertauthor=M.+Drewauthor=M.+Fieldingauthor=G.+Fordauthor=L.+Frodshamauthor=M.+Goldenauthor=K.+Leslieauthor=S.+Lyonsauthor=B.+McKeever-Abbasauthor=A.+Starkauthor=P.+Tomlinauthor=S.+Gottschlingauthor=A.+Hajarauthor=J.-l.+Jiangauthor=J.+Loauthor=B.+Suchozak&title=Isoindolone+formation+via+intramolecular+Diels-Alder+reaction&doi=10.1021%2Fop300002f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28cR"><div class="casContent"><span class="casTitleNuber">28c</span><div class="casTitle"><span class="NLM_cas:atitle">Isoindolone formation via intramolecular Diels-Alder reaction</span></div><div class="casAuthors">Ball, Matthew; Boyd, Alistair; Churchill, Gwydion; Cuthbert, Murray; Drew, Mark; Fielding, Mark; Ford, Gair; Frodsham, Lianne; Golden, Michael; Leslie, Kevin; Lyons, Sarah; McKeever-Abbas, Ben; Stark, Andrew; Tomlin, Paula; Gottschling, Stephen; Hajar, Abraham; Jiang, Ji-long; Lo, Josephine; Suchozak, Bob</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The intramol. Diels-Alder reaction provides a useful synthetic methodol. to build biol. active and synthetically useful isoindolone ring systems.  An application of this methodol., providing an efficient manufg. route to an mGluR2 pos. allosteric modulator via a 1,5,7-substituted isoindolone, is reported herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn-kJxO1Cip7Vg90H21EOLACvtfcHk0lgJ4DA46fUWKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFartLw%253D&md5=4c6dc750782e83440200699e464fdc1b</span></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1021%2Fop300002f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop300002f%26sid%3Dliteratum%253Aachs%26aulast%3DBall%26aufirst%3DM.%26aulast%3DBoyd%26aufirst%3DA.%26aulast%3DChurchill%26aufirst%3DG.%26aulast%3DCuthbert%26aufirst%3DM.%26aulast%3DDrew%26aufirst%3DM.%26aulast%3DFielding%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DG.%26aulast%3DFrodsham%26aufirst%3DL.%26aulast%3DGolden%26aufirst%3DM.%26aulast%3DLeslie%26aufirst%3DK.%26aulast%3DLyons%26aufirst%3DS.%26aulast%3DMcKeever-Abbas%26aufirst%3DB.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DTomlin%26aufirst%3DP.%26aulast%3DGottschling%26aufirst%3DS.%26aulast%3DHajar%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DJ.-l.%26aulast%3DLo%26aufirst%3DJ.%26aulast%3DSuchozak%26aufirst%3DB.%26atitle%3DIsoindolone%2520formation%2520via%2520intramolecular%2520Diels-Alder%2520reaction%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2012%26volume%3D16%26spage%3D741%26epage%3D747%26doi%3D10.1021%2Fop300002f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zaytsev, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikhailova, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Airiyan, I. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galkina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golubev, V. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">Cycloaddition of furfurylamines to maleic anhydride and its substituted derivatives</span> <span class="citation_source-journal">Chem. Heterocycl. Compd.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">513</span><span class="refDoi"> DOI: 10.1007/s10593-012-1023-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs10593-012-1023-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFKnsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=505-513&author=V.+P.+Zaytsevauthor=N.+M.+Mikhailovaauthor=I.+K.+Airiyanauthor=E.+V.+Galkinaauthor=V.+D.+Golubevauthor=E.+V.+Nikitinaauthor=F.+I.+Zubkovauthor=A.+V.+Varlamov&title=Cycloaddition+of+furfurylamines+to+maleic+anhydride+and+its+substituted+derivatives&doi=10.1007%2Fs10593-012-1023-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28dR"><div class="casContent"><span class="casTitleNuber">28d</span><div class="casTitle"><span class="NLM_cas:atitle">Cycloaddition of furfurylamines to maleic anhydride and its substituted derivatives</span></div><div class="casAuthors">Zaytsev, V. P.; Mikhailova, N. M.; Airiyan, I. K.; Galkina, E. V.; Golubev, V. D.; Nikitina, E. V.; Zubkov, F. I.; Varlamov, A. V.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry of Heterocyclic Compounds (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">505-513</span>CODEN:
                <span class="NLM_cas:coden">CHCCAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-3122</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The regio- and stereoselectivity of the [4 + 2] cycloaddn. of maleic, citraconic, dichloromaleic, and dibromomaleic anhydrides to difurfuryl amines and secondary furfurylamines were studied.  N-Furfuryl-, N-phenyl-, and N-benzylhexahydrooxoepoxyisoindole-7-carboxylic acids were synthesized.  An approach was developed for obtaining hexahydroepoxyoxoisoindole-7-carboxylic acid unsubstituted at the nitrogen atom.  Aromatization of the oxabicycloheptene fragment of the dihaloepoxyisoindolonecarboxylic acids gave a series of 7-carboxy-2-R-isoindol-1-ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OzSoQnPcRrVg90H21EOLACvtfcHk0lgJ4DA46fUWKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFKnsL0%253D&md5=c46aa05f050544b27d6a620c0615b4ad</span></div><a href="/servlet/linkout?suffix=cit28d&amp;dbid=16384&amp;doi=10.1007%2Fs10593-012-1023-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10593-012-1023-1%26sid%3Dliteratum%253Aachs%26aulast%3DZaytsev%26aufirst%3DV.%2BP.%26aulast%3DMikhailova%26aufirst%3DN.%2BM.%26aulast%3DAiriyan%26aufirst%3DI.%2BK.%26aulast%3DGalkina%26aufirst%3DE.%2BV.%26aulast%3DGolubev%26aufirst%3DV.%2BD.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DCycloaddition%2520of%2520furfurylamines%2520to%2520maleic%2520anhydride%2520and%2520its%2520substituted%2520derivatives%26jtitle%3DChem.%2520Heterocycl.%2520Compd.%26date%3D2012%26volume%3D48%26spage%3D505%26epage%3D513%26doi%3D10.1007%2Fs10593-012-1023-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">De Cesco, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deslandes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cueto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantin, L.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittermaier, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juillerat-Jeanneret, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moitessier, N.</span><span> </span><span class="NLM_article-title">Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6306</span><span class="NLM_x">–</span> <span class="NLM_lpage">6315</span><span class="refDoi"> DOI: 10.1021/jm3002839</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002839" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Onu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6306-6315&author=S.+De+Cescoauthor=S.+Deslandesauthor=E.+Therrienauthor=D.+Levanauthor=M.+Cuetoauthor=R.+Schmidtauthor=L.-D.+Cantinauthor=A.+Mittermaierauthor=L.+Juillerat-Jeanneretauthor=N.+Moitessier&title=Virtual+screening+and+computational+optimization+for+the+discovery+of+covalent+prolyl+oligopeptidase+inhibitors+with+activity+in+human+cells&doi=10.1021%2Fjm3002839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28eR"><div class="casContent"><span class="casTitleNuber">28e</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening and Computational Optimization for the Discovery of Covalent Prolyl Oligopeptidase Inhibitors with Activity in Human Cells</span></div><div class="casAuthors">De Cesco, Stephane; Deslandes, Sebastien; Therrien, Eric; Levan, David; Cueto, Mickael; Schmidt, Ralf; Cantin, Louis-David; Mittermaier, Anthony; Juillerat-Jeanneret, Lucienne; Moitessier, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6306-6315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Our docking program, Fitted, implemented in our computational platform, Forecaster, has been modified to carry out automated virtual screening of covalent inhibitors.  With this modified version of the program, virtual screening and further docking-based optimization of a selected hit led to the identification of potential covalent reversible inhibitors of prolyl oligopeptidase activity.  After visual inspection, a virtual hit mol. together with four analogs were selected for synthesis and made in one-five chem. steps.  Biol. evaluations on recombinant POP and FAPα enzymes, cell exts., and living cells demonstrated high potency and selectivity for POP over FAPα and DPPIV.  Three compds. even exhibited high nanomolar inhibitory activities in intact living human cells and acceptable metabolic stability.  This small set of mols. also demonstrated that covalent binding and/or geometrical constraints to the ligand/protein complex may lead to an increase in bioactivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaE7_T4KEl5rVg90H21EOLACvtfcHk0lgJ4DA46fUWKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Onu7Y%253D&md5=4c6cd8245e91cad790e4bab9254dcb3f</span></div><a href="/servlet/linkout?suffix=cit28e&amp;dbid=16384&amp;doi=10.1021%2Fjm3002839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002839%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BCesco%26aufirst%3DS.%26aulast%3DDeslandes%26aufirst%3DS.%26aulast%3DTherrien%26aufirst%3DE.%26aulast%3DLevan%26aufirst%3DD.%26aulast%3DCueto%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCantin%26aufirst%3DL.-D.%26aulast%3DMittermaier%26aufirst%3DA.%26aulast%3DJuillerat-Jeanneret%26aufirst%3DL.%26aulast%3DMoitessier%26aufirst%3DN.%26atitle%3DVirtual%2520screening%2520and%2520computational%2520optimization%2520for%2520the%2520discovery%2520of%2520covalent%2520prolyl%2520oligopeptidase%2520inhibitors%2520with%2520activity%2520in%2520human%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6306%26epage%3D6315%26doi%3D10.1021%2Fjm3002839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turchin, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borisov, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">New synthetic approach to substituted isoindolo[2,1-<i>a</i>]quinoline carboxylic acids via intramolecular Diels-Alder reaction of 4-(<i>N</i>-furyl-2)-4-arylaminobutenes-1 with maleic anhydride</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">4099</span><span class="NLM_x">–</span> <span class="NLM_lpage">4113</span><span class="refDoi"> DOI: 10.1016/j.tet.2005.02.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tet.2005.02.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVyisrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=4099-4113&author=F.+I.+Zubkovauthor=E.+V.+Boltukhinaauthor=K.+F.+Turchinauthor=R.+S.+Borisovauthor=A.+V.+Varlamov&title=New+synthetic+approach+to+substituted+isoindolo%5B2%2C1-a%5Dquinoline+carboxylic+acids+via+intramolecular+Diels-Alder+reaction+of+4-%28N-furyl-2%29-4-arylaminobutenes-1+with+maleic+anhydride&doi=10.1016%2Fj.tet.2005.02.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29aR"><div class="casContent"><span class="casTitleNuber">29a</span><div class="casTitle"><span class="NLM_cas:atitle">New synthetic approach to substituted isoindolo[2,1-a]quinoline carboxylic acids via intramolecular Diels-Alder reaction of 4-(N-furyl-2)-4-arylaminobutenes-1 with maleic anhydride</span></div><div class="casAuthors">Zubkov, Fedor I.; Boltukhina, Ekaterina V.; Turchin, Konstantin F.; Borisov, Roman S.; Varlamov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4099-4113</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acylation of substituted 4-(2-furyl)-4-arylaminobut-1-enes I (R1 = H, Me; R2 = H, 2-Me, 4-MeO, etc.) with maleic anhydride provided 2-allyl-6-carboxy-4-oxo-3-aza-10-oxatricyclo[5.2.1.01.5]dec-8-enes II in high yields under mild reaction conditions.  The Diels-Alder adducts II are formed via an initial amide formation followed by a stereoselective intramol. [4 + 2] exo-cycloaddn. reaction.  Treatment of the tricyclic compds. II with phosphoric acid at high temps. (70-120 °C) promoted cyclic ether opening, intramol. cyclization and aromatization to give the corresponding tetracyclic compds., 5,6,6a,11-tetrahydro-10-carboxyisoindolo[2,1-a]quinolines III, in moderate yields.  The influence of the acid and the reaction temp. on the cyclization reactions are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2D8UY4749vrVg90H21EOLACvtfcHk0lhGwFK2BS29Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVyisrs%253D&md5=30ea646d218c5d98cf50dd24fa53e511</span></div><a href="/servlet/linkout?suffix=cit29a&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.02.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.02.017%26sid%3Dliteratum%253Aachs%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DTurchin%26aufirst%3DK.%2BF.%26aulast%3DBorisov%26aufirst%3DR.%2BS.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DNew%2520synthetic%2520approach%2520to%2520substituted%2520isoindolo%255B2%252C1-a%255Dquinoline%2520carboxylic%2520acids%2520via%2520intramolecular%2520Diels-Alder%2520reaction%2520of%25204-%2528N-furyl-2%2529-4-arylaminobutenes-1%2520with%2520maleic%2520anhydride%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D4099%26epage%3D4113%26doi%3D10.1016%2Fj.tet.2005.02.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boltukhina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zubkov, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikitina, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varlamov, A. V.</span><span> </span><span class="NLM_article-title">Novel approach to isoindolo[2,1-<i>a</i>]quinolines: synthesis of 1- and 3-halo-substituted 11-oxo-5,6,6a,11-tetrahydroisoindolo[2,1-<i>a</i>]quinoline-10-carboxylic acids</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2005</span><span class="NLM_x">, </span> <span class="NLM_fpage">1859</span><span class="NLM_x">–</span> <span class="NLM_lpage">1875</span><span class="refDoi"> DOI: 10.1055/s-2005-869948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1055%2Fs-2005-869948" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2005&publication_year=2005&pages=1859-1875&author=E.+V.+Boltukhinaauthor=F.+I.+Zubkovauthor=E.+V.+Nikitinaauthor=A.+V.+Varlamov&title=Novel+approach+to+isoindolo%5B2%2C1-a%5Dquinolines%3A+synthesis+of+1-+and+3-halo-substituted+11-oxo-5%2C6%2C6a%2C11-tetrahydroisoindolo%5B2%2C1-a%5Dquinoline-10-carboxylic+acids&doi=10.1055%2Fs-2005-869948"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.1055%2Fs-2005-869948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2005-869948%26sid%3Dliteratum%253Aachs%26aulast%3DBoltukhina%26aufirst%3DE.%2BV.%26aulast%3DZubkov%26aufirst%3DF.%2BI.%26aulast%3DNikitina%26aufirst%3DE.%2BV.%26aulast%3DVarlamov%26aufirst%3DA.%2BV.%26atitle%3DNovel%2520approach%2520to%2520isoindolo%255B2%252C1-a%255Dquinolines%253A%2520synthesis%2520of%25201-%2520and%25203-halo-substituted%252011-oxo-5%252C6%252C6a%252C11-tetrahydroisoindolo%255B2%252C1-a%255Dquinoline-10-carboxylic%2520acids%26jtitle%3DSynthesis%26date%3D2005%26volume%3D2005%26spage%3D1859%26epage%3D1875%26doi%3D10.1055%2Fs-2005-869948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Gandhi, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinghofer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giranda, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penning, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, G.-D.</span><span> </span><span class="NLM_article-title">Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1023</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.12.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2009.12.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1023-1026&author=V.+B.+Gandhiauthor=Y.+Luoauthor=X.+Liuauthor=Y.+Shiauthor=V.+Klinghoferauthor=E.+F.+Johnsonauthor=C.+Parkauthor=V.+L.+Girandaauthor=T.+D.+Penningauthor=G.-D.+Zhu&title=Discovery+and+SAR+of+substituted+3-oxoisoindoline-4-carboxamides+as+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase+%28PARP%29+for+the+treatment+of+cancer&doi=10.1016%2Fj.bmcl.2009.12.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.12.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.12.042%26sid%3Dliteratum%253Aachs%26aulast%3DGandhi%26aufirst%3DV.%2BB.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DKlinghofer%26aufirst%3DV.%26aulast%3DJohnson%26aufirst%3DE.%2BF.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DGiranda%26aufirst%3DV.%2BL.%26aulast%3DPenning%26aufirst%3DT.%2BD.%26aulast%3DZhu%26aufirst%3DG.-D.%26atitle%3DDiscovery%2520and%2520SAR%2520of%2520substituted%25203-oxoisoindoline-4-carboxamides%2520as%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase%2520%2528PARP%2529%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1023%26epage%3D1026%26doi%3D10.1016%2Fj.bmcl.2009.12.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Mei, T.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maugel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.-Q.</span><span> </span><span class="NLM_article-title">Pd<sup>II</sup>-Catalyzed monoselective <i>ortho</i> halogenation of C-H bonds assisted by counter cations: a complementary method to directed <i>ortho</i> lithiation</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5215</span><span class="NLM_x">–</span> <span class="NLM_lpage">5219</span><span class="refDoi"> DOI: 10.1002/anie.200705613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fanie.200705613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD1cXos1antL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5215-5219&author=T.-S.+Meiauthor=R.+Giriauthor=N.+Maugelauthor=J.-Q.+Yu&title=PdII-Catalyzed+monoselective+ortho+halogenation+of+C-H+bonds+assisted+by+counter+cations%3A+a+complementary+method+to+directed+ortho+lithiation&doi=10.1002%2Fanie.200705613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PdII-catalyzed monoselective ortho halogenation of C-H bonds assisted by counter cations: a complementary method to directed ortho lithiation</span></div><div class="casAuthors">Mei, Tian-Sheng; Giri, Ramesh; Maugel, Nathan; Yu, Jin-Quan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">5215-5219</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The yield and selectivity of monoselective ortho halogenation of benzoic acid derivs. were improved greatly by using tetraalkyl ammonium salts as additives.  These effects are attributed to the influence of counter cations.  The halogenated products are versatile intermediates for the construction of substituted arom. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhdHMzxnlpsbVg90H21EOLACvtfcHk0lhGwFK2BS29Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXos1antL8%253D&md5=2766ba56d107e3d2b57fc8a712fa1f60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fanie.200705613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200705613%26sid%3Dliteratum%253Aachs%26aulast%3DMei%26aufirst%3DT.-S.%26aulast%3DGiri%26aufirst%3DR.%26aulast%3DMaugel%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DJ.-Q.%26atitle%3DPdII-Catalyzed%2520monoselective%2520ortho%2520halogenation%2520of%2520C-H%2520bonds%2520assisted%2520by%2520counter%2520cations%253A%2520a%2520complementary%2520method%2520to%2520directed%2520ortho%2520lithiation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2008%26volume%3D47%26spage%3D5215%26epage%3D5219%26doi%3D10.1002%2Fanie.200705613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Jagtap, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southan, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baloglu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ram, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mabley, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marton, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzman, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabo, C.</span><span> </span><span class="NLM_article-title">The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">85</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2003.10.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=81-85&author=P.+G.+Jagtapauthor=G.+J.+Southanauthor=E.+Balogluauthor=S.+Ramauthor=J.+G.+Mableyauthor=A.+Martonauthor=A.+Salzmanauthor=C.+Szabo&title=The+discovery+and+synthesis+of+novel+adenosine+substituted+2%2C3-dihydro-1H-isoindol-1-ones%3A+potent+inhibitors+of+poly%28ADP-ribose%29+polymerase-1+%28PARP-1%29&doi=10.1016%2Fj.bmcl.2003.10.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DJagtap%26aufirst%3DP.%2BG.%26aulast%3DSouthan%26aufirst%3DG.%2BJ.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DRam%26aufirst%3DS.%26aulast%3DMabley%26aufirst%3DJ.%2BG.%26aulast%3DMarton%26aufirst%3DA.%26aulast%3DSalzman%26aufirst%3DA.%26aulast%3DSzabo%26aufirst%3DC.%26atitle%3DThe%2520discovery%2520and%2520synthesis%2520of%2520novel%2520adenosine%2520substituted%25202%252C3-dihydro-1H-isoindol-1-ones%253A%2520potent%2520inhibitors%2520of%2520poly%2528ADP-ribose%2529%2520polymerase-1%2520%2528PARP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D81%26epage%3D85%26doi%3D10.1016%2Fj.bmcl.2003.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Papeo, G. M. E.; Anatolievna Busel, A.; Khvat, A.; Krasavin, M. Y.; Forte, B.; Zuccotto, F.</span><span> </span><span class="NLM_article-title">3-Oxo-2,3-dihydro-1<i>H</i>-isoindole-4-carboxamides as PARP inhibitors</span>. Patent WO2011/006794,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=G.+M.+E.+Papeo&author=A.+Anatolievna+Busel&author=A.+Khvat&author=M.+Y.+Krasavin&author=B.+Forte&author=F.+Zuccotto&title=3-Oxo-2%2C3-dihydro-1H-isoindole-4-carboxamides+as+PARP+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPapeo%26aufirst%3DG.%2BM.%2BE.%26atitle%3D3-Oxo-2%252C3-dihydro-1H-isoindole-4-carboxamides%2520as%2520PARP%2520inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. N.</span><span> </span><span class="NLM_article-title">An efficient InCl<sub>3</sub>-catalyzed hydration of nitriles to amides: acetaldoxime as an effective water surrogate</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1589</span><span class="NLM_x">–</span> <span class="NLM_lpage">1591</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2010.01.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.tetlet.2010.01.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhvF2qt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=1589-1591&author=E.+S.+Kimauthor=H.+S.+Leeauthor=S.+H.+Kimauthor=J.+N.+Kim&title=An+efficient+InCl3-catalyzed+hydration+of+nitriles+to+amides%3A+acetaldoxime+as+an+effective+water+surrogate&doi=10.1016%2Fj.tetlet.2010.01.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An efficient InCl3-catalyzed hydration of nitriles to amides: acetaldoxime as an effective water surrogate</span></div><div class="casAuthors">Kim, Eun Sun; Lee, Hyun Seung; Kim, Sung Hwan; Kim, Jae Nyoung</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1589-1591</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An efficient InCl3-catalyzed hydration protocol of nitriles to amides was developed.  The reaction was carried out in toluene at refluxing temp. with the aid of acetaldoxime as an effective water surrogate to produce amides in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlkQc6OhyvbVg90H21EOLACvtfcHk0ljVe-fqNXTE6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhvF2qt7Y%253D&md5=5df76d0d04e146ab1223a803285255f3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.01.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.01.063%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DJ.%2BN.%26atitle%3DAn%2520efficient%2520InCl3-catalyzed%2520hydration%2520of%2520nitriles%2520to%2520amides%253A%2520acetaldoxime%2520as%2520an%2520effective%2520water%2520surrogate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D1589%26epage%3D1591%26doi%3D10.1016%2Fj.tetlet.2010.01.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Li, J.-H.; Zhang, J.; Jackson, P. F.; Maclin, K. M.</span><span> </span><span class="NLM_article-title">Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage</span>. U.S. Patent 6306889,<span class="NLM_x"> </span><span class="NLM_year">2001</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2001&author=J.-H.+Li&author=J.+Zhang&author=P.+F.+Jackson&author=K.+M.+Maclin&title=Compounds%2C+methods+and+pharmaceutical+compositions+for+treating+neural+or+cardiovascular+tissue+damage"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.-H.%26atitle%3DCompounds%252C%2520methods%2520and%2520pharmaceutical%2520compositions%2520for%2520treating%2520neural%2520or%2520cardiovascular%2520tissue%2520damage%26date%3D2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36aR"><div class="casContent"><span class="casTitleNuber">36a</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0ljVe-fqNXTE6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perišić, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bento, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Lazikani, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. E.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">804</span><span class="NLM_x">–</span> <span class="NLM_lpage">811</span><span class="refDoi"> DOI: 10.1016/j.drudis.2010.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.drudis.2010.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=20727982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KqurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2010&pages=804-811&author=C.+Abad-Zapateroauthor=O.+Peri%C5%A1i%C4%87author=J.+Wassauthor=A.+P.+Bentoauthor=J.+Overingtonauthor=B.+Al-Lazikaniauthor=M.+E.+Johnson&title=Ligand+efficiency+indices+for+an+effective+mapping+of+chemico-biological+space%3A+the+concept+of+an+atlas-like+representation&doi=10.1016%2Fj.drudis.2010.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36bR"><div class="casContent"><span class="casTitleNuber">36b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation</span></div><div class="casAuthors">Abad-Zapatero, Cele; Perisic, Ognjen; Wass, John; Bento, A. Patricia; Overington, John; Al-Lazikani, Bissan; Johnson, Michael E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19/20</span>),
    <span class="NLM_cas:pages">804-811</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  We propose a numerical framework that permits an effective atlas-like representation of chemico-biol. space based on a series of Cartesian planes mapping the ligands with the corresponding targets connected by an affinity parameter (K i or related).  The numerical framework is derived from the concept of ligand efficiency indexes, which provide a natural coordinate system combining the potency toward the target (biol. space) with the physicochem. properties of the ligand (chem. space).  This framework facilitates navigation in the multidimensional drug discovery space using map-like representations based on pairs of combined variables related to the efficiency of the ligands per Dalton (mol. wt. or no. of non-hydrogen atoms) and per unit of polar surface area (or no. of polar atoms).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM4D5FkxdfoLVg90H21EOLACvtfcHk0liR5TlFEePn9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KqurrJ&md5=8ccee251c53513905dbd13c93a4ec1ed</span></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2010.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2010.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26aulast%3DPeri%25C5%25A1i%25C4%2587%26aufirst%3DO.%26aulast%3DWass%26aufirst%3DJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DOverington%26aufirst%3DJ.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520an%2520effective%2520mapping%2520of%2520chemico-biological%2520space%253A%2520the%2520concept%2520of%2520an%2520atlas-like%2520representation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2010%26volume%3D15%26spage%3D804%26epage%3D811%26doi%3D10.1016%2Fj.drudis.2010.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lord, A.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahon, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lloyd, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Threadgill, M. D.</span><span> </span><span class="NLM_article-title">Design, synthesis and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">877</span><span class="refDoi"> DOI: 10.1021/jm8013629</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8013629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=868-877&author=A.-M.+Lordauthor=M.+F.+Mahonauthor=M.+D.+Lloydauthor=M.+D.+Threadgill&title=Design%2C+synthesis+and+evaluation+in+vitro+of+quinoline-8-carboxamides%2C+a+new+class+of+poly%28adenosine-diphosphate-ribose%29polymerase-1+%28PARP-1%29+inhibitor&doi=10.1021%2Fjm8013629"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=10.1021%2Fjm8013629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8013629%26sid%3Dliteratum%253Aachs%26aulast%3DLord%26aufirst%3DA.-M.%26aulast%3DMahon%26aufirst%3DM.%2BF.%26aulast%3DLloyd%26aufirst%3DM.%2BD.%26aulast%3DThreadgill%26aufirst%3DM.%2BD.%26atitle%3DDesign%252C%2520synthesis%2520and%2520evaluation%2520in%2520vitro%2520of%2520quinoline-8-carboxamides%252C%2520a%2520new%2520class%2520of%2520poly%2528adenosine-diphosphate-ribose%2529polymerase-1%2520%2528PARP-1%2529%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D868%26epage%3D877%26doi%3D10.1021%2Fjm8013629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Gorobets, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yermolayev, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurley, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurinov, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolstoy, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenderovich, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leadbeater, N. E.</span><span> </span><span class="NLM_article-title">Difference between <sup>1</sup>H NMR signals of primary amide protons as a simple spectral index of the amide intramolecular hydrogen bond strength</span> <span class="citation_source-journal">J. Phys. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">287</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1002/poc.1910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fpoc.1910" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVams78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=287-295&author=N.+Y.+Gorobetsauthor=S.+A.+Yermolayevauthor=T.+Gurleyauthor=A.+A.+Gurinovauthor=P.+M.+Tolstoyauthor=I.+G.+Shenderovichauthor=N.+E.+Leadbeater&title=Difference+between+1H+NMR+signals+of+primary+amide+protons+as+a+simple+spectral+index+of+the+amide+intramolecular+hydrogen+bond+strength&doi=10.1002%2Fpoc.1910"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37bR"><div class="casContent"><span class="casTitleNuber">37b</span><div class="casTitle"><span class="NLM_cas:atitle">Difference between 1H NMR signals of primary amide protons as a simple spectral index of the amide intramolecular hydrogen bond strength</span></div><div class="casAuthors">Gorobets, Nikolay Yu.; Yermolayev, Sergey A.; Gurley, Thomas; Gurinov, Andrey A.; Tolstoy, Peter M.; Shenderovich, Ilya G.; Leadbeater, Nicholas E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Organic Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">287-295</span>CODEN:
                <span class="NLM_cas:coden">JPOCEE</span>;
        ISSN:<span class="NLM_cas:issn">0894-3230</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The effect of the intramol. H-bonding of the primary amide group on the spectral properties and reactivity of this group towards electrophiles has been studied in systematic rows of 1,2,5,6,7,8-hexahydro-7,7-dimethyl-2,5-dioxo-1-R-quinoline-3-carboxamides and 2-aryliminocoumarin-3-carboxamides using 1H and 15N NMR spectroscopy and the kinetics of model reactions.  The upfield signal of the amide proton that is not intramolecularly H-bonded (Ha) depends on external factors such as solvent nature and concn.  At the same time, the downfield chem. shift of the Hb proton (bonded by the intramol. hydrogen bond) depends mostly on the strength of the intramol. H-bond, which is affected by such internal factor as electron nature of substituent R.  The substituent's influence on the Hb proton's chem. shift is more effective in deuterochloroform medium than in DMSO-d6 where the intramol. hydrogen bond is less stable.  The value Δδ(H) = δ(Hb) - δ(Ha) is suggested as a simple comparative spectral index of the intramol. hydrogen bond strength in these and similar compds.  By contrast, the effect of R on the 15N NMR chem. shift of the amide nitrogen has turned out to be too small to est. changes of the electron d. at the nitrogen.  The effect of the intramol. H-bond on the reactivity of the amide group is twofold.  When the cleavage of the H-bond occurs on the rate limiting step it dramatically reduces the reaction rate.  In the other case, the strengthening of the H-bond favors the reaction rate because of the increase of the electron d. at the amide nitrogen.  Copyright © 2011 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyxnyXz8SSrrVg90H21EOLACvtfcHk0liR5TlFEePn9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVams78%253D&md5=87e009b30f3aec3f5a0ff3901b230e4d</span></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=10.1002%2Fpoc.1910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpoc.1910%26sid%3Dliteratum%253Aachs%26aulast%3DGorobets%26aufirst%3DN.%2BY.%26aulast%3DYermolayev%26aufirst%3DS.%2BA.%26aulast%3DGurley%26aufirst%3DT.%26aulast%3DGurinov%26aufirst%3DA.%2BA.%26aulast%3DTolstoy%26aufirst%3DP.%2BM.%26aulast%3DShenderovich%26aufirst%3DI.%2BG.%26aulast%3DLeadbeater%26aufirst%3DN.%2BE.%26atitle%3DDifference%2520between%25201H%2520NMR%2520signals%2520of%2520primary%2520amide%2520protons%2520as%2520a%2520simple%2520spectral%2520index%2520of%2520the%2520amide%2520intramolecular%2520hydrogen%2520bond%2520strength%26jtitle%3DJ.%2520Phys.%2520Org.%2520Chem.%26date%3D2012%26volume%3D25%26spage%3D287%26epage%3D295%26doi%3D10.1002%2Fpoc.1910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Abraham, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abraham, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acree, W. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliev, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whaley, W. L.</span><span> </span><span class="NLM_article-title">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">11075</span><span class="NLM_x">–</span> <span class="NLM_lpage">11083</span><span class="refDoi"> DOI: 10.1021/jo502080p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo502080p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=11075-11083&author=M.+H.+Abrahamauthor=R.+J.+Abrahamauthor=W.+E.+Acreeauthor=A.+E.+Alievauthor=A.+J.+Leoauthor=W.+L.+Whaley&title=An+NMR+Method+for+the+Quantitative+Assessment+of+Intramolecular+Hydrogen+Bonding%3B+Application+to+Physicochemical%2C+Environmental%2C+and+Biochemical+Properties&doi=10.1021%2Fjo502080p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">An NMR Method for the Quantitative Assessment of Intramolecular Hydrogen Bonding; Application to Physicochemical, Environmental, and Biochemical Properties</span></div><div class="casAuthors">Abraham, Michael H.; Abraham, Raymond J.; Acree, William E.; Aliev, Abil E.; Leo, Al J.; Whaley, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11075-11083</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">1H NMR chem. shifts have been obtained in the solvents deuterochloroform and DMSO.  The difference in the chem. shifts of an OH or NH group in these two solvents, Δδ = δ(DMSO) - δ(CDCl3), can be converted into the hydrogen bond acidity, A, of the group using the equation A = 0.0065 + 0.133Δδ.  The NMR A value, ANMR, can be used as a quant. assessment of intramol. hydrogen bonding.  We list values of Δδ and ANMR for 55 compds. contg. an OH group and 60 compds. with an NH group.  For the hydroxy compds., if A > 0.5 then the OH group is not part of an intramol. hydrogen bond, but if A < 0.1 then the OH group forms part of an intramol. hydrogen bond.  For NH compds., if A > 0.16 the NH group is not part of an intramol. hydrogen bond, and if A < 0.05 the NH group is part of an intramol. hydrogen bond.  No comparison compds. are needed, and the method is extremely simple.  We further show how it is possible to relate intramol. hydrogen bonding to the actual effect on values of a no. of physicochem., environmental, and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS3GZXQi7robVg90H21EOLACvtfcHk0liR5TlFEePn9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVensLrM&md5=b5e9948a04237fadb3b4fc3237bde8b1</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjo502080p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo502080p%26sid%3Dliteratum%253Aachs%26aulast%3DAbraham%26aufirst%3DM.%2BH.%26aulast%3DAbraham%26aufirst%3DR.%2BJ.%26aulast%3DAcree%26aufirst%3DW.%2BE.%26aulast%3DAliev%26aufirst%3DA.%2BE.%26aulast%3DLeo%26aufirst%3DA.%2BJ.%26aulast%3DWhaley%26aufirst%3DW.%2BL.%26atitle%3DAn%2520NMR%2520Method%2520for%2520the%2520Quantitative%2520Assessment%2520of%2520Intramolecular%2520Hydrogen%2520Bonding%253B%2520Application%2520to%2520Physicochemical%252C%2520Environmental%252C%2520and%2520Biochemical%2520Properties%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D11075%26epage%3D11083%26doi%3D10.1021%2Fjo502080p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">As the <i>K</i><sub>D</sub> sensitivity limit of the fluorescence polarization assay used to evaluate the biochemical potency of the inhibitors is 0.030 μM, a <i>K</i><sub>D</sub> ≥ 2 μM threshold against PARP-2 was introduced to evaluate the selectivity of the compounds that reach the aforementioned assay limit against PARP-1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">The 4,4-difluorocyclohexyl moiety was chosen in light of its purported superior metabolic stability compared to the corresponding unsubstituted cyclohexyl derivative. See, for example:</p></div><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dorr, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westby, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Irvine, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macartney, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith-Burchnell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Napier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armour, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stammen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perros, M.</span><span> </span><span class="NLM_article-title">Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">4721</span><span class="NLM_x">–</span> <span class="NLM_lpage">4732</span><span class="refDoi"> DOI: 10.1128/AAC.49.11.4721-4732.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1128%2FAAC.49.11.4721-4732.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=16251317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Siu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=4721-4732&author=P.+Dorrauthor=M.+Westbyauthor=S.+Dobbsauthor=P.+Griffinauthor=B.+Irvineauthor=M.+Macartneyauthor=J.+Moriauthor=G.+Rickettauthor=C.+Smith-Burchnellauthor=C.+Napierauthor=R.+Websterauthor=D.+Armourauthor=D.+Priceauthor=B.+Stammenauthor=A.+Woodauthor=M.+Perros&title=Maraviroc+%28UK-427%2C857%29%2C+a+Potent%2C+Orally+Bioavailable%2C+and+Selective+Small-Molecule+Inhibitor+of+Chemokine+Receptor+CCR5+with+Broad-Spectrum+Anti-Human+Immunodeficiency+Virus+Type+1+Activity&doi=10.1128%2FAAC.49.11.4721-4732.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity</span></div><div class="casAuthors">Dorr, Patrick; Westby, Mike; Dobbs, Susan; Griffin, Paul; Irvine, Becky; Macartney, Malcolm; Mori, Julie; Rickett, Graham; Smith-Burchnell, Caroline; Napier, Carolyn; Webster, Rob; Armour, Duncan; Price, David; Stammen, Blanda; Wood, Anthony; Perros, Manos</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4721-4732</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Maraviroc (UK-427,857) is a selective CCR5 antagonist with potent antihuman immunodeficiency virus type 1 (HIV-1) activity and favorable pharmacol. properties.  Maraviroc is the product of a medicinal chem. effort initiated following identification of an imidazopyridine CCR5 ligand from a high-throughput screen of the Pfizer compd. file.  Maraviroc demonstrated potent antiviral activity against all CCR5-tropic HIV-1 viruses tested, including 43 primary isolates from various clades and diverse geog. origin (geometric mean 90% inhibitory concn. of 2.0 nM).  Maraviroc was active against 200 clin. derived HIV-1 envelope-recombinant pseudoviruses, 100 of which were derived from viruses resistant to existing drug classes.  There was little difference in the sensitivity of the 200 viruses to maraviroc, as illustrated by the biol. cutoff in this assay (= geometric mean plus two std. deviations [SD] of 1.7-fold).  The mechanism of action of maraviroc was established using cell-based assays, where it blocked binding of viral envelope, gp120, to CCR5 to prevent the membrane fusion events necessary for viral entry.  Maraviroc did not affect CCR5 cell surface levels or assocd. intracellular signaling, confirming it as a functional antagonist of CCR5.  Maraviroc has no detectable in vitro cytotoxicity and is highly selective for CCR5, as confirmed against a wide range of receptors and enzymes, including the hERG ion channel (50% inhibitory concn., > 10 μM), indicating potential for an excellent clin. safety profile.  Studies in preclin. in vitro and in vivo models predicted maraviroc to have human pharmacokinetics consistent with once- or twice-daily dosing following oral administration.  Clin. trials are ongoing to further investigate the potential of using maraviroc for the treatment of HIV-1 infection and AIDS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoN0Z8KdsHODrVg90H21EOLACvtfcHk0lgATqDCrD_UAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Siu7rM&md5=561aea68490f7c6d3ec0f65676450155</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.11.4721-4732.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.11.4721-4732.2005%26sid%3Dliteratum%253Aachs%26aulast%3DDorr%26aufirst%3DP.%26aulast%3DWestby%26aufirst%3DM.%26aulast%3DDobbs%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DP.%26aulast%3DIrvine%26aufirst%3DB.%26aulast%3DMacartney%26aufirst%3DM.%26aulast%3DMori%26aufirst%3DJ.%26aulast%3DRickett%26aufirst%3DG.%26aulast%3DSmith-Burchnell%26aufirst%3DC.%26aulast%3DNapier%26aufirst%3DC.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DArmour%26aufirst%3DD.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DPerros%26aufirst%3DM.%26atitle%3DMaraviroc%2520%2528UK-427%252C857%2529%252C%2520a%2520Potent%252C%2520Orally%2520Bioavailable%252C%2520and%2520Selective%2520Small-Molecule%2520Inhibitor%2520of%2520Chemokine%2520Receptor%2520CCR5%2520with%2520Broad-Spectrum%2520Anti-Human%2520Immunodeficiency%2520Virus%2520Type%25201%2520Activity%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D4721%26epage%3D4732%26doi%3D10.1128%2FAAC.49.11.4721-4732.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kuduk, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiPardo, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Marco, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ransom, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reiss, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prueksaritanont, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pettibone, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bock, M. G.</span><span> </span><span class="NLM_article-title">Bradykinin B<sub>1</sub> receptor antagonists: An α-hydroxy amide with an improved metabolism profile</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5107</span><span class="NLM_x">–</span> <span class="NLM_lpage">5110</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1016%2Fj.bmcl.2008.07.126" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5107-5110&author=S.+D.+Kudukauthor=R.+K.+Changauthor=R.+M.+DiPardoauthor=C.+N.+Di+Marcoauthor=K.+L.+Murphyauthor=R.+W.+Ransomauthor=D.+R.+Reissauthor=C.+Tangauthor=T.+Prueksaritanontauthor=D.+J.+Pettiboneauthor=M.+G.+Bock&title=Bradykinin+B1+receptor+antagonists%3A+An+%CE%B1-hydroxy+amide+with+an+improved+metabolism+profile&doi=10.1016%2Fj.bmcl.2008.07.126"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.126%26sid%3Dliteratum%253Aachs%26aulast%3DKuduk%26aufirst%3DS.%2BD.%26aulast%3DChang%26aufirst%3DR.%2BK.%26aulast%3DDiPardo%26aufirst%3DR.%2BM.%26aulast%3DDi%2BMarco%26aufirst%3DC.%2BN.%26aulast%3DMurphy%26aufirst%3DK.%2BL.%26aulast%3DRansom%26aufirst%3DR.%2BW.%26aulast%3DReiss%26aufirst%3DD.%2BR.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DPrueksaritanont%26aufirst%3DT.%26aulast%3DPettibone%26aufirst%3DD.%2BJ.%26aulast%3DBock%26aufirst%3DM.%2BG.%26atitle%3DBradykinin%2520B1%2520receptor%2520antagonists%253A%2520An%2520%25CE%25B1-hydroxy%2520amide%2520with%2520an%2520improved%2520metabolism%2520profile%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5107%26epage%3D5110%26doi%3D10.1016%2Fj.bmcl.2008.07.126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Robichaud, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thérien, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oballa, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKay, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isabel, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimmel, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesolowski, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Percival, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massé, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desmarais, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falgueyret, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crane, S. N.</span><span> </span><span class="NLM_article-title">Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">6410</span><span class="NLM_x">–</span> <span class="NLM_lpage">6420</span><span class="refDoi"> DOI: 10.1021/jm800610j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800610j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=6410-6420&author=J.+Robichaudauthor=W.+C.+Blackauthor=M.+Th%C3%A9rienauthor=J.+Paquetauthor=R.+M.+Oballaauthor=C.+I.+Baylyauthor=D.+J.+McKayauthor=Q.+Wangauthor=E.+Isabelauthor=S.+L%C3%A9gerauthor=C.+Mellonauthor=D.+B.+Kimmelauthor=G.+Wesolowskiauthor=M.+D.+Percivalauthor=F.+Mass%C3%A9author=S.+Desmaraisauthor=J.-P.+Falgueyretauthor=S.+N.+Crane&title=Identification+of+a+nonbasic%2C+nitrile-containing+cathepsin+K+inhibitor+%28MK-1256%29+that+is+efficacious+in+a+monkey+model+of+osteoporosis&doi=10.1021%2Fjm800610j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm800610j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800610j%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DJ.%26aulast%3DBlack%26aufirst%3DW.%2BC.%26aulast%3DTh%25C3%25A9rien%26aufirst%3DM.%26aulast%3DPaquet%26aufirst%3DJ.%26aulast%3DOballa%26aufirst%3DR.%2BM.%26aulast%3DBayly%26aufirst%3DC.%2BI.%26aulast%3DMcKay%26aufirst%3DD.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DIsabel%26aufirst%3DE.%26aulast%3DL%25C3%25A9ger%26aufirst%3DS.%26aulast%3DMellon%26aufirst%3DC.%26aulast%3DKimmel%26aufirst%3DD.%2BB.%26aulast%3DWesolowski%26aufirst%3DG.%26aulast%3DPercival%26aufirst%3DM.%2BD.%26aulast%3DMass%25C3%25A9%26aufirst%3DF.%26aulast%3DDesmarais%26aufirst%3DS.%26aulast%3DFalgueyret%26aufirst%3DJ.-P.%26aulast%3DCrane%26aufirst%3DS.%2BN.%26atitle%3DIdentification%2520of%2520a%2520nonbasic%252C%2520nitrile-containing%2520cathepsin%2520K%2520inhibitor%2520%2528MK-1256%2529%2520that%2520is%2520efficacious%2520in%2520a%2520monkey%2520model%2520of%2520osteoporosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D6410%26epage%3D6420%26doi%3D10.1021%2Fjm800610j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Boudra, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fouquin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaremba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaslin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordeliéres, F. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mégnin-Chanet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaudon, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernet, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennaneach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, J.</span><span> </span><span class="NLM_article-title">PARP-2 depletion results in lower radiation cell survival but cell line specific differences in poly(ADP-ribose) levels</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1585</span><span class="NLM_x">–</span> <span class="NLM_lpage">1597</span><span class="refDoi"> DOI: 10.1007/s00018-014-1765-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs00018-014-1765-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=25336152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsl2gt73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2015&pages=1585-1597&author=M.+T.+Boudraauthor=C.+Bolinauthor=S.+Chikerauthor=A.+Fouquinauthor=T.+Zarembaauthor=L.+Vaslinauthor=D.+Biardauthor=F.+P.+Cordeli%C3%A9resauthor=F.+M%C3%A9gnin-Chanetauthor=V.+Favaudonauthor=M.+Fernetauthor=V.+Pennaneachauthor=J.+Hall&title=PARP-2+depletion+results+in+lower+radiation+cell+survival+but+cell+line+specific+differences+in+poly%28ADP-ribose%29+levels&doi=10.1007%2Fs00018-014-1765-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">PARP-2 depletion results in lower radiation cell survival but cell line-specific differences in poly(ADP-ribose) levels</span></div><div class="casAuthors">Boudra, Mohammed-Tayyib; Bolin, Celeste; Chiker, Sara; Fouquin, Alexis; Zaremba, Tomasz; Vaslin, Laurence; Biard, Denis; Cordelieres, Fabrice P.; Megnin-Chanet, Frederique; Favaudon, Vincent; Fernet, Marie; Pennaneach, Vincent; Hall, Janet</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1585-1597</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">Poly(ADP-ribose) polymerase-2 (PARP-2) activity contributes to a cells' poly(ADP-ribosyl)ating potential and like PARP-1, has been implicated in several DNA repair pathways including base excision repair and DNA single strand break repair.  Here the consequences of its stable depletion in HeLa, U20S, and AS3WT2 cells were examd.  All three PARP-2 depleted models showed increased sensitivity to the cell killing effects on ionizing radiation as reported in PARP-2 depleted mouse embryonic fibroblasts providing further evidence for a role in DNA strand break repair.  The PARP-2 depleted HeLa cells also showed both higher constitutive and DNA damage-induced levels of polymers of ADP-ribose (PAR) assocd. with unchanged PARP-1 protein levels, but higher PARP activity and a concomitant lower PARG protein levels and activity.  These changes were accompanied by a reduced maximal recruitment of PARP-1, XRCC1, PCNA, and PARG to DNA damage sites.  This PAR-assocd. phenotype could be reversed in HeLa cells on re-expression of PARP-2 and was not seen in U20S and AS3WT2 cells.  These results highlight the complexity of the relationship between different members of the PARP family on PAR metab. and suggest that cell model dependent phenotypes assocd. with the absence of PARP-2 exist within a common background of radiation sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSltAiaCa2JbVg90H21EOLACvtfcHk0lhAWm20fennBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsl2gt73F&md5=8c7788a7d7b2e3765044e1d4bfad55e4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1765-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1765-2%26sid%3Dliteratum%253Aachs%26aulast%3DBoudra%26aufirst%3DM.%2BT.%26aulast%3DBolin%26aufirst%3DC.%26aulast%3DChiker%26aufirst%3DS.%26aulast%3DFouquin%26aufirst%3DA.%26aulast%3DZaremba%26aufirst%3DT.%26aulast%3DVaslin%26aufirst%3DL.%26aulast%3DBiard%26aufirst%3DD.%26aulast%3DCordeli%25C3%25A9res%26aufirst%3DF.%2BP.%26aulast%3DM%25C3%25A9gnin-Chanet%26aufirst%3DF.%26aulast%3DFavaudon%26aufirst%3DV.%26aulast%3DFernet%26aufirst%3DM.%26aulast%3DPennaneach%26aufirst%3DV.%26aulast%3DHall%26aufirst%3DJ.%26atitle%3DPARP-2%2520depletion%2520results%2520in%2520lower%2520radiation%2520cell%2520survival%2520but%2520cell%2520line%2520specific%2520differences%2520in%2520poly%2528ADP-ribose%2529%2520levels%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2015%26volume%3D72%26spage%3D1585%26epage%3D1597%26doi%3D10.1007%2Fs00018-014-1765-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Karlberg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarström, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Svensson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schüler, H.</span><span> </span><span class="NLM_article-title">Crystal Structure of the Catalytic Domain of Human PARP2 in Complex with PARP Inhibitor ABT-888</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1056</span><span class="NLM_x">–</span> <span class="NLM_lpage">1058</span><span class="refDoi"> DOI: 10.1021/bi902079y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi902079y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=1056-1058&author=T.+Karlbergauthor=M.+Hammarstr%C3%B6mauthor=P.+Sch%C3%BCtzauthor=L.+Svenssonauthor=H.+Sch%C3%BCler&title=Crystal+Structure+of+the+Catalytic+Domain+of+Human+PARP2+in+Complex+with+PARP+Inhibitor+ABT-888&doi=10.1021%2Fbi902079y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fbi902079y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi902079y%26sid%3Dliteratum%253Aachs%26aulast%3DKarlberg%26aufirst%3DT.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DP.%26aulast%3DSvensson%26aufirst%3DL.%26aulast%3DSch%25C3%25BCler%26aufirst%3DH.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520PARP2%2520in%2520Complex%2520with%2520PARP%2520Inhibitor%2520ABT-888%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D1056%26epage%3D1058%26doi%3D10.1021%2Fbi902079y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Colombo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirtori, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzo, V.</span><span> </span><span class="NLM_article-title">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span> <span class="citation_source-journal">Rapid Commun. Mass Spectrom.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1002/rcm.1368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Frcm.1368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=14966861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2004&pages=511-517&author=M.+Colomboauthor=F.+R.+Sirtoriauthor=V.+Rizzo&title=A+fully+automated+method+for+accurate+mass+determination+using+high-performance+liquid+chromatography+with+a+quadrupole%2Forthogonal+acceleration+time-of-flight+mass+spectrometer&doi=10.1002%2Frcm.1368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer</span></div><div class="casAuthors">Colombo, Maristella; Sirtori, Federico Riccardi; Rizzo, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-517</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">A generic LC/ESI(+)-oaTOFMS method has been developed for routine automated high accuracy mass detns. of different classes of substances.  The system makes use of micro-high-performance liq. chromatog. and a hybrid quadrupole/orthogonal acceleration time-of-flight (Q-oaTOF) mass spectrometer.  Reproducible and accurate mass measurements were obtained using an electrospray dual sprayer with reserpine as ref. compd., introduced into the mass spectrometer alternating with the samples.  Expts. were performed to optimize analyte/ref. response ratio, statistical algorithm correction setting, and analyte concn.  In these expts., a clear dependence of the mass measurement error on the analyte/ref. response ratio was obsd.  The dependence of av. mass error vs. different dead time correction algorithm settings (Np factors) was also explored.  In the final automated procedure, verified for a statistically significant set of compds. (∼550) obtained from a medicinal chem. department, about 70% of the analyzed samples satisfied the acceptance criteria fixed at a max. error of ±5 ppm (mass range 150-800 Da).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro5JNVhGdzjrVg90H21EOLACvtfcHk0lhAWm20fennBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1equr8%253D&md5=6f1f93c5e2fb4e24257b77f5ce6dfa37</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1002%2Frcm.1368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.1368%26sid%3Dliteratum%253Aachs%26aulast%3DColombo%26aufirst%3DM.%26aulast%3DSirtori%26aufirst%3DF.%2BR.%26aulast%3DRizzo%26aufirst%3DV.%26atitle%3DA%2520fully%2520automated%2520method%2520for%2520accurate%2520mass%2520determination%2520using%2520high-performance%2520liquid%2520chromatography%2520with%2520a%2520quadrupole%252Forthogonal%2520acceleration%2520time-of-flight%2520mass%2520spectrometer%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2004%26volume%3D18%26spage%3D511%26epage%3D517%26doi%3D10.1002%2Frcm.1368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Felder, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Badari, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disingrini, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantegani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orrenius, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salom, B.</span><span> </span><span class="NLM_article-title">The generation of purinome-targeted libraries as a means to diversify ATP-mimetic chemical classes for lead finding</span> <span class="citation_source-journal">Mol. Diversity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">51</span><span class="refDoi"> DOI: 10.1007/s11030-012-9361-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1007%2Fs11030-012-9361-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=27-51&author=E.+R.+Felderauthor=A.+Badariauthor=T.+Disingriniauthor=S.+Manteganiauthor=C.+Orreniusauthor=N.+Avanziauthor=A.+Isacchiauthor=B.+Salom&title=The+generation+of+purinome-targeted+libraries+as+a+means+to+diversify+ATP-mimetic+chemical+classes+for+lead+finding&doi=10.1007%2Fs11030-012-9361-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1007%2Fs11030-012-9361-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11030-012-9361-6%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DE.%2BR.%26aulast%3DBadari%26aufirst%3DA.%26aulast%3DDisingrini%26aufirst%3DT.%26aulast%3DMantegani%26aufirst%3DS.%26aulast%3DOrrenius%26aufirst%3DC.%26aulast%3DAvanzi%26aufirst%3DN.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DSalom%26aufirst%3DB.%26atitle%3DThe%2520generation%2520of%2520purinome-targeted%2520libraries%2520as%2520a%2520means%2520to%2520diversify%2520ATP-mimetic%2520chemical%2520classes%2520for%2520lead%2520finding%26jtitle%3DMol.%2520Diversity%26date%3D2012%26volume%3D16%26spage%3D27%26epage%3D51%26doi%3D10.1007%2Fs11030-012-9361-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span>GraphPad Prism; <span class="NLM_publisher-name">GraphPad Software, Inc.</span>: <span class="NLM_publisher-loc">7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA.</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=GraphPad+Prism%3B+GraphPad+Software%2C+Inc.%3A+7825+Fay+Avenue%2C+Suite+230+La+Jolla%2C+CA+92037+USA.."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DGraphPad%2520Prism%26pub%3DGraphPad%2520Software%252C%2520Inc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Leslie, A. G. W.</span><span> </span><span class="NLM_article-title">Integration of macromolecular diffraction data</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1696</span><span class="NLM_x">–</span> <span class="NLM_lpage">1702</span><span class="refDoi"> DOI: 10.1107/S090744499900846X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS090744499900846X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1999&pages=1696-1702&author=A.+G.+W.+Leslie&title=Integration+of+macromolecular+diffraction+data&doi=10.1107%2FS090744499900846X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS090744499900846X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS090744499900846X%26sid%3Dliteratum%253Aachs%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26atitle%3DIntegration%2520of%2520macromolecular%2520diffraction%2520data%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1999%26volume%3D55%26spage%3D1696%26epage%3D1702%26doi%3D10.1107%2FS090744499900846X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Collaborative Computational Project, Number 4</span><span> </span><span class="NLM_article-title">The CCP4 suite: programs for protein crystallography</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">763</span><span class="refDoi"> DOI: 10.1107/S0907444994003112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444994003112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15299374" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1994&pages=760-763&author=Collaborative+Computational+Project%2C+Number+4&title=The+CCP4+suite%3A+programs+for+protein+crystallography&doi=10.1107%2FS0907444994003112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444994003112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444994003112%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DThe%2520CCP4%2520suite%253A%2520programs%2520for%2520protein%2520crystallography%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1994%26volume%3D50%26spage%3D760%26epage%3D763%26doi%3D10.1107%2FS0907444994003112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Murshudov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodson, E. J.</span><span> </span><span class="NLM_article-title">Refinement of Macromolecular Structures by the Maximum-Likelihood Method</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">255</span><span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+Macromolecular+Structures+by+the+Maximum-Likelihood+Method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0ljfdB6n7o8Zgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520Macromolecular%2520Structures%2520by%2520the%2520Maximum-Likelihood%2520Method%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljfdB6n7o8Zgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Beria, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinari, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borghi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasca, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappella, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caruso, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceccarelli, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciavolella, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristiani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Croci, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fachin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesenti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Posteri, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rocchetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storici, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volpi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valsasina, B.</span><span> </span><span class="NLM_article-title">Identification of 4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline derivatives as a new class of orally and selective polo-like kinase 1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3532</span><span class="NLM_x">–</span> <span class="NLM_lpage">3551</span><span class="refDoi"> DOI: 10.1021/jm901713n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901713n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3532-3551&author=I.+Beriaauthor=D.+Ballinariauthor=J.+A.+Bertrandauthor=D.+Borghiauthor=R.+T.+Bossiauthor=M.+G.+Brascaauthor=P.+Cappellaauthor=M.+Carusoauthor=W.+Ceccarelliauthor=A.+Ciavolellaauthor=C.+Cristianiauthor=V.+Crociauthor=A.+De+Pontiauthor=G.+Fachinauthor=R.+D.+Fergusonauthor=J.+Lansenauthor=J.+K.+Mollauthor=E.+Pesentiauthor=H.+Posteriauthor=R.+Peregoauthor=M.+Rocchettiauthor=P.+Storiciauthor=D.+Volpiauthor=B.+Valsasina&title=Identification+of+4%2C5-dihydro-1H-pyrazolo%5B4%2C3-h%5Dquinazoline+derivatives+as+a+new+class+of+orally+and+selective+polo-like+kinase+1+inhibitors&doi=10.1021%2Fjm901713n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm901713n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901713n%26sid%3Dliteratum%253Aachs%26aulast%3DBeria%26aufirst%3DI.%26aulast%3DBallinari%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26aulast%3DBorghi%26aufirst%3DD.%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DBrasca%26aufirst%3DM.%2BG.%26aulast%3DCappella%26aufirst%3DP.%26aulast%3DCaruso%26aufirst%3DM.%26aulast%3DCeccarelli%26aufirst%3DW.%26aulast%3DCiavolella%26aufirst%3DA.%26aulast%3DCristiani%26aufirst%3DC.%26aulast%3DCroci%26aufirst%3DV.%26aulast%3DDe%2BPonti%26aufirst%3DA.%26aulast%3DFachin%26aufirst%3DG.%26aulast%3DFerguson%26aufirst%3DR.%2BD.%26aulast%3DLansen%26aufirst%3DJ.%26aulast%3DMoll%26aufirst%3DJ.%2BK.%26aulast%3DPesenti%26aufirst%3DE.%26aulast%3DPosteri%26aufirst%3DH.%26aulast%3DPerego%26aufirst%3DR.%26aulast%3DRocchetti%26aufirst%3DM.%26aulast%3DStorici%26aufirst%3DP.%26aulast%3DVolpi%26aufirst%3DD.%26aulast%3DValsasina%26aufirst%3DB.%26atitle%3DIdentification%2520of%25204%252C5-dihydro-1H-pyrazolo%255B4%252C3-h%255Dquinazoline%2520derivatives%2520as%2520a%2520new%2520class%2520of%2520orally%2520and%2520selective%2520polo-like%2520kinase%25201%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3532%26epage%3D3551%26doi%3D10.1021%2Fjm901713n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petusky, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jupp, P.</span><span> </span><span class="NLM_article-title">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">1440</span><span class="NLM_x">–</span> <span class="NLM_lpage">1453</span><span class="refDoi"> DOI: 10.1002/jps.20075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=10.1002%2Fjps.20075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=15124203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2004&pages=1440-1453&author=E.+H.+Kernsauthor=L.+Diauthor=S.+Petuskyauthor=M.+Farrisauthor=R.+Leyauthor=P.+Jupp&title=Combined+application+of+parallel+artificial+membrane+permeability+assay+and+Caco-2+permeability+assays+in+drug+discovery&doi=10.1002%2Fjps.20075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery</span></div><div class="casAuthors">Kerns, Edward H.; Di, Li; Petusky, Susan; Farris, Michele; Ley, Rob; Jupp, Phil</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1440-1453</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Data from permeability profiling using the parallel artificial membrane permeability assay (PAMPA) and cell monolayer (Caco-2 and MDR1-MDCKII) methods were compared for two published compd. sets and one inhouse set.  A majority of compds. in each set correlated (R2 = 0.76-0.92), indicating the predominance of passive diffusion in the permeation of these compds.  Compds. that did not correlate grouped into two subsets.  One subset had higher PAMPA permeability than cell monolayer permeability and consisted of compds. that are subject to secretory mechanisms: efflux or reduced passive diffusion of bases under Caco-2 when run under a pH gradient.  The other subset had higher cell monolayer permeability than PAMPA permeability and consisted of compds. that are subject to absorptive mechanisms: paracellular, active transport, or increased passive diffusion of acids under Caco-2 when run under a pH gradient.  Given the characteristics of the two methods, these studies suggest how PAMPA and Caco-2 can be synergistically applied for efficient and rapid investigation of permeation mechanisms in drug discovery.  During early discovery, all compds. can be rapidly screened using PAMPA at low pH and neutral pH to assess passive diffusion permeability to indicate potential for gastrointestinal and cell assay permeation.  During intermediate discovery, selected compds. can be addnl. assayed by apical-to-basolateral Caco-2, which, in combination with PAMPA data, indicates susceptibility to addnl. permeation mechanisms (secretory and absorptive).  During mid-to-late discovery, selected candidates can be examd. in detail via multiple directional Caco-2 expts. and with transporter inhibitors for complete characterization of permeation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG1M-v5UG2RLVg90H21EOLACvtfcHk0liBKWw7jf970g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks12iu7w%253D&md5=428596e93f30763e94ced9341d23a02e</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fjps.20075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.20075%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DPetusky%26aufirst%3DS.%26aulast%3DFarris%26aufirst%3DM.%26aulast%3DLey%26aufirst%3DR.%26aulast%3DJupp%26aufirst%3DP.%26atitle%3DCombined%2520application%2520of%2520parallel%2520artificial%2520membrane%2520permeability%2520assay%2520and%2520Caco-2%2520permeability%2520assays%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2004%26volume%3D93%26spage%3D1440%26epage%3D1453%26doi%3D10.1002%2Fjps.20075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UK0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UK0','PDB','1UK0'); return false;">PDB: 1UK0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ','PDB','4ZZZ'); return false;">PDB: 4ZZZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX','PDB','4ZZX'); return false;">PDB: 4ZZX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00','PDB','5A00'); return false;">PDB: 5A00</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY','PDB','4ZZY'); return false;">PDB: 4ZZY</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-3"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i128"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00680">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_86505"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00680">10.1021/acs.jmedchem.5b00680</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Quantitative assessment of the intramolecular hydrogen bond strength of selected isoindolinones; detailed kinetic parameters and kinetic analysis of surface plasmon resonance binding assay; experimental details concerning in vitro evaluation of cross species metabolism, cytochrome P450 inhibition, and mielotoxicity of compound <b>20by</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Isoindolinones preliminary SAR investigation molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_002.xls">XLS</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_001.pdf">jm5b00680_si_001.pdf (86.05 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00680/suppl_file/jm5b00680_si_002.xls">jm5b00680_si_002.xls (25.0 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">All structures have been deposited to the Protein Data Bank (PDB) with accession codes: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZX">4ZZX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZY">4ZZY</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4ZZZ">4ZZZ</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A00">5A00</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00680&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00680%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-17%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00680" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679970558975195f","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
